

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047458 A2

(51) International Patent Classification⁷: C12N

A. [CN/US]; 11111 Via Abajo #A, San Diego, CA 92129 (US). ZHANG, Qian [CN/US]; 88348D Via Sanoma, San Diego, CA 92037 (US).

(21) International Application Number:
PCT/US2004/019866

(74) Agents: SEIDMAN, Stephanie, L. et al.; Fish and Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).

(22) International Filing Date: 18 June 2004 (18.06.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
03013826.7 18 June 2003 (18.06.2003) EP
03018478.2 14 August 2003 (14.08.2003) EP
03024283.8 22 October 2003 (22.10.2003) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 03013826.7 (CON)
Filed on 18 June 2003 (18.06.2003)
US 03018478.2 (CON)
Filed on 14 August 2003 (14.08.2003)
US 03024283.8 (CON)
Filed on 22 October 2003 (22.10.2003)

Published:
— without international search report and to be republished upon receipt of that report

(71) Applicant (for all designated States except US): GENELUX CORPORATION [US/US]; 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): SZALAY, Aladar, A. [US/US]; 7704 North Fork Road, Highland, CA 92346 (US). TIMIRYASOVA, Tatyana [RU/US]; 7524 Charmant Drive #525, San Diego, CA 92122 (US). YU, Yong,

A2

WO 2005/047458

(54) Title: MICROORGANISMS FOR THERAPY

(57) Abstract: Recombinant *vaccinia* viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organism. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products.. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism as well as antibodies reactive therewith are provided.

BEST AVAILABLE COPY

-1-

MICROORGANISMS FOR THERAPY

RELATED APPLICATIONS

Benefit of priority is claimed to each of EP 03 013 826.7, filed 18 June 2003, entitled "Recombinant vaccinia viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination;" EP 03 018 478.2, filed 14 August 2003, entitled "Method for the production of a polypeptide, RNA or other compound in tumor tissue;" and EP 03 024 283.8, filed 22 October 2003, entitled "Use of a Microorganism or Cell to Induce Autoimmunization of an Organism Against a Tumor." Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

This application also is related U.S. application Serial No. (Attorney docket number 17248-002wo1 (4802PC)), filed the same day herewith. This application also is related to U.S. Application filed June 10, 2004 (attorney docket number 17248-003002), entitled "Light emitting microorganisms and cells for diagnosis and therapy of tumors," which is a continuation of U.S. Application Serial No. 10/189,918, filed July 3, 2002; U.S. Application filed May 19, 2004 (attorney docket number 17248-004002), entitled, "Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue" which is a continuation of U.S. Application Serial No. 10/163,763, filed June 5, 2003; International PCT Application WO 03/014380, filed July 31, 2002, entitled "Microorganisms and Cells for Diagnosis and Therapy of Tumors;" PCT Application WO 03/104485, filed June 5, 2003, entitled, "Light Emitting Microorganisms and Cells for Diagnosis and Therapy of Diseases Associated with Wounded or Inflamed tissue;" EP Application No. 01 118 417.3, filed July 31, 2001, entitled "Light-emitting microorganisms and cells for tumour diagnosis/therapy;" EP Application No. 01 125 911.6, filed October 30, 2001, entitled "Light emitting microorganisms and cells for diagnosis and therapy of tumors;" EP Application No. 02 0794 632.6, filed January 28, 2004, entitled "Microorganisms and Cells for Diagnosis and Therapy of Tumors;" and EP Application No. 02 012 552.2, filed June 5, 2002, entitled "Light Emitting

-2-

Microorganisms and Cells for Diagnosis and Therapy of Diseases associated with wounded or inflamed tissue." Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

FIELD OF THE INVENTION

5 Vaccines that contain attenuated or modified microorganisms, including microbes and cells, and methods for preparing the microorganisms and vaccines are provided. In particular, modified bacteria, eukaryotic cells and viruses are provided and methods of use thereof for treatment of proliferative and inflammatory disorders and for production of products in tumors are provided.

10 BACKGROUND

In the late 19th century, a variety of attempts were made to treat cancer patients with microorganisms. One surgeon, William Coley, administered live *Streptococcus pyogenes* to patients with tumors with limited success. In the early 20th century, scientists documented vaccinia viral oncolysis in mice, which lead to 15 administration of several live viruses to patients with tumors from the 1940s through the 1960s. These forays into this avenue of cancer treatment were not successful.

Since that time, a variety of genetically engineered viruses have been tested for treatment of cancers. In one study, for example, nude mice bearing 20 nonmetastatic colon adenocarcinoma cells were systemically injected with a WR strain of vaccinia virus modified by having a vaccinia growth factor deletion and an enhanced green fluorescence protein inserted into the thymidine kinase locus. The virus was observed to have antitumor effect, including one complete response, despite a lack of exogenous therapeutic genes in the modified virus (McCart *et al.* (2001) *Cancer Res* 1:8751-8757). In another study, vaccinia melanoma oncolysate 25 (VMO) was injected into sites near melanoma positive lymph nodes in a Phase III clinical trial of melanoma patients. As a control, New York City Board of Health strain vaccinia virus (VV) was administered to melanoma patients. The melanoma patients treated with VMO had a survival rate better than that for untreated patients, but similar to patients treated with the VV control (Kim *et al.* (2001) *Surgical Oncol* 30 10:53-59).

-3-

Other studies have demonstrated limited success with this approach. This therapy is not completely effective, particularly for systemically delivered viruses or bacteria. Limitations on the control of microbial vehicle function in vivo result in ineffective therapeutic results as well as raising safety concerns. It would be
5 desirable to improve this type of therapy or to develop more effective approaches for treatments of neoplastic disease. Therefore, among the objects herein, it is an object to provide therapeutic methods and microorganisms for the treatment of neoplastic and other diseases.

SUMMARY

10 Provided herein are therapeutic methods and microorganisms, including viruses, bacteria and eukaryotic cells, for uses in the methods for the treatment of neoplastic diseases and other diseases. Diseases for treatment are those in which the targeted tissues and/or cells are immunoprivileged in that they, and often the local environment thereof, somehow escape or are inaccessible to the immune system.
15 Such tissues include tumors and other tissues and cells involved in other proliferative disorders, wounds and other tissues involved in inflammatory responses. The microorganisms, which include bacterial cells, viruses and mammalian cells, are selected or are designed to be non-pathogenic and to preferentially accumulate in the immunoprivileged tissues. The microorganisms,
20 once in the tissues or cells or vicinity thereof, affect the cell membranes of the cells in such tissues so that they become leaky or lyse, but sufficiently slowly so that the targeted cells and tumors leak enough antigen or other proteins for a time sufficient to elicit an immune response.

The microorganisms are administered by any route, including systemic
25 administration, such as i.v. or using oral or nasal or other delivery systems that direct agents to the lymphatics. In exemplary methods, the microorganisms are used to treat tumors and to prevent recurrence and metastatic spread. Exemplary microorganisms include highly attenuated viruses and bacteria, as well as mammalian cells. The microorganisms are optionally modified to deliver other
30 products, including other therapeutic products to the targeted tissues.

-4-

When the microorganisms are administered to a host that contains tumors, the tumors in the host essentially become antigen and protein factories. This can be exploited so that the tumors can be used to produce proteins or other cellular products encoded by or produced by the microorganisms. In addition, the host sera 5 can be harvested to isolate antibodies to products produced by the microorganisms as well as the tumor cells. Hence also provided are methods for producing gene products by administering the microorganisms to an animal, generally a non-human animal, and harvesting the tumors to isolate the product. Also provided are methods for producing antibodies to selected proteins or cell products, such as metabolites or 10 intermediates, by administering a microorganism that expresses or produces the protein or other product to a host, typically a non-human host; and harvesting serum from the host and isolating antibodies that specifically bind to the protein or other product.

Thus provided are methods and microorganisms for elimination of 15 immunoprivileged cells or tissues, particularly tumors. The methods include administration, typically systemic administration, with a microorganism that preferentially accumulates in immunoprivileged cells, such as tumor cells, resulting in leakage proteins and other compounds, such as tumor antigens, resulting in vaccination of the host against non-host proteins and, such as the tumor antigens, 20 providing for elimination of the immunoprivileged cells, such as tumor cells, by the host's immune system. The microorganisms are selected not for their ability to rapidly lyse cells, but rather for the ability accumulate in immunoprivileged cells, such as tumors, resulting in a leakage of antigens in a sufficient amount and for a sufficient time to elicit an immune response.

Hence provided are uses of microorganism or cell containing heterologous 25 DNA, polypeptides or RNA to induce autoimmunization of an organism against a tumor. In particular, the microorganisms are selected or designed to accumulate in tumors and to accumulate very little, if at all (to be non-toxic to the host) in non-tumorous cells, tissues or organs, and to in some manner result in the tumor cell 30 lyses or cell membrane disruption such that tumor antigens leak. Exemplary of such

-5-

microorganism are the LIVP-derived vaccinia virus and the bacteria described herein and also mammalian cells modified to target the tumors and to disrupt the cells membrane. The microorganisms can be modified to express heterologous products that mediate or increase the leakage of the tumor cell antigens and/or that are therapeutic, such as anti-tumor compounds.

5 Also provided are methods for production of antibodies against a tumor by (a) injecting a microorganism or cell containing a DNA sequence encoding a desired polypeptide or RNA into an organism bearing a tumor and (b) isolating antibodies against the tumor.

10 Provided are attenuated microorganisms that accumulate in immunoprivileged tissues and cells, such as tumor cells, but do not accumulate to toxic levels in non-targeted organs and tissues, and that upon administration to an animal bearing the immunoprivileged tissues and cells, result in autoimmunity, such as by production of anti-tumor (or anti-tumor antigen) antibodies against the 15 immunoprivileged cells or products thereof. The microorganisms are selected or produced to render the immunoprivileged cells leaky, such as by a slow lysis or apoptotic process. The goal is to achieve such leakiness, but to not lyse the cells so rapidly that the host cannot mount an immune response.

20 Uses of and methods of use of the microorganisms for eliminating immunoprivileged are provided. The microorganisms optionally include reporter genes and/or other heterologous nucleic acids that disrupt genes in the microorganism and can also encode and provide therapeutic products or products, such as RNA, including RNAi, that alter gene and/or protein expression in the cells 25 or tissues where the microorganism accumulates. Among the viruses provided are attenuated pox viruses that contain a modified TK and HA gene and a modified F3 gene or locus that corresponds to the F3 gene in vaccinia. In particular, provided are recombinant vaccinia viruses that contain a modified TK and HA gene and optionally a modified F3 gene or locus, wherein the resulting virus does not accumulate to toxic levels in non-targeted organs. Vaccinia viruses where the TK gene and F3 30 gene are modified and vaccinia viruses where the HA and F3 gene are modified, and

-6-

viruses where all three genes are modified are provided. Modification includes inactivation by insertion, deletion or replacement of one or more nucleotide bases whereby an activity or product of the virus is altered. Included among the alterations is insertion of heterologous nucleic acid, such as therapeutic protein-
5 encoding nucleic acids.

In exemplary embodiments, the vaccinia viruses are Lister strain viruses, particularly LIVP strain viruses (LIVP refers to the Lister virus from the Institute of Viral Preparations, Moscow, Russia, the original source for this now widely disseminated virus strain). Modifications include modification of the virus at the
10 unique *NotI* site in the locus designed F3. In particular, the modification is at position 35 of the F3 gene or at position 1475 inside of the HindIII-F fragment of vaccinia virus DNA strain LIVP.

The heterologous nucleic acid can include regulatory sequence operatively linked to the nucleic acid encoding the protein. Regulatory sequences include
15 promoters, such as the vaccinia virus early/late promoter p7.5. and an early/late vaccinia pE/L promotor. The heterologous nucleic acid in the microorganism can encoded a detectable protein or a product capable of inducing a detectable signal. Inclusion of detectable protein or a product that can generate a detectable signal permits monitoring of the distribution of the administered microorganism as well as
20 monitoring therapeutic efficacy, since the microorganism will be eliminated when the immprivileged cells are eliminated.

Host cells containing the recombinant viruses, such as the triple mutant vaccinia virus exemplified herein are provided. Also contemplated are tumor cells that contain any of the microorganisms provided herein or used in the methods.

25 Pharmaceutical composition containing the microorganisms in a pharmaceutically acceptable vehicle for use in the methods herein are provided. The pharmaceutical compositions can be formulated for any mode of administration, including, but not limited to systemic administration, such as for intravenous administration or is formulated. The compositions can contain a delivery

vehicle, such as a lipid-based carrier, including liposomes and micelles associated with the microorganism.

Also provided are methods (and uses of the microorganisms) for eliminating immunoprivileged cells, such as tumor cells in an animal, by administering the pharmaceutical compositions to an animal, whereby the virus accumulates in the immunoprivileged cells, thereby mediating autoimmunization resulting in elimination of the cells or a reduction in their number

Therapeutic methods for eliminating immunoprivileged cells or tissues, in an animal, by administering a microorganism to an animal, where the microorganism accumulates in the immunoprivileged cells; the microorganism does not accumulate in unaffected organs and tissues and has low toxicity in the animal; and the microorganism results in leakage of the cell membranes in the immunoprivileged cells, whereby the animal produces autoantibodies against the cells or products of the cells are provided. These methods include tumor treatment, treatment for inflammatory conditions, including wounds, and proliferative disorders, including psoriasis, cancers, diabetic retinopathies, restinosis and other such disorders. It is desirable for the microorganisms to not accumulate in unaffected organs, particularly the ovaries or testes

The microorganisms attenuated bacteria, an attenuated viruses and mammalian cells, such as pox viruses and other cytoplasmid viruses, bacterial such as vibrio, E. coli, salmonella, streptococcus and listeria and mammalian cells, such as immune cells, including B cells and lymphocytes, such as TIL cells, and stem cells.

Methods for a recombinant vaccinia virus by : (a) generating (i) a vaccinia shuttle plasmid containing the modified F3 gene inserted at restriction site x and (ii) a dephosphorylated wt VV (VGL) DNA digested at a restriction site; transfecting host cells infected with psoralen -UV (PUV)-inactivated helper VV (VGL) with a mixture of constructs (i) and (ii) of step a; and (c) isolating the recombinant vaccinia viruses from the transfectants. Host cells include CV-1 cells.

-8-

Also provided are methods for production of a polypeptide or RNA or compound, such as a cellular product and uses of the microorganism therefore are provided. Such methods can include the steps of : (a) administering a microorganism containing nucleic acid encoding the polypeptide or RNA or 5 producing the product compound to tumor-bearing animal, where the microorganism accumulates in the immunoprivileged cells; and the microorganism does not accumulate to toxic levels in organs and tissues that do not comprise immunoprivileged cells or tissues; (b) harvesting the tumor tissue from the the animal; and (c) isolating the polypeptide or RNA or compound from the tumor.

As noted, the microorganisms include eukaryotic cells, prokaryotic cells and viruses., such as a cytoplasmic virus or an attenuated bacterium or a stem cell or an immune cell. The bacterium can be selected from among attenuated *vibrio*, *E. coli*, *lysteria*, *salmonella* and *streptococcus* strains. The microorganism can express or produce detectable products, such as a fluorescent protein (*i.e.*, green, red and 15 blue fluorescent proteins and modified variants thereof), and/or luciferase which, when contacted with a Lucifer produces light, and also can encode additional products, such as therapeutic products. In the methods and uses provided herein, the animals can be non-human animals or can include humans.

Also provide are methods for simultaneously producing a polypeptide, 20 RNA molecule or cellular compound and an antibody that specifically reactions with the polypeptide, RNA molecule or compound, by: a) administering a microorganism to a tumor-bearing animal, wherein the microorganism expresses or produces the compoiund, polypeptide or RNA molecule; and b) isolating the antibody from serum in the animal. The method optionally includes, after step a) 25 harvesting the tumor tissue from the animal; and isolating the polypeptide, RNA molecule or cellular compound from the tumor tissue.

Also provided are methods for eliminating immunoprivileged cells or tissues in an animal, such as tumor cells, and uses of the microorganisms therefore by administering at least two microorganisms, wherein the microorganisms are 30 administered simultaneously, sequentially or intermittently, wherein the

microorganisms accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues.

Use of at least two microorganism for formulation of a medicament for elimination of immunoprivileged cells or tissues, wherein the accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues are provided. Combinations containing at least two microorganisms formulated for administration to an animal for elimination of immunoprivileged cells or tissues are provided. Kits containing packaged combination optionally with instructions for administration and other reagents are provided.

Uses of a microorganism encoding heterologous nucleic acid for inducing autoimmunization against products produced in immunoprivileged cells, wherein, when administered, the microorganism accumulates in immunoprivileged tissues and does not accumulate or accumulates at a sufficiently low level in other tissues or organs to be non-toxic to an animal containing the immunoprivileged tissues are provided.

Methods for the production of antibodies against products produced in immunoprivileged tissues or cells by: (a) administering a microorganism containing nucleic acid encoding a selected protein or RNA into an animal containing the immunoprivileged tissues or cells ; and (b) isolating antibodies against the protein or RNA from the blood or serum of the animal are provided.

Also provided are methods for inhibiting growth of immunoprivileged cells or tissue in a subject by: (a) administering to a subject a modified microorganism, wherein the modified microorganism encodes a detectable gene product; (b) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and (c) administering to a subject a therapeutic compound that works in conjunction with the microorganism to inhibit growth of immunoprivileged cells or tissue or by: (a) administering to a subject a modified microorganism that encodes a detectable gene product; (b) administering to a subject

-10-

a therapeutic substance that reduces the pathogenicity of the microorganism; (c) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and (d) terminating or suspending administration of the
5 therapeutic compound, whereby the microorganism increases in pathogenicity and the growth of the immunoprivileged cells or tissue is inhibited.

DESCRIPTION OF THE FIGURES

Figure 1A: Schematic representation of the recombinant vaccinia virus RVGL8 used. The recombinant vaccinia virus RVGL8 was constructed by using the in vivo recombination method described in Example 1. The complex of wild-type vaccinia virus DNA digested with *NotI* and non-digested plasmid DNA pNZ2 was transfected for in vivo recombination into PUV-VV-infected cells. VGL, wild type vaccinia virus (strain Lister ATCC VR-1549); RVGL8, recombinant vaccinia virus encoding the lacZ gene in the *NotI* site; Not_L and Not_R, left and right segments of unique *NotI* restriction site in vaccinia virus genome.; pE/L, synthetic early/late vaccinia virus promoter; p7.5, early/late vaccinia virus promoter; lacZ, lacZ gene of *E. coli*.

Figure 1B: Schematic of the various vaccinia strains described in the Examples. Results achieved the viruses are described in the Examples.
20 Figure 2 sets forth a flow chart for a method for producing products, such as nucleic acid molecules, proteins and metabolic compounds or other cellular products in tumors.

DETAILED DESCRIPTION

- A. Definitions
- B. Microorganisms for Tumor-Specific Therapy
 - B. Microorganisms for Tumor-Specific Therapy
 - 1. Characteristics
 - a. Attenuated
 - i. Reduced toxicity
 - ii. Accumulate in tumor, not substantially in other organs
 - iii. Ability to Elicit or Enhance Immune Response to Antigens
 - iv. Balance of Pathogenicity and Release of Tumor

-11-

- b. Immunogenicity
 - c. Replication Competent
 - d. Genetic Variants
 - i. Modified Characteristics
 - ii. Exogenous Gene Expression
 - iii. Detectable gene product
 - iv. Therapeutic gene product
 - v. Expressing a superantigen
 - vi. Expressing a gene product to be harvested
- 5 10 15 20 25 30 35 40 45 50 10 15 20 25 30 35 40 45 50 2. Viruses
 - a. Cytoplasmic viruses
 - i. Poxviruses
 - a. Vaccinia Virus
 - b. Modified Vaccinia Viruses
 - c. The F3 Gene
 - d. Multiple Modifications
 - e. The Lister Strain
 - ii. Other cytoplasmic viruses
 - b. Adenovirus, Herpes, Retroviruses
- 3. Bacteria
 - a. Aerobic bacteria
 - b. Anaerobic bacteria
- 4. Eukaryotic cells

- C. Methods for Making an Attenuated Microorganism
- 1. Genetic Modifications
- 2. Screening for above characteristics
- 3. Methods for developing such a microorganism in humans
- D. Therapeutic Methods
- 1. Administration
 - a. Steps prior to administering the microorganism
 - b. Mode of administration
 - c. Dosage
 - d. Number of administrations
 - e. Co-administrations
 - i. Administering a plurality of microorganisms
 - ii. Therapeutic compounds
 - f. State of subject
- 2. Monitoring
 - a. Monitoring microorganismal gene expression
 - b. Monitoring tumor size
 - c. Monitoring antibody titer
 - d. Monitoring general health diagnostics
 - e. Monitoring coordinated with treatment
- E. Methods of Producing Gene Products and Antibodies
- 1. Production of Recombinant Proteins and RNA molecules
- 2. Production of Antibodies
- F. Pharmaceutical Compositions, combinations and kits
- 1. Pharmaceutical Compositions
- 2. Host Cells
- 3. Combinations
- 4. Kits
- G. Examples
- A. Definitions

-12-

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information is known and can be readily accessed, such as by searching the internet and/or appropriate databases. Reference thereto evidences the availability and public dissemination of such information.

As used herein, microorganisms refers to isolated cells or viruses, including eukaryotic cells, such as mammalian cells, viruses and bacteria. The microorganisms are modified or selected for their ability to accumulate in tumors and other immunoprivileged cells and tissues, and to minimize accumulation in other tissues or organs. Accumulation occurs by virtue of selection or modification of the microorganisms for particular traits or by proper selection of cells. The microorganism can be further modified to alter a trait thereof and/or to deliver a gene product. The microorganisms provided herein are typically modified relative to wild type to exhibit one or more characteristics such as reduced pathogenicity, reduced toxicity, preferential accumulation in tumor relative to normal organs or tissues, increased immunogenicity, increased ability to elicit or enhance an immune response to tumor cells, increased lytic or tumor cell killing capacity, decreased lytic or tumor cell killing capacity.

As used herein, immunoprivileged cells and tissues refer to cells and tissues, such as solid tumors and wounded tissues, which are sequestered from the immune system. Generally administration of a microorganism elicits an immune response that clears the microorganism; immunoprivileged sites, however, are shielded or sequestered from the immune response, permitting the microorganisms to survive

-13-

and generally to replicate. Immunoprivileged tissues include inflamed tissues, such as wounded tissues, and proliferating tissues, such as tumor tissues.

As used herein, "modified" with reference to a gene refers to a deleted gene, or a gene encoding a gene product having one or more truncations, mutations, 5 insertions or deletions, typically accompanied by at least a change, generally a partial loss of function.

As used herein F3 gene refers to a gene or locus in a virus, such as a vaccinia virus, that corresponds to the F3 gene of vaccinia virus strain LIVP. This includes the F3 gene of any vaccinia virus strain or poxvirus encoding a gene product having substantially the same or at least a related biological function or locus in the 10 genome. F3 genes encompassed herein typically have at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity along the full 15 length of the sequence of nucleotides set forth in SEQ ID No:1. The proteins encoded by F3 genes encompassed herein typically have at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the sequence 20 of amino acids set forth SEQ ID No. 2 along the full length thereof. Also included are corresponding loci in other viruses that when modified or eliminated result in reduced toxicity and/or enhanced accumulation in tumors (compared to non-tumorous cells, tissues and organs). The corresponding loci in other viruses equivalent to the F3 gene in LIVP can be determined by the structural location of the 25 gene in the viral genome: the LIVP F3 gene is located on the HindIII-F fragment of vaccinia virus between open reading frames F14L and F15L as defined by Goebel *et al.*, Virology (1990) 179:247-266, and in the opposite orientation of ORFs F14L and F15L; thus corresponding loci in other viruses such as poxviruses including orthopoxviruses are included.

-14-

As used herein, attenuate toxicity of a microorganism means to reduce or eliminate deleterious or toxic effects to a host upon administration of the microorganism compared to the unattenuated microorganism.

As used herein, a microorganism with low toxicity means that upon 5 administration a microorganism does not accumulate in organs and tissues in the host to an extent that results in damage or harm to organs or that impact on survival of the host to a greater extent than the disease being treated does.

As used herein, subject (or organism) refers to an animal, including a human being.

10 As used herein, animal includes any animal, such as, but are not limited to primates including humans, gorillas and monkeys; rodents, such as mice and rats; fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; ovine, and other animals including pigs, horses, cats, dogs, and rabbits. Non-human animals exclude humans as the contemplated animal.

15 As used herein, accumulation of a microorganism in a targeted tissue refers to the distribution of the microorganism throughout the organism after a time period long enough for the microbes to infect the host's organs or tissues. As one skilled in the art will recognize, the time period for infection of a microbe will vary depending on the microbe, the targeted organ(s) or tissue(s), the immunocompetence of the 20 host, and dosage. Generally, accumulation can be determined at time point from about 1 day to about 1 week after infection with the microbes. For purposes herein, the microorganisms preferentially accumulate in the target tissue, such as a tumor, but are cleared from other tissues and organs in the host to the extent that toxicity of the microorganism is mild or tolerable and at most not fatal.

25 As used herein, preferential accumulation refers to accumulation of a microorganism at a first location at a higher level than accumulation at a second location. Thus, a microorganism that preferentially accumulates in immunoprovileged tissue such as tumor relative to normal tissues or organs refers to a microorganism that accumulates in immunoprovileged tissue such as tumor at 30 a higher level than the microorganism accumulates in normal tissues or organs.

-15-

As used herein, a "compound" produced in a tumor or other immunoprivileged site refers to any compound that is produced in the tumor by virtue of the presence of an introduced microorganism, generally a recombinant microorganism, expressing one or more genes. For example, a compound produced
5 in a tumor can be, for example, a metabolite, an encoded polypeptide or RNA, or compound that is generated by a recombinant polypeptide (e.g., enzyme) and the cellular machinery of the tumor or immunoprivileged tissue or cells.

As used herein, a delivery vehicle for administration refers to a lipid-based or other polymer based composition, such as liposome, micell or reverse micelle, that
10 associates with an agent, such as a microorganism provided herein, for delivery into a host animal.

As used herein, the term "viral vector" is used according to its art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral
15 vector particles can be used for the purpose of transferring DNA, RNA or other nucleic acids into cells either in vitro or in vivo. Viral vectors include, but are not limited to, retroviral vectors, vaccinia vectors, lentiviral vectors, herpes virus vectors (e.g., HSV), baculoviral vectors, cytomegalovirus (CMV) vectors, papillomavirus vectors, simian virus (SV40) vectors, vectors, semliki forest virus vectors, phage
20 vectors, adenoviral vectors, and adeno-associated viral (AAV) vectors.

As used herein, oncolytic viruses refer to viruses that replicate selectively in tumor cells.

As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from, e.g., infection or genetic defect, and characterized by
25 identifiable symptoms.

As used herein, neoplasm (neoplasia) refers to abnormal new growth, and thus means the same as tumor, which can be benign or malignant. Unlike hyperplasia, neoplastic proliferation persists even in the absence of the original stimulus.

-16-

As used herein, neoplastic disease refers to any disorder involving cancer, including tumor development, growth, metastasis and progression.

As used herein, cancer is a general term for diseases caused by or characterized by any type of malignant tumor.

5 As used herein, malignant, as applies to tumors, refers to primary tumors that have the capacity of metastasis with loss of growth control and positional control.

As used herein, metastasis refers to a growth of abnormal or neoplastic cells distant from the site primarily involved by the morbid process.

10 As used herein, an anti-cancer agent or compound (used interchangeably with "anti-tumor or anti-neoplastic agent") refers to any agents or compounds used in anti-cancer treatment. These include any agents, when used alone or in combination with other compounds, that can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with neoplastic disease, tumors and cancer, and can be used in
15 methods, combinations and compositions provided herein. Exemplary anti-neoplastic agents include the microorganism provided herein used singly or in combination and/or in combination with other agents, such as alkylating agents, antimetabolite, certain natural products, platinum coordination complexes, anthracenediones, substituted ureas, methylhydrazine derivatives, adrenocortical suppressants, certain hormones, zantagonists and anti-cancer polysaccharides.
20

25 In general, for practice of the methods herein and when using the microorganisms provided herein, the original tumor is not excised, but is employed to accumulate the administered microorganism and as the cells become leaky or lyse to become an antigen or other product factor. The antigens can serve to elicit an immune response in the host. The antigens and products can be isolated from the tumor.

As used herein, angiogenesis is intended to encompass the totality of processes directly or indirectly involved in the establishment and maintenance of new vasculature (neovascularization), including, but not limited to,

-17-

neovascularization associated with tumors and neovascularization associated with wounds.

As used herein, by homologous means about greater than 25% nucleic acid sequence identity, such as 25%, 40%, 60%, 70%, 80%, 90% or 95%. If necessary 5 the percentage homology will be specified. The terms "homology" and "identity" are often used interchangeably but homology for proteins can include conservative amino acid changes. In general, sequences (protein or nucleic acid) are aligned so that the highest order match is obtained (see, e.g.: Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 10 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carillo *et al.* (1988) 15 SIAM J Applied Math 48:1073). By sequence identity, the number of identical amino acids is determined by standard alignment algorithm programs, and used with default gap penalties established by each supplier. Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80% 20 or 90% of the full length nucleic acid molecule of interest. Also provided are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule. (For proteins, for determination of homology conservative amino acids can be aligned as well as identical amino acids; in this case percentage of identity and percentage homology vary). Whether any two nucleic 25 acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FASTA" program, using for example, the default parameters as in Pearson *et al.* (1988) Proc. Natl. Acad. Sci. USA 85:2444 (other programs 30 include the GCG program package (Devereux, J., *et al.*, Nucleic Acids Research 12(I):387 (1984)), BLASTP, BLASTN, FASTA Atschul, S.F., *et al.*, J Molec Biol

-18-

215:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo *et al.* (1988) SIAM J Applied Math 48:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly
5 available programs include, DNASTar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI). Percent homology or identity of proteins and/or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (*e.g.*, Needleman *et al.* (1970) J. Mol. Biol. 48:443,
10 as revised by Smith and Waterman ((1981) Adv. Appl. Math. 2:482).

Briefly, a GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) that are similar, divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for
15 identities and 0 for non-identities) and the weighted comparison matrix of Gribskov *et al.* (1986) Nucl. Acids Res. 14:6745, as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.
20 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide.

As used herein, recitation that amino acids of a polypeptide correspond to amino acids in a disclosed sequence, such as amino acids set forth in the Sequence listing, refers to amino acids identified upon alignment of the polypeptide with the
25 disclosed sequence to maximize identity or homology (where conserved amino acids are aligned) using a standard alignment algorithm, such as the GAP algorithm.

As used herein, the term "at least 90% identical to" refers to percent identities from 90 to 100% relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes
30 a test and reference polynucleotide length of 100 amino acids are compared, no

-19-

more than 10% (*i.e.*, 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or
5 they can be clustered in one or more locations of varying length up to the maximum allowable, *e.g.*, 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of
10 identity can be assessed readily, often without relying on software.

As used herein, primer refers to an oligonucleotide containing two or more deoxyribonucleotides or ribonucleotides, typically more than three, from which synthesis of a primer extension product can be initiated. Experimental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent
15 for polymerization and extension, such as DNA polymerase, and a suitable buffer, temperature and pH.

As used herein, chemiluminescence refers to a chemical reaction in which energy is specifically channeled to a molecule causing it to become electronically excited and subsequently to release a photon thereby emitting visible light.
20 Temperature does not contribute to this channeled energy. Thus, chemiluminescence involves the direct conversion of chemical energy to light energy.

As used herein, luminescence refers to the detectable EM radiation, generally, UV, IR or visible EM radiation that is produced when the excited product
25 of an exergic chemical process reverts to its ground state with the emission of light. Chemiluminescence is luminescence that results from a chemical reaction. Bioluminescence is chemiluminescence that results from a chemical reaction using biological molecules (or synthetic versions or analogs thereof) as substrates and/or enzymes.

-20-

As used herein, bioluminescence, which is a type of chemiluminescence, refers to the emission of light by biological molecules, particularly proteins. The essential condition for bioluminescence is molecular oxygen, either bound or free in the presence of an oxygenase, a luciferase, which acts on a substrate, a luciferin.

5 Bioluminescence is generated by an enzyme or other protein (luciferase) that is an oxygenase that acts on a substrate luciferin (a bioluminescence substrate) in the presence of molecular oxygen, and transforms the substrate to an excited state, which, upon return to a lower energy level releases the energy in the form of light.

10 As used herein, the substrates and enzymes for producing bioluminescence are generically referred to as luciferin and luciferase, respectively. When reference is made to a particular species thereof, for clarity, each generic term is used with the name of the organism from which it derives, for example, bacterial luciferin or firefly luciferase.

15 As used herein, luciferase refers to oxygenases that catalyze a light emitting reaction. For instance, bacterial luciferases catalyze the oxidation of flavin mononucleotide (FMN) and aliphatic aldehydes, which reaction produces light. Another class of luciferases, found among marine arthropods, catalyzes the oxidation of Cypridina (Vargula) luciferin, and another class of luciferases catalyzes the oxidation of Coleoptera luciferin.

20 Thus, luciferase refers to an enzyme or photoprotein that catalyzes a bioluminescent reaction (a reaction that produces bioluminescence). The luciferases, such as firefly and *Gaussia* and *Renilla* luciferases, are enzymes which act catalytically and are unchanged during the bioluminescence generating reaction. The luciferase photoproteins, such as the aequorin photoprotein to which luciferin is 25 non-covalently bound, are changed, such as by release of the luciferin, during bioluminescence generating reaction. The luciferase is a protein that occurs naturally in an organism or a variant or mutant thereof, such as a variant produced by mutagenesis that has one or more properties, such as thermal stability, that differ from the naturally-occurring protein. Luciferases and modified mutant or variant

-21-

forms thereof are well known. For purposes herein, reference to luciferase refers to either the photoproteins or luciferases.

Thus, reference, for example, to "Renilla luciferase" means an enzyme isolated from member of the genus Renilla or an equivalent molecule obtained from 5 any other source, such as from another related copepod, or that has been prepared synthetically. It is intended to encompass Renilla luciferases with conservative amino acid substitutions that do not substantially alter activity. Suitable conservative substitutions of amino acids are known to those of skill in this art and can be made generally without altering the biological activity of the resulting 10 molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson *et al.* Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224).

As used herein, "Aequora GFP" refers to GFPs from the genus Aequora and 15 to mutants or variants thereof. Such variants and GFPs from other species are well known and are available and known to those of skill in the art. This nomenclature encompasses GFPs with conservative amino acid substitutions that do not substantially alter activity and physical properties, such as the emission spectra and ability to shift the spectral output of bioluminescence generating systems. The luciferases and 20 luciferin and activators thereof are referred to as bioluminescence generating reagents or components. Typically, a subset of these reagents will be provided or combined with an article of manufacture. Bioluminescence will be produced upon contacting the combination with the remaining reagents. Thus, as used herein, the component luciferases, luciferins, and other factors, such as O₂, Mg²⁺, Ca²⁺ are also 25 referred to as bioluminescence generating reagents (or agents or components).

As used herein, bioluminescence substrate refers to the compound that is oxidized in the presence of a luciferase, and any necessary activators, and generates light. These substrates are referred to as luciferins herein, are substrates that undergo oxidation in a bioluminescence reaction. These bioluminescence substrates 30 include any luciferin or analog thereof or any synthetic compound with which a

-22-

luciferase interacts to generate light. Typical substrates include those that are oxidized in the presence of a luciferase or protein in a light-generating reaction. Bioluminescence substrates, thus, include those compounds that those of skill in the art recognize as luciferins. Luciferins, for example, include firefly luciferin,
5 Cypridina (also known as Vargula) luciferin (coelenterazine), bacterial luciferin, as well as synthetic analogs of these substrates or other compounds that are oxidized in the presence of a luciferase in a reaction that produces bioluminescence.

As used herein, capable of conversion into a bioluminescence substrate means susceptible to chemical reaction, such as oxidation or reduction, that yields a
10 bioluminescence substrate. For example, the luminescence producing reaction of bioluminescent bacteria involves the reduction of a flavin mononucleotide group (FMN) to reduced flavin mononucleotide (FMNH₂) by a flavin reductase enzyme. The reduced flavin mononucleotide (substrate) then reacts with oxygen (an activator) and bacterial luciferase to form an intermediate peroxy flavin that
15 undergoes further reaction, in the presence of a long-chain aldehyde, to generate light. With respect to this reaction, the reduced flavin and the long chain aldehyde are substrates.

As used herein, a bioluminescence generating system refers to the set of reagents required to conduct a bioluminescent reaction. Thus, the specific
20 luciferase, luciferin and other substrates, solvents and other reagents that can be required to complete a bioluminescent reaction form a bioluminescence system. Thus a bioluminescence generating system refers to any set of reagents that, under appropriate reaction conditions, yield bioluminescence. Appropriate reaction conditions refers to the conditions necessary for a bioluminescence reaction to occur, such as pH, salt concentrations and temperature. In general, bioluminescence systems include a bioluminescence substrate, luciferin, a luciferase, which includes enzymes luciferases and photoproteins, and one or more activators. A specific bioluminescence system may be identified by reference to the specific organism from which the luciferase derives; for example, the Renilla bioluminescence system
25 includes a Renilla luciferase, such as a luciferase isolated from the Renilla or
30

produced using recombinant means or modifications of these luciferases. This system also includes the particular activators necessary to complete the bioluminescence reaction, such as oxygen and a substrate with which the luciferase reacts in the presence of the oxygen to produce light.

5 As used herein, a fluorescent protein refers to a protein that possesses the ability to fluoresce (*i.e.*, to absorb energy at one wavelength and emit it at another wavelength). For example, a green fluorescent protein refers to a polypeptide that has a peak in the emission spectrum at about 510 nm.

As used herein, genetic therapy or gene therapy involves the transfer of 10 heterologous nucleic acid, such as DNA, into certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The nucleic acid, such as DNA, is introduced into the selected target cells, such as directly or in a vector or other delivery vehicle, in a manner such that the heterologous nucleic acid, such as DNA, is expressed and a therapeutic product 15 encoded thereby is produced. Alternatively, the heterologous nucleic acid, such as DNA, can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy also can be used to deliver nucleic acid encoding a gene product that replaces a 20 defective gene or supplements a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid can encode a therapeutic compound, such as a growth factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a 25 therapeutically useful time. The heterologous nucleic acid, such as DNA, encoding the therapeutic product can be modified prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof. Genetic therapy also can involve delivery of an inhibitor or repressor or other modulator of gene expression.

-24-

As used herein, heterologous nucleic acid is nucleic acid that is not normally produced *in vivo* by the microorganism from which it is expressed or that is produced by a microorganism but is at a different locus or expressed differently or that mediates or encodes mediators that alter expression of endogenous nucleic acid,

5 such as DNA, by affecting transcription, translation, or other regulatable biochemical processes. Heterologous nucleic acid is often not endogenous to the cell into which it is introduced, but has been obtained from another cell or prepared synthetically. Heterologous nucleic acid, however, can be endogenous, but is nucleic acid that is expressed from a different locus or altered in its expression or

10 sequence. Generally, although not necessarily, such nucleic acid encodes RNA and proteins that are not normally produced by the cell or in the same way in the cell in which it is expressed. Heterologous nucleic acid, such as DNA, also can be referred to as foreign nucleic acid, such as DNA. Thus, heterologous nucleic acid or foreign nucleic acid includes a nucleic acid molecule not present in the exact orientation or

15 position as the counterpart nucleic acid molecule, such as DNA, is found in a genome. It also can refer to a nucleic acid molecule from another organism or species (*i.e.*, exogenous). Any nucleic acid, such as DNA, that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which the nucleic acid is expressed is herein encompassed by heterologous nucleic acid;

20 heterologous nucleic acid includes exogenously added nucleic acid that also is expressed endogenously. Examples of heterologous nucleic acid include, but are not limited to, nucleic acid that encodes traceable marker proteins, such as a protein that confers drug resistance, nucleic acid that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and nucleic acid,

25 such as DNA, that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous nucleic acid can be secreted or expressed on the surface of the cell in which the heterologous nucleic acid has been introduced.

As used herein, a therapeutically effective product for gene therapy is a product that is encoded by heterologous nucleic acid, typically DNA, (or an RNA product such as dsRNA, RNAi, including siRNA, that, upon introduction of the

nucleic acid into a host, a product is expressed that ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures the disease. Also included are biologically active nucleic acid molecules, such as RNAi and antisense.

5 As used herein, cancer or tumor treatment or agent refers to any therapeutic regimen and/or compound that, when used alone or in combination with other treatments or compounds, can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with deficient angiogenesis.

10 As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double-stranded. When referring to probes or primers, which are optionally labeled, such as with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are provided. Such molecules are typically of a length such that 15 their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous nucleotides of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

20 As used herein, operative linkage of heterologous nucleic acid to regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences refers to the relationship between such nucleic acid, such as DNA, and such sequences of nucleotides. For example, operative linkage of heterologous DNA to a promoter refers to the physical 25 relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. Thus, operatively linked or operationally associated refers to the functional relationship of nucleic acid, such as DNA, with regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences.

-26-

For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. In order to optimize expression and/or in vitro transcription, it can be necessary to remove, add or alter 5' untranslated portions of the clones to eliminate extra, potentially inappropriate alternative translation initiation (*i.e.*, start) codons or other sequences that can interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites (see, *e.g.*, Kozak J. Biol. Chem. 10 266:19867-19870 (1991)) can be inserted immediately 5' of the start codon and can enhance expression. The desirability of (or need for) such modification can be empirically determined.

As used herein, a sequence complementary to at least a portion of an RNA, with reference to antisense oligonucleotides, means a sequence of nucleotides having sufficient complementarity to be able to hybridize with the RNA, generally under moderate or high stringency conditions, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA (or dsRNA) can thus be tested, or triplex formation can be assayed. The ability to hybridize depends on the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an encoding RNA it can contain and still form a stable duplex (or triplex, as the case can be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

As used herein, amelioration of the symptoms of a particular disorder such as by administration of a particular pharmaceutical composition, refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

As used herein, antisense polynucleotides refer to synthetic sequences of 30 nucleotide bases complementary to mRNA or the sense strand of double-stranded

-27-

DNA. Admixture of sense and antisense polynucleotides under appropriate conditions leads to the binding of the two molecules, or hybridization. When these polynucleotides bind to (hybridize with) mRNA, inhibition of protein synthesis (translation) occurs. When these polynucleotides bind to double-stranded DNA,
5 inhibition of RNA synthesis (transcription) occurs. The resulting inhibition of translation and/or transcription leads to an inhibition of the synthesis of the protein encoded by the sense strand. Antisense nucleic acid molecules typically contain a sufficient number of nucleotides to specifically bind to a target nucleic acid, generally at least 5 contiguous nucleotides, often at least 14 or 16 or 30 contiguous
10 nucleotides or modified nucleotides complementary to the coding portion of a nucleic acid molecule that encodes a gene of interest.

As used herein, antibody refers to an immunoglobulin, whether natural or partially or wholly synthetically produced, including any derivative thereof that retains the specific binding ability of the antibody. Hence antibody includes any
15 protein having a binding domain that is homologous or substantially homologous to an immunoglobulin binding domain. Antibodies include members of any immunoglobulin class, including IgG, IgM, IgA, IgD and IgE.

As used herein, antibody fragment refers to any derivative of an antibody that is less than full length, retaining at least a portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab)2, single-chain Fvs (scFV), FV, dsFV diabody and Fd fragments. The fragment can include multiple chains linked together, such as by disulfide bridges. An antibody fragment generally contains at least about 50 amino acids and typically at least 200 amino acids.
20

As used herein, a Fv antibody fragment is composed of one variable heavy chain domain (VH) and one variable light chain domain linked by noncovalent interactions.
25

As used herein, a dsFV refers to an Fv with an engineered intermolecular disulfide bond, which stabilizes the VH-VL pair.

-28-

As used herein, a F(ab)2 fragment is an antibody fragment that results from digestion of an immunoglobulin with pepsin at pH 4.0-4.5; it can be recombinantly produced to produce the equivalent fragment.

As used herein, Fab fragments are antibody fragments that result from 5 digestion of an immunoglobulin with papain; it can be recombinantly produced to produce the equivalent fragment.

As used herein, scFVs refer to antibody fragments that contain a variable light chain (VL) and variable heavy chain (VH) covalently connected by a polypeptide linker in any order. The linker is of a length such that the two variable 10 domains are bridged without substantial interference. Included linkers are (Gly-Ser)n residues with some Glu or Lys residues dispersed throughout to increase solubility.

As used herein, humanized antibodies refer to antibodies that are modified to include human sequences of amino acids so that administration to a human does not 15 provoke an immune response. Methods for preparation of such antibodies are known. For example, to produce such antibodies, the encoding nucleic acid in the hybridoma or other prokaryotic or eukaryotic cell, such as an E. coli or a CHO cell, that expresses the monoclonal antibody is altered by recombinant nucleic acid techniques to express an antibody in which the amino acid composition of the non-variable region is based on human antibodies. Computer programs have been 20 designed to identify such non-variable regions.

As used herein, diabodies are dimeric scFV; diabodies typically have shorter peptide linkers than scFVs, and they generally dimerize.

As used herein, production by recombinant means by using recombinant 25 DNA methods means the use of the well known methods of molecular biology for expressing proteins encoded by cloned DNA.

As used herein the term assessing or determining is intended to include quantitative and qualitative determination in the sense of obtaining an absolute value for the activity of a product, and also of obtaining an index, ratio, percentage, visual

-29-

or other value indicative of the level of the activity. Assessment can be direct or indirect.

As used herein, biological activity refers to the *in vivo* activities of a compound or microorganisms or physiological responses that result upon *in vivo* administration of thereof or of composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures. Biological activities can be observed in *in vitro* systems designed to test or use such activities.

As used herein, an effective amount of a microorganism or compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the disease. Such an amount can be administered as a single dosage or can be administered according to a regimen, whereby it is effective. The amount can cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Repeated administration can be required to achieve the desired amelioration of symptoms.

As used herein equivalent, when referring to two sequences of nucleic acids, means that the two sequences in question encode the same sequence of amino acids or equivalent proteins. When equivalent is used in referring to two proteins or peptides or other molecules , it means that the two proteins or peptides have substantially the same amino acid sequence with only amino acid substitutions (such as, but not limited to, conservative changes) or structure and the any changes do not substantially alter the activity or function of the protein or peptide. When equivalent refers to a property, the property does not need to be present to the same extent (e.g., two peptides can exhibit different rates of the same type of enzymatic activity), but the activities are usually substantially the same. Complementary, when referring to two nucleotide sequences, means that the two sequences of nucleotides are capable of hybridizing, typically with less than 25%, 15% or 5% mismatches between opposed nucleotides. If necessary, the percentage of complementarity will be specified. Typically the two molecules are selected such that they will hybridize under conditions of high stringency.

-30-

As used herein, an agent or compound that modulates the activity of a protein or expression of a gene or nucleic acid either decreases or increases or otherwise alters the activity of the protein or, in some manner, up- or down-regulates or otherwise alters expression of the nucleic acid in a cell.

5 As used herein, a method for treating or preventing neoplastic disease means that any of the symptoms, such as the tumor, metastasis thereof, the vascularization of the tumors or other parameters by which the disease is characterized are reduced, ameliorated, prevented, placed in a state of remission, or maintained in a state of remission. It also means that the hallmarks of neoplastic disease and metastasis can
10 be eliminated, reduced or prevented by the treatment. Non-limiting examples of the hallmarks include uncontrolled degradation of the basement membrane and proximal extracellular matrix, migration, division, and organization of the endothelial cells into new functioning capillaries, and the persistence of such functioning capillaries.

15 As used herein, a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, the pharmaceutically active compound is modified such that the active compound is regenerated by metabolic processes. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or
20 toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g., Nogradi (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press,
25 New York, pages 388-392).

As used herein, a promoter region or promoter element or regulatory region refers to a segment of DNA or RNA that controls transcription of the DNA or RNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription
30 initiation. This portion of the promoter region is referred to as the promoter. In

addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences can be cis acting or can be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, can be constitutive or regulated. Exemplary
5 promoters contemplated for use in prokaryotes include the bacteriophage T7 and T3 promoters.

As used herein, a receptor refers to a molecule that has an affinity for a ligand. Receptors can be naturally-occurring or synthetic molecules. Receptors also can be referred to in the art as anti-ligands. As used herein, the receptor and anti-ligand are interchangeable. Receptors can be used in their unaltered state or bound to other polypeptides, including as homodimers. Receptors can be attached to, covalently or noncovalently, or in physical contact with, a binding member, either directly or indirectly via a specific binding substance or linker. Examples of receptors, include, but are not limited to: antibodies, cell membrane receptors
10 surface receptors and internalizing receptors, monoclonal antibodies and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials), drugs, polynucleotides, nucleic acids, peptides, cofactors, lectins, sugars, polysaccharides, cells, cellular membranes, and organelles.
15

As used herein, sample refers to anything that can contain an analyte for which an analyte assay is desired. The sample can be a biological sample, such as a biological fluid or a biological tissue. Examples of biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like. Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure,
20 including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s).

As used herein: stringency of hybridization in determining percentage mismatch is as follows:

30 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C

-32-

2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C

3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C

Those of skill in this art know that the washing step selects for stable hybrids and also know the ingredients of SSPE (see, e.g., Sambrook, E.F. Fritsch, T.

5 Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), vol. 3, p. B.13, see, also, numerous catalogs that describe commonly used laboratory solutions). SSPE is pH 7.4 phosphate-buffered 0.18 M NaCl. Further, those of skill in the art recognize that the stability of hybrids is determined by Tm, which is a function of the sodium ion concentration and 10 temperature : ($T_m = 81.5 + C - 16.6(\log_{10}[Na^+]) + 0.41(\%G+C)-600/l$), so that the only parameters in the wash conditions critical to hybrid stability are sodium ion concentration in the SSPE (or SSC) and temperature. Any nucleic acid molecules provided herein can also include those that hybridize under conditions of at least low stringency, generally moderate or high stringency, along at least 70, 80, 90% of the 15 full length of the disclosed molecule. It is understood that equivalent stringencies can be achieved using alternative buffers, salts and temperatures. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, Proc. Natl. Acad. Sci. USA 78:6789-6792 (1981)):

20 Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μ g/ml denatured salmon sperm DNA (10X SSC is 1.5 M sodium chloride, and 0.15 M sodium citrate, adjusted to a pH of 7). Hybridizations are carried out in the same solution with the following 25 modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10^6 cpm 32 P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh 30 solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and

-33-

exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which can be used are well known in the art (e.g., as employed for cross-species hybridizations).

By way of example and not way of limitation, procedures using conditions of moderate stringency include, for example, but are not limited to, procedures using such conditions of moderate stringency as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 μ g/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10^6 cpm 32 P-labeled probe is used.

Filters are incubated in hybridization mixture for 18- 20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which can be used are well-known in the art. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.1% SDS.

By way of example and not way of limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μ g/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 μ g/ml denatured salmon sperm DNA and 5-20 X 10^6 cpm of 32 P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 minutes before autoradiography. Other conditions of high stringency which can be used are well known in the art.

The term substantially identical or homologous or similar varies with the context as understood by those skilled in the relevant art and generally means at least 60% or 70%, preferably means at least 80%, more preferably at least 90%, and most preferably at least 95%, 96%, 97%, 98%, 99% or greater identity.

-34-

As used herein, substantially identical to a product means sufficiently similar so that the property of interest is sufficiently unchanged so that the substantially identical product can be used in place of the product.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further purification might increase the specific activity of the compound.

As used herein, a molecule, such as an antibody, that specifically binds to a polypeptide typically has a binding affinity (K_a) of at least about 10^6 l/mol, 10^7 l/mol, 10^8 l/mol, 10^9 l/mol, 10^{10} l/mol or greater and binds to a protein of interest generally with at least 2-fold, 5-fold, generally 10-fold or even 100-fold or greater, affinity than to other proteins. For example, an antibody that specifically binds to the protease domain compared to the full-length molecule, such as the zymogen form, binds with at least about 2-fold, typically 5-fold or 10-fold higher affinity, to a polypeptide that contains only the protease domain than to the zymogen form of the full-length. Such specific binding also is referred to as selective binding. Thus, specific or selective binding refers to greater binding affinity (generally at least 2-fold, 5-fold, 10-fold or more) to a targeted site or locus compared to a non-targeted site or locus.

As used herein, the terms a therapeutic agent, therapeutic compound, therapeutic regimen, or chemotherapeutic include conventional drugs and drug therapies, including vaccines, which are known to those skilled in the art.

-35-

As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the microorganisms described and provided herein.

5 As used herein, proliferative disorders include any disorders involving abnormal proliferation of cells. Such disorders include, but are not limited to, neoplastic diseases, psoriasis, restenosis, macular degeneration, diabetic retinopathies, inflammatory responses and disorders, including wound healing responses.

10 As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial 15 chromosomes and mammalian artificial chromosomes. Selection and use of such vectors are well known to those of skill in the art. An expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA 20 construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

25 As used herein, a combination refers to any association between two or among more items.

As used herein, a composition refers to any mixture. It can be a solution, a suspension, an emulsion, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.

As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.

As used herein, a kit is a packaged combination optionally including
5 instructions for use of the combination and/or other reactions and components for such use.

For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow.

B. Microorganisms for Tumor-Specific Therapy

10 Provided herein are microorganisms, and methods for making and using such microorganisms for therapy of neoplastic disease and other proliferative disorders and inflammatory disorders. The microbe (or microorganism)-mediated treatment methods provided herein involve administration of microorganisms to hosts, accumulation of the microorganism in the targeted cell or tissue, such as in a tumor,
15 resulting in leaking or lysing of the cells, whereby an immune response against leaked or released antigens is mounted, thereby resulting in an inhibition of the tissues or cells in which the microorganism accumulates.

In addition to the gene therapeutic methods of cancer treatment, live
attenuated microorganisms can be used for vaccination, such as in cancer
20 vaccination or antitumor immunity. Immunization, for example, against a tumor can include a tumor-specific T-cell-mediated response through microbe-delivered antigens or cytokines. To do so, the microbes can be specifically targeted to the tumor tissues, with minimal infection to any other key organs and also can be modified or provided to produce the antigens and/or cytokines.

25 The microorganisms provided herein and the use of such microorganisms herein can accumulate in immunoprivileged cells or immunoprivileged tissues, including tumors and/or metastases, and also including wounded tissues and cells. While the microorganisms provided herein can typically be cleared from the subject to whom the microorganisms are administered by activity of the subject's immune system, microorganisms can nevertheless accumulate, survive and proliferate in
30

-37-

immunoprivileged cells and tissues such as tumors because such immunoprivileged areas are sequestered from the host's immune system. Accordingly, the methods provided herein, as applied to tumors and/or metastases, and therapeutic methods relating thereto, can readily be applied to other immunoprivileged cells and tissues,
5 including wounded cells and tissues.

1. Characteristics

The microorganisms provided herein and used in the methods herein are attenuated, immunogenic, and replication competent.

a. Attenuated

10 The microbes used in the methods provided herein are typically attenuated. Attenuated microbes have a decreased capacity to cause disease in a host. The decreased capacity can result from any of a variety of different modifications to the ability of a microbe to be pathogenic. For example, a microbe can have reduced toxicity, reduced ability to accumulate in non-tumorous organs or tissue, reduced
15 ability to cause cell lysis or cell death, or reduced ability to replicate compared to the non-attenuated form thereof. The attenuated microbes provided herein, however, retain at least some capacity to replicate and to cause immunoprivileged cells and tissues, such as tumor cells to leak or lyse, undergo cell death, or otherwise cause or enhance an immune response to immunoprivileged cells and tissues, such as tumor
20 cells.

i. Reduced toxicity

Microbes can be toxic to their hosts by manufacturing one or more compounds that worsen the health condition of the host. Toxicity to the host can be manifested in any of a variety of manners, including septic shock, neurological
25 effects, or muscular effects. The microbes provided herein can have a reduced toxicity to the host. The reduced toxicity of a microbe of the present methods and compositions can range from a toxicity in which the host experiences no toxic effects, to a toxicity in which the host does not typically die from the toxic affects of the microbes. In some embodiments, the microbes are of a reduced toxicity such
30 that a host typically has no significant long-term effect from the presence of the

microbes in the host, beyond any affect on tumorous, metastatic or necrotic organs or tissues. For example, the reduced toxicity can be a minor fever or minor infection, which lasts for less than about a month, and following the fever or infection, the host experiences no adverse affects resultant from the fever or
5 infection. In another example, the reduced toxicity can be measured as an unintentional decline in body weight of about 5% or less for the host after administration of the microbes. In other examples, the microbe has no toxicity to the host.

Exemplary vaccinia viruses of the LIVP strain (a widely available attenuated Lister strain) that have reduced toxicity compared to other vaccinia viruses employed and are further modified. Modified LIVP were prepared. These LIVP include insertions in the TK and HA genes and optionally in the locus designed F3. As an example of reduced toxicity, these recombinant vaccinia viruses were tested for their toxicity to mice with impaired immune systems (nude mice) relative to the
15 corresponding wild type vaccinia virus. Intervenous (i.v.) injection of wild type vaccinia virus VGL (strain LIVP) at 1×10^7 PFU/mouse causes toxicity in nude mice: three mice out of seven lost the weight and died (one mouse died in one week after virus injection, one mouse died ten days after virus injection). Recombinant vaccinia virus designated RVGL8 (LacZ inserted into F3 locus) did not show toxic
20 effects in nude mice after i.v. injection of 1×10^7 PFU/mouse. There were no readily detectable signs of RVGL8 virus-related toxicity. . Therefore, insertion into NotI site (located in F3 gene) of vaccinia virus genome strain LIVP reduces toxicity of the vaccinia virus to the host. Similar modifications can be made to other pox viruses and other viruses to reduce toxicity thereof. Such modifications can be
25 empirically identified, if necessary.

**ii. Accumulate in immunoprivileged cells and tissues,
such as tumor, not substantially in other organs**

Microbes can accumulate in any of a variety of tissues and organs of the host. Accumulation can be evenly distributed over the entire host organism, or can
30 be concentrated in one or a few organs or tissues. The microbes provided herein can accumulate in targeted tissues, such as immunoprivileged cells and tissues, such as

-39-

tumors and also metastases. In some embodiments, the microbes provided herein exhibit accumulation in immunoprivileged cells and tissues, such as tumor cells relative to normal organs or tissues that is equal to or greater than the accumulation that occurs with wild type microbes. In other embodiments the microbes provided
5 herein exhibit accumulation in immunoprivileged cells and tissues, such as tumor cells that is equal to or greater than the accumulation in any other particular organ or tissue. For example, the microbes provided herein can demonstrate an accumulation in immunoprivileged cells and tissues, such as tumor cells that is at least about 2-fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about
0 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the accumulation in any other particular organ or tissue.

In some embodiments, a microbe can accumulate in targeted tissues and cells, such as immunoprivileged cells and tissues, such as tumor cells, without
5 accumulating in one or more selected tissues or organs. For example, a microbe can accumulate in tumor cells without accumulating in the brain. In another example, a microbe can accumulate in tumor cells without accumulating in neural cells. In another example, a microbe can accumulate in tumor cells without accumulating in ovaries. In another example, a microbe can accumulate in tumor cells without
0 accumulating in the blood. In another example, a microbe can accumulate in tumor cells without accumulating in the heart. In another example, a microbe can accumulate in tumor cells without accumulating in the bladder. In another example, a microbe can accumulate in tumor cells without accumulating in testes. In another example, a microbe can accumulate in tumor cells without accumulating in the
5 spleen. In another example, a microbe can accumulate in tumor cells without accumulating in the lungs.

One skilled in the art can determine the desired capability for the microbes to selectively accumulate in targeted tissue or cells, such as in a immunoprivileged cells and tissues, such as tumor rather than non-target organs or tissues, according to
10 a variety of factors known in the art, including, but not limited to, toxicity of the

-40-

microbes, dosage, tumor to be treated, immunocompetence of host, and disease state of the host.

Provided herein as an example of selective accumulation in immunoprivileged cells and tissues, such as tumors relative to normal organs or 5 tissues, presence of various vaccinia viruses was assayed in tumor samples and different organs. Wild type VGL virus was recovered from tumor, testes, bladder, and liver and as well as from brain. Recombinant virus RVGL8 was found mostly in tumors (in mouse #24, virus was found in testes, bladder and liver; in mouse #22 in testes), and no virus was recovered from brain tissue in six tested animals. 10 Therefore, this finding demonstrates the tumor accumulation properties of a recombinant vaccinia virus of the LIVP strain with an insertion in the F3 gene for tumor therapy purposes.

iii. Ability to Elicit or Enhance Immune Response to Tumor Cells

15 The microorganisms herein cause or enhance an immune response to antigens in the targeted tissues or cells, such as immunoprivileged cells and tissues, such as tumor cells. The immune response can be triggered by any of a variety of mechanisms, including the presence of immunostimulatory cytokines and the release antigenic compounds that can cause an immune response.

20 Cells, in response to an infection such as a microorganismal infection, can send out signals to stimulate an immune response against the cells. Exemplary signals sent from such cells include antigens, cytokines and chemokines such as interferon-gamma and interleukin-15. The microorganism provided herein can cause targeted cells to send out such signals in response to infection by the microbes, 25 resulting in a stimulation of the host's immune system against the targeted cells or tissues, such as tumor cells.

In another embodiments, targeted cells or tissues, such as tumor cells, can contain one or more compounds that can be recognized by the host's immune system in mounting an immune response against a tumor. Such antigenic compounds can 30 be compounds on the cell surface or the tumor cell, and can be protein, carbohydrate, lipid, nucleic acid, or combinations thereof. Microbe-mediated

-41-

release of antigenic compounds can result in triggering the host's immune system to mount an immune response against the tumor. The amount of antigenic compound released by the tumor cells is any amount sufficient to trigger an immune response in a subject ; for example, the antigenic compounds released from one or more tumor cells can trigger a host immune response. actions in the organism that is known to be accessible to leukocytes.

The time duration of antigen release is an amount of time sufficient for the host to establish an immune response to one or more tumor antigens. In some embodiments, the duration is an amount of time sufficient for the host to establish a sustained immuned response to one or more tumor antigens. One skilled in the art can determine such a time duration based on a variety of factors affecting the time duration for a subject to develop an immune response, including the level of the tumor antigen in the subject, the number of different tumor antigens, the antigenicity of the antigen, the immunocompetence of the host, and the access of the antigenic material to the vasculature of the host. Typically, the duration of antigen release can be at least about a week, at least about 10 days, at least about two weeks, or at least about a month.

The microorganism provided herein can have any of a variety of properties that can cause target cells and tissues, such as tumor cells, to release antigenic compounds. Exemplary properties are the ability to lyse cells and the ability to elicit apoptosis in tumor cells. Microbes that are unable to lyse tumor cells or cause tumor cell death can nevertheless be used in the methods provided herein when such microbes can cause some release or display of antigenic compounds from tumor cells. A variety of mechanisms for antigen release or display without lysis or cell death are known in the art, and any such mechanism can be used by the microbes provided herein, including, but not limited to, secretion of antigenic compounds, enhanced cell membrane permeability, or altered cell surface expression or altered MHC presentation in tumor cells when the tumor cells can be accessed by the host's immune system. Regardless of the mechanism by which the host's immune system is activated, the net result of the presence of the microbes in the tumor is a

stimulation of the host's immune system, at least in part, against the tumor cells. In one example, the microbes can cause an immune response against tumor cells not infected by the microbes.

In one embodiment, the microbes provided herein can cause tumor cells to release an antigen that is not present on the tumor cell surface. Tumor cells can produce compounds such as proteins that can cause an immune response; however, in circumstances in which the antigenic compound is not on the tumor cell surface, the tumor can proliferate, and even metastasize, without the antigenic compound causing an immune response. Within the scope of the present methods, the microbes provided herein can cause antigenic compounds within the cell to release away from the cell and away from the tumor, which can result in triggering an immune response to such an antigen. Even if not all cells of a tumor are releasing antigens, the immune response can initially be targeted toward the "leaky" tumor cells, and the bystander effect of the immune response can result in further tumor cell death around the "leaky" tumor cells.

iv. Balance of Pathogenicity and Release of Tumor Antigens

Typical methods of involving treatment of targeted cells and tissues, such as immunoprivileged cells and tissues, such as tumors, are designed to cause rapid and complete removal thereof. For example, many viruses, bacterial or eukaryotic cells can cause lysis and/or apoptosis in a variety of cells, including tumor cells. Microorganisms that can vigorously lyse or cause cell death can be highly pathogenic, and can even kill the host. Furthermore, therapeutic methods based upon such rapid and complete lysis are typically therapeutically ineffective.

In contrast, the microorganisms provided herein are not aggressive in causing cell death or lysis. They can have only a limited or no ability to cause cell death as long as they accumulate in the target cells or tissues and result in alteration of cell membranes to cause leakage of antigens against which an immune response is mounted. It is desirable that their apoptotic or lytic effect is sufficiently slow or ineffective to permit sufficient antigenic leakage for a sufficient time for the host to mount an effective immune response against the target tissues. Such immune

-43-

response alonge or in combination with the lytic/apoptotic effect of the microorganism results in elimination of the target tissue and also elimination of future development, such as metastases and reoccurrence, of such tissues or cells. While the microbes provided herein can have a limited ability to cause cell death, 5 the microbes provided herein can nevertheless stimulate the host's immune system to attack tumor cells. As a result, such microorganisms also are typically unlikely to have substantial toxicity to the host.

In one embodiment, the microbes have a limited, or no, ability to cause tumor cell death, while still causing or enhancing an immune response against tumor 10 cells. In one example, the rate of microorganism-mediated tumor cell death is less than the rate of tumor cell growth or replication. In another example, the rate of microorganism-mediated tumor cell death is slow enough for the host to establish a sustained immune response to one or more tumor antigens. Typically, the time for of cell death is sufficient to establish an anti-tumor immune response and can be at 15 least about a week, at least about 10 days, at least about two weeks, or at least about a month, depending upon the host and the targeted cells or tissues.

In another embodiment, the microbes provided herein can cause cell death in tumor cells, without causing substantial cell death in non-tumor tissues. In such an embodiment, the microbes can aggressively kill tumor cells, as long as no 20 substantial cell death occurs in non-tumor cells, and optionally, so long as the host has sufficient capability to mount an immune response against the tumor cells.

In one embodiment, the ability of the microbes to cause cell death is slower than the host's immune response against the microbes. The ability for the host to control infection by the microbes can be determined by the immune response (e.g., 25 antibody titer) against microorganismal antigens. Typically, after the host has mounted immune response against the microbes, the microbes can have reduced pathogenicity in the host. Thus, when the ability of the microbes to cause cell death is slower than the host's immune response against the microbes, microbe-mediated cell death can occur without risk of serious disease or death to the host. In one

-44-

example, the ability of the microbes to cause tumor cell death is slower than the host's immune response against the microbes.

b. Immunogenicity

The microorganisms provided herein also can be immunogenic. An immunogenic microorganism can create a host immune response against the microorganism. In one embodiment, the microorganisms can be sufficiently immunogenic to result in a large anti-(microorganism) antibody titer. The microorganisms provided herein can have the ability to elicit an immune response. The immune response can be activated in response to viral antigens or can be activated as a result of microorganismal-infection induced cytokine or chemokine production. Immune response against the microorganism can decrease the likelihood of pathogenicity toward the host organism.

Immune response against the microorganism also can result in target tissue or cell, such as tumor cell, killing. In one embodiment, the immune response against microorganismal infection can result in an immune response against tumor cells, including developing antibodies against tumor antigens. In one example, an immune response mounted against the microorganism can result in tumor cell killing by the "bystander effect," where uninfected tumor cells nearby infected tumor cells are killed at the same time as infected cells, or alternatively, where uninfected tumor cells nearby extracellular microorganisms are killed at the same time as the microorganisms. As a result of bystander effect tumor cell death, tumor cell antigens can be released from cells, and the host organism's immune system can mount an immune response against tumor cell antigens, resulting in an immune response against the tumor itself.

In one embodiment, the microorganism can be selected or modified to express one or more antigenic compounds, including superantigenic compounds. The antigenic compounds such as superantigens can be endogenous gene products or can be exogenous gene products. Superantigens, including toxoids, are known in the art and described elsewhere herein.

c. Replication Competent

The microorganisms provided herein can be replication competent. In a variety of viral or bacterial systems, the administered microorganism is rendered replication incompetent to limit pathogenicity risk to the host. While replication incompetence can protect the host from the microorganism, thalso is limits the ability of the microorganism to infect and kill tumor cells, and typically results in only a short-lived affect. In contrast, the microorganisms provided herein can be attenuated but replication competent, resulting in low toxicity to the host and accumulation mainly or solely in tumors. Thus, the microorganisms provided herein 10 can be replication competent without creating a pathogenicity risk to the host.

Attenuation of the microorganisms provided herein can include, but is not limited to, reducing the replication competence of the microorganism. For example, a microorganism can be modified to decrease or eliminate an activity related to replication, such as a transcriptional activator that regulates replication in the 15 microorganism. In an example, a microorganism, such as a virus, can have the viral thymidine kinase gene modified.

d. Genetic Variants

The microorganisms provided herein can be modified from their wild type form. Modifications can include any of a variety of changes, and typically include 20 changes to the genome or nucleic acid molecules of the microorganisms. Exemplary nucleic acid molecular modifications include truncations, insertions, deletions and mutations. In an exemplary modification, a microorganismal gene can be modified by truncation, insertion, deletion or mutation. In an exemplary insertion, an exogenous gene can be inserted into the genome of the microorganism.

i. Modified Characteristics

Modifications of the microorganisms provided herein can result in a 30 modification of microorganismal characteristics, including those provided herein such as pathogenicity, toxicity, ability to preferentially accumulate in tumor, ability to lyse cells or cause cell death, ability to elicit an immune response against tumor cells, immunogenicity, replication competence. Variants can be obtained by general

methods such as mutagenesis and passage in cell or tissue culture and selection of desired properties, as is known in the art, as exemplified for respiratory syncytial virus in Murphy *et al.*, Virus Res. 1994, 32:13-26.

Variants also can be obtained by mutagenic methods in which nucleic acid residues of the microorganism are added, removed or modified relative to the wild type. Any of a variety of known mutagenic methods can be used, including recombination-based methods, restriction endonuclease-based methods, and PCR-based methods. Mutagenic methods can be directed against particular nucleotide sequences such as genes, or can be random, where selection methods based on desired characteristics can be used to select mutated microorganisms. Any of a variety of microorganismal modifications can be made, according to the selected microorganism and the particular known modifications of the selected microorganism.

ii. Exogenous Gene Expression

The microorganisms provided herein also can have the ability to express one or more exogenous genes. Gene expression can include expression of a protein encoded by a gene and/or expression of an RNA molecule encoded by a gene. In some embodiments, the microorganisms can express exogenous genes at levels high enough that permit harvesting products of the exogenous genes from the tumor.

Expression of endogenous genes can be controlled by a constitutive promotor, or by an inducible promotor. Expression can also be influenced by one or more proteins or RNA molecules expressed by the microorganism. An exemplary inducible promotor system can include a chimeric transcription factor containing a progesterone receptor fused to the yeast GAL4 DNA-binding domain and to the activation domain of the herpes simplex virus protein VP16, and a synthetic promoter containing a series of GAL4 recognition sequences upstream of the adenovirus major late E1B TATA box, linked to one or more exogenous genes; in this exemplary system, administration of RU486 to a subject can result in induction of the exogenous genes. Exogenous genes expressed can include genes encoding a therapeutic gene product, genes encoding a detectable gene product such as a gene

product that can be used for imaging, genes encoding a gene product to be harvested, genes encoding an antigen of an antibody to be harvested. The microorganisms provided herein can be used for expressing genes in vivo and in vitro. Exemplary proteins include reporter proteins (*E. coli* β -galactosidase, 5 β -glucuronidase, xanthineguanine phosphoribosyltransferase), proteins facilitating detection, *i.e.*, a detectable protein or a protein capable of inducing a detectable signal, (*e.g.*, luciferase, green and red fluorescent proteins, transferrin receptor), proteins useful for tumor therapy (*pseudomonas A* endotoxin, diphtheria toxin, p53, Arf, Bax, tumor necrosis factor-alfa, HSV TK, *E. coli* purine nucleoside phosphorylase, angiostatin, endostatin, different cytokines) and many other proteins. 10

iii. Detectable gene product

The microorganisms provided herein can express one or more genes whose products are detectable or whose products can provide a detectable signal. A variety of detectable gene products, such as detectable proteins are known in the art, and can 15 be used with the microorganisms provided herein. Detectable proteins include receptors or other proteins that can specifically bind a detectable compound, proteins that can emit a detectable signal such as a fluorescence signal, enzymes that can catalyze a detectable reaction or catalyze formation of a detectable product.

In some embodiments, the microorganism expresses a gene encoding a 20 protein that can emit a detectable signal or the can catalyze a detectable reaction. A variety of DNA sequences encoding proteins that can emit a detectable signal or the can catalyze a detectable reaction, such as luminescent or fluorescent proteins, are known and can be used in the microorganisms and methods provided herein.

Exemplary genes encoding light-emitting proteins include genes from bacterial 25 luciferase from *Vibrio harveyi* (Belas et al., *Science* 218 (1982), 791-793), bacterial luciferase from *Vibrio fischerii* (Foran and Brown, *Nucleic acids Res.* 16 (1988), 177), firefly luciferase (de Wet et al. , *Mol. Cell. Biol.* 7(1987), 725-737), aequorin from *Aequorea victoria* (Prasher et al. , *Biochem.* 26 (1987), 1326-1332), *Renilla* luciferase from *Renilla reniformis* (Lorenz et al. , *PNAS USA* 88 (1991), 4438-4442) 30 and green fluorescent protein from *Aequorea victoria* (Prasher et al. , *Gene* 111

-48-

(1987), 229-233). Transformation and expression of these genes in microorganisms can permit detection of microorganismal colonies, for example, using a low light imaging camera. Fusion of the lux A and lux B genes can result in a fully functional luciferase protein (Escher *et al.*, PNAS 86 (1989), 6528-6532). This fusion gene
5 (Fab2) has been introduced into a variety of microorganisms followed by microorganismal infection and imaging based on luciferase expression. In some embodiments, luciferases expressed in bacteria can require exogenously added substrates such as decanal or coelenterazine for light emission. In other embodiments, microorganisms can express a complete lux operon, which can
10 include proteins that can provide luciferase substrates such as decanal. For example, bacteria containing the complete lux operon sequence, when injected intraperitoneally, intramuscularly, or intravenously, allowed the visualization and localization of bacteria in live mice indicating that the luciferase light emission can penetrate the tissues and can be detected externally (Contag *et al.*, Mol. Microbiol.
15 18 (1995), 593-603).

In other embodiments, the microorganism can express a gene that can bind a detectable compound or that can form a product that can bind a detectable compound. A variety of gene products, such as proteins, that can specifically bind a detectable compound are known in the art, including receptors, metal binding
20 proteins, ligand binding proteins, and antibodies. Any of a variety of detectable compounds can be used, and can be imaged by any of a variety of known imaging methods. Exemplary compounds include receptor ligands and antigens for antibodies. The ligand can be labeled according to the imaging method to be used. Exemplary imaging methods include any of a variety magnetic resonance methods
25 such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), and also include any of a variety of tomographic methods including computed tomography (CT), computed axial tomography (CAT), electron beam computed tomography (EBCT), high resolution computed tomography (HRCT), hypocycloidal tomography, positron emission tomography (PET), single-photon

emission computed tomography (SPECT), spiral computed tomography and ultrasonic tomography.

Labels appropriate for magnetic resonance imaging are known in the art, and include, for example, gadolinium chelates and iron oxides. Use of chelates in contrast agents is known in the art. Labels appropriate for tomographic imaging methods are known in the art, and include, for example, β -emitters such as ^{11}C , ^{13}N , ^{15}O or ^{64}Cu or (b) γ -emitters such as ^{123}I . Other exemplary radionuclides that can, be used, for example, as tracers for PET include ^{55}Co , ^{67}Ga , ^{68}Ga , $^{60}\text{Cu(II)}$, $^{67}\text{Cu(II)}$, ^{57}Ni , ^{52}Fe and ^{18}F . Examples of useful radionuclide-labeled agents are ^{64}Cu -labeled engineered antibody fragment (Wu *et al.*, PNAS USA 97 (2002), 8495-8500), ^{64}Cu -labeled somatostatin (Lewis *et al.*, J. Med. Chem. 42(1999), 1341-1347), ^{64}Cu -pyruvaldehyde-bis (N4methylthiosemicarbazone)(64Cu-PTSM) (Adonai *et al.*, PNAS USA 99 (2002), 3030-3035), ^{52}Fe -citrate (Leenders *et al.*, J. Neural. Transm. Suppl. 43 (1994), 123-132), $^{52}\text{Fe}/^{52\text{m}}\text{Mn}$ -citrate (Calonder *et al.*, J. Neurochem. 73 (1999), 2047-2055) and ^{52}Fe -labeled iron (III) hydroxide-sucrose complex (Beshara *et al.*, Br. J. Haematol. 104 (1999), 288-295,296-302).

iv. Therapeutic gene product

The microorganisms provided herein can express one or more genes whose products cause cell death or whose products cause an anti-tumor immune response, such genes can be considered therapeutic genes. A variety of therapeutic gene products, such as toxic or apoptotic proteins, or siRNA, are known in the art, and can be used with the microorganisms provided herein. The therapeutic genes can act by directly killing the host cell, for example, as a channel-forming or other lytic protein, or by triggering apoptosis, or by inhibiting essential cellular processes, or by triggering an immune response against the cell, or by interacting with a compound that has a similar effect, for example, by converting an less active compound to a cytotoxic compound.

In some embodiments, the microorganism can express a therapeutic protein. A large number of therapeutic proteins that can be expressed for tumor treatment are known in the art, including, but not limited to tumor suppressors, toxins, cytostatic

-50-

proteins, and cytokines. An exemplary, non-limiting list of such proteins includes WT1, p53, p16, Rb, BRCA1, cystic fibrosis transmembrane regulator (CFTR), Factor VIII, low density lipoprotein receptor, beta-galactosidase, alpha-galactosidase, beta-glucocerebrosidase, insulin, parathyroid hormone, alpha-1-5 antitrypsin, rsCD40L, Fas-ligand, TRAIL, TNF, antibodies, microcin E492, diphtheria toxin, Pseudomonas exotoxin, Escherichia coli Shig toxin, Escherichia coli Verotoxin 1, and hyperforin.

In other embodiments, the microorganism can express a protein that converts a less active compound into a compound that causes tumor cell death. Exemplary 10 methods of conversion of such a prodrug compound include enzymatic conversion and photolytic conversion. A large variety of protein/compound pairs are known in the art, and include, but are not limited to Herpes simplex virus thymidine kinase/gancyclovir, varicella zoster thymidine kinase/gancyclovir, cytosine deaminase/5-fluorouracil, purine nucleoside phosphorylase/6-methylpurine 15 deoxyriboside, beta lactamase/cephalosporin-doxorubicin, carboxypeptidase G2/4-[$(2\text{-chloroethyl})(2\text{-mesuloxethyl})\text{amino}$]benzoyl-L-glutamic acid, cytochrome P450/acetominophen, horseradish peroxidase/indole-3-acetic acid, nitroreductase/CB1954, rabbit carboxylesterase/7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampothecin, mushroom tyrosinase/bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, beta galactosidase/1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole, beta 20 glucuronidase/epirubicin-glucoronide, thymidine phosphorylase/5'-deoxy5-fluorouridine, deoxycytidine kinase/cytosine arabinoside, and linamerase/linamarin.

In another embodiment, the therapeutic gene product can be an siRNA 25 molecule. The siRNA molecule can be directed against expression of a tumor-promoting gene, such as, but not limited to, an oncogene, growth factor, angiogenesis promoting gene, or a receptor. The siRNA molecule also can be directed against expression of any gene essential for cell growth, cell replication or cell survival. The siRNA molecule also can be directed against expression of any 30 gene that stabilizes the cell membrane or otherwise limits the number of tumor cell

-51-

antigens released from the tumor cell. Design of an siRNA can be readily determined according to the selected target of the siRNA; methods of siRNA design and downregulation of genes are known in the art, as exemplified in U.S. Pat. Pub. No. 20030198627.

5 In one embodiment, the therapeutic compound can be controlled by a regulatory sequence. Suitable regulatory sequences which, for example, are functional in a mammalian host cell are well known in the art. In one example, the regulatory sequence can contain a natural or synthetic vaccinia virus promoter. In another embodiment, the regulatory sequence contains a poxvirus promoter. When
10 viral microorganisms are used, strong late promoters are can be used to achieve high levels of expression of the foreign genes. Early and intermediate-stage promoters, however, can also be used. In one embodiment, the promoters contain early and late promoter elements, for example, the vaccinia virus early/late promoter p7.5, vaccinia late promoter p11, a synthetic early/late vaccinia pE/L promoter (Patel *et al.*, (1988), Proc. Natl. Acad. Sci. USA 85, 9431-9435; Davison and Moss, (1989), J Mol Biol 210, 749-769; Davison *et al.*, (1990), Nucleic Acids Res. 18, 4285-4286; 15 Chakrabarti *et al.*, (1997), BioTechniques 23, 1094-1097).

v. Expressing a superantigen

The microorganisms provided herein can be modified to express one or more superantigens. Superantigens are antigens that can activate a large immune response, often brought about by a large response of T cells. A variety of superantigens are known in the art including, but not limited to, diphtheria toxin, staphylococcal enterotoxins (SEA, SEB, SEC1, SEC2, SED, SEE and SEH), Toxic Shock Syndrome Toxin 1, Exfoliating Toxins (EXft), Streptococcal Pyrogenic 20 Exotoxin A, B and C (SPE A, B and C), Mouse Mammary Tumor Virus proteins (MMTV), Streptococcal M proteins, Clostridial Perfringens Enterotoxin (CPET), mycoplasma arthritis superantigens.

Since many superantigens also are toxins, if expression of a microorganism of reduced toxicity is desired, the superantigen can be modified to retain at least 30 some of its superantigenicity while reducing its toxicity, resulting in a compound

such as a toxoid. A variety of recombinant superantigens and toxoids of superantigens are known in the art, and can readily be expressed in the microorganisms provided herein. Exemplary toxoids include toxoids of diphtheria toxin, as exemplified in U.S. Pat. No. 6,455,673 and toxoids of Staphylococcal enterotoxins, as exemplified in U.S. Pat. Pub. No. 20030009015.

vi. Expressing a gene product to be harvested

Exemplary genes expressible by a microorganism for the purpose of harvesting include human genes. An exemplary list of genes includes the list of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins University and elsewhere, and developed for the World Wide Web by NCBI, the National Center for Biotechnology Information. Online Mendelian Inheritance in Man, OMIM™. Center for Medical Genetics, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), 1999. and those available in public databases, such as pubmed and genbank (see, e.g., ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM) These genes include, but are not limited to: 239f2h9, 3pk, 4ebp1, 4ebp2, al1, al2m1, al2m2, al2m3, al2m4, al5, alb, albg, alst, a2m, a2mr, a2mrap, aa, aaa, aaa, aabt, aac1, aac2, aact, aadac, aanat, aars, aas, aat, aavs1, abc1, abc2, abc3, abc7, abc8, abcr, abi1, abl1, abl2, abl1, abo, abp, abp1, abpa, abpx, abr, acaa, acac, acaca, acacb, acad1, acadm, acads, acadsb, acadv1, acat, acat1, acat2, acc, accb, accn1, accn2, accpn, ace1, ach,ache, achm1, achm2, achrb, achrd, achrg, acls, acly, aco1, aco2, acox, acox1, acox2, acox3, acp1, acp2, acp5, acpp, acr, acrv1, acs3, acs3, acs4, act2, act35, acta1, acta2, acta3, actb, actc, actg1, actg2, act11, actn1, actn2, actn3, actsa, acug, acvr1, acvr2b, acvrl1, acvrlk1, acvrlk2, acvrlk3, acyl, ad1, ad2, ad3, ad4, ad5, ada, adam10, adam11, adam12, adam3, adam3a, adam3b, adam8, adar, adarb1, adarb2, adcp1, adcp2, adcy1, adcy2, adcy3, adcy3, adcy4, adcy5, adcy6, adcy7, adcy8, adcy9, adcyap1, adcyaplr1, add1, add2, add3, add1, adfn, adh1, adh2, adh3, adh4, adh5, adh7, adhaps, adhc1@, adhr, adhr, adk, ad1, adm, admlx, adora1, adora2a, adora2b, adora21, adora21, adora3, adprt, adra1a, adra1b, adra1c, adra1d, adra2a, adra2b,

-53-

adra2c, adra211, adra212, adra2r, adrb1, adrb1r, adrb2, adrb2rl1, adrb3, adrbk1,
adrbk2, ads1, adss, adtb1, adx, adxr, ae1, ae2, ae3, aegl1, aemk, aes, af10, af17, af4,
af6, af8t, af9, afd1, afdn, afg3, afg311 , afm, afp, afx1, aga, agc1, ager, ag1, agmx1,
agmx2, agp1, agp7, agps, agrn, agrp, agrt, ags, agt, agti1, agtr1, agtr1a, agtr2, agtr1l,
5 agxt, ahc, ahcy, ahd, ahds, ahnak, aho2, ahr, ahsg, ahx, aib1, aic, aic1, aied, aih1,
aih2, aih3, aim1, air, airc, aire, ak1, ak2, ak3, akap149, akt1, akt2, aku, alad, alas1,
alas2, alb, alb2, alba, alciam, ald, aldh1, aldh10, aldh2, aldh3, aldh4, aldh5, aldh6,
aldh9, ald11, aldoa, aldob, aldoch, aldr1, alds, alk, alk1, alk2, alk3, alk6, alms1,
alox12, alox15, alox5, alp, alpi, alp1, alpp, alpp12, alr, alr, als1, als2, als4, als5, als5,
10 ambn, ambp, amcd1, amcd2b, amcn, amcn1, amcx1, amd1, amdm, amelx, amely,
amfr, amg, amg1, amgx, amh, amhr, amhr2, aml1, aml1t1, aml2, aml3, amog,
ampd1, ampdd2, ampdd3, amph, amph1, ampk, amt, amy1a, amy1b, amy1c, amy2a,
amy2b, an2, anc, ancr, ang, ang1, anh1, ank1, ank2, ank3, anop1, anova, anp, anpep,
anpra, anprb, anprc, ans, ant1, ant2, ant3, ant3y, anx1, anx11, anx13, anx2, anx214,
15 anx3, anx4, anx5, anx6, anx7, anx8, aoah, aoc2, aox1, ap2tf, apah1, apba1, apba2,
apbb1, apbb2, apc, apcs, ape, apced, apeh, apex, api1, api2, api3, apj, aplp, aplp1,
apl2, apnh, apo31, apo1, apo2, apo4, apob, apobec1, apoc1, apoc2, apoc3,
apoc4, apod, apoe, apoer2, apoh, apolmt, apolp1@, apolp2@, app, appbp1, appl1,
apr1, aprt, aps, apt1, apt1g1, apx1, apy, aqdq, aqp0, aqp1, aqp2, aqp21, aqp3, aqp4,
20 aqp5, aqp6, aqp7, ar, ar1, ara, araf1, araf2, arcn1, ard1, ard1, areg, arf1, arf2, arf3,
arf41, arf5, arg, arg1, args, arh12, arh6, arh9, arha, arhb, arhc, arhg, arhgap2,
arhgap3, arhgap6, arhgdia, arhgdib, arhh, arix, arl2, armd1, arnt, arnt1, aro, arp,
arp1, arpkd, arr3, arrb1, arrb2, arsa, arsacs, arsb, arsc1, arsc2, arsd, arse, arsf, art,
art1, art3, art4, arts, arvd1, arvd2, arvd3, arvd4, as, asat, asb, ascl1, ascl2, asct1,
25 asd1, asd2, asgr1, asgr2, ash1, asip, as1, asln, asm1, asma, asmd, asmt, asmtlx,
asmty, asnrs, asns, aspa, ass, astm1, astn, asv, at, at1, at2rl, at3, ata, atbfl, atcay,
atf1, ath1, aths, atm, atoh1, atox1, atp1a1, atp1a2, atp1a3, atp1a11, atp1b1, atp1b2,
atp1b3, atp1b11, atp1g1, atp2a1, atp2a2, atp2a3, atp2b, atp2b1, atp2b2, atp2b2,
atp2b3, atp2b4, atp4a, atp4b, atp5, atp5a, atp5b, atp5g1, atp5g2, atp5g3, atp5o,
30 atp6a, atp6b1, atp6c, atp6e, atp6n1, atp7a, atp7b, atpm, atpsb, atpsk1, atpsk2, atql,

atr, atr, atr1, atr1, atr2, atrc1, atrc2, atrx, ats, atsv, atx1, atx2, au, aufl, aufla, aut,
avcd, aved, avp, avpr1a, avpr1b, avpr2, avpr3, avrp, avsd, awa1, ax1, ax11g, axsf,
azfl, azf2, azgp1, azu1, b120, b144, blg1, b29, b2m, b2mr, b3galt4, b4galt1, ba2r,
bab1, bag1, bai1, bai2, bai3, bak1, bam22, bap1, bap135, bapx1, bard1, bark2, bas,
5 bat1, bat2, bat3, bat4, bat5, bax, bb1, bbbg1, bbbg2, bbs1, bbs2, bbs3, bbs4, bbs5,
bcas1, bcat1, bcat2, bcate2, bcd1, bcei, bche, bckdha, bckdhb, bcl1, bcl10, bcl2,
bcl2a1, bcl212, bcl3, bcl5, bcl6, bcl7, bcl7a, bcl8, bcl9, bclw, bcm, bcm1, bcma,
bcns, bcns, bcp, bcpm, bcpr, bcr, bcrl2, bcrl3, bcrl4, bcsq1, bct1, bct2, bdb, bdb1,
bdc, bde, bdkrb1, bdkrb2, bdmf, bdmr, bdnf, bed, bedp, bek, bene, bevi, bf, bf1, bf2,
10 bfhd, bfic, bfls, bfnc2, bfp, bfsp1, bft, bglap, bgmr, bgn, bgp, bhd, bhpcdh, bhr1,
bicd1, bid, bigh3, bin1, bir, bjs, bkma1, blast1, blau, blk, blm, blmh, bltr, blvra,
blvrb, blym, bmal1, bmd, bmh, bmi1, bmp1, bmp2, bmp2a, bmp2b1, bmp3, bmp4,
bmp5, bmp6, bmp7, bmp8, bmp1a, bmp1b, bmx, bmyb, bn51t, bnc, bnc1, bnp,
bor, bpad, bpag1, bpag2, bpes, bpes1, bpes2, bpgm, bph1, bpi, br, br140, braf, brca1,
15 brca2, brca3, brcacox, brcd1, brcd2, brdt, brfl, brhc, bric, brks, brn3a, brn3b, brn3c,
brm1, brw1c, bs, bsap, bsep, bsf2, bsg, bsnd, bss1, bst1, bst2, btak, btc, btd, bteb,
bteb1, btg1, btg2, bths, btk, btk1, btn, bts, bub1b, bubr1, bwr1a, bwr1b, bws,
bwscr1a, bwscr1b, bzrp, bzx, c11orf13, c1nh, c1qa, c1qb, c1qbp, c1qg, c1r, c1s, c2,
c21orf1, c21orf2, c21orf3, c2ta, c3, c3br, c3dr, c3g, c4a, c4b, c4bpa, c4bp, c4f, c4s,
20 c5, c5ar, c5r1, c6, c7, c8a, c8b, c8g, c9, ca1, ca12, ca125, ca2, ca21h, ca3, ca4, ca5,
ca6, ca7, ca8, ca9, caaf1, cabp9k, cac, cac@, caca, cacd, cacnala, cacnab, cacnac1c,
cacnald, cacnale, cacnalf, cacnals, cacna2, cacnb1, cacnb2, cacnb3, cacnb4, cacng,
cacn1a1, cacn1a2, cacn1a3, cacn1a4, cacn1a5, cacn1a6, cacn1a2, cacnlb1,
cacnlg, cacp, cact, cacy, cad, cad11, cadasi1, cae1, cae3, caf, cafla, caga, cagb, cain,
25 cak, cak1, cal11, calb1, calb2, calb3, calc1, calc2, calca, calcb, calcr, cald1, calla,
calm1, calm2, calm3, calm11, calm13, calna, calna3, calnb, calnb1, calr, cals, calt,
calu, cam, camk4, camkg, caml1, camlg, camp, can, canp3, canx, cap2, cap3, cap37,
capb, capg, cap1, capn1, capn2, capn3, capn4, cappa2, cappb, capr, caps, capza2,
capzb, car, carp, cars, cart1, cas, cas2, casi1, casp1, casp10, casp2, casp3, casp3,
30 casp4, casp5, casp6, casp7, casp8, casq1, casq2, casr cast, cat, cat1, cat4, catfl,

-55-

catm, cav1, cav2, cav3, cbbm, cbd, cbfa1, cbfa2, cbfa2t1, cbfa3, cbfb, cbg, cb1,
cb12, cbln2, cbp, cbp, cbp2, cbp68, cbr1, cbs, cbt, cbt1, cc10, cca, cca1, cca11,
cca12, ccb11, ccckr5, ccg1, ccg2, cchl1a1, cchl1a2, cchl1a3, cchl1b1, cck, cckar,
cckbr, cc1, ccm1, ccm2, ccm3, ccn1, ccna, ccnb1, ccnc, ccnd1, ccnd2, ccnd3, ccne,
5 ccnf, ccng1, ccnh, ccnt, ccnt1, cco, ccr10, ccr2, ccr3, ccr9, ccsp, cct, ccv, cczs, cd,
cd10, cd11a, cd11b, cd11c, cd13, cd137, cd14, cd15, cd151, cd156, cd16, cd164,
cd18, cd19, cd1a, cd1b, cd1c, cd1d, cd1e, cd2, cd20, cd22, cd23, cd24, cd26, cd27,
cd271, cd28, cd281g, cd281g2, cd30, cd32, cd33, cd34, cd36, cd3611, cd3612,
cd37, cd38, cd39, cd3911, cd3d, cd3e, cd3g, cd3z, cd4, cd40, cd401g, cd41b, cd43,
10 cd44, cd45, cd46, cd47, cd48, cd49b, cd49d, cd5, cd53, cd57, cd58, cd59, cd51, cd6,
cd63, cd64, cd68, cd69, cd7, cd70, cd71, cd72, cd74, cd79a, cd79b, cd80, cd81,
cd82, cd82, cd86, cd8a, cd8b, cd8b1, cd9, cd94, cd95, cd97, cd99, cda, cda1, cda3,
cdan1, cdan2, cdan3, cdb2, cdc2, cdc20, cdc25a, cdc25b, cdc25c, cdc27, cdc211,
cdc212, cdc214, cdc34, cdc42, cdc51, cdc7, cdc711, cdcd1, cdcd2, cdcd3, cdc11,
15 cdcre1, cdg1, cdgd1, cdgg1, cdgs2, cdh1, cdh11, cdh12, cdh13, cdh14, cdh15,
cdh16, cdh16, cdh17, cd2, cdh3, cdh3, cdh5, cdh7, cdh8, cdhb, cdhh, cdhp, cdhs,
cdk2, cdk3, cdk4, cdk5, cdk7, cdk8, cdk9, cdkn1, cdkn1a, cdkn1b, cdkn1c, cdkn2a,
cdkn2b, cdkn2d, cdkn3, cdkn4, cdl1, cdm, cdmp1, cdmt, cdpx1, cdpx2, cdpxr, cdr1,
cdr2, cdr3, cdr62a, cdsn, cdsp, cdtb, cdw50, cdx1, cdx2, cdx3, cdx4, cea, cebp,
20 cebpa, cebpb, cebpd, cebpe, cecr, ce1, cel1, cen1, cenpa, cenpb, cenpc, cenpc1,
cenpe, cenpf, cerd4, ces, ces1, cetcn1, cetp, cf, cf2r, cfag, cfag, cfc, cfd1, cfeom1,
cfeom2, cfh, cfl1, cfl2, cfnd, cfns, cftr, cg1, cga, cgat, cgb, cgd, cgf1, cgh, cgrp,
cgs23, cgt, cgthba, chac, chat, chc1, chd1, chd2, chd3, chd4, chd5, chdr, che1, che2,
ched, chek1, chga, chgb, chgc, chh, chi311, chip28, chit, chk1, chlr1, chlr2, chm,
25 chm1, chn, chn1, chn2, chop10, chr, chr39a, chr39b, chr39c, chrm1, chrm2, chrm3,
chrm4, chrm5, chrna1, chrna2, chrna3, chrna4, chrna5, chrna7, chrnb1, chrnb2,
chrnb3, chrnb4, chrnd, chrne, chrng, chrs, chs1, chx10, ciipx, cip1, cirbp, cish,
ck2a1, ckap1, ckb, ckbb, ckbe, ckm, ckmm, ckmt1, ckmt2, ckn1, ckn2, ckr3, ckr11,
ckr13, c1, cl100, cla1, cla1, clac, clapb1, clapm1, claps3, clc, clc7, clck2, clcn1,
30 clcn2, clcn3, clcn4, clcn5, clcn6, clcn7, clcnka, clcnkb, cld, cldn3, cldn5, clg1,

-56-

clg3, clg4a, clg4b, cli, clim1, clim2, clk2, clk3, cln1, cln2, cln3, cln5, cln6, cln80,
clns1a, clns1b, clp, clpp, clps, clta, cltb, cltc, cltc11, cltd, clth, clu, cma1, cmah,
cmar, cmd1, cmd1a, cmd1b, cmd1c, cmd1d, cmd1e, cmd1f, cmd3a, cmdj, cmh1,
cmh2, cmh3, cmh4, cmh6, cmkbr1, cmkbr2, cmkbr3, cmkbr5, cmkbr6, cmkbr7,
5 cmkbr8, cmkbr9, cmkbr12, cmklr1, cmkr11, cmkr12, cml, cmm, cmm2, cmoat, cmp,
cmpd1, cmpd2, cmpd2, cmpd3, cmpx1, cmt1a, cmt1b, cmt2a, cmt2b, cmt2d, cmt2d,
cmt4a, cmt4b, cmtnd, cmtx1, cmtx2, cna1, cna2, cnbp1, cnc, cncg1, cncg2, cncg31,
cnd, cng3, cnga1, cnga3, cngb1, cnn1, cnn2, cnn3, cnp, cnr1, cnsn, cntf, cntfr, ctn1,
co, coca1, coca2, coch, cod1, cod2, coh1, coil, col10a1, col11a1, col11a2, col12a11,
10 col13a1, col15a1, col16a1, col17a1, col18a1, col19a1, col1a1, col1a2, col1ar,
col2a1, col3a1, col4a1, col4a2, col4a3, col4a4, col4a5, col4a6, col5a1, col5a2,
col6a1, col6a2, col6a3, col7a1, col8a1, col8a2, col9a1, col9a1, col9a2, col9a3, colq,
comp, comt, copeb, copt1, copt2, cord1, cord2, cord5, cord6, cort, cot, cox10, cox4,
cox5b, cox6a1, cox6b, cox7a1, cox7a2, cox7a3, cox7am, cox8, cp, cp107, cp115,
15 cp20, cp47, cp49, cpa1, cpa3, cpb2, cpb2, cpd, cpe, cpetr2, cpm, cpn, cpn1, cpn2,
cpo, cpp, cpp32, cpp32, cippi, cps1, cpsb, cpsd, cpt1a, cpt1b, cpt2, cpu, cpx, cpx,
cpxd, cr1, cr2, cr3a, crabp1, crabp2, crapb, crarf, crat, crbp1, crbp2, crd, crd1, creb1,
creb2, crebbp, creb11, crem, crfb4, crfi2, crh, crhbp, crhr, crhr1, crhr2, crip, crk,
crk1, crm1, crmp1, crmp2, crp, crp1, crs, crs1c, crs2, crs3, crsa, crt, crt11, crt1m, crx,
20 cry1, cry2, crya1, crya2, cryaa, cryab, cryb1, cryb2, cryb3, cryba1, cryba2, cryba4,
crybb1, crybb2, crybb3, cryg1, cryg2, cryg3, cryg4, cryg8, cryg@, cryga, crygb,
crygc, crygd, crygs, crym, cryz, cs, csa, csb, csbp1, csci, csd, csd2, csda, cse, cse11,
csf1, csf1r, csf2, csf2ra, csf2rb, csf2ry, csf3, csf3r, csh1, csh2, csk, csmf, csn1,
csn10, csn2, csn3, csnb1, csnb2, csnb3, csnk1a1, csnk1d, csnk1e, csnk1g2, csnk2a1,
25 csnk2a2, csnk2b, csnu3, cso, cspb, cspg1, cspg2, cspg3, csr, csrb, csrp, csrp1, csrp2,
cst1, cst1, cst2, cst3, cst4, cst4, cst5, cst6, csta, cstb, csx, ct2, ctaa1, ctaa2, ctag, ctb,
ctbp1, ctbp2, ctgf, cth, cthm, ctk, ctl1, ctl1a3, ctl1a4, ctl1a8, ctm, ctnna1, ctnna2,
ctnnb1, ctnnd, ctnnd1, ctnr, ctns, ctp, ctpct, ctps, ctr1, ctr2, ctrb1, ctr1, ctsa, ctsb,
ctsc, ctsd, ctse, ctsg, ctsg12, ctsh, ctsk, cts1, ctss, ctsz, ctx, cubn, cul3, cul4b,
30 cul5, cut11, cvap, cvd1, cvl, cx26, cx31, cx32, cx37, cx40, cx43, cx46, cx50, cxb3s,

-57-

cxcr4, cxorf4, cyb5, cyb561, cyba, cybb, cyc1, cyk4, cyl1, cymp, cyp1, cyp11a,
cyp11b1, cyp11b2, cyp17, cyp19, cyp1a1, cyp1a2, cyp1b1, cyp21, cyp24, cyp27,
cyp27a1, cyp27b1, cyp2a, cyp2a3, cyp2a6, cyp2b, cyp2c, cyp2c19, cyp2c9, cyp2d,
cyp2d@, cyp2e, cyp2e1, cyp2f1, cyp2j2, cyp3a4, cyp4a11, cyp4b1, cyp51, cyp7,
5 cyp7a1, cyr61, cyrn1, cyrn2, czp3, d10s105e, d10s170, d10s170, d11s302e,
d11s636, d11s813e, d11s833e, d12s2489e, d12s53e, d13s1056e, d13s25, d14s46e,
d15s12, d15s226e, d15s227e, d16s2531e, d16s469e, d17s136e, d17s811e, d18s892e,
d19s204, d19s381e, d1s111, d1s155e, d1s166e, d1s1733e, d1s2223e, d1s61, d2h,
d2s201e, d2s448, d2s488e, d2s69e, d3s1231e, d3s1319e, d3s48e, d4, d4s90,
10 d5s1708, d5s346, d6, d6s1101, d6s207e, d6s2245e, d6s228e, d6s229e, d6s230e,
d6s231e, d6s51e, d6s52e, d6s54e, d6s81e, d6s82e, d7s437, d8s2298e, d9s46e, da1,
da2b, dab2, dac, dad1, daf, dag, dag1, dag2, dagk1, dagk4, dam10, dam6, damox,
dan, dao, dap, dap3, dap5, dapk1, dar, dat1, dax1, daxx, daz, dazh, daz1, dba,
dbccr1, dbcn, dbh, dbi, dbi, db1, dbm, dbn1, dbp, dbp, dbp1, dbp2, dbpa, dbt, dbx,
15 dby, dcc, dce, dci, dck, dcn, dcoh, dcp1, dcr, dcr3, dct, dctn1, dcx, ddb1, ddb2, ddc,
ddh1, ddh2, ddit1, ddit3, ddost, ddp, ddpac, ddr, ddx1, ddx10, ddx11, ddx12, ddx15,
ddx16, ddx2a, ddx3, ddx5, ddx6, ddx9, dec, decr, def1, def4, def5, def6, defal,
defa4, defa5, defa6, defb1, defb2, dek, denn, dents, dep1, der12, des, dff1, dffa,
dffrx, dffry, dfn1, dfn2, dfn3, dfn4, dfn6, dfna1, dfna10, dfna11, dfna12, dfna13,
20 dfna2, dfna2, dfna4, dfna5, dfna6, dfna7, dfna8, dfna9, dfnb1, dfnb12, dfnb13,
dfnb14, dfnb16, dfnb17, dfnb18, dfnb2, dfnb3, dfnb4, dfnb5, dfnb6, dfnb7, dfnb8,
dfnb9, dgcr, dgcr2, dgcr6, dgi1, dgka, dgkq, dgpt, dgpt, dgs, dgs2, dgsi, dgu,
dhc2, dhcr7, dhfr, dhlag, dhp, dhpr, dhps, dhrd, dhtr, di, di1, dia, dia1, dia2, dia4,
diaph1, diaph2, dif2, diff6, dipi, dir, dkc, dkc1, dlc1, dld, dlg1, dlg2, dlg3, dlg4, dlst,
25 dlx1, dlx2, dlx2, dl3, dlx4, dlx5, dlx6, dlx7, dlx8, dm, dm2, dmahp, dmbo1, dmd,
dmbo1, dmbo1, dmh, dmk, dmp1, dmpk, dmsfh, dmt, dmt1, dmtn, dna21, dnah,
dnah1, dnah11, dnah12, dnah2, dnahc1, dnahc11, dnahc2, dnahc3, dnase1,
dnase111, dnase113, dnase2, dnch2, dnc1, dnec1, dne11, dn1, dn11, dn111,
dnm1, dnmt1, dnmt2, dnpk1, dns, dntt, do, doc1, doc2, dock1, dock180, dod, dok1,
30 dom, dp1, dp1, dp2, dp3, dpagt2, dpc4, dpd, dpde1, dpde2, dpde3, dpde4, dpep1,

-58-

dph212, dpp, dpp4, dpp6, dpt, dpyd, dpys, dpys11, dpys12, dr1, dr3, dr31g, dr5, dra,
drad, drada, dra1, drd1, drd1b, drd1b, drd112, drd2, drd3, drd4, drd5, dri11, drp1,
drp1, drp2, drp2, drp3, drp1a, drt, dsc1, dsc2, dsc3, dsc3, dsc4, dscam, dscr, dsg1,
dsg2, dsg3, dsp, dsppg3, dspp, dss, dss1, dtd, dtddp2, dtddst, dtta, dtr, dts, dus, dusp1,
5 dusp11, dusp2, dusp3, dusp4, dusp5, dusp6, dusp7, dusp8, dut, dv1, dv11, dv11,
dv13, dxf68s1e, dxs1272e, dxs128, dxs1283e, dxs423e, dxs435e, dxs522e, dxs648,
dxs707, dxs8237e, dxsys155e, dylx2, dyrk, dys, dysf, dyt1, dyt3, dyt5, dyt6, dyt7,
dyt8, dyt9, dyx1, dyx2, e11s, e14, e1b, e2a, e2f1, e2f2, e2f3, e2f4, e3, e4f, e4f1,
e4tf1a, e4tf1b, ea1, eaac1, eaat1, eaat2, eac, ead, eag, eap, earl, ear2, ear3, eba, ebf,
10 ebi1, ebm, ebn1, ebn1, ebn2, ebr2a, ebs1, ebvm1, ebvs1, ec1, eca1, ecb2, ece1,
ecgf1, ech1, echs1, eck, ecm1, ecp, ecs1, ect2, ed1, ed2, ed3, ed4, eda, eda3, eddr1,
edg3, edg6, edh, edh17b2, edh17b3, edh17b3, edm1, edm2, edm3, edmd, edmd2,
edn, edn1, edn2, edn3, ednra, ednrb, eec1, eec2, eef1a1, eef1a2, eef1b1, eef1b2,
15 eef1b3, eef1b4, eef2, eeg1, eegv1, eek, een, efla, ef2, efe2, efemp1, efl6, efmr,
efna1, efna3, efna4, efnb1, efnb2, efnb3, efp, eftu, egf, egfr, egi, egr1, egr2, egr3,
egr4, ehhadh, ehoc1, ei, eif1a, eif2g A, eif2s3 A, eif3s10, eif3s6, eif4a1, eif4a2,
eif4c, eif4e, eif4ebp1, eif4e2, eif4e11, eif4e12, eif4g, eif4g1, eif4g2, eif5a, ejm1,
el1, ela1, ela2, elam1, elanh2, elav11, elav12, elav14, elc, ele1, elf3, elk1, elk2, elk3,
20 elk4, el1, eln, em9, emap, emap1, emd, emd2, emk 1, emp1, emp55, emr1, ems1,
emt, emtb, emx1, emx2, en1, en2, ena78, end, endog, enfl2, eng, en1, eno1, eno2,
eno3, enpep, ent1, entk, enur1, enur2, enx2, eos, ep3, ep300, epa, epb3, epb311,
epb41, epb4112, epb42, epb49, epb72, epha1, epha2, epha3, epha8, ephb1, ephb2,
ephb3, ephb4, ephb6, eph1, eph2, eph3, ephx1, ephx2, epim, eplg1, eplg2, eplg3,
25 eplg4, eplg5, eplg8, epm1, epm2, epm2a, epmr, epo, epo, eppk, eprs, eps15, eps8,
ept, erba1, erba2, erba12, erba13, erbb2, erbb3, erbb4, erc55, ercc1, ercc2, ercc3,
ercc4, ercc5, ercc6, ercm1, erda1, erf1, erg, erg3, ergic53, erh, erk, erk1, erk2, erk3,
erm, erp11, erv1, erv1, erv3, ervr, ervt1ervt2, ervt3, ervt4, ervt5, eryf1, es1, es130,
esa, esa1, esa4, esat, esb3, esd, esg, esr, esr1, esr2, esr11, esr12, esrra, esrrb, esrrg,
ess1, est, est, est2, est25263, esx, etfa, etfb, etfdh, etk1, etk2, etm1, etm2, eto, ets1,
30 ets2, etv1, etv3, etv4, etv5, etv6, evc, evc1, evda, evdb, evi1, evi2a, evi2b,

-59-

evp1, evr1, evx1, evx2, ews, ewsr1, exlm1, ext1, ext2, ext3, ext11, ext12, eya1,
eya2, eya3, eyc11, eyc13, ezh1, ezh2, f10, f11, f12, f13a, f13a1, f13b, f2, f2r,
f2rl2, f2rl3, f3, f5, f5f8d, f7, f7e, f7r, f8a, f8b, f8c, f8vuw, f9, fa, fa1, faa, fabp1,
fabp2fabp3, fabp4, fabp6, fac1, faca, facc, facd, face, fac11, fac12, fac13, fac14,
5 facv11, fad, fadd, fadk, fah, fak2, faldh, fal139, falz, fanca, fancc, fancd, fance,
fancg, fap, fapa, farr, fas, fas1, fasn, fast1, fat, fau, fbln1, fbln2, fbn1, fbn2, fbn1,
fbp1, fcar, fcc1, fce, fce2, fcera1a, fcera1b, fcera1g, fcera2, fcgr1a, fcgr1b, fcgr1c,
fcgr2a, fcgr3a, fcgrt, fcnd, fcn1, fcn2, fcp, fcp1, fcpx, fct3a, fdc, fdft1, fdh, fdps11,
fdps12, fdps13, fdps14, fdps15, fdx1, fdxr, fe65, fe6511,fea, feb1, feb2, fecb, fech,
10 fen1, feo, feom, feom1, feom2, fer, fes, fet1, fevr, ffn, fga, fgarat, fgb, fgc@, fgd1,
fgdy, fgf1, fgf10, fgf11, fgf12, fgf13, fgf14, fgf2, fgf2, fgf3, fgf4, fgf5, fgf6, fgf7,
fgf8, fgf9, fgfa, fgfb, fgfr1, fgfr2, fgfr3, fgfr4, fgg, fgr, fgs1, fh, fh, fh3, fhc, fnf1,
fhf3, fhf4, fhh2, fhit, fh11, fh12, fhr2, fic1, figf, fih, fim, fim1, fim3, fimg, fkbp12,
15 fkbp1a, fkbp2, fkh2, fkh11, fkh110, fkh112, fkh115, fkh116, fkh117, fkh12, fkh15,
fkh16, fkh17, fkh18, fkh19, fkhr, fkhr11, flg, fli1, flii, fln1, fln2, flna, flnb, flnms,
flot2, flt1, flt2, flt3, flt4, fmf, fmn, fmo1, fmo2, fmo3, fmod, fmr1, fmr2, fms, fl1,
fn12, fnra, fnrb, fnrb1, fnta, fntb, folh, folh1, folr1, folr2, folt, fos, fosb, fos11,
20 fos12, fpah, fpc, fpd1, fpdmm, fpf, fpgs, fp1, fpp, fpr1, fprh1, fprh2, fpr11, fpr12,
fprp, fps12, fps13, fps14, fps15, fr, frap1, fraxa, fraxe, fraxf, frda, freac2, freac6,
freac9, frg1, frp1, frv1, frv2, frv3, fsg1, fsgs, fshb, fshd1a, fshmd1a, fshprh1, fshr,
fssv, fth1, fth16, ft1, ftz1, ftzfl, fuca1, fuca2, fur, fus, fuse, fut1, fut2, fut3, fut4,
fut5, fut6, fut7, fut8, fvt1, fxr1, fxy, fy, fyn, fzd1, fzd2, fzd3, fzd5, fzd6, fzd7, fzr,
25 g0s8, g10p1, g10p2, g17, g17p1, g19p1, g1p1, g1p2, g1p3, g22p1, g6pc, g6pd,
g6pd1, g6pd1, g6pt, g6pt1, g6s, g7p1, ga2, gaa, gabatr, gabpa, gabpb1, gabra1,
gabra2, gabra3, gabra4, gabra5, gabra6, gabrb1, gabrb2, gabrb3, gabrd, gabre,
gabrg1, gabrg2, gabrg3, gabrr1, gabrr2, gad1, gad2, gad3, gadd153, gadd45, gak,
ga1, galbp, galc, gale, galgt, galk1, galk2, galn, galnact, galnr, galnr1, galns, galnt1,
galnt2, galnt3, galr1, galt, gan, gan1, ganab, ganc, gap, gap1m, gap43, gapd, gar22,
garp, gars, gart, gas, gas1, gas2, gas41, gas6, gas7, gasr, gast, gata1, gata2, gata3,
30 gata4, gata6, gay1, gba, gbas, gbbb1, gbbb2, gbe1, gbp1, gbx2, gc, gcap, gcap2,

-60-

gcdh, gcfl, gcf2, gcfx, gcg, gcgr, gch1, gck, gckr, gcn511, gcn512, gcnf, gcnt1,
gcnt2, gcp, gcp2, gcs, gcs1, gcsf, gcsfr, gcsp, gctg, gcy, gda, gde, gdf5, gdf8, gdh,
gdi1, gdi2, gdid4, gdld, gdnf, gdnfr, gdnfra, gdnfrb, gdx, gdxy, ge, gem, geney, gey,
gfl, gfl, gfap, gfer, gfer, gfi1, gfpt, gfra1, gfra2, ggcx, ggt1, ggt2, ggtal, ggtb1,
5 ggtb2, gh1, gh2, ghc.RTM., ghdx, ghn, ghr, ghrf, ghrh, ghrhr, ghs, ghv, gif, gifb,
gip, gip, gipr, girk1, girk2, girk3, girk4, gja1, gja3, gja4, gja5, gja8, gjb1, gjb2, gjb3,
gk, gk2, gla, glat, glb1, glb2, glc1a, glc1b, glc1c, glc1d, glc1f, glc3a, glc3b, glc1c,
glc1r, glct2, glct3, gldc, glepp1, glg1, gli, gli2, gli3, gli4, glnn, glns, glo1, glo2,
10 glp1r, glra1, glra2, glra3, glrb, glrx, gls, glud1, glud2, glu1, glur1, glur2, glur3,
glur4, glur5, glur6, glur7, glut1, glut2, glut3, glut4, glut5, glvr1, glvr2, gly96, glya,
glyb, glys1, glyt1, glyt1, glyt2, gm2a, gma, gmcsf, gmcs, gm1, gmpr, gmpr, gna11,
gnal5, gna16, gnai1, gnai2, gnai2a, gnai2b, gnai21, gnai3, gna1, gnao1, gnaq, gnas,
gnas1, gnat1, gnat2, gnaz, gnb1, gnb2, gnb3, gng5, gn11, gnpta, gnrh1, gnrh2, gnrrh,
gns, gnt1, golga4, got1, got2, gp130, gp1ba, gp1bb, gp2, gp2b, gp39, gp3a, gp75,
15 gp78, gp9, gpa, gpam, gpat, gpb, gpc, gpc1, gpc3, gpc4, gpd, gpd1, gpd2, gpds1,
gpe, gpi, gpi2, gpm6a, gpm6b, gpoa, gpr1, gpr10, gpr11, gpr12, gpr13, gpr15,
gpr17, gpr18, gpr19, gpr2, gpr20, gpr21, gpr22, gpr23, gpr25, gpr29, gpr3, gpr30,
gpr31, gpr32, gpr35, gpr37, gpr39, gpr4, gpr5, gpr6, gpr7, gpr8, gpr9, gprcy4,
gprk21, gprk4, gprk5, gprk6, gprv28, gpsa, gpsc, gpt, gpx1, gpx2, gpx3, gpx4, gr2,
20 grb1, grb10, grb2, grf2, gria1, gria2, gria3, gria4, grid2, grik1, grik2, grik3, grik4,
grik5, grin1, grin2a, grin2b, grin2c, grin2d, grina, grk1, grk5, grk6, gr1, gr111,
grm3, grm8, grmp, grn, gro1, gro2, gro3, grp, grp58, grp78, grpr, grx, gs, gs1, gsas,
gsc, gsc1, gse, gshs, gs1, gsm1, gsn, gsp, gspt1, gsr, gss, gst12, gst11, gst2, gst2,
gst3, gst4, gst5, gsta1, gsta2, gstm1, gstm11, gstm2, gstm3, gstm4, gstm5, gstp1,
25 gstt2, gt1, gt335, gta, gtb, gtbp, gtd, gtf2e2, gtf2f1, gtf2h1, gtf2h2, gtf2h4, gtf2i,
gtf2s, gtf3a, gtg, guc1a2, guc1a3, guc1b3, guc2c, guc2d, guc2f, guca1a, guca1b,
guca2, guca2, guca2a, guca2b, gucsa3, gucsb3, gucy1a2, gucy1a3, gucy1b3, gucy2c,
guicy2d, gucy2f, guk1, guk2, gulo, gulop, gusb, gusm, gust, gxp1, gypa, gypb, gypc,
gype, gys, gys1, gys2, gzma, gzmb, gzmh, gzmm, h, h142t, h19, h1f0, h1f1, h1f2,
30 h1f3, h1f4, h1f5, h1fv, h2a, h2ax, h2az, h2b, h2b, h3f2, h3f3b, h3ft, h3t, h4, h4f2,

-61-

h4f5, h4fa, h4fb, h4fe, h4fg, h4fh, h4fi, h4fj, h4fk, h4fl, h4fm, h4m, h6, ha2, habp1,
hadha, hadhb, hadhsc, haf, hagh, hah1, haip1, ha1, hap, hap1, hap2, hars, has2, hat1,
hausp, hb1, hb1, hb6, hba1, hba2, hbac@, hbb, hbdc@, hbd, hbe1, hbegf, hbf2,
hbg1, hbg2, hbgr, hbhr, hbm, hbp, hbq1, hbz, hc2, hc3, hca, hcat2, hccs, hcdh, hcf2,
5 hcfc1, hcg, hck, h11, hc12, hc13, hc1s1, hcp, hcp1, hcs, hcvs, hd, hdac1, hdc, hdgf,
hdhc7, hdlbp, hdld, hdldt1, hdr, hed, hed, hegfl, hek, hek3, heln1, hem1, hema,
hemb, hemc, hempas, hen1, hen2, hep, hep10, her2, her4, herg, herv1, hes1, hesx1,
het, hexa, hexb, hf1, hf10, hfc1, hfe, hfe2, hfh11, hfsp, hgd, hgf, hgfl, hg1, hh,
hh72, hhc1, hhc2, hhd, hhh, hhmjg, hhr23a, hht1, hht2, hiap2, higm1, hilda, hint,
10 hiomt, hip, hip1, hip116, hip2, hir, hira, his1, his2, hive1, hivep1, hivep2, hjcd, hk1,
hk2, hk3, hk33, hke4, hke6, hkr1, hkr2, hkr3, hkr4, hl 11, hl19, hla-a, hla-b, hla-c,
hla-cda12, hla-dma, hla-dmb, hla-dna, hla-dob, hla-dpa1hla-dpb1, hla-dqa1, hla-
drlb, hla-dra, hla-e, hla-f, hla-g, hla-ha2, hladp, hlaf, hlals, hlcs, hlm2, hlp, hlp3,
hlr1, hlr2, hlt, hlx1, hlx9, hmaa, hmab, hmat1, hmbs, hmcs, hmg1, hmg14, hmg17,
15 hmg2, hmgc1, hmgcr, hmgcs1, hmgcs2, hmgic, hmgiy, hmgx, hmmr, hmnn2, hmox1,
hmox2, hmr, hms1, hmsn1, hmx1, hmx2, hnd, hnfla, hnf2, hnf3a, hnf3b, hnf4a,
hnp36, hnpcc6, hnrsa1, hnrsa2b1, hnrd, hnrf, hnrg, hnph1, hnph2, hnph3,
hnrpk, homg, hops, hox10, hox11, hox12, hox1@, hox1a, hox1b, hox1c, hox1d,
hox1e, hox1f, hox1g, hox1h, hox1i, hox1j, hox2@, hox2a, hox2b, hox2c, hox2d,
20 hox2e, hox2f, hox2g, hox2h, hox2i, hox3@, hox3a, hox3b, hox3c, hox3d, hox3e,
hox3f, hox3g, hox4@, hox4a, hox4b, hox4c, hox4d, hox4e, hox4f, hox4g, hox4h,
hox4i, hox7, hox8, hoxa1, hoxa10, hoxa11, hoxa13, hoxa3, hoxa4, hoxa5, hoxa6,
hoxa7, hoxa9, hoxa@, hoxb1, hoxb2, hoxb3, hoxb4, hoxb5, hoxb6, hoxb7, hoxb8,
hoxb9, hoxb@, hoxc12, hoxc13, hoxc4, hoxc5, hoxc6, hoxc8, hoxc9, hoxc@,
25 hoxd1, hoxd10, hoxd11, hoxd12, hoxd13, hoxd3, hoxd4, hoxd8, hoxd9, hoxd@,
hoxhb9, hp, hp4, hpafp, hpc1, hpc2, hpc4, hpcal1, hpcx, hpd, hpdr1, hpdr2, hpe1,
hpe2, hpe3, hpe4, hpe5, hpect1, hpfh, hpfh2, hpgd, hplh1, hplh2, hpn, hpr, hprt,
hprt1, hps, hpt, hpt1, hptp, hptx, hpv18i1, hpv18i2, hpx, hr, hras, hrb, hrc, hrc1,
hrca1, hrd, hres1, hrf, hrg, hrga, hrh1, hrh2, hrmt111, hrpt2, hrx, hrx, hry, hsa11,
30 hsa12, hsan1, hsas1, hsas2, hsd11, hsd11b1, hsd11b2, hsd11k, hsd111, hsd17b1,

-62-

hsd17b2, hsd17b3, hsd17b4, hsd3b1, hsd3b2, hsh, hsn1, hsorc1, hsp27, hsp73,
hspa1a, hspa1b, hspa11, hspa2, hspa3, hspa4, hspa5, hspa6, hspa7, hspa8, hspa9,
hspb1, hspb2, hspc2, hspca11, hspca12, hspca13, hspca14, hspcb, hspg1, hspg2,
hsr1, hsst, hstd, hstf1, htc2, htf4, htk, htk1, ht1, htlf, htlvr, htn1, htn2, htn3, htnb,
5 htor, htr1a, htr1b, htr1d, htr1e, htr1e1, htr1f, htr2a, htr2b, htr2c, htr3, htr4, htr5a,
htr6, htr7, htrx1, hts1, htt, htx, htx1, hub, hud, hup2, hur, hus, hvls, hvbs1, hvbs6,
hvbs7, hvem, hvh2, hvh3, hvh8, hxb, hxb1, hy, hya, hya11, hyd2, hygn1, hy1, hyp,
hyplip1, hypp, hypx, hyr, hyrc1, hys, ia1, ia2, iap, iapp, iar, iars, ibd1, ibd2, ibm2,
ibsp, ica1, icam1, icam2, icam3, icca, ich1, icr2, icr2b, ics1, id1, id2, id3, id4, ida,
10 idd, iddm1, iddm10, iddm11, iddm12, iddm13, iddm15, iddm17, iddm2, iddm3,
iddm4, iddm5, iddm6, iddm7, iddm8, iddmx, ide, idg2, idh1, idh2, idh3a, idh3g, ido,
ids, idua, ier1, ier3, iex1, if, ifcr, ifgr2, ifi16, ifi27, ifi35, ifi4, ifi5111, ifi54, ifi56,
ifi616, ifi78, ifna1, ifna10, ifna13, ifna14, ifna16, ifna17, ifna21, ifna6, ifna7, ifna8,
ifna@, ifnai1, ifnar1, ifnar2, ifnb1, ifnb2, ifnb3, ifng, ifngr1, ifngr2, ifngt1, ifnr,
15 ifnw1, ifrd2, iga, igat, igs, igbp1, igd1, igda1, igdc1, igds2, iger, iges, igf1, igf1r,
igf2, igf2r, igfbp1, igfbp10, igfbp2, igfbp3, igfbp4, igfbp6, igfbp7, igfr1, igfr2, igfr3,
igh@, igha1, igha2, ighd, ighdy2, ighg1, ighg2, ighg3, ighg4, ighj, ighm,
ighmbp2, ighr, ighv@, igi, igj, igk@, igkc, igkde1, igkj, igkjr1, igkv, iglc, iglc1,
iglj, iglp1, iglp2, iglv, igm, igo1, igsf1, ihh, ik1, ikba, il10, il10r, il11, il11ra, il12a,
20 il12b, il12rb1, il12rb2, il13, il13ra1, il13ra2, il15, il15ra, il17, il1a, il1b, il1bc, il1r1,
il1r2, il1ra, il1rap, il1rb, il1rn, il2, il2r, il2ra, il2rb, il2rg, il3, il3ra, il3ray, il4, il4r,
il4ra, il5, il5ra, il6, il6r, il6st, il7, il7r, il8, il8ra, il8rb, il9, il9r, ila, ilf1, illbp, imd1,
imd2, imd4, imd5, imd6, impa1, impdh1, impdh2, impdh11, impg1, impt1, indx,
infa2, infa4, infa5, ing1, inha, inhba, inhbb, inhbc, ini1, ink4b, inlu, inp10, inpp1,
25 inpp5a, inpp5b, inpp5d, inpp11, ins, insig1, ins1, ins13, ins14, insr, insrr, int1,
int111, int2, int3, int4, int6, iosca, ip2, ipf1, ip1, ipm150, ipox, ipp, ipp2, ipw,
iqgap1, ir10, ir20, ireb1, ireb2, irf1, irf2, irf4, irf4, irr, irs1, isa, iscw, is11, islr, isot,
issx, it15, itba1, itba2, itf, itf2, itga1, itga2, itga2b, itga4, itga5, itga6, itga7, itgad,
itga1, itgam, itgav, itgax, itgb1, itgb2, itgb3, itgb4, itgb6, itgb7, iti, itih1, itih2, itih3,
30 itih4, itih11, iti1, itk, itm1, itpa, itpka, itpkb, itpr1, itpr2, itpr3, itsn, ivd, iv1, jag1,

-63-

jak1, jak2, jak3, jbs, jcap, jh8, jip, jk, jme, jmj, joag, jpd, jrk, jrk1, jtk14, jtv1, jun,
junb, jund, jup, jv18, jws, k12t, kai1, kal1, kar, kars, katp1, kcna1, kcna10, kcna1b,
kcna2b, kcna3, kcna4, kcna5, kcna6, kcna7, kcna8, kcna9, kcnab1, kcnab2, kcnb1,
kcnc1, kcnc2, kcnc3, kcnc4, kcne1, kcnh1, kcnh2, kcnj1, kcnj10, kcnj11, kcnj12,
5 kcnj15, kcnj3, kcnj4, kcnj5, kcnj6, kcnj6, kcnj7, kcnj8, kcnjn1, kcnk1, kcnk2,
kcnk3, kcnma1, kcnq1, kcnq2, kcnq3, kcnq4, kcns2, kd, kdr, ke1, kera, kf1, kfs,
kfsd, kfs1, khk, kiaa0122, kid, kid1, kif2, kif3c, kif5b, kip1, kip2, kiss1, kit, klc2,
klk1, klk2, klk3, klk3, klkb1, klkr, klr1, klrc1, klrc2, klrc3, klrc4, kld1, klst, kms,
kms, kng, kno, kns1, kns2, kns11, kns14, kox1, kox11, kox12, kox13, kox15, kox16,
10 kox18, kox19, kox2, kox2, kox22, kox25, kox30, kox32, kox4, kox5, kox6, kox7,
kox9, kpna3, kpps1, kpps2, krag, kras1p, kras2, krev1, krg2, krn1, krn11, krox20,
krt1, krt10, krt12, krt13, krt14, krt15, krt16, krt17, krt18, krt19, krt2a, krt2e, krt3,
krt4, krt5, krt6a, krt6b, krt7, krt8, krt9, krtha2, krtha5, krthb1, krthb6, ks, ktn1, ku70,
kup, kvlqt1, kwe, 11.2, 11 cam, 123mrp, lab7, lab72, lac, laci, lacs, lad, lad, lad1,
15 laf4, lag3, lag5, lair1, lak1, lalba, lal1, lam1, lama1, lama2, lama3, lama4,
lama5, lamb1, lamb2, lamb2, lamb2t, lamb3, lambr, lamc1, lamc2, lamm, lamnb2,
lamp, lamp1, lamp2, lamr1, lams, lap, lap18, laptm5, lar, lar1, lard, large, lars, lbp,
lbr, lca, lca1, Icad, Icam, lcat, lccs, lcfs2, lch, lck, lcn1, lcn2, lco, lcp1, lcp2, lct, ld,
ld78, ldb1, ldb2, ldc, ldh1, ldh3, ldha, ldhb, ldhc, ld1r, le, lect2, lefl, lefty1, lefty2,
20 lep, lepr, lerk5, lerk8, leu1, leu7, leut, lfa1a, lfa3, lf11, lfp, lga1s1, lga1s3,
lga1s3bp, lga1s7, lgcr, Igmd1, lgmd1a, lgmd1b, lgmd1c, lgmd1d, lgmd2b, lgmd2c,
lgmd2d, lgmd2e, lgmd2f, lgmd2g, lgmd2h, lgs, lgtn, lhb, lhcgr, lhs, lhx1, lhx3, li,
li2, lif, lifr, lig1, lig3, lig4, lim1, lim2, limab1, limk1, limpii, lip2, lipa, lipb, lipc,
lipd, lipe, lipo, lis1, lis2, lisx, litaf, lkb1, lkn1, llg11, lman1, lm1, lm2, lmna,
25 lmnb1, lmnb2, lmo1, lmo2, lmo3, lmo4, lmo5, lmp10, lmp2, lmp7, lmpx, lms, lmx1,
lmx1a, lmx1b, lmvc, lnhr, lnrh, locr, loh11cr2a, lor, lot1, lox, lox1, lox11, lpa, lpaab,
lpaata, lpap lpc1, lpc2d, lpd1, lph, lpi, lp1, lpna3, lpp, lps, lpsa, lqt1, lqt2, lqt3, lqt4,
lr3, lrel, lre2, lrp, lrp1, lrp2, lrp5, lrp7, lrp8, lrpa1, lrpr1, lrs1, lsamp, lsirf, ls1, lsn,
Isp1, lss, lst1, lta, lta4h, ltb, ltb4r, ltb1, ltb2, ltb3, ltb3, ltb3, ltb3, ltb3, ltc4s, Itf, ltk,
30 ltn, lu, lum, luxs, luzp, lw, ly64, ly6e, ly9, lyam1, lyb2, lyf1, ly11, lyn, lyp, lyst,

-64-

lyt10, lyz, lztr1, m11s1, m130, m17s1, m17s2, m195, m1s1, m3s1, m4s1, m6a, m6b,
m6p2, m6pr, m6s1, m7v1, m7vs1, mab211, mac1a, mac2, mac25, macam1, macs,
mad, mad211, madd, madh1, madh2, madh3, madh4, madh5, madh6, madh6,
madh7, madh9, madm, madr1, maf, mafd1, mafd2, mag, mage1, mageb3, mageb4,
5 mage11, magoh, magp, magp1, magp2, mak, ma1, ma11, man2a2, mana1, mana2,
mana2x, manb, manb1, manba, maoa, maob, map1a, map1a1c3, map1b, map1b1c3,
map2, map4, map80, map97, mapk1, mapkap3, mapkkk4, mapt, mar, mark3, mars,
mas1, masp1, mat1a, mat2a, mata1, mata2, matk, matn1, matn3, max, maz, mb,
mbd1, mb1, mb12, mbp, mbp1, mbs, mbs2, mc1r, mc2r, mc3r, mc4r, mc5r, mcad,
10 mcc, mcdc1, mcdr1, mcf2, mcf3, mcf1, mch2, mch3, mch4, mch5, mckd, mc1,
mc11, mcm, mcm2, mcm2, mcm3, mcm6, mcm7, mcmt, mcop, mcor, mcp, mcp1,
mcp3, mcph1, mcr, mcs, mcsf, mcsp, mct1, md1, mdb, mdc, mder, mddc, mdeg,
mdfl1, mdg, mdg1, mdh1, mdh2, mdk, mdk, mdm2, mdm4, mdr1, mdr3, mdrs1,
mdrv, mds, mds1, mdu1, mdu2, mdu3, mdx, me1, me2, mea, mea6, mec11, mecp2,
15 med, mef, mef2a, mef2b, mef2c, mef2d, mefv, mehmo, meis1, meis2, mekk, mekk1,
mekk4, me1, mel18, melf, memo1, men1, men2a, meox1, meox2, mep1a, mep1b,
mer2, mer6, mest, met, metrs, mfap1, mfap2, mfap3, mfap4, mfd1, mfi2, mfs1,
mfs2, mft, mfts, mg50, mga, mga1, mga3, mgat1, mgat2, mgat5, mgc1, mgcn, mgcr,
mgct, mgdf, mgea, mgf, mgi, mgmt, mgp, mgsa, mgst1, mgst2, mhc, mhc2ta, mhp2,
20 mhs, mhs2, mhs3, mhs4, mhs6, mia, mic10, mic11, mic12, mic17, mic18, mic2,
mic2x, mic2y, mic3, mic4, mic7, mica, micb, mid1, midas, mif, mif, mig, mip,
mip2a, mip2b, mip3b, mipep, mitf, miwc, mjd, mk, mki67, mkks, mkp2, mkp3,
mkpx, mks, mks, mks1, mks2, mla1, mlck, mlfl1, mlfl2, mlh1, mlk1, mlk3, ml1,
ml12, ml1t1, ml1t2, ml1t3, ml1t4, ml1t6, ml1t7, mlm, mlm, mln, mlp, mlr, mrlg,
25 mlrw, mls, mltn, mlvar, mlvi2, mlvt, mmacl, mme, mmpl1, mmpl10, mmpl11,
mmpl12, mmpl13, mmpl14, mmpl15, mmpl16, mmpl17, mmpl19, mmpl2, mmpl21,
mmpl22, mmpl3, mmpl7, mmpl8, mmpl9, mn, mn, mnb, mnbb, mnnd, mng1, mnk,
mns, mnt, mocod, mocs1, mocs2, mody1, mody3, mog, mok2, mom1, mos, mot2,
mov34, mox1, mox2, mox44, moz, mp19, mpb1, mpd1, mpdz, mpe, mpe16, mpg,
30 mpi, mpif2, mp1, mp11g, mpo, mpp1, mpp2, mpp3, mppb, mpri, mprn, mps2,

-65-

mps3a, mps3c, mps4a, mpsh, mpts, mpv17, mpz, mr1, mr77, mrbc, mrc1, mre11,
mre11a, mrg1, mrgh, mros, mrp, mrp, mrp1, mrp123, mrs, mrsd, mrsr, mrst, mrx1,
mrx14, mrx2, mrx20, mrx21, mrx23, mrx29, mrx41, mrx48, mrx49, mrx9, mrxa,
mrxs1, mrxs2, mrxs3, mrxs4, mrxs5, mrxs6, mrxs8, ms3315, ms336, msg1, msh2,
5 msh3, msh4, msh6, msi1, msk16, msk39, msk41, mslr1, msmb, msn, msr1, mss1,
mss4, mss4, msse, mst, mst1, mst1r, mstd, mstn, msud1, msx1, msx2, mt1a, mt1b,
mt1e, mt1f, mt1g, mt1h, mt1i, mt1j, mt1k, mt1l, mt1x, mt2, mt2a, mt3, mtacr1,
mtap, mtbt1, mtcp1, mterf, mtfl, mth1, mthfc, mthfd, mthfr, mtk1, mtm1, mtmr1,
mtmx, mtnr1a, mtnr1b, mtp, mtpa, mtr, mtrns, mtrr, mts, mts, mts1, mts1, mts2,
10 mttf1, mtx, mtn, mu, muc1, muc2, muc3, muc4, muc5, muc5ac, muc5b, muc6,
muc8, mu1, mum1, mupp1, musk, mut, mvk, mvlk, mvwf, mwfe, mx, mx1, mx2,
mxi1, mxs1, myb, myb11, myb12, mybpc1, mybpc2, mybpc3, mybpcf, mybph,
myc, myc11, myc12, myclk1, mycn, myd88, myf3, myf4, myf5, myf6, myh1,
myh10, myh11, myh12, myh2, myh3, myh4, myh6, myh7, myh8, myh9, myk1,
15 my1, my11, my12, my13, my14, my15, mylk, mymy, myo10, myo15, myo1a,
myo1c, myo1d, myo1e, myo5a, myo6, myo7a, myo9b, myoc, myod1, myog, myp1,
myp2, myp3, myr5, mzfl, n33, nab1, nab2, nabc1, nac1a, naca, nace, nacp, nadmr,
naga, nagc@, naglu, nagr1, naip, namsd, nanta3, nap114, nap2, nap21, napb, naptb,
nars, nat1, nat1, nat2, nb, nb4s, nbat, nbc3, nbccs, nbccs, nbial, nbs, nbs, nbs1, nca,
20 ncad, ncad1, ncan, ncbp, ncc1, ncc2, ncc3, ncc4, ncct, ncfl, ncf2, ncf4, nck, nc1,
ncst2, ncx1, ncx2, nd, ndhii, ndn, ndp, ndst1, ndufa1, ndufa2, ndufa5, ndufa6,
ndufa7, ndufb8, ndufb9, ndufs1, ndufs2, ndufs4, ndufs7, ndufs8, ndufv1, ndufv2,
ndufv3, neb, nec1, nec2, nedd1, nedd2, nedd4, nefh, nef1, negf1, negf2, ne111,
neb112, nem1, neo1, nep, net, net1, neu, neu, neud4, neurod, neurod2, neurod3, nf1,
25 nf1a, nf2, nfatcl, nfatc2, nfatp, nfe1, nfe2, nfe211, nfe212, nfe2u, nfia, nfib, nfic,
nfix, nkfb1, nkfb2, nkfb3, nkfbia, nkfb11, nkfb, nfya, nfyb, ngal, ngbe, ngfb, ngfg,
ngfic, ngfr, ng1, ngn, nhbp, nhcp1, nhcp2, nhe1, nhe3, nhe4, nhe5, nhlh1, nhlh2,
nhp211, nhs, nid, niddm1, ninj1, nipp1, nipsnap1, nipsnap2, nis, nkrl, nkcc1, nkcc2,
nkg2, nkg2a, nkg2c, nkg2e, nkg2f, nkhc, nkna, nknar, nknb, nkRp1a, nks1, nksf2,
30 nktr, nkx2a, nkx3.2, nkx3a, nkx6a, nli, nm, nm1, nm23, nmb, nmbr, nmdar1,

-66-

nmdar2a, nmdar2b, nmdar2c, nmdar2d, nmdara1, nme1, nme2, nme4, nmor1,
nmor2, nms1, nmvc, nnat, nmnt, nno1, nog, noll, nos1, nos2a, nos2b, nos2c, nos3,
not, notch1, notch2, notch3, notch4, nov, nov, nov2, nova1, nova3, novp, np, np10,
npat, npc, npc1, npd, nph1, nph2, nphl2, nphn, nphp1, nphp2, nphs1, npm1, nppa,
5 nppb, nppc, npps, npr1, npr2, npr3, nps1, npt1, npt2, nptx2, npy, npy1r, npy2r,
npy3r, npy5r, npy6r, nqo2, nramp, nramp1, nramp2, nrap, nras, nrb54, nrcam, nrd1,
nrfl1, nrfl1, nrf2, nrgn, nrip1, nrk2, nr1, nrtn, nru, ns1, nsf, nsp, nsp11, nsrd9, nt4, nt5,
nt5, ntcp1, ntcp2, ntf3, ntf4, ntf5, nth11, ntn, ntn, ntn21, ntrk1, ntrk2, ntrk3, ntrk4,
ntrkr1, ntrkr3, nts, ntt, ntu, nuc1, nucb1, numal1, nup214, nup98, nurr1, nv1, nys1,
10 nys2, nysa, oa1, oa2, oa3, oar, oasd, oat, oat11, oat22, oat23, oatp, oaz, ob, ob10,
obf1, obp, obr, oca2, ocm, ocp2, ocr1, ocr11, oct, oct1, oct1, oct2, oct2, oct3, oct7,
octn2, octs3, odc1, oddd, odf1, odg1, odod, ofc1, ofc2, ofc3, ofd1, ofe og22, ogdh,
ogg1, ogr1, ogs1, ogs2, ohds, ohs, oias, oip1, ok, olf1, olfimf, olfr1, olfr2, omg,
omgp, omp, on, op2, opa1, opa2, opa3, opca3, opcm1, opd1, opg1, ophn1, op11,
15 opn, oppg, oprd1, oprk1, oprm1, oprt, opta2, optb1, oqt1, orld2, orlf1, orc11, orc21,
orc41, orc51, orfx, orm1, orm2, orw, osbp, osm, osp, ost, ost48, osx, otc, ofl1, oft2,
oft3, otm, ofof, ots, otx1, otx2, ovc, ovcs, ovo11, ox40, oxal1, oxct, oxt, oxtr, ozf, p,
p, p1, p15, p16, p167, p28, p2rx3, p2rx4, p2ry1, p2ry2, p2ry4, p2ry7, p2u, p2x3,
p2x4, p2y1, p2y2, p2y4, p3p40phox, p450c11, p450c17, p450c2a, p450c2d,
20 p450c2e, p450scc, p4ha, p4ha1, p4hb, p5cdh, p79r, pa2g4, pab1, pab2,
pabp2, pabp11, pac1, pac1, pacapr, pace, pace4, paep, pafl, paf2, pafah, pafah1b1,
pafah1b2, pafah1b3, paga, pah, pahx, pai1, pai2, paics, pak1, pak3, palb, pals, pam,
pang, pap, papa, papa2, pappa, par1, par1, par2, par3, par4, par4, par5, park1, park2,
park3, pawr, pax1, pax2, pax3, pax4, pax5, pax6, pax7, pax8, pax9, pbca, pbcra,
25 pbfe, pbgt, pbgt, pbx1, pbx2, pbx3, pc, pc1, pc2, pc3, pc3, pca1, pcad, pcap, pcar1,
pcbc, pcbd, pcgp1, pcgp2, pcca, pccb, pcdh7, pcdx, pchc, pchc1, pci, pck1, pc1,
pc1p, pcm1, pcm1, pcmt1, pcna, pcnt, pcolce, pcp, pcp4, pcs, pcsk1, pcsk2, pcsk3,
pcsk4, pcsk5, pcsk6, pctk1, pctk3, pcyt1, pdb, pdb2, pdc, pdc, pdcd1, pdcd2, pddr,
pde1a, pde1b, pde1b1, pde3b, pde4a, pde4b, pde4c, pde4d, pde5a, pde6a, pde6b,
30 pde6c, pde6d, pde6g, pde6h, pde7a, pdea, pdea2, pdeb, pdeb, pdeg, pdeslb, pdgb,

-67-

pdgfa, pdgfb, pdgfr, pdgfra, pdgfrb, pdha1, pdha2, pdhb, pdj, pdk4, pdnp1, pdnp2,
pdnp3, pdr, pds, pds1, pdx1, pdyn, pe1, pea15, pebp2a1, pebp2a3, pecam1, ped, ped,
pedf, pee, peg1, peg3, pemp, penk, pent, peo, peo1, peo2, pepa, pepb, pepc, pepd,
pepe, pepn, peps, per, per2, peta3, pets1, pex1, pex5, pex6, pex7, pf4, pf4v1, pfas,
5 pfbi, pfc, pfd, pfhb1, pfic1, pfic2, pfkfb1, pfkfb2, pfk1, pfk-mn, pfkp, pfkx, pf1,
pfm, pfn1, pfn2, pfrx, pga3, pga4, pga5, pgam1, pgam2, pgamm, pgc, pgd, pgf, pgft,
pgk1, pgk2, pgka, pg1, pgl1, pgl2, pgm1, pgm2, pgm3, pgm5, pgn, pgp, pgp1, pgr,
pgs, pgt, pgy1, pgy3, pha1, pha2, pha2a, pha2b, phap1, phb, phc, phe1a, phe3, phex,
phf1, phhi, phhi, phk, phka1, phka2, phkb, phkd, phkg1, phkg2, ph1, phl11, phog,
10 phox1, phox2a, php, php1b, phpx, phyh, pi, pi10, pi3, pi4, pi5, pi6, pi7, pi8, pi9,
piga, pigc, pigf, pigh, pigr, pik3c2b, pik3ca, pik3r1, pik4cb, pi1, pim1, pin, pin1,
pin11, pip, pip5k1b, pir1, pir51, pit, pit1, pitpn, pitx1, pitx2, pitx3, pjs, pk1, pk120,
pk3, pk428, pkca, pkcb, pkcc, pkcg, pkcs1, pkd1, pkd2, pkd4, pkdts, pkhd1, pklr,
pkm2, pkp1, pks1, pks1, pks2, pku1, pl, pla2, pla2a, pla2b, pla2g1b, pla2g2a,
15 pla2g4, pla2g4a, pla2g5, pla21, pla21, plag1, plag11, planh1, planh2, planh3, plat,
plau, plaur, plb, plc, plc1, plcb3, plcb4, plcd1, plce, plcg1, plcg2, plc1, pld1, plec1,
plg, plgf, plg1, pli, pln, plod, plod2, plos1, plp, pls, pls1, plt1, pltn, pltp, plzf, pmca1,
pmca2, pmca3, pmca4, pmch, pmch11, pmch12, pmd, pme117, pmi1, pm1, pmm1,
pmm2, pmp2, pmp22, pmp35, pmp69, pmp70, pms1, pms2, pms11, pms12, pmx1,
20 pn1, pnd, pnem, pnkd, pnlip, pnmt, pnoc, pod1, podx1, pof, pof1, po12rb, pola,
polb, pold1, pold2, pole, polg, polr2a, polr2c, polr2e, polr2g, polr2i, polrmt, polz,
pomc, pon, pon1, pon2, pon3, por, porc, potx, pou1f1, pou2af1, pou3f1, pou3f2,
pou3f3, pou3f4, pou4f1, pou4f3, pou5f1, pp, ppl4, pp2, pp4, pp5, ppac, ppard,
pparg, pparg1, pparg2, ppat, ppbp, ppcd, ppd, ppef1, ppef2, ppfia3, ppgb, pph, pph1,
25 ppi, ppid, ppi1, ppkb, ppks1, ppks2, pp1, ppla2, ppmx, ppnd, ppnoc, ppo1, ppox,
ppp1a, ppp1ca, ppp1cb, ppp1cc, ppp1r2, ppp1r5, ppp1r7, pppd1r8, ppp2b, ppp2ca,
ppp2cb, ppp2r1b, ppp2r4, ppp2r5a, ppp2r5b, ppp2r5c, ppp2r5d, ppp2r5e, ppp3ca,
ppp3cb, ppp3cc, pp3r1, ppp4c, ppp5c, ppt, ppt2, ppx, ppy, ppyr1, pr@, prad1, prb1,
prb2, prb3, prb4, prca1, prca2, prcc, prcp, pre1p, prep, prf1, prg, prg1, prg1, prgs,
30 prh1, prh2, prim1, prim2a, prim2b, pripl, prk1, prkaal, prkaa2, prkab1, prkaca,

-68-

prkacb, prkacg, prkag1, prkag2, prkar1a, prkar1b, prkar2b, prkca, prkcb1, prkcd,
prkcg, prkci, prkcl1, prkcnh1, prkcq, prkcsh, prkdc, prkg1, prkg1b, prkg2, prkgr1b,
prkgr2, prkm1, prkm3, prkm4, prkm9, prkn, prkr, prkx, prky, prl1, prlr, prm1, prm2,
prmt2, prnp, proa, proc, prodh, prohb, prop1, pros1, pros30, prox1, prp8, prph,
5 prps1, prps2, pipsap1, prr1, prr2, prs, prsc1, prss1, prss11, prss2, prss7, prss8, prss11,
prtn3, prts, psa, psa, psach, psap, psbg1, psbg2, psc2, psc5, psca, psd, psen1, psen2,
psf1, psf2, psg1, psg11, psg12, psg13, psg2, psg3, psg4, psg5, psg6, psg7, psg8,
psg11, pskh1, psm, psma1, psma2, psma3, psma5, psmb1, psmb10, psmb2, psmb3,
psmb4, psmb5, psmb8, psmb9, psmc1, psmc2, psmc3, psmc5, psmd7, psmd9,
10 psme1, psme2, psors1, psors2, psors3, psp, psp1, psp2, pss1, psst, pst, pst, pst1,
pst1, ptafr, ptc, ptc, ptc, ptch, ptd, pten, ptgds, ptger1, ptger2, ptger3, ptgfr, ptgfrn,
ptgir, ptgs1, ptgs2, pth, pthlh, pthrh, pthr1, pthr2, ptk1, ptk2, ptk2b, ptk3, ptk7, ptlah,
ptma, ptms, ptn, ptos1, ptp18, ptp1b, ptp4a1, ptp4a2, ptpa, ptpa, ptpd, ptpg, ptpg1,
ptpgmc1, ptpn1, ptpn10, ptpn11, ptpn12, ptpn13, ptpn14, ptpn2, ptpn5, ptpn6,
15 ptpn7, ptpra, ptprb, ptprc, ptprcap, ptprd, ptpre, ptprf, ptprg, ptprh, ptppj, ptprk,
ptpr11, ptpr12, ptprm, ptprn, ptpro, ptprs, ptprz1, ptpt, pts, pts1r, ptx1, ptx3, pujo,
pum, pur1, pur1, pura, pvalb, pvr, pvr11, pvr12, pvrr1, pvrr2, pvs, pvt1, pwcr, pwp2,
pwp2h, pws, pxaaa1, pxe, pxe1, pxf, pxmp1, pxmp11, pxmp3, pxr1, pycr1, pycs,
pygb, pyg1, pygm, pyk2, pyst1, pyst2, pzp, qars, qdpr, qin, qm, qpc, qprs, rab, rab1,
20 rab13, rab1a, rab21, rab3a, rab3b, rab4, rab5, rab5a, rab6, rab7, rabgdla, rabgdib,
rabggta, rabggtb, rabif, rac2, rac3, rad1, rad17, rad23a, rad23b, rad51a, rad51c,
rad51d, rad5311, rad52, rad54, rad6a, rad6b, raf1, rafa1, rag1, rag2, rage, rala, ralb,
ralgds, ramp, ranbp211, ranbp3, rao, rap1a, rap1b, rap1ga1, rap1gds1, rap2a, rap74,
rapsn, rara, rarb, rarg, rars, rasa1, rasa2, rasgfr3, rask2, rb1, rbbp2, rbbp5, rbbp6,
25 rb11, rb12, rbm1, rbm2, rbm3, rbmy1a1, rbp1, rbp2, rbp3, rbp4, rbp5, rbp56, rbp6,
rbq3, rbtn1, rbtn11, rbtn12, rca1, rcac@, rcc1, rccp1, rccp2, rcd1, rcd2, rcdp1, rcn1,
rcn2, rcp, rcv1, rd, rdbp, rdc7, rdp, rdpa, rdrc, rds, rdt, rdx, reca, recc1, recq1, red1,
red2, reg, reg1a, reg1, rel1, rela, reln, ren, renbp, rents1, rent1, rep8, req, ret, rev3,
rev31, rfc1, rfc2, rfc3, rfc4, rfc5, rfp, rfx1, rfx2, rfx5, rfxank, rfxap, rgc1, rgr, rgs,
30 rgs1, rgs14, rgs16, rgs2, rgs2, rgs3, rgs5, rh50a, rhag, rhbd1, rhc, rhce, rhd, rheb2,

-69-

rho, rho7, rhogap2, rhogap3, rhoh12, rhoh6, rhoh9, rhok, rhom1, rhom2, rhom3,
rieg1, rieg2, rige, rigui, ring1, ring10, ring11, ring12, ring3, ring31, ring4, ring5,
ring6, ring7, rip, rip140, riz, rk, r1, rlpb1, rlf, rln1, rln2, rmch1, rmd1, rmrp, rmrpr,
rn5s1@, rnase1, rnase2, rnase3, rnase4, rnase5, rnase6, rnase1, rmaseli, rne1, rnfl,
5 rnf3, rnf4, rnf5, rnh, rmep, mpulz, mnr1, mnr2, mnr3, mnr4, mnr5, rms1, rms2, rms3, rms4,
rms4, rms4i, rntmi, rnu1, rnu15a, rnu17a, rnu17b, rnula, rnu2, rnu3, ro52, rom1,
romk1, ron, ror1, rora, rorb, rorc, rorg, ros1, rosp1, rox, rp1, rp10, rp105, rp11, rp12,
rp13, rp14, rp15, rp17, rp18, rp19, rp2, rp22, rp24, rp25, rp3, rp4, rp6, rp7, rp9,
rp1, rpa2, rpa3, rpd311, rpe, rpe65, rpe119rp122, rp123a, rp1231, rp129, rp130,
10 rp135a, rp136a, rp17a, rpms12, rpn1, rpn2, rpo12, rps11, rps14, rps17, rps17a,
rps17b, rps1711, rps1712, rps18, rps20a, rps20b, rps24, rps25, rps3, rps4x, rps4y,
rps6, rps6ka1, rps6ka2, rps6ka3, rps8, rpsm12, rptpm, rpu1, rpx, rrad, rras, rrbp1,
rreb1, rrm1, rrm2, rrp, rrp22, rs1, rs1, rscl1, rsk1, rsk2, rsk3, rsn, rss, rsts, rsu1, rt6,
rtef1, rtkn, rtn1, rtn2, rts, rts, rtt, rws, rxra, rxrb, rxrg, ryr1, ryr2, ryr3, rzrb, rzrg,
15 s100a1, s100a10, s100a11, s100a12, s100a13, s100a2, s100a3, s100a4, s100a5,
s100a6, s100a7, s100a8, s100a9, s100b, s100d, s100e, s100, s100p, s152, s4, s7,
saa1, saa2, saa4, sacs, safb, sag, sah, sahh, sai1, sakap84, sal11, sal12, sams1,
sams2, sap, sap1, sap1, sap2, sap62, sar, sar1, sar2, sard, sas, sat, satb1, satt, sbma,
sc, sc1, sc5d1, sca1, sca10, sca2, sca2, sca3, sca4, sca5, sca6, sca7, sca8, sca8, scar,
20 scca1, scca2, sccd, scd, sceh, scg1, scg2, scg3, schad, scida, scidx, scidx1, sc1, sclc1,
scl1, scn, scn1a, scn1b, scn2a, scn2a1, scn2a2, scn2b, scn3a, scn4a, scn5a, scn6a,
scn8a, scnn1a, scnn1b, scnn1d, scnn1g, scot, scp, scp1, scp2, scp, scra1, scra1, scs,
sctr, scya1, scya11, scya13, scya14, scya15, scya16, scya19, scya2, scya21, scya22,
scya24, scya25, scya3, scya311, scya4, scya5, scya7, scya8, scyb5, scyb6, scyd1,
25 sczd1, sczd2, sczd3, sczd4, sczd5, sczd6, sczd7, sczd8, sdc1, sdc2, sdc4, sdf1, sdf2,
sdh1, sdh2, sdha, sdhb, sdhc, sdhd, sdhf, sds22, sdty3, sdys, se, sea, sec1311, sec13r,
sec14l, sec7, sed1, sedt, sef2, sel11, sele, sel1, sepl, sepl1g, sema3f, sema4, sema5,
semg, semg1, semg2, sen1, sep, sepp1, serca1, serca3, serk1, ses1, set, sex, sf, sf1,
sf1, sfd, sfmd, sfra1, sfra2, sfra7, sfra3, sfra1, sfra2, sfra4, sfra1, sfra2, sfra3,
30 sfra4, sfra5, sfra6, sfra7, sfra8, sfra9, sfra10, sfra11, sfra12, sfra13, sfra14, sfra15,

-70-

sgpa, sgsh, sh2d1a, sh3bp2, sh3d1a, sh3gbr, sh3p17, shb, shbg, shc1, shc11, shfd1,
shfd2, shfm1, shfm2, shfm3, shh, ship, shmt1, shmt2, shoc2, shot, shox, shox2,
shps1, shs, shsf1, si, siah1, siah2, siasd, siat1, siat4, siat4c, siat8, sids, si1, silv, sim1,
sim2, sipa1, sis, siv, six1, six5, sja, sjt, ski, ski2, ski2w, skiv21, skp1a, skp1b, skp2,
5 sla, slap, slbp, slc, slc10a1, slc10a2, slc12a1, slc12a2, slc12a3, slc14a1, slc14a2,
 slc15a1, slc16a1, slc16a2, slc17a1, slc17a2, slc18a1, slc18a2, slc18a3, slc19a1,
 slc1a1, slc1a2, slc1a3, slc1a4, slc1a5, slc20a1, slc20a2, slc20a3, slc21a2, slc21a3,
 slc22a1, slc22a2, slc22a5, slc2a1, slc2a2, slc2a3, slc2a4, slc2a5, slc2c, slc3a1,
 slc4a1, slc4a2, slc4a6, slc5a1, slc5a2, slc5a3, slc5a5, slc6a1, slc6a10, slc6a12,
10 slc6a2, slc6a3, slc6a4, slc6a6, slc6a8, slc6a9, slc7a1, slc7a2, slc7a4, slc7a5, slc7a7,
 slc8a1, slc8a2, slc9a1, slc9a2, slc9a3, slc9a4, slc9a5, sld, sle1, sleb1, slim1, sln, slo,
 slos, slp76, sls, slug, sm1, sm22, sma4, smad1, smad1, smad2, smad3, smad4,
 smad5, smad6, smad7, smad9, sma1, smam1, smarca1, smarca2, smarca3, smarca5,
 smarcb1, smax2, smc1, smcc, smcr, smcx, smcy, sml1, smn, smn1, smn2, smnr,
15 smo, smoh, smpd1, sms, smt3, smt3h1, smtn, smubp2, sn, snap25, snat, snca, sncb,
 sncg, snf2h, snf211, snf212, snf213, snf5, sn1, snn, snrp70, snrpa, snrpe, snrpn, snt1,
 snt2b1, snt2b2, sntb1, snt1, snx, soat, sod1, sod2, sod3, solh, son, sord, sor11, sos1,
 sos2, sox1, sox10, sox11, sox2, sox20, sox22, sox3, sox4, sox9, sp1, sp1, sp3, sp3,
 sp4, spa1, spag1, spag4, spam1, sparc, spat, spbp, spch1, spd, spf30, spg3a, spg4,
20 spg5a, spg6, spg7, spg8, spg9, spgp, spgyla, sph2, spi1, spink1, spk, spmd, spn,
 spp1, spp2, sppm, spr, sprk, sprrla, sprrlb, sprr2a, sprr2b, sprr2c, sprr3, sps1,
 spsma, spta1, sptan1, sptb, sptbn1, sra1, sra2, src, src1, src1, src2, srd5a1, srd5a2,
 srebf1, srebf2, sri, srk, srm, srn1, srp14, srp19, srp46, srpr, srpx, srs, svrx, sry, ss, ss,
 ssa, ssa1, ssa2, ssadh, ssav1, ssbp, ssdd, ssr2, ssr, sst, sstr1, sstr2, sstr3, sstr4, sstr5,
25 ssx1, ssxt, st2, st3, st4, st5, st6, st8, sta, stac, stam, star, stat, stat1, stat3, stat4, stat5,
 ssx1, stc1, stch, std, std, ste, step, stf1, stfb, stgd1, stgd2, stgd3, stgd4, sthe,
 stk1, stk11, stk15, stk2, stk6, st1, stm, stm2, stm7, stmy1, stmy2, stmy3, stp, stp1,
 stp2, sts, sts1, stx, stxl1b, stx7, stxbp1, stxbp2, supt6h, sur, sur1, surf1, surf2,
 surf3, surf4, surf5, surf6, svct2, svmt, sw, sxi2, syb1, syb2, syb11, sycp1, syk, sym1,
30 syn1, syn2, syn3, syngap, syns1, syp, syt, syl1, syl2, syl3, syl4, syl5, t, t3d, taa16,

-71-

tac1r, tac2, tac2r, tac3, tacr1, tacr2, taf2, taf2a, taf2d, taf2h, taf2n, tafi100,
tagln, tak1, tal1, tal2, taldo1, tam, tan1, tap1, tap2, tapa1, tapbp, tapvr1, tars, tas,
task, tat, taut, tax, tax1, taz, tbg, tbg, tbg1, tbs, tbx1, tbx2, tbx3, tbx5, tbxa2r, tbxas1,
tc1, tc2, tcbp, tcd, tcea1, tceb11, tceb3, tcf1, tcf12, tcf13, tcf1311, tcf14, tcf15, tcf17,
5 tcf19, tcf2, tcf20, tcf21, tcf3, tcf4, tcf5, tcf611, tcf612, tcf7, tcf8, tcf9, tcfcb, tcf11,
tcf14, tcl1, tcl1a, tcl2, tcl3, tcl4, tcl5, tcn1, tcn2, tco, tcof1, tcp1, tcp10, tcp11,
tcp228, tcpt, tcra, tcrb, tcrd, tcrg, tcrz, tcs1, tcta, tcte1, tcte3, tcte11, tdf, tdfa, tdfx,
tdg, tdgfl, tdn, tdo, tdo2, tdt, tead4, tec, tec, teck, tecta, tef, tegt, tek, te1, tem, tep1,
terc, terf1, tert, tes1, tesk1, tex28, tf, tf2s, tf6, tfa, tfam, tfap2a, tfap2b, tfap2c, tfap4,
10 tfcoup1, tfcoup2, tfcp2, tfdp1, tfdp2, tfe3, tff1, tff2, tff3, tfiiia, tfn, tfpi, tfpi2, tfr,
tfrc, tfs1, tft, tg, tg737, tgb1, tgb2, tgd, tgfa, tgfb1, tgfb2, tgfb3, tgfb4, tgfb1, tgfb1,
tgfb2, tgfb3, tgfbre, tgfr, tgm1, tgm2, tgm3, tgm4, tgn38, tgn46, th, thas, thbd,
thbp1, thbs1, thbs2, thbs3, thc, thh, th1, thop1, thpo, thr1, thra, thra1, thra1, thrb,
thrm, thrsp, thy1, tial1, tiam1, tiar, tic, tie, tie1, tie2, tigr, ti1, til3, til4, tim, timp,
15 timp1, timp2, timp3, tinur, titf1, titf2, tjp1, tk1, tk2, tkc, tker, tkr, tkt, tkt2, tkt11,
tla519, tlcn, tle1, tle2, tle3, tlh1, tln, tlr1, tlr2, tlr3, tlr4, tlr5, tm4sf1, tm4sf2, tm7sf2,
tmc, tmd, tmdci, tmem1, tmf1, tmip, tmod, tmp, tmprss2, tms, tmsa, tmsb,
tmvcf, tna, tndm, tnf, tnfa, tnfaip1, tnfaip2, tnfaip4, tnfaip6, tnfar, tnfbr, tnfc,
tnfcr, tnfr1, tnfr2, tnfrsf10b, tnfrsf12, tnfrsf14, tnfrsf16, tnfrsf17, tnfrsf1a, tnfrsf1b,
20 tnfrsf4, tnfrsf5, tnfrsf6, tnfrsf6b, tnfrsf7, tnfrsf8, tnfrsf9, tnfsf11, tnfsf12, tnfsf5,
tnfsf6, tnfsf7, tnnc1, tnnc2, tnni1, tnni2, tnni3, tnnt1, tnnt2, tnnt3, tnp1, tnp2, tnr,
tns, tnx, tnx, toc, top1, top2, top2a, top2b, top3, tp1, tp120, tp250, tp53, tp53bp2,
tp63, tp73, tpa, tpb, tpc, tpc, tph, tph2, tpi1, tp12, tpm1, tpm2, tpm3, tpm4, tpm4, tpm4,
25 tpo, tpo, tpp2, tpr, tpr1, tprd, tps1, tps2, tpsn, tpst1, tpst2, tpt, tpt1, tptps, tpx, tpx1,
tr, tr2, tr4, tra1, trafl, traf5, trailr2, tran, trance, trap170, trc3, trc8, tre, treb36, trek,
trf1, trg1, trh, trhr, tric5, trio, trip1, trip14, trip6, trk, trk1, trka, trkb, trkc, trke, trl1,
trl2, trm1, trm1, trm2, trma, trmi1, trmi2, trn, trn1, tro, trp1, trp1, trp2, trp3, trpc1,
trpm2, trpo, trps1, trps2, trq1, trr, trr3, trrap, trsp, trt1, trt2, trv1, trv2, trv3, trv4, trv5,
try1, try2, ts, ts13, ts546, tsbn51, tsc tsc1, tsc2, tsd, tse1, tsg101, tsg7, tshb, tshr, tsix,
30 tsp3, tspy, tssc3, tst1, tst1, tsta3, tsy, ttc1, ttc3, ttf, ttf1, ttg2, ttim1, ttn, ttp, ttp1,

-72-

tppa, ttr, tuba3, tubal1, tubb, tufm, tuft1, tulp1, tuple1, tw, tweak, twik1, twist,
txgp11, txk, txn, txnr, txnrd1, tyh, tyk1, tyk2, tyk3, tyms, tyr, tyr1, tyro3, tyrp1,
tyrp2, tys, u17hg, ulrnp, u22hg, u2af1, u2aflrs1, u2aflrs2, u2aflrs3, uba52, ubb, ubc,
ubc4, ubc7, ubc8, ubch2, ubc1, ube1, ube2, ube2a, ube2b, ube2e2, ube2g, ube2g2,
5 ube2h, ube2i, ube211, ube2v1, ube3a, ubh1, ubid4, ub11, uch11, ucn, ucp1, ucp2,
ucp3, udpgdh, uev1, ufd11, ufs, ugalt, ugb, ugcg, ugdh, ugn, ugp1, ugp2, ugpp2,
ugt1, ugt1a1, ugt2b11, ugt2b15, ugt2b17, ugt2b4, ugt2b7, ugt2b8, ugt2b9, ugt1, uhg,
uhx1, ukhc, umod, umph2, umps, unc18, unc18b, und, ung, unr, unr, uox, up,
upk1b, ups, uqbp, uqcrb, uqcrc1, uqcrc2, uqcrfs1, uqor1, uqor13, uqor22, urk, urkr,
10 uroc, urod, uros, usf1, usf2, ush1, ush1a, ush1b, ush1c, ush1d, ush1e, ush1f, ush2a,
ush3, usp11, usp5, usp7, usp9x, usp9y, ut1, ut2, ute, utr, utrn, utx, uty, uv20, uv24,
uvo, vacht, vacm1, vamp1, vamp2, vars1, vasp, vat1, vat2, vav, vav1, vav2, vbch,
vbp1, vcaml, vcf, vc1, vcp, vdac1, vdac2, vdd1, vdi, vdr, vegf, vegfb, vegfd, vegfr3,
vgf, vg1, vgr1, vh1, vhr, vill, vil2, vim, vip, vipr1, vipr2, vis1, vla1, vla5a, vlacs,
15 vlcad, vldlr, vmat1, vmcm, vmd1, vmd2, vnra, vnt, vp, vpp1, vpp3, vpreb1, vpreb2,
vrf, vrk1, vrk2, vrnf, vrni, vsn11, vtn, vwf, vws, waf1, wars, was, wbs, wd1, wdr2,
weel, wfrs, wfs, wfs1, wgn1, whcr, wi, wisp1, wisp2, wisp3, wnd, wnt1, wnt10b,
wnt13, wnt14, wnt15, wnt2, wnt3, wnt5a, wnt7a, wnt7b, wnt8b, wrb, wrn, ws1,
ws2a, ws2b, ws4, wsn, wss, wss, wt1, wt2, wt3, wt4, wt5, wts, wts1, wws, x11,
20 xbp1, xbp2, xce, xdh, xe169, xe7, xe7y, xg, xgr, xh2, xiap, xic, xist, xk, xla, xla2,
xlp, xlpd, xlr1, xm, xpa, xpb, xpc, xpcc, xpct, xpf, xpf, xpg, xpmc2h, xpnpep2,
xpo1, xrcc1, xrcc2, xrcc3, xrcc4, xrcc5, xrcc9, xrs, xs, xwnt2, yb1, yes1, yk140, y11,
yrrm1, yt, ywha1, ywhab, ywhah, ywhaz, yy1, zac, zag, zan, zap70, zf87, zfm1,
zfp3, zfp36, zfp37, zfx, zfy, zic1, zic2, zic3, zipk, znfl1, znfl10, znfl117, znfl11a,
25 znfl11b, znfl12, znfl21, znfl123, znfl124, znfl125, znfl126, znfl13, znfl14, znfl141,
znfl144, znfl146, znfl147, znfl157, znfl16, znfl160, znfl162, znfl163, znfl165, znfl169,
znfl173, znfl179, znfl189, znfl19, znfl192, znfl193, znfl195, znfl198, znf2, znf20, znf200,
znf204, znf217, znf22, znf23, znf24, znf25, znf26, znf27, znf29, znf3, znf32, znf34,
znf35, znf36, znf38, znf4, znf40, znf41, znf42, znf44, znf45, znf46, znf5, znf6,
30 znf69, znf7, znf70, znf71, znf72, znf73, znf74, znf75, znf75a, znf75c, znf76, znf77,

-73-

znf79, znf8, zn80, znf81, znf83, znf9, znfC150, znfC25, znfxy, znt3, znt4, zp3a, zp3b, zpk, zws1, and zyx.

Furthermore, genes from bacteria, plants, yeast, and mammals (*e.g.*, mice) can be used with the microorganisms provided herein. Non-limiting examples of E. coli genes include: aarF, aas, aat, abpS, abs, accA, accB, accC, accD, acd, aceA, aceB, aceE, aceF, aceK, ackA, ackB, acnA, acnB, acpD, acpP, acpS, acpX, acrA, acrB, acrC, acrD, acrE, acrF, acrR, acs, ada, add, adhB, adhC, adhE, adhR, adiA, adiY, adk, aegA, aer, aes, agaA, agaB, agaC, agaD, agaI, agaR, agaS, agaV, agaW, agaZ, agp, ahpC, ahpF, aidB, ais, alaS, alaT, alaU, alaV, alaW, alaX, aldA, aldB, 10 aldH, alkA, alkB, alpA, alr, alsA, alsB, alsC, alsE, alsK, alx, amiA, amiB, amn, ampC, ampD, ampE, ampG, ampH, amtB, amyA, ansA, ansB, apaG, apaH, aphA, appA, appB, appC, appY, apt, aqpZ, araA, araB, araC, araD, araE, araF, araG, araH, araJ, arcA, arcB, argA, argB, argC, argD, argE, argF, argG, argH, argI, argM, argP, argQ, argR, argS, argT, argU, argV, argW, argX, argY, argZ, aroA, aroB, aroC, 15 aroD, aroE, aroF, aroG, aroH, aroI, aroK, aroL, aroM, aroP, aroT, arsB, arsC, arsR, artI, artJ, artM, artP, artQ, ascB, ascF, ascG, asd, aslA, aslB, asmA, asnA, asnB, asnC, asnS, asnT, asnU, asnV, asnW, aspA, aspC, aspS, aspT, aspU, aspV, asr, asu, atoA, atoB, atoC, atoD, atoS, atpA, atpB, atpC, atpD, atpE, atpF, atpG, atpH, atpI, avtA, azaA, azaB, azl, bacA, baeR, baeS, barA, basR, basS, bax, bcp, bcr, betA, 20 betB, betI, betT, bfd, bfm, bfr, bglA, bglB, bglF, bglG, bglJ, bglT, bglX, bioA, bioB, bioC, bioD, bioF, bioH, bioP, bipA, birA, bisC, bisZ, blc, bolA, bRNQ, brnR, brnS brnT, btuB, btuc, btuD, btuE, btuR, bymA, cadA, cadB, cadC, cafA, caiA, caiB, caiC, caiD, caiE, caiF, caiT, calA, caiC, calD, can, carA, carB, cbl, cbpA, cbt, cca, ccmA, ccmB, ccmC, ccmD, ccmE, ccmF, ccmG, ccmH, cdd, cde, cdh, cdsA, cdsS, 25 cedA, celA, celB, ceIC, celD, celF, cfa, cfcA, chaA, chaB, chaC, cheA, cheB, cheR, cheW, cheY, cheZ, chpA, chpB, chpR, chpS, cirA, citA, citB, cld, cipA, clpB, clpP, clpX, cls, cmk, cmlA, cmr, cmtA, cmtB, coaA, cobS, cobT, cobU, codA, codB, cof, cog?, corA, cpdA, cpdB, cpsA, cpsB, cpsC, cpsD, cpsE, cpsF, cpsG, cpxA, cpxB, cpxP, cpxR, crcA, crcB, creA, creB, creC, creD, crg, crl, crp, crr, csdA, csgA, csgB, 30 csgD, csgE, csgF, csgG, csiA, csiB, csiC, csiD, csiE, csiF, cspA, cspB, cspC, cspD,

-74-

cspE, cspG, csrA, csrB, cstA, cstC, cup, cutA, cutC, cutE, cutF, cvaA(CoIV),
cvaB(CoIV), cvaC(Co-IV), cvi(CoIV), cvpA, cxm, cyaA, cybB, cybC, cycA, cydA,
cydB, cydC, cydD, cynR, cynS, cynT, cynX, cyoA, cyoB, cyoC, cyoD, cyoE, cysA,
cysB, cysC, cysD, cysE, cysG, cysH, cysI, cysJ, cysK, cysM, cysN, cysP, cysQ,
5 cysS, cysT, cysU, cysW, cysX?, cysZ?, cytR, dacA, dacB, dacC, dacD, dadA, dadB,
dadQ, dadX, dam, dapA, dapB, dapD, dapE, dapF, dbpA, dcd, dcm, dcp, dcrB, dctA,
dctB, dcuA, dcuB, dcuC, ddIA, ddIB, ddPA, ddPB, ddPC, ddPD, ddPF, ddPX, deaD,
dedA, dedD, def, degP, degQ, degS, del, deoA, deoB, deoC, deoD, deoR, dfp, dgD,
dgkA, dgkR, dgoA, dgoD, dgoK, dgoR, dgoT, dgsA, dgt, dicA, dicB, dicC, dicF,
10 dinB, dinD, dinF, dinG, dinI, dinY, dipZ, djIA, dksA, dld, dmsA, dmsB, dmsC,
dnaA, dnaB, dnaC, dnaE, dnaG, dnaI, dnaJ, dnaK, dnaL, dnaN, dnaQ, dnaT, dnaX,
dppA, dppB, dppC, dppD, dppF, dppG, dps, dsbA, dsbB, dsbC, dsbG, dsdA, dsdC,
dsdX, dsrA, dsrB, dut, dvl, dxs, ebgA, ebgB, ebgC, ebgR, ecfa, eco, ecpD, eda, edd,
efp, enirA, emrB, emrD, emrE, endA, eno, entA, entB, entC, entD, entE, entF, envN
15 envP, envQ, envR, envT, envY, envZ, epd, EppA, minigene, EppB, minigene,
EppC, minigene, EppD, minigene, EppE, minigene, EppG, minigene, EppH,
minigene, era, esp, evgA, evgS, exbB, exbC, exbD, expA, exuR, exuT, fabA, fabB,
fabD, fabF, fabG, fabH, fabI, fabZ, fadA, fadB, fadD, fadE, fadH, fadL, fadR, farR,
fatA, fbaA, fbaB, fbp, fcl, fcsA, fdhD, fdhE, fdhF, fdnG, fdnH, fdnI, fdoG, fdoH,
20 fdoI, fdrA, fdx, feaB, feaR, fecA, fecB, fecC, fecD, fecE, fecI, fecR, feoA, feoB,
fepA, fepB, fepC, fepD, fepE, fepG, fes, fexB, ffh, ffs, fhlA, fhlB, fhuA, fhuB,
fhuD, fhuE, fhuF, fic, fimA, fimB, fimC, fimD, fimE, fimF, fimG, fimH, fimI, fipB,
fipC, fis, fiu, fixA, fixB, fixC, fixX, fklB, fkpA, fldA, flgA, flgB, flgC, flgD, flgE,
flgF, flgG, flgH, flgI, flgJ, flgK, flgL, flgM, flgN, flhA, flhB, flhc, flhD, fliA, fliC,
25 fliD, fliE, fliF, fliG, fliH, fliI, fliJ, fliK, fliL, fliM, fliN, fliO, flip, fliQ, fliR, fliS,
fliT, fliY, fliZ, flk, flu, fmt, fnr, focA, focB, folA, folC, folD, folE, folK, folP, folX,
fpr, frdA, frdB, frdC, frdD, frr, fruA, fruB, fruK, fruR, fsr, ftn, ftsA, ftsE, ftsI, ftsJ,
ftsK, ftsL, ftsN, ftsQ, ftsW, ftsX, ftsY, ftsZ, fucA, fucI, fucK, fucO, fucP, fucR,
fumA, fumB, fumC, fur, fusA, fusB, gabC, gabD, gabP, gabT, gadA, gadB, gadR,
30 galE, galF, galK, galM, galP, gaiR, galS, galT, galU, gapA, gapC, garA, garB, gatA,

-75-

gatB, gatC, gatD, gatR, gatY, gatZ, gcd, gcl, gcpE, gcvA, gcvH, gcvP, gcvR, gcvT,
gdhA, gef, ggt, gidA, gidB, gip, glcB, glcC, glcD, glcE, glcG, gldA, glf, glgA, glgB,
glgC, glgP, glgS, glgX, glk, glmM, glmS, glmU, glmX, glnA, glnB, glnD, glnE,
glnG, glnH, glnK, glhL, glnP, glnQ, glnR, glnS, glnT, glnU, glnV, glnW, glnX,
5 gloA, glpA, glpB, glpC, glpD, gipE, gipF, gipG, glpK, glpQ, gipR, glpT, glpX,
gltA, gltB, gltD, gltE, gltF, gltH, gltJ, gltK, gltL, gltM, gltP, gltR, gltS, gltT, gltU,
gltv, gltW, gltX, glyA, glyQ, glyS, glyT, glyU, glyv, glyW, glyX, glyY, gmd, gmk,
gmm, gnd, gntK, gntP, gntR, gntS, gntT, gntU, gntV, goaG, gor, gph, gpmA, gpp,
gprA, gprB, gpsA, gpt, greA, greB, groL, groS, grpE, grxA, grxB, grxC, gshA,
10 gshB, gsk, gsp, gsp*, gst, guaA, guaB, guaC, gurB, gurC, gutM, gutQ, gyrA, gyrB,
hcaB, hcaC, hcaD, hcaE, hcaF, hcaR, hcaT, hdeA, hdeB, hdeD, hdhA, helD, hemA,
hemB, hemC, hemD, hemE, hemF, hemG, hemH, hemK, hemL, hemM, hemX,
hemY, hepA, het, hflB, hflC, hflK, hflX, hfq, hha, hipA, hipB, hisA, hisB, hisC,
hisD, hisF, hisG, hisH, hisI, hisJ, hisM, hisP, hisQ, hisR, hisS, hipA, hlyE, hmp, hns,
15 holA, holB, holC, holD, holE, hopB, hopC, hopD, hpt, hrpA, hrpB, hrsA, hscA,
hscB, hsdM, hsdR, hsdS, hslC, hslD?, hslE-H, hslJ, hslK, hslL-N, hslO-R, hslU,
hslV, hslW, htgA, htpG, htpX, htrB, htrC, htrE, htrL, hupA, hupB, hyaA, hyaB,
hyaC, hyaD, hyaE, hyaF, hybA, hybB, hybC, hybD, hybE, hybF, hybG, hycA,
hycB, hycC, hycD, hycE, hycF, hycG, hycH, hycI, hydA, hydG, hydH, hydN, hyfA,
20 hyfB, hyfC, hyfD, hyfE, hyfF, hyfG, hyfH, hyfI, hyfJ, hyfR, hypA, hypB, hypC,
hypD, hypE, hypF, iadA, iap, ibpA, ibpB, icd, iclR, ihfA, ihfB, ileR, ileS, ileT, ileU,
ileV, ileX, ileY, ilvA, ilvB, ilvC, ilvD, ilvE, ilvF, ilvG, ilvH, ilvI, ilvJ, ilvM, ilvN,
ilvR, ilvU, ilvY, imp, inaA, inaR?, infA, infB, infC, inm, insA(IS1), intA, isb(IS1),
isfA, ispA, ispB, KanR, katE, katG, kba, kbl, kch, kdgK, kdgR, kdgT, kdpA, kdpB,
25 kdpC, kdpD, kdpE, kdpF, kdsA, kdsB, kdtA, kdtB, kefB, kefC, kgtp, ksgA, ksgB,
ksgC, ksgD, lacA, lacI, lacY, lacZ, lamB, lar, ldcC, ldhA, lepA, lepB, leuA, leuB,
leuC, leuD, leuJ, leuO, leuP, leuQ, leuR, leuS, leuT, leuU, leuV, leuW, leuX, leuY,
leuZ, lev, lexA, lgt, lhr, ligA, ligT, linB, lipA, lipB, lit, livF, livG, livH, livJ, livK,
livM, lldD, lldP, lldR, lolA, lon, lpcA, lpcB, lpd, lplA, lpp, lpxA, lpxB, lpxC, lpxD,
30 lpxK, lrb, lrhA, lrp, lrs, lspA, lysA, lysC, lysP, lysQ, lysR, lysS, lysT, lysU, lysV,

-76-

lysW, lysX, lysY, lysZ, lytA, lytB, lyx, maa, mac, mae, mafA, mafB, malE, malF,
malG, malI, malK, malM, malP, malQ, malS, malT, malX, malY, malZ, manA,
manC, manX, manY, manZ, map, marA, marB, marR, mbrB, mcrA, mcrB, mcrC,
mcrD, mdaB, mdh, mdoB, mdoG, mdoH, meb, melA, melB, melR, menA, menB,
5 menC, menD, menE, menF, mepA, mesJ, metA, metB, metC, metD, metE, metF,
metG, metH, metJ, metK, metL, metR, metT, metU, metV, metW, metY, metZ, mfd,
mglA, mglB, mglC, mglR, mgsA, mgtA, mhpA, mhpB, mhpC, mhpD, mhpE, mhpF,
mhpR, miaA, miaD, micF, minC, minD, minE, mioC, mltA, mltB, mltC, mltD,
mmrA(rhlB?), mng, mntA, moaA, moaB, moaC, moaD, moaE, mobA, mobB, moc,
10 modA, modB, modC, modE, modF, moeA, moeB, mog, molR, motA, motB, mpl,
mppA, mprA, mraA--?, mraY, mrcA, mrcB, mrdA, mrdB, mreB, mreC, mreD, mrp,
mrr, msbA, msbB, mscL, msrA, msyB, mtg, mtgA, mtlA, mtlD, mtlR, mtr, mttA,
mttB, mttC, mukB, mukE, mukF, mul, murA, murB, murC, murD, murE, murF,
murG, murH, murI, mutG(putative), mutH, mutL, mutM, mutS, mutT, mutY, nac,
15 nadA, nadB, nadC, nadE, nagA, nagB, nagC, nagD, nagE, nalB, nalD, nanA, nanE,
nanK, nanR, nanT, napA, napB, napC, napD, napF, napG, napH, narG, narH, narI,
narJ, narK, narL, narP, narQ, narU, narV, narW, narX, narY, narZ, ndh, ndk, neaB,
nei, nemA, nfi, nfnA, nfnB, nfo, nfrA, nfrB, nfrD, nfsA, nhaA, nhaB, nhaR, nikA,
nikB, nikC, nikD, nikE, nirB, nirC, nirD, nlpA, nlpB, nlpC, nlpD, nmpC(qsr'), non,
20 npr, nrdA, nrdB, nrdD, nrdE, nrdF, nrdG, nrfA, nrfB, nrfC, nrfD, nrfE, nrfF, nrfG,
nth, ntpA, nuoA, nuoB, nuoC, nuoE, nuoF, nuoG, nuoH, nuoI, nuoJ, nuoK, nuoL,
nuoM, nuoN, nupC, nupG, nusA, nusB, nusG, nuvA, nuvC, ogrK, ogt, ompA,
ompC, ompF, ompG, ompR, ompT, ompX, oppA, oppB, oppC, oppD, oppE, oppF,
opr, ops, oraA, ordL, orf-23(purB, reg)orfl95(nikA-reg), orn, osmB, osmC, osmE,
25 osmY, otsA, otsB, oxyR, oxyS, pabA, pabB, pabC, pac, pal, panB, panC, panD,
panF, parC, parE, pat, pbpG, pck, pcm, pcnB, pdhR, pdxA, pdxB, pdxH, pdxJ,
pdxK, pdxL, pdxY, pepA, pepD, pepE, pepN, pepP, pepQ, pepT, pfkA, pfkB, pflA,
pflB, pflC, pflD, pfs, pgi, pgk, pgl, pgm, pgpA, pgpB, pgsA, pheA, pheP, pheS,
pheT, pheU, pheV, phnC, phnD, phnE, phnF, phnG, phnH, phnI, phnJ, phnK, phnL,
30 phnM, phnN, phnO, phnP, phoA, phoB, phoE, phoH, phoP, phoQ, phoR, phoU,

-77-

phrB, phxB, pin, pioO, pit, pldA, pldB, plsB, plsC, plsX, pmbA, pncA, pncB, pnp,
pntA, pntB, pnuC, poaR, polA, polB, popD, potA, potB, potC, potD, potE, potF,
potG, potH, potI, poxA, poxB, ppa, ppc, pphA, pphB, ppiA, ppiB, ppiC, ppk, pppA,
pps, ppx, pqiA, pqiB, pqqL, pqqM, prc, prfA, prfB, prfC, priA, priB, priC, prlC,
5 prlZ, prmA, prmB, proA, proB, proC, proK, proL, proM, proP, proQ, proS, proT,
proV, proW, proX, prpA, prpC, prpR, prr, prs, psd, psiF, pspA, pspB, pspC, pspE,
pspF, pssA, pssR, pstA, pstB, pstC, pstS, psu, pta, pth, ptrA, ptrB, ptsG, ptsH, ptsI,
ptsN"-", ptsP, purA, purB, purC, purD, purE, purF, purH, purK, purL, purM, purN,
purP, purR, purT, purU, pus, putA, putP, pykA, pykF, pyrB, pyrC, pyrD, pyrE,
10 pyrF, pyrG, pyrH, pyrI, qmeC, qmeD, qmeE, qor, queA, racC, racR, radA, radC,
ranA, rarD, ras, rbfA, rbn, rbsA, rbsB, rbsC, rbsD, rbsK, rbsR, rcsA, rcsB, rcsC,
rcsF, rdgA, rdgB, recA, recB, recC, recD, recE, recF, recG, recJ, recN, recO, recQ,
recR, recT, relA, relB, relE, relF, relX, rep, rer, rfaB, rfaC, rfaD, rfaF, rfaG, rfaH,
rfaI, rfaJ, rfaK, rfaL, rfaP, rfaQ, rfaS, rfaY, rfaZ, rfbA, rfbB, rfbC, rfbD, rfbX, rfc,
15 rfe, rffA, rffC, rffD, rffE, rffG, rffH, rffM, rffT, rhaA, rhaB, rhaD, rhaR, rhaS, rhaT,
rhlB, rhlE, rho, ribA, ribB, ribC, ribD, ribE, ribF, ridA, ridB, rimB, rimC, rimD,
rimE, rimG, rimH, rimI, rimJ, rimK, rimL, rimM, rit, rlpA, rlpB, rluA, rluC, rluD,
rmf, rna, rnb, rnc, rnd, rne, mnhA, mnhB, rnk, rnpA, rnpB, rnr, rnt, rob, rorB, rpe, rph,
20 rpiA, rpiB, rpiR, rplA, rplB, rplC, rplD, rplE, rplF, rplI, rplJ, rplK, rplL, rplM, rplN,
rplO, rplP, rplQ, rplR, rplS, rplT, rplU, rplV, rplW, rplX, rplY, rpmA, rpmB, rpmC,
rpmD, rpmE, rpmF, rpmG, rpmH, rpmI, rpmJ, rpoA, rpoB, rpoC, rpoD, rpoE, rpoH,
rpoN, rpoS, rpoZ, rpsA, rpsB, rpsC, rpsD, rpsE, rpsF, rpsG, rpsH, rpsI, rpsJ, rpsK,
rpsL, rpsM, rpsN, rpsO, rpsP, rpsQ, rpsR, rpsS, rpsT, rpsU, rrfA, rrfB, rrfC, rrfD,
25 rrfE, rrfF, rrfG, rrfH, rrlA, rrlB, rrlC, rrlD, rrlE, rrlG, rrlH, rrmA, rrsA, rrsB, rrsC,
rrsD, rrsE, rrsG, rrsH, rsd, rseA, rseB, rseC, rspA, rspB, rssA, rssB, rsuA, rtcA, rtcB,
rtcR, rtn, rus(qsr'), ruvA, ruvB, ruvC, sad, sanA, sapA, sapB, sapC, sapD, sapF,
sbaA, sbcB, sbcC, sbcD, sbmA, sbmC(gyrI), sbp, sdaA, sdaB, sdaC, sdhA, sdhB,
sdhC, sdhD, sdiA, sds, secA, secB, secD, secE, secF, secG, secY, selA, selB, selC,
selD, semA, seqA, serA, serB, serC, serR, serS, serT, serU, serV, serW, serX, sfa,
30 sfcA, sfiC, sfsA, sfsB, shiA, sipC, sipD, sir, sixA, sloB, slp, slr,slt, slyD, slyX, smp,

-78-

smtA, sodA, sodB, sodC, sohA, sohB, solA, soxR, soxS, speA, speB, speC, speD,
speE, speF, speG, spf, spoT, sppA, spr, srlA, srlB, srlD, srlE, srlR, srmB, srnA,
ssaE, ssaG, ssaH, ssb, sseA, sseB, sspA, sspB, ssrA, ssrS, ssyA, ssyD stfZ, stkA,
stkB, stkC, stkD, stpA, strC, strM, stsA, sucA, sucB, sucC, sucD, sufI, sugE, suhA,
5 suhB, sulA, supQ, surA, surE, syd, tabC, tag, talA, talB, tanA, tanB, tap, tar, tas,
tauA, tauB, tauC, tauD, tdpA, tdcA, tdcB, tdcC, tdcD, tdcE, tdcF, tdcG, tdcR, tdh,
tdi tdk, tehA, tehB, tesA, tesB, tgt, thdA, thdC, thdD, thiB?, thiC, thiD, thiE, thiF,
thiG, thiH, thiI, thiJ, thiK, thiL, thiM, thrA, thrB, thrC, thrS, thrT, thrU, thrV, thrW,
thyA, tig, tktA, tktB, tldD, tlnA, tmk, tnaA, tnaB, tnaC, tnm, tol-orf1, tol-orf2, tolA,
10 tolB, tolC, tolD, tolE, tolI, tolM, tolQ, tolR, tonB, topA, topB, torA, torC, torD,
torR, torS, torT, tpiA, tpr, tpx, treA, treB, treC, treF, treR, trg, trkA, trkD, trkG,
trkH, trmA, trmB, trmC, trmD, trmE, trmF, trmH, trmU, trnA, trpA, trpB, trpC,
trpD, trpE, trpR, trpS, trpT, truA, truB, trxA, trxB, trxC, tsaA, tsf, tsmA, tsr, tsx,
ttdA, ttdB, ttk, tufA, tuffB, tus, tynA, tyrA, tyrB, tyrP, tyrR, tyrS, tyrT, tyrU, tyrV,
15 ubiA, ubiB, ubiC, ubiD, ubiE, ubiF, ubiG, ubiH, ubiX, ucpA[], udk, udp, ugpA,
ugpB, ugpC, ugpE, ugpQ, uhpA, uhpB, uhpC, uhpT, uidA, uidB, uidR, umuC,
umuD, ung, upp, uppS, ups, uraA, usg-1, usbA, uspA, uup, uvh, uvrA, uvrB, uvrC,
uvrD, uvs, uxaA, uxaB, uxaC, uxuA, uxuB, uxuR, valS, valT, valU, valV, valW,
valX, valY, valZ, vsr, wrbA, xapA, xapB, xapR, xasA, xerC, xerD, xni, xseA, xseB,
20 xthA, xylA, xylB, xylE, xylF, xylG, xylH, xylR, yccA, yhhP, yihG, yjaB, fl47, yjaD,
yohF, yqiE, yrfE, zipA, zntA, znuA, znuB, znuC, zur, and zwf.

Non-limiting examples of mouse genes include: Ilr1, Ilr2, Gas10, Tnp1,
Inhbb, Inha, Creb1, Mpmv34, Acrd , Acrg , Il110, Otf1, Rab11b-r, Abl1, ald, Amh-
rs1, Bc12B , Cchlla3, Ccnb1-rs2, Gpcr16, Htr5b, Idd5, Igfbp2, Igfbp5, I18rb, Kras2-
25 rs1, Mov7, Mpmv6, Mpmv16, Mpmv22, Mpmv25, Mpmv29, Mpmv42, Mtv7 ,
Mtv27, Mtv39, Oprk1, Otf3-rs1, Otf8, Otf11-rs1, Ptgs2, Ren1, Ren2 , Ril3, Sxv,
Taz4-rs 1, Tgfb2, Wnt6, Xmmv6 , Xmmv9, Xmmv36, Xmmv61, Xmmv74, Xmv21,
Xmv32, Xmv41, I12ra, Ab1, Mpmv3, Rap1a-ps2, anx, Mpmv43, Ryr3, Ras12-4,
Adra2b, Avp, Glvr1, Il1a, Il1b, Mpmv28, Oxt, Pcsk2, a, Xmv10, Tcf4 , Acra, Acra4,
30 Ak1, Bdnf, bs, Cyct, Cyp24, Dbh, Fshb, Gcg, Gdf5 , Gnas, Gpcr8, Grin1, Hcs4,

-79-

Hior2, Hsp84-2, Idd12, Ilrn, Jund2, Kras3, Mc3r, Mpmv14, Mtv40, Mxi1-rs1, Otf3-rs2, Ptgs1, Ptpra, Rapsn, Src, Svp1, Svp3, Tcf3b, Wt1, Xmmv71, Xmv48, Ccna, Fgf2, Fth-rs1, Csfm, Mov10, Egf, Acrb2, Cap1, Crh, Fim3, Fps11, Glut2, Gpcr2, Gria2, Hsd3b-1, Hsd3b-2, Hsd3b-3, Hsd3b-4, Hsp86-ps2, Idd3, I12, I17, Mpvmv9,
5 Mpmv20, Mtv4.8, Ngfb, Npra, Nras, Nras, Ntrk, Otf3-rs3, Otf3-rs4, Rap1a, Tshb, Xmrnv22, Xmmv65, Mos, Ras12-7, Lyr, Ifa, Ifb, Jun, azh, db, Ipp, Mp1, Do1, Ak2, Ccnb1-rs4, Cdc211, Cga, Fgr, Foc1, Fps12, Gabrr1, Gabrr2, Gdf6, Glut1, Gnb1, Gpcr14, Grb2-ps, Grik3, Grik5, Hsp86-1ps4, Htr1da, Htr1db, Idd9, Ifa1, Ifa2, Ifa3, Ifa4, Ifa5, Ifa6, Ifa7, Ifa8, Ifa9, Ifa10, Lap18, Lmyc1, Mpmv19, Mpmv44,
10 Mtv13, Mtv14, Mtv17, Nppb, Otf6, Otf7, Ri12, Ski, Tnfr2, Wnt4, Xmmv8, Xmrnv23, Xmmv62, Xmv1, Xmv2, Xmv8, Xmv9, Xmv14, Xmv44, Xpa, Tec, Fgf5, Nos1, Tcf1, Epo, Gnb2, Flt1, Flt3, Ache, Adra2c, Adrbk2, Afp, Alb1, Ccnb1-rs1, Clock, Cyp3, Cyp3a11, Cyp3a13, Drd1b, Drd5, Fgfr3, Flk1, Gc, Gnrhr, Gpcr1, Hcs5, Hnf1, Htr5a, I15r, I16, Kit, Ltrm3, Mgsa, Mpmv7, Mpmv13, Mpmv23,
15 Mtv32, Mtv41, Pdgfa, Pdgfra, Por, Txk, Xmmv3, Xmmv5, Xmmv52, Xmv17, Xmv28, Xmv34, Xmv38, Xmv45, Zp3, Trh, Raf1, Fth-rs2, Ntf3, Kras2, Pthlh, Mov1, Alox5, Braf2, Cftr, Egr4, Fpsl10, Fgf6, Gdf3, Ghrfr, Glut3, Grin2a, Hior3, Hoxa10, hop, Ica1, I15r, Int41, Itpr1, Krag, Mad, Met, Mi, Mtv8, Mtv23, Mtv29, Mtv33, Mtv34, Nkna, Npy, ob, Otf3-rs5, Tgfa, Tnfr1, Wnt2, Wnt5B, Wnt7A,
20 Xmmv27, Xmv24, Xmv61, Fosb, Ryr1, Ngfa, Ufo, Xrcc1, Abpa, Abpga, Gabra4, Gas2, Acra7, Ccnb1-rs7, Egfbp3, Xmv30, Zp2, Fes, Pcsk3, Calc, Ccnb1-rs10, Pth, Ad, Bc13, Cea, Cea2, Cea3, Cea4, Cea5, Cea6, Cebp, Dm9, Dm15, Drd4, Egfbp1, Egfbp2, Ercc2, Fgf3, Fgfr2, Gabra5, Gabrb3, Gtx, Hcs1, Igf1r, Igf2, I14r, Ins2, Int40, Lhb, Mpmv1, Mtv1, Mtv35, Ngfg, Ntf5, Otf2, 2, Pkcc, Ras14, Rras, Ryr,
25 Svp2, Tcf3g, Tgfb1, tub, Xmmv31, Xmmv35, Xmmv73, Xmv33, Xmv53, Taz83, Adrb3, Junb, Jund1, Me1, Gpcr19-rs2, Agt, Cadp, Ccnb1-rs9, E, Fgfr1, Gas6, Gnb-rs1, Hcs2, Insr, Maf, Mov34, Mpmv21, Mpmv41, Mtv21, Mtnrla, Plat, Ras15-2, Ras16, Sntb2, Xmmv29, Xmv12, Xmv26, Xmv62, Epor, Gpcr13, Otf11, Pthr, Acra3, Acra5, Acrb4, Camk1, Cdc25Mm, Crbp, Crbp2, Csk, Cyp11a, Cyp19, Drd2,
30 Ets1, Fli1, Gnai2, Gnat1, Gpcr6, Gria4, Hgfl, Hior1, Hpx, Hsp86-1ps3, Hst2, Idd2,

-80-

I11bc, Lag-rs1, Lap18-rs1, M11, Mpmv27, Penk, Pgr, Ras12-2, Tp11, Trf, Xmmv2,
Xmmv67, Xmv15, Xmv16, Xmv25, Xmv60, Mgf, Amh, Braf, Cdc2a, Dmd1, Estr,
Fps13 , Fps14 , Fps15 , Gli, Gpcr17, Grik2 , Ifgr, Igf1, Mpmv5, Mpmv12, Mpmv40,
Myb, Oprm, Pg, Pmch, Ros1, Xmv31, Xmv51, Xmv54, Camk2b, Egfr, Int6, Lif,
5 Mtv44, Ews, Csfgm, Flt4, I13, I14, I15, Irf1, Gria1, Glut4, Crhr, Csfg, Mov9,
Xmv20, Acrb, Mpmv4, Mpmv15, Ngfr, Nos2, Rara, Taz4, Tcf2, Xmv42, Mtv3,
Adra1, Crko, df, Erbb2, Gabra1, Gabra6, Gabrg2, Gh, Glra1, Grb2, Hnflb, Hsp86-
ps1, Idd4, Igfbp1, Igfbp3, I113, Int4, Mpmv2, Mpmv8, Mpmv18, Mtv45, nu, Pkca,
Rab1, Re1, Shbg, Tcf7, Thra, Tnz1, Trp53, Wnt3, Wnt3A, Xmv4, Xmv5, Xmv47,
10 Xmv49, Xmv63, Akt, Amh-rs4, Ccs1, Fps16, Fos, Gdf7, Hcs3, Hsp70-2, Hsp84-3,
Hsp86-1, hyt, Ltrm1, Max, Mpmv11, Mpmv24, Mtv9, Mtv30, Pomc1, Tcf3a, Tda2,
Tgfb3, Tpo, Tshr, Xmmv21, Xmmv25, Xmmv34, Xmmv50, Gli3, Xmv55, Ryr2,
Inhba, Gas1, Pcsk1, Amh-rs2, Ccnb1-rs6, Ccnb1-rs13, Crhpb, Dat1, Drd1a, Fgfr4,
Fps17, Fim1, Gpcr15, Gpcr18, Hbvi, Hilda, Htr1a, Idd11, I19, Ltrm4, Mak, mes,
15 P11, P12, Pr1, Ra1, Rasa, Srd5a1, Tpbp, Xmv13, Xmv27, Rarb, Rbp3, Htr2, Rb1,
Acra2, Camkg, Cch11a2, Ccnb1-rs5, Ccnb1-rs12, Gnrh, Mtv11, Nras-ps, Otf3-rs6,
Plau, Ptprg, Trp53-ps, Wnt5A, Xmv19, Ghr, I17r, Lifr, Mlvi2, Prlr , Myc , Ril1,
cog, Amh-rs7, I12rb, Pdgfb, Acr, CP2, Rarg, Sp1-1, Wnt1, Afr1, Atf4, Bzrp, Ccnb1-
rs11, Cyp11b, I13rb1, I13rb2, Ins3, Itga, Mlvi1, Mlvi3, Mtv36, Pdgfec, Svp5, Tef,
20 Trhr, Wnt7B, Xmmv55, Xmmv72, Xmv37, Tnp2, Ets2, Casr, Chuck-rs1, din, Drd3,
Erg, G22p1, Gap43, Gas4, Grik1, Htr1f, Ifgt, Int53, Ltrm2, Mpmv17, Mtv6, Mtvr1,
Pit1, Xmv3, Xmv35, Xmv50, Igf2r, Mas, Tcd3, Glp1r, Idd1, Tla , Aeg1, Ccnb1-rs3,
Cdc2b, Csi, Cyp21, Cyp21-ps1, Fps18 , Gna-rs1, Gpcr19-rs1, Grr1, Grr2, Hom1,
Hsc70t, Hsp70, Hsp70-1, Hsp70-3, Hsp84-1, Hst1, Hst4, Hst5, Hst6, Hye, Int3,
25 Itpr3, Lap18-rs2, Otf3, Ptprs, Rab11b, Ras12-1, Ras12-3, Ras13, Rrs, Rxrb, Tas,
Tcd1, Tcd2, Tera1, Tla-rs, Tnfa, Tnfb, Tpx1, Tpx2, Xmmv15, Xmv36, Xmv57,
Csfmr, Pdgfrb, Adrb2, Apc, Camk2a, Camk4, Dcc, Fgf1, Gna1, Gpcr7, Gr11, Grp,
Hsp74, Mcc, Mtv2, Mtv38, Ptpn2, Tp12, Xmv22, Xmv23, Xmv29, Fth, Csfgmra,
Mxi1, Adra2a, Adrb1, Adrbk1, Chuck, Cyp17, Gna14, Gnb-ps1, Hcs6, Htr7, Ide,
30 Ins1, Lpc1, Pomc2, Seao, Tlx1, Xmmv42, Xmv18, Tcfe3, Araf, Avpr2, mdx, Ar,

-81-

Zfx, Otf9, Ccg1, Ccnb1-rs8, Fps19, Gabra3, Glra2, Glra4, Gria3, Grpr, Hsp74-ps1, Hst3, Htr1c, I12rg, Mov14, Mov15, Mtv28, Otf3-rs8, Sts, Sxa, Sxr, Xta, Tdy, Hyd, Zfy1, Zfy2, Mov15, Mov24, Mtv31, Mtv42, Sdma, Spy, Sts, Sxa, Sxr, XmmvY, Xmv7, Xmv11, and Xmv40.

5 Non-limiting examples of Phaseolus vulgaris genes include: Acc, ace, Adk, Am, Amv-1, Amv-2, Ane, aph, Arc, Are, arg, Ar1 (Arc), asp, B, bc-u, bc-1.sup.1, bc-1.sup.2, bc-2.sup.1, bc-2.sup.2, bc-3, Bcm, Beg, Bip, blu, Bpm, Bsm, By-1, By-2, C, C/c, c.sup.cr, C.sup.cir, C.sup.ma (M, R.sup.ma), C.sup.r, C.sup.res, C.sup.rho, C.sup.st, [C.sup.st R Acc] (Aeq), c.sup.u (inh, i.sub.e), [c.sup.u Prp.sup.i] (Prp, c.sup.ui, Nud), [c.sup.uprp.sup.st] (prp.sup.st), [C Prp] (Prp), c.sup.v, [C R] (R), [C r] (r), Ca, Cam, Cav, cc, ch1, c1, cm1, Co-1 (A), Co-2 (Are), Co-3 (Mexique 1), Co-3.sup.2, Co-4 (Mexique 2), Co-5 (Mexique 3), Co-6, Co-7, cr-1 cr-2, cry, cs, Ct, ctv-1 ctv-2, cyv (by-3), D (Can, Ins), Da, Db, def, dgs (g1, le), dia, Diap-1, Diap-2, diff, dis, D1-1 D1-2 (DL.sub.1 DL.sub.2), do, ds (te), dt-1.sup.a dt-2.sup.a, dt-1.sup.b dt-2.sup.b, dw-1 dw-2, Ea Eb, ers (restr), ers-2, Est-1, Est-2, exp, F, Fa, fast, Fb Fc, fa fb fc, Fcr, Fcr-2, fd, Fe-1 Fe-2, Fin (in), Fop-1, Fop-2, Fr, Fr-2, G (Flav, Ca, Och), Ga, gas, glb, Gpi-c1, Gr, Hb1 (L.sub.HB-1), Hbnc (SC.sub.HB-1), Hbp (PD.sub.HB-1), hmb, Hss, Hsw, Ht-1 Ht-2 (L-1 L-2), I, Ia Ib, ian-1 ian-2 (ia), lbd, ico, Igr (Ih), ilo, ip, iter, iv, iw, J (Sh), Ke, L, la, Lan, Ld, Lds (Ds), Lec, Li (L), lo, 20 Ir-1 lr-2, mar, Me, Mel (Me), Mel-2 (Me-2), mel-3 (me-3), Mf, mi, mia, Mic (Mip), miv, Mrf, Mrf.sup.2, mrf, ms-1, Mue, mu mutator, Nag, Nd-1 Nd-2 (D-1 D-2), nie, nnd (sym-1), nnd-2, No, nts (nod), Nudus, ol, P, p.sup.gri (Gri, v.sup.Pal), pa, pc, pg (pa.sub.1), Pha, Pmv, ppd (neu), Pr, prc (pc), Prx, punc, ram, Rbcs (rbcs), rf-1, rf-2, rf-3, rfi (i), Rfs (m), Rk, rk, rk.sup.d (lin), rn-1 rn-2 (r r), rnd, Ro, Sal, sb, sb.sup.ms, 25 sb-2, sb-3, si1, Skdh, s1, Smv, St, Sur, sw-1 sw-2, T, t (z-1), Th-1 Th-2, Tm, To, Tor (T), Tr, tri, trv, Ts, tw, uni, Uni-2, uni.sup.nde, uni.sup.nie, Ur-1, Ur-2, Ur-2.sup.2, Ur-3 (Ur-3, Ur-4), Ur-3.sup.2, Ur-4, (Up-2, Ur-C), Ur-5, (B-190), Ur-6 (Ur.sub.a, Ur-G), Ur-7 (R.sub.B11), Ur-8 (Up-1), Ur-9 (Ur.sub.p), us, V (B1), v.sup.lae (Cor), v, var, vi (vir.sub.f), wb, Wmv, X.sup.su, y, and Z.

-82-

Non-limiting examples of *Saccharomyces cerevisiae* genes include: PRE3, PUP1, PUP3, PRE2, PRE10, PRE1, PRE8, SCL1, PUP2, PRE5, PRE7, PRE4, RPT2, RPT3, RPN3, RPN11, RPN12, RPT6, RPN1, RPN2, RPT1, RPT5, RPT4, SKI6, RRP4, DIS3, TSC10, RAT1, GND1, EXO70, ERG10, ACC1, RPP0, ACT1, 5 ARP100, ARP3, PAN1, ARP2, ARP4, ARP9, SPE2, CYR1, ALA1, TPS1, TUB1, ABF1, DED81, NIP1, YHC1, SNU71, ATM1, MAK5, ROK1, DED1, SPB4, AUR1, PSE1, ALG1, TUB2, BPL1, MSL5, ERG24, ERG26, ERG25, CMD1, HCA4, SHE9, SHE10, CAK1, PIS1, CHO1, CDS1, ESR1, NUD1, CDC47, CDC13, CDC37, CDC1, CDC4, CDC20, CDC6, CDC46, CDC3, KAR1, BBP1, HRP1, 10 CCT2, CCT3, HSP10, SMC1, SMC2, CHC1, CFT2, CLP1, COP1, SEC26, SEC27, RET2, SEC21, COF1, CCT4, CCT1, CCT6, SEC24, SEC7, PCF11, RNA15, RNA14, FIP1, YSH1, TFB4, TSM1, APC2, APC5, SEC31, TAF47, TAP42, MPP10, CDC53, CKS1, CDC28, KIN28, CNS1, ERG11, DBP10, DBP8, PRO3, DYS1, ALR1, TID3, DNA2, SSL2, RAD3, RFA3, RFA2, RFA1, RFC4, RFC5, 15 RFC3, RFC2, RFC1, TOP2, RAP1, RPC25, PRI2, PRI1, POL1, POL12, HUS2, CDC2, POL2, DPB2, RPB10, RPA135, RPA190, RPA43, RPB8, RPO26, RPB5, RPC40, RPC19, SRB7, SRB4, RGR1, RPB11, SRB6, RPB2, RPB7, RPO21, RET1, RPO31, RPC31, RPC34, RPC53, RPC82, RPB12, RPB3, DPM1, DIP2, RNT1, CDC8, CDC14, DUT1, UBA2, UBA1, UBC9, CDC34, ENP1, ERD2, SSS1, 20 SEC61, SEC63, SEC62, GNA1, GPI8, DAM1, DUO1, IRR1, PRP3, TIM9, HSH49, SUP35, EXM2, MEX67, ERG9, ERG20, FAS2, FAS1, NOP1, FAD1, AOS1, FBA1, NCB2, BRN1, TUB4, GDI1, GOG5, SRM1, CDC25, SPT16, YIF2, BET4, CDC43, MRS6, BET2, PRO1, GLN1, GLN4, GRS1, YIP1, FOL2, GPA1, CDC42, SAR1, YPT1, SEC4, GSP1, TEM1, RHO1, CDC24, RNA1, GUK1, VMA16, 25 PMA1, HKR1, SIS1, MGE1, HSP60, HSF1, HAS1, MOT3, HTS1, ESA1, HSL7, HOM6, RIB7, SLY1, CSL4, PUR5, CSE1, IPP1, MDM1, USO1, SOF1, MAK11, LAS1, TEL2, DPB11, SGD1, FAL1, MTR3, MTR4, SPP2, SIK1, RRP7, POP4, RRP1, POP3, BFR2, CDC5, NRD1, MET30, MCM6, RRP46, SAS10, SCC2, ECO1, PRP43, BET3, BET5, STN1, NFS1, IDI1, SRP1, KAP95, CBF2, SKP1, 30 CEP3, CTF13, ERG7, KRS1, PSA1, PMI40, ALG2, SSF1, MED7, RSC4, CDC54,

-83-

MCM2, AFG2, ERG12, MVD1, CDC48, MHP1, ERV1, SSC1, TIM44, TIM17,
TIM23, TOM22, TOM40, MAS1, MCD1, MMC1, STU1, JAC1, ABD1, CEG1,
PAB1, MTR2, SEC16, ROT1, INO1, MLC1, MYO2, GPI2, SPT14, NAT2, NMT1,
5 TRM1, NCP1, NBP1, ACF2, SPP41, NUT2, LCP5, PRP19, NMD3, RFT1, NNF1,
NDC1, CRM1, KAR2, NIP29, NAB2, NIC96, NUP145, NUP49, NUP57, NUP159,
NSP1, NUP82, CDC39, NPL4, POP7, NTF2, MAK16, NPL3, NOP2, NOP4, NHP2,
NOP10, GAR1, NBP35, WBP1, STT3, SWP1, OST2, OST1, ORC1, ORC6, ORC5,
ORC4, ORC3, RRR1, SAT2, PWP2, PEX3, TOR2, PIK1, SEC14, STT4, MSS4,
PCM1, GPM1, SEC53, ERG8, YPD1, PAP1, NAB3, RRN7, SEN1, CFT1, PRP11,
10 PRP21, PRP39, PRP24, PRP9, SLU7, PRP28, PRP31, IFH1, PTA1, SUB2, FMI1,
MAS2, ESS1, PFY1, POL30, POP1, PDI1, RAM2, CDC7, SMP3, CDC15, YTH1,
QRI2, YAE1, SFI1, SEC1, BET1, SEC6, SEC13, SEC2, SEC8, CBF5, CDC19,
YRB1, RHC18, DBF4, SDS22, MCM3, CEF1, ALG11, GAA1, MOB1, NIP7,
TIP20, SEC5, SEC10, GPI10, RRP3, CDC45, DIB1, MIF2, HOP2, PBN1, NOP5,
15 RPP1, POP5, POP8, POP6, ERO1, MPT1, DNA43, ESP1, SMC3, LST8, STS1,
RPM2, RNR1, RNR2, RNR4, RPS20, RPL25, RPL3, RPL30, RPL32, RPL37A,
RPL43A, RPL5, RPL10, RPS3, CET1, YRA1, SNM1, GLE1, DBP5, DRS1, DBP6,
BRR2, RRN3, RRN6, RRN11, MED6, PRP16, RPR2, DIM1, RRP43, RRP42,
RRP45, SEC20, BOS1, CDC12, GLC7, PKC1, IPL1, SGV1, NRK1, RAD53,
20 LCB2, LCB1, MPS1, SES1, SPC3, SEC11, RIO1, ARP7, NEO1, YJU2, POB3,
ARH1, IQG1, HRT1, HYM1, MAK21, FUN20, FUN9, NBN1, STB5, YIF1,
SMX4, YKT6, SFT1, SMD1, PRP6, LSM2, NUF1, SPC97, SPC42, SPC98,
CDC31, SPC19, SPC25, SPC34, SPC24, NUF2, PRP40, MCD4, ERG1, SMC4,
CSE4, KRR1, SME1, TRA1, RLP7, SCH9, SMD3, SNP2, SSF2, SPC72, CDC27,
25 CDC23, CDC16, APC1, APC11, APC4, ARC19, RPN6, RPN5, RSC6, RSC8,
STH1, SFH1, TIM12, TIM22, TIM10, SQT1, SLS1, JSN1, STU2, SCD5, SSU72,
ASM4, SED5, UFE1, SYF1, SYF2, CCT5, TBF1, TOA2, TOA1, SUA7, TAF90,
TAF61, TAF25, TAF60, TAF17, TAF145, TAF19, TAF40, TAF67, TFA2, TFA1,
FCP1, TFG1, TFG2, TFB1, CCL1, SSL1, TFB3, TFB2, PZF1, BRF1, TFC5, TFC4,
30 TFC3, TFC7, TFC6, TFC1, SPT15, THI80, THS1, SPT6, SPT5, ROX3, REB1,

-84-

MCM1, MED4, MOT1, MED8, EFB1, YEF3, SUI1, CDC95, TIF11, SUI3, GCD11, SUI2, GCD6, GCD7, GCD2, GCD1, RPG1, GCD10, PRT1, TIF34, CDC33, TIF5, SUP45, GCD14, TIM54, SEC17, TPT1, TRL1, CCA1, SEN54, SEN2, SEN15, SEN34, WRS1, SLN1, TYS1, SNU56, PRP42, CUS1, PRP4, PRP8, SNU114,
5 USS1, UFD1, SMT3, RSP5, QRI1, ALG7, UGP1, VTI1, VAS1, SEC18, CTR86, and ZPR1.

2. Viruses

The microorganisms provided herein include viruses. Such viruses typically have one or more of the microorganism characteristics provided herein. For
10 example, viruses provided herein can have attenuated pathogenicity, reduced toxicity, preferential accumulation in immunoprivileged cells and tissues, such as tumor, ability to activate an immune response against tumor cells, immunogenic, replication competent, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the viruses have an ability to activate an immune
15 response against tumor cells without aggressively killing the tumor cells.

The viruses provided herein can be cytoplasmic viruses, such as poxviruses, or can be nuclear viruses such as adenoviruses. The viruses provided herein can have as part of their life cycle lysis of the host cell's plasma membrane.
Alternatively, the viruses provided herein can have as part of their life cycle exit of
20 the host cell by non-lytic pathways such as budding or exocytosis. The viruses provided herein can cause a host organism to develop an immune response to virus-infected tumor cells as a result of lysis or apoptosis induced as part of the viral life cycle. The viruses provided herein also can be genetically engineered to cause a host organism to develop an immune response to virus-infected tumor cells as a
25 result of lysis or apoptosis, regardless of whether or not lysis or apoptosis is induced as part of the viral life cycle. In some embodiments, the viruses provided herein can cause the host organism to mount an immune response against tumor cells without lysing or causing cell death of the tumor cells.

One skilled in the art can select from any of a variety of viruses, according to
30 a variety of factors, including, but not limited to, the intended use of the virus (e.g.,

exogenous protein production, antibody production or tumor therapy), the host organism, and the type of tumor.

a. Cytoplasmic viruses

The viruses provided herein can be cytoplasmic viruses, where the life cycle of the virus does not require entry of viral nucleic acid molecules into the nucleus of the host cell. A variety of cytoplasmic viruses are known, including, but not limited to, pox viruses, African swine flu family viruses, and various RNA viruses such as picorna viruses, calici viruses, toga viruses, corona viruses and rhabo viruses. In some embodiments, viral nucleic acid molecules do not enter the host cell nucleus throughout the viral life cycle. In other embodiments, the viral life cycle can be performed without use of host cell nuclear proteins. In other embodiments, the virulence or pathogenicity of the virus can be modulated by modulating the activity of one or more viral proteins involved in viral replication.

i. Poxviruses

In one embodiment, the virus provided herein is selected from the pox virus family. Pox viruses include Chordopoxvirinae such as orthopoxvirus, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipoxvirus and yatapoxvirus, as well as Entomopoxvirinae such as entomopoxvirus A, entomopoxvirus B, and entomopoxvirus A. Chordopoxvirinae are vertebrate poxviruses and have similar antigenicities, morphologies and host ranges; thus, any of a variety of such poxviruses can be used herein. One skilled in the art can select a particular genera or individual chordopoxvirinae according to the known properties of the genera or individual virus, and according to the selected characteristics of the virus (*e.g.*, pathogenicity, ability to elicit an immune response, preferential tumor localization), the intended use of the virus, the tumor type and the host organism. Exemplary chordopoxvirinae genera are orthopoxvirus and avipoxvirus.

Avipoxviruses are known to infect a variety of different birds and has been administered to humans. Exemplary avipoxviruses include canarypox, fowlpox, juncopox, mynahpox, pigeonpox, psittacinepox, quailpox, peacockpox, penguinpox, sparrowpox, starlingpox, and turkeypox viruses.

-86-

Orthopoxviruses are known to infect a variety of different mammals including rodents, domesticated animals, primates and humans. Several orthopoxviruses have a broad host range, while others have narrower host range. Exemplary orthopoxviruses include buffalopox, camelpox, cowpox, ectromelia, 5 monkeypox, raccoon pox, skunk pox, tatera pox, uasin gishu, vaccinia, variola and volepox viruses. In some embodiments, the orthopoxvirus selected can be an orthopoxvirus known to infect humans, such as cowpox, monkeypox, vaccinia or variola virus. Optionally, the orthopoxvirus known to infect humans can be selected from the group of orthopoxviruses with a broad host range, such as cowpox, 10 monkeypox, or vaccinia virus.

a. Vaccinia Virus

One exemplary orthopoxvirus is vaccinia virus. A variety of vaccinia virus strains are available, including Western Reserve (WR), Copenhagen, Tashkent, Tian Tan, Lister, Wyeth, IHD-J, and IHD-W, Brighton, Ankara, MVA, Dairen I, L-IPV, 15 LC16M8, LC16MO, LIVP, WR 65-16, Connaught, New York City Board of Health. Exemplary vaccinia viruses are Lister or LIVP vaccinia viruses. Any known vaccinia virus, or modifications thereof that correspond to those provided herein or known to those of skill in the art to reduce toxicity of a vaccinia virus. Generally, however, the mutation will be a multiple mutant and the virus will be further 20 selected to reduce toxicity. .

The linear dsDNA viral genome of vaccinia virus is approximately 200 kb in size, encoding a total of approximately 200 potential genes. Viral gene expression can be divided into three stages. In the early stage, gene expression is mainly for viral replication, and for defense against the host's immune system. In the 25 intermediate stage, genes not available for expression in the early stage can be expressed, including late stage transactivators. In the late stage, active transcription is mainly for viral structural components for building mature viruses.

Vaccinia virus possesses a variety of features for use in cancer gene therapy and vaccination. It has a broad host and cell type range. Vaccinia is a cytoplasmic 30 virus, thus, it does not insert its genome into the host genome during its life cycle.

Unlike many other viruses that require the host's transcription machinery, vaccinia virus can support its own gene expression in the host cell cytoplasm using enzymes encoded in the viral genome. The vaccinia virus genome has a large carrying capacity for foreign genes, where up to 25 kb of exogenous DNA fragments (approximately 12% of the vaccinia genome size) can be inserted. The genomes of several of the vaccinia strains have been completely sequenced, and many essential and nonessential genes identified. Due to high sequence homology among different strains, genomic information from one vaccinia strain can be used for designing and generating modified viruses in other strains. Finally, the techniques for production of modified vaccinia strains by genetic engineering are well established (Moss, Curr. Opin. Genet. Dev. 3 (1993), 86-90; Broder and Earl, Mol. Biotechnol. 13 (1999), 223-245; Timiryasova *et al.*, Biotechniques 31 (2001), 534-540).

Historically, vaccinia virus was used to immunize against smallpox infection. More recently, modified vaccinia viruses are being developed as vaccines to combat a variety of diseases. Attenuated vaccinia virus can trigger a cell-mediated immune response. Strategies such as prime/boost vaccination, vaccination with nonreplicating vaccinia virus or a combination of these strategies, have shown promising results for the development of safe and effective vaccination protocols. Mutant vaccinia viruses from previous studies exhibit a variety of shortcomings, including a lack of efficient delivery of the viral vehicle to the desired tissue only (e.g., specific accumulation in a tumor), a lack of safety because of possible serious complications (e.g., in young children, eczema vaccinatum and encephalitis, and in adults disseminated or progressive vaccinia may result if the individual is severely immunodeficient).

25

b. Modified Vaccinia Viruses

Provided herein are vaccinia viruses with insertions, mutations or deletions, as described more generally elsewhere herein. The vaccinia viruses are modified or selected to have low toxicity and to accumulate in the target tissue. Exemplary of such viruses are those from the LIVP strain.

-88-

Exemplary insertions, mutations or deletions are those that result in an attenuated vaccinia virus relative to the wild type strain. For example, vaccinia virus insertions, mutations or deletions can decrease pathogenicity of the vaccinia virus, for example, by reducing the toxicity, reducing the infectivity, reducing the ability to 5 replicate, or reducing the number of non-tumor organs or tissues to which the vaccinia virus can accumulate. Other exemplary insertions, mutations or deletions include, but are not limited to, those that increase antigenicity of the microorganism, those that permit detection or imaging, those that increase toxicity of the microorganism (optionally, controlled by an inducible promotor). For example, 10 modifications can be made in genes that are involved in nucleotide metabolism, host interactions and virus formation. Any of a variety of insertions, mutations or deletions of the vaccinia virus known in the art can be used herein, including insertions, mutations or deletions of: the thymidine kinase (TK) gene, the hemagglutinin (HA) gene, the VGF gene (as taught in U.S. Pat. Pub. No. 15 20030031681); a hemorrhagic region or an A type inclusion body region (as taught in U.S. Pat. No. 6,596,279); Hind III F, F13L, or Hind III M (as taught in U.S. Pat. No. 6,548,068); A33R, A34R, A36R or B5R genes (see, e.g., Katz *et al.*, J. Virology 77:12266-12275 (2003)); SalF7L (see, e.g., Moore *et al.*, EMBO J. 1992 11:1973-1980); N1L (see, e.g., Kotwal *et al.*, Virology 1989 171:579-587); M1 lambda (see, 20 e.g., Child *et al.*, Virology. 1990 174:625-629); HR, HindIII-MK, HindIII-MKF, HindIII-CNM, RR, or BamF (see, e.g., Lee *et al.*, J Virol. 1992 66:2617-2630); or C21L (see, e.g., Isaacs *et al.*, Proc Natl Acad Sci U S A. 1992 89:628-632).

c. The F3 Gene

In addition to the mutations known in the art, the vaccinia viruses provided 25 herein can have an insertion, mutation or deletion of the F3 gene (SEQ ID No: 1; an exemplary F3 gene is provided in GenBank Accession No. M57977, which contains the nucleotide and predicted amino acid sequences for LIVP strain F3; see also Mikryukov *et al.*, Biotekhnologiya 4:442-449 (1988)). For example, the F3 gene has been modified at the unique single NotI restriction site located within the 30 F3 gene at position 35 or at position 1475 inside of the HindIII-F fragment of

-89-

vaccinia virus DNA strain LIVP (Mikryukov *et al.*, Biotekhnologiy 4 (1988), 442-449) by insertion of a foreign DNA sequence into the NotI digested virus DNA. As provided herein, an insertion of a nucleic acid molecule containing lacZ or luciferase/GFP into the NotI site of the F3 gene of the LIVP strain (nucleotides 5 1473-1480 in M57977, or nucleotides 33-40 of SEQ ID NO: 1) can result in decreased accumulation of vaccinia viruses in non-tumorous organs of nude mice, including brain and heart, relative to wild type vaccinia virus. Thus for use in the methods provided herein, vaccinia viruses can contain an insertion, mutation or deletion of the F3 gene or a mutation of a corresponding locus.. For example, as 10 provided herein, F3-interrupted modified LIVP vaccinia virus can selectively replicate in tumor cells *in vivo*. Therefore, modified vaccinia viruses (*e.g.*, modified strain LIVP) with the interrupted F3 gene can be used in the methods provided herein, such as methods of tumor-directed gene therapy and for detection of tumors and metastases.

15 Thus, provided herein are vaccinia viruses having a modification of the F3 gene. For example, the vaccinia viruses provided herein can contain an insertion of foreign DNA into the F3 gene. An exemplary insertion of foreign DNA is an insertion at a site equivalent to the NotI site of the F3 gene in vaccinia strain LIVP, or at position 35 of SEQ ID No:1. An F3-modified vaccinia virus provided herein 20 can colonize in tumors specifically, and therefore, can be used tumor-specific therapeutic gene delivery. A GenBank data analysis with BLAST (Basic Local Alignment Search Tool) on nucleotide sequences of different strains of vaccinia virus was performed. Based on this analysis, it was found that in vaccinia virus strain Copenhagen (Goebel *et al.*, Virology 179 (1990), 247-266) the NotI restriction 25 site is located between two open reading frames (ORF) encoding F14L and F15L genes. Therefore, insertion of foreign genes into NotI site of the VV genome strain Copenhagen will not interrupt any vital genes. In VV strain LIVP, the NotI restriction site is located in the ORF encoding the F3 gene with unknown function (Mikryukov *et al.*, Biotekhnologiya 4 (1988), 442-449). Thus, the insertion of 30 foreign genes into the NotI site of the F3 gene interrupted the F3 gene. The ability

-90-

to modify the F3 gene suggests that it may have a nonessential role for virus replication. Although the F3 gene is likely nonessential for virus replication, the results of the animal experiments suggest that interruption of the F3 gene is correlated with decreased viral virulence, the inability to replicate in brain or ovary,
5 and the ability to replicate preferentially in tumor tissue.

The F3 gene is conserved in a variety of different vaccinia virus strains, including WR (nucleotides 42238-42387 of GenBank Accession No. AY243312.1, Ankara (nucleotides 37155-37304 of GenBank Accession No. U94848.1), Tian Tan (nucleotides 41808-41954 of GenBank Accession No. AF095689), Acambis 3000
10 (nucleotides 31365-31514 of GenBank Accession No. AY603355.1) and Copenhagen (nucleotides 45368-45517 of GenBank Accession No. M35027.1) strains. The F3 gene also is conserved in the larger family of poxviruses, particularly among orthopoxviruses such as cowpox (nucleotides 58498-58647 of GenBank Accession No. X94355.2), rabbitpox (nucleotides 46969-47118 of
15 GenBank Accession No. AY484669.1), camelpox (nucleotides 43331-43480 of GenBank Accession No. AY009089.1), ectromelia (nucleotides 51008-51157 of GenBank Accession No. AF012825.2), monkeypox (nucleotides 42515-42660 of GenBank Accession No. AF380138.1), and variola viruses (nucleotides 33100-
33249 of GenBank Accession No. X69198.1). Accordingly, also provided are
20 modifications of the equivalent of the F3 gene in poxviruses, such as orthopoxviruses including a variety of vaccinia virus strains. One skilled in the art can identify the location of the equivalent F3 gene in a variety of poxviruses, orthopoxviruses and vaccinia viruses. For example, an equivalent of the F3 gene in poxviruses, orthopoxviruses and vaccinia viruses can include a gene that contains at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at
25 least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence of the F3 gene in SEQ ID No:1. In another example, an equivalent of the F3 gene in poxviruses, orthopoxviruses and vaccinia viruses can include a gene that contains at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino
30 acid sequence of the F3 gene in SEQ ID No:1.

-91-

acid sequence of F3 in SEQ ID No:2. In another example, the equivalent to the F3 gene in LIVP can be determined by its structural location in the viral genome: the F3 gene is located on the HindIII-F fragment of vaccinia virus between open reading frames F14L and F15L as defined by Goebel *et al.*, Virology (1990) 179:247-266, 5 and in the opposite orientation of ORFs F14L and F15L; one skilled in the art can readily identify the gene located in the structurally equivalent region in a large variety of related viruses, such as a large variety of pox viruses.

Comparative protein sequence analysis revealed some insight into protein function. The closest match with the protein encoded by the F3 gene (strain LIVP) 10 is a prolyl 4-hydroxylase alpha subunit precursor (4-PH alpha) from the nematode *Caenorhabditis elegans* (Veijola *et al.*, J. Biol. Chem. 269 (1994), 26746-26753). This alpha subunit forms an active alpha-beta dimer with the human protein disulfide isomerase beta subunit. Prolyl 4-hydroxylase (EC 1.14.11.2) catalyzes the formation of 4-hydroxyproline in collagen. The vertebrate enzyme is an alpha 2- 15 beta 2 tetramer, the beta subunit of which is identical to the protein disulfide-isomerase (PDI). The importance of this protein for vaccinia viral replication is unknown, but a deficiency of this protein can result in retargeting vaccinia virus to tumor tissue.

d. Multiple Modifications

20 The vaccinia viruses provided herein also can contain two or more insertions, mutations or deletions. Thus, included are vaccinia viruses containing two or more insertions, mutations or deletions of the loci provided herein or other loci known in the art. In one embodiment, a vaccinia virus contains an insertion, mutation or deletion in the F3 gene, and one or more additional insertions, mutations or 25 deletions. In one embodiment of the modified vaccinia virus, at least the F3 gene has been modified by insertion of a foreign nucleotide sequence. Modifications such as modification of the F3 gene will typically result in at least partial inactivation of the gene or gene product. In one example, the F3 gene and the TK gene have been modified by insertion of a foreign nucleotide sequence. In another example, the F3 30 gene and the HA gene have been modified by insertion of a foreign nucleotide

-92-

sequence. In another example, the F3 gene and both the TK and HA genes have been modified by insertion of a foreign nucleotide sequence. In another example, the HA gene and the TK gene have been modified by insertion of a foreign nucleotide sequence. Accordingly, the present compositions and methods include a 5 modified vaccinia virus wherein two or more of (a) the F3 gene, (b) the TK gene, and (c) the HA gene have been modified. In one embodiment, at least two of the F3 gene, TK gene and HA gene have been inactivated, for example by insertion, deletion and/or replacement of nucleotide(s) within the coding region, or regulatory sequences of two or more of these genes have been inactivated by insertion, deletion 10 or mutation.

e. The Lister Strain

In another embodiment, the viruses and methods provided herein can be based on modifications to the Lister strain of vaccinia virus. Lister (also referred to as Elstree) vaccinia virus is available from any of a variety of sources. For example, 15 the Elstree vaccinia virus is available at the ATCC under Accession Number VR-1549. The Lister vaccinia strain has high transduction efficiency in tumor cells with high levels of gene expression.

In one embodiment, the Lister strain can be an attenuated Lister strain, such as the LIVP (Lister virus from the Institute of Viral Preparations, Moscow, Russia) 20 strain, which was produced by further attenuation of the Lister strain. The LIVP strain was used for vaccination throughout the world, particularly in India and Russia, and is widely available.

The LIVP strain has a reduced pathogenicity while maintaining a high transduction efficiency. For example, as provided herein, F3-interrupted modified 25 LIVP vaccinia virus can selectively replicate in tumor cells *in vivo*. In one embodiment, provided herein are modified LIVP viruses, including viruses having a modified TK gene, viruses having a modified HA gene, viruses having a modified F3 gene, and viruses having two or more of: modified HA gene, modified TK gene, and modified F3 gene.

ii. Other cytoplasmic viruses

Also provided herein are cytoplasmic viruses that are not poxviruses.

Cytoplasmic viruses can replicate without introducing viral nucleic acid molecules into the nucleus of the host cell. A variety of such cytoplasmic viruses are known in the art, and include African swine flu family viruses and various RNA viruses such as arenaviruses, picornaviruses, caliciviruses, togaviruses, coronaviruses, paramyxoviruses, flaviviruses, reoviruses, and rhabdoviruses. Exemplary togaviruses include Sindbis viruses. Exemplary arenaviruses include lymphocytic choriomeningitis virus. Exemplary rhabdoviruses include vesicular stomatitis viruses. Exemplary paramyxo viruses include Newcastle Disease viruses and measles viruses. Exemplary picornaviruses include polio viruses, bovine enteroviruses and rhinoviruses. Exemplary flaviviruses include Yellow fever virus; attenuated Yellow fever viruses are known in the art, as exemplified in Barrett *et al.*, *Biologicals* 25:17-25 (1997), and McAllister *et al.*, *J. Virol.* 74:9197-9205 (2000).

Also provided herein are modifications of the viruses provided above to enhance one or more characteristics relative to the wild type virus. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified viruses have an ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In other embodiments, the viruses can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the viruses can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

b. Adenovirus, Herpes, Retroviruses

Further provided herein are viruses that include in their life cycle entry of a nucleic acid molecule into the nucleus of the host cell. A variety of such viruses are

-94-

known in the art, and include herpesviruses, papovaviruses, retroviruses, adenoviruses, parvoviruses and orthomyxoviruses. Exemplary herpesviruses include herpes simplex type 1 viruses, cytomegaloviruses, and Epstein-Barr viruses. Exemplary papovaviruses include human pappilomaviruses and SV40 viruses.

5 Exemplary retroviruses include lentiviruses. Exemplary orthomyxoviruses include influenza viruses. Exemplary parvoviruses include adeno associated viruses.

Also provided herein are modifications of the viruses provided above to enhance one or more characteristics relative to the wild type virus. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced 10 toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified viruses have an ability to activate an immune response against tumor cells without aggressively killing the 15 tumor cells. In other embodiments, the viruses can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the viruses can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

20 **3. Bacteria**

Bacteria can also be used in the methods provided herein. Any of a variety of bacteria possessing the desired characteristics can be used. In one embodiment, aerobic bacteria can be used. In another embodiment, anaerobic bacteria can be used. In another embodiment, extracellular bacteria can be used. In another 25 embodiment, intracellular bacteria can be used.

In some embodiments, the bacteria provided herein can be extracellular bacteria. A variety of extracellular bacteria are known in the art and include vibrio, lactobacillus, streptococcus, escherichia. Exemplary bacteria include Vibrio cholerae, Streptococcus pyogenes, and Escherichia coli. In other embodiments, the 30 bacteria provided herein can be intracellular bacteria. A variety of intracellular

bacteria are known in the art and include listeria, salmonella, clostridium, and bifidobacterium. Exemplary intracellular bacteria include Listeria monocytogenes, Salmonella typhimurium, Clostridium histolyticus, Clostridium butyricum, Bifidobacterium longum, and Bifidobacterium adolescentis. Additional bacteria 5 include plant bacteria such as Clavibacter michiganensis subsp. michiganensis, Agrobacterium tumefaciens, Erwinia herbicola, Azorhisobium caulinodans, Xanthomonas campestris pv. vesicatoria, and Xanthomonas campestris pv. campestris.

A further example of a bacteria provided herein are magnetic bacteria. Such 10 bacteria allow tumor detection through the accumulation of iron-based contrast agents. Magnetic bacteria can be isolated from fresh and marine sediments.

Magnetic bacteria can produce magnetic particles (Fe₃O₄) (Blakemore, Annu. Rev. Microbiol. 36 (1982), 217-238). To do so, the magnetic bacteria have efficient iron uptake systems, which allow them to utilize both insoluble and soluble forms of 15 iron. Magnetospirillum magnetic AMB-1 is an example of such magnetic bacteria that has been isolated and cultured for magnetic particle production (Yang *et al.*, Enzyme Microb. Technol. 29 (2001), 13-19). As provided herein, these magnetic bacteria (naturally occurring or genetically modified), when injected intravenously, can selectively accumulate in tumor. Accordingly, these bacteria can be used for 20 accumulating iron-based contrast agents in the tumors, which in turn allows tumor detection by MRI. Similarly, other naturally isolated metal accumulating strains of bacteria can be used for tumor targeting, absorption of metals from contrast agents, and tumor imaging.

Also provided herein are modifications of bacteria to enhance one or more 25 characteristics relative to the wild type bacteria. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. 30 In some embodiments, the modified bacteria have an ability to activate an immune

response against tumor cells without aggressively killing the tumor cells. In other embodiments, the bacteria can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the bacteria can be modified to express one or more genes for harvesting the gene products
5 and/or for harvesting antibodies against the gene products.

a. Aerobic bacteria

Previous studies have postulated that anaerobic bacteria are preferred for administration to tumors (Lemmon *et al.*, 1997 Gene Therapy 4:791-796). As provided herein, it has been determined that aerobic bacteria can survive and grow
10 in tumors. Accordingly, a bacteria used in the methods provided herein can include a bacteria that can survive and grow in an oxygenated environment. In some embodiments, the bacteria must be in an oxygenated environment in order to survive and grow. A variety of aerobic bacteria are known in the art, including lactobacilli, salmonella, streptococci, staphylococci, vibrio, lysteria, and escherichia. Exemplary
15 bacteria include Vibrio cholerae, Listeria monocytogenes, Salmonella typhimurium, Streptococcus pyogenes, Escherichia coli, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus salivarius,
20 Lactobacillus sporogenes, Lactobacillus lactis, Lactobacillus fermentum, Streptococcus thermophilus, Bacillus subtilis, Bacillus megaterium, Bacillus polymyxa, Myobacterium smegmatis, Mycobacterium vaccae, Mycobacterium microti, Mycobacterium habana, Enterococcus faecalis, Pseudomonas fluorescens, and Pseudomonas putida.

b. Anaerobic bacteria

25 A bacteria used in the methods provided herein can include a bacteria that does not require oxygen to survive and grow. In some embodiments, the bacteria must be in an oxygen-free environment in order to survive and grow. A variety of aerobic bacteria are known in the art, including clostridium, bifidobacterium. Exemplary bacteria include Clostridium histolyticus, Clostridium butyricum,
30 Clostridium novyi, Clostridium sordellii, Clostridium absonum, Clostridium

bifidum, Clostridium difficile, Clostridium histolyticum, Clostridium perfringens, Clostridium beijerinckii, Clostridium sporogenes, Staphylococcus aureus, Staphylococcus epidermidis, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium laterosporus, Bifidobacterium animalis, Actinomyces israelii, Eubacterium lentum, Peptostreptococcus anaerobius, Peptococcus prevotti, and Acidaminococcus fermentans.

4. Eukaryotic cells

Also encompassed within the microorganisms provided herein and the methods of making and using such microorganisms are eukaryotic cells, including cells from multicellular eukaryotes, including mammals such as primates, where exemplary cells are human cells. Typically the cells are isolated cells. For example, eukaryotic cells can be tumor cells, including mammalian tumor cells such as primate tumor cells, where exemplary primate tumor cells are human tumor cells such as human breast cancer cells. In another example, eukaryotic cells can include fibrosarcoma cells such as human fibrosarcoma cells. Exemplary human fibrosarcoma cells include HT1080 (ATCC Accession Nos. CCL-121, CRL-12011 or CRL-12012). In another example, eukaryotic cells can include stem cells, including mammalian stem cells such as primate stem cells, where exemplary primate stem cells are human stem cells.

Also provided herein are modifications of eukaryotic cells to enhance one or more characteristics relative to the wild type cells. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified eukaryotic cells have an ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In other embodiments, the eukaryotic cells can be modified to express one or more detectable genes, including genes that can be used for imaging. In other

embodiments, the eukaryotic cells can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

C. Methods for Making a Modified Microorganism

5 The microorganisms provided herein can be formed by standard methodologies well known in the art for modifying microorganisms such as viruses, bacteria and eukaryotic cells. Briefly, the methods include introducing into microorganisms one or more genetic modification, followed by screening the microorganisms for properties reflective of the modification or for other desired properties.

10 1. Genetic Modifications

Standard techniques in molecular biology can be used to generate the modified microorganisms provided herein. Such techniques include various nucleic acid manipulation techniques, nucleic acid transfer protocols, nucleic acid amplification protocols, and other molecular biology techniques known in the art. For example, point mutations can be introduced into a gene of interest through the use of oligonucleotide mediated site-directed mutagenesis. Alternatively, homologous recombination can be used to introduce a mutation or exogenous sequence into a target sequence of interest. Nucleic acid transfer protocols include calcium chloride transformation/transfection, electroporation, liposome mediated nucleic acid transfer, N-[1-(2,3-Dioloyloxy)propyl]-N,N,N-trimethylammonium methylsulfate mediated transformation, and others. In an alternative mutagenesis protocol, point mutations in a particular gene can also be selected for using a positive selection pressure. See, e.g., *Current Techniques in Molecular Biology*, (Ed. Ausubel, *et al.*). Nucleic acid amplification protocols include but are not limited to the polymerase chain reaction (PCR). Use of nucleic acid tools such as plasmids, vectors, promoters and other regulating sequences, are well known in the art for a large variety of viruses and cellular organisms. Further a large variety of nucleic acid tools are available from many different sources including ATCC, and various commercial sources. One skilled in the art will be readily able to select the

-99-

appropriate tools and methods for genetic modifications of any particular virus or cellular organism according to the knowledge in the art and design choice.

Any of a variety of modifications can be readily accomplished using standard molecular biological methods known in the art. The modifications will typically be 5 one or more truncations, deletions, mutations or insertions of the microorganismal genome. In one embodiment, the modification can be specifically directed to a particular sequence. The modifications can be directed to any of a variety of regions of the microorganismal genome, including, but not limited to, a regulatory sequence, to a gene-encoding sequence, or to a sequence without a known role. Any of a 10 variety of regions of microorganismal genomes that are available for modification are readily known in the art for many microorganisms, including the microorganisms specifically listed herein. As a non-limiting example, the loci of a variety of vaccinia genes provided hereinelsewhere exemplify the number of different regions that can be targeted for modification in the microorganisms provided herein. In 15 another embodiment, the modification can be fully or partially random, whereupon selection of any particular modified microorganism can be determined according to the desired properties of the modified the microorganism.

In some embodiments, the microorganism can be modified to express an exogenous gene. Exemplary exogenous gene products include proteins and RNA 20 molecules. The modified microorganisms can express a detectable gene product, a therapeutic gene product, a gene product for manufacturing or harvesting, or an antigenic gene product for antibody harvesting. The characteristics of such gene products are described hereinelsewhere. In some embodiments of modifying an organism to express an exogenous gene, the modification can also contain one or 25 more regulatory sequences to regulate expression of the exogenous gene. As is known in the art, regulatory sequences can permit constitutive expression of the exogenous gene or can permit inducible expression of the exogenous gene. Further, the regulatory sequence can permit control of the level of expression of the exogenous gene. In some examples, inducible expression can be under the control 30 of cellular or other factors present in a tumor cell or present in a microorganism-

-100-

infected tumor cell. In other examples, inducible expression can be under the control of an administerable substance, including IPTG, RU486 or other known induction compounds. Any of a variety of regulatory sequences are available to one skilled in the art according to known factors and design preferences. In some 5 embodiments, such as gene product manufacture and harvesting, the regulatory sequence can result in constitutive, high levels of gene expression. In some embodiments, such as anti-(gene product) antibody harvesting, the regulatory sequence can result in constitutive, lower levels of gene expression. In tumor therapy embodiments, a therapeutic protein can be under the control of an internally 10 inducible promotor or an externally inducible promotor.

In other embodiments, organ or tissue-specific expression can be controlled by regulatory sequences. In order to achieve expression only in the target organ, for example, a tumor to be treated, the foreign nucleotide sequence can be linked to a tissue specific promoter and used for gene therapy. Such promoters are well known 15 to those skilled in the art (see e.g., Zimmermann *et al.*, (1994) *Neuron* 12, 11-24; Vidal *et al.*; (1990) *EMBO J.* 9, 833-840; Mayford *et al.*, (1995), *Cell* 81, 891-904; Pinkert *et al.*, (1987) *Genes & Dev.* 1, 268-76).

In some embodiments, the microorganisms can be modified to express two or more proteins, where any combination of the two or more proteins can be one 20 more detectable gene products, therapeutic gene products, gene products for manufacturing or harvesting, or antigenic gene products for antibody harvesting. In one embodiment, a microorganism can be modified to express a detectable protein and a therapeutic protein. In another embodiment, a microorganism can be modified to express two or more gene products for detection or two or more therapeutic gene 25 products. For example, one or more proteins involved in biosynthesis of a luciferase substrate can be expressed along with luciferase. When two or more exogenous genes are introduced, the genes can be regulated under the same or different regulatory sequences, and the genes can be inserted in the same or different regions of the microorganismal genome, in a single or a plurality of genetic manipulation 30 steps. In some embodiments, one gene, such as a gene encoding a detectable gene

-101-

product, can be under the control of a constitutive promotor, while a second gene, such as a gene encoding a therapeutic gene product, can be under the control of an inducible promotor. Methods for inserting two or genes in to a microorganism are known in the art and can be readily performed for a wide variety of microorganisms
5 using a wide variety of exogenous genes, regulatory sequences, and/or other nucleic acid sequences.

In an example of performing microorganismal modification methods, vaccinia virus strain LIVP was modified to contain insertions of exogenous DNA in three different locations of the viral genome. Using general methods known in the
10 art, known molecular biology tools, and sequences known in the art or disclosed herein can be used to create modified vaccinia virus strains, including viruses containing insertions in the F3 gene, TK gene and/or HA gene. See, e.g., Mikryukov, *et al.*, Biotekhnologya 4 (1998), 442-449; Goebel *et al.*, Virology 179 (1990), 247-266; Antoine *et al.*, Virology 244 (1998), 365-396; Mayr *et al.*, Zentbl.
15 Bakteriol. Hyg. Abt 1 Orig. B 167 (1978), 375-390; Ando and Matumoto, Jpn. J. Microbial. 14 (1979), 181-186; Sugimoto *et al.*, Microbial. Immuno. 29 (1985), 421-428; Takahashi-Nishimaki *et al.*, J. Gen. Virol. 68 (1987), 2705-2710). These methods include, for example, in vitro recombination techniques, synthetic methods and in vivo recombination methods as described, for example, in Sambrook *et al.*,
20 Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, cold Spring Harbor NY (1989), and in the Examples disclosed herein. The person skilled in the art can isolate the gene encoding the gene product of F3 (or a related gene product) from any vaccinia strain using, for example, the nucleotide sequence of the F3 gene of SEQ ID No:1 or SEQ ID NOs:10, 12, 14, 16,
25 18, 20, 22, 24, 26, 28, 30 or 32, or a fragment thereof as a probe for screening a library.

Methods of producing recombinant microorganisms are known in the art. Provided herein for exemplary purposes are methods of producing a recombinant vaccinia virus. A recombinant vaccinia virus with an insertion in the F3 gene can be prepared by the following steps: (a) generating (i) a vaccinia shuttle plasmid
30

-102-

containing the modified F3 gene inserted at restriction site X and (ii) a dephosphorylated wt VV (VGL) DNA digested at restriction site X; (b) transfecting host cells infected with PUV-inactivated helper VV (VGL) with a mixture of the constructs of (i) and (ii) of step a; and (c) isolating the recombinant vaccinia viruses
5 from the transfectants. One skilled in the art knows how to perform such methods, for example by following the instructions given in Example 1 and the legend to Figure 1; see also Timiryasova *et al.*, *Biotechniques* 31 (2001), 534-540. In one embodiment, restriction site X is a unique restriction site. A variety of suitable host cells also are known to the person skilled in the art and include many mammalian, 10 avian and insect cells and tissues which are susceptible for vaccinia virus infection, including chicken embryo, rabbit, hamster and monkey kidney cells, for example, HeLa cells, RK₁₃, CV-1, Vero, BSC40 and BSC-1 monkey kidney cells.

2. Screening for above characteristics

Modified microorganisms can be screened for any desired characteristics, 15 including the characteristics described herein such as attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. For example, the modified microorganisms can be screened 20 for the ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In another example, the microorganisms can be screened for expression of one or more detectable genes, including genes that can be used for imaging, or for expression of one or more genes for manufacture or harvest of the gene products and/or for harvest of antibodies against the gene products.

Any of a variety of known methods for screening for such characteristics can 25 be performed, as demonstrated in the Examples provided herein. One Exemplary method for screening for desired characteristics includes, but is not limited to, monitoring growth, replication and/or gene expression (including expression of an exogenous gene) in cell culture or other invitro medium. The cell culture can be 30 from any organism, and from any tissue source, and can include tumorous tissues.

-103-

Other exemplary methods for screening for desired characteristics include, but are not limited to, administering a microorganism to animal, including non-human animals such as a mouse, monkey or ape, and optionally also including humans, and monitoring the microorganism, the tumor, and/or the animal; monitoring can be

5 performed by in vivo imaging of the microorganism and/or the tumor (e.g., low light imaging of microorganismal gene expression or ultrasonic tumor imaging), external monitoring of the tumor (e.g., external measurement of tumor size), monitoring the animal (e.g., monitoring animal weight, blood panel, antibody titer, spleen size, or liver size). Other exemplary methods for screening for desired characteristics

10 include, but are not limited to, harvesting a non-human animal for the effects and location of the microorganism and expression by the microorganism, including methods such as harvesting a variety of organs including a tumor to determine presence of the microorganism and/or gene expression by the microorganism in the organs or tumor, harvesting of organs associated with an immune response or

15 microorganismal clearance such as the spleen or liver, harvesting the tumor to determine tumor size and viability of tumor cells, harvesting antibodies or antibody producing cells. Such screening and monitoring methods can be used in any of a variety of combinations, as is known in art. In one embodiment, a microorganism can be screened by administering the microorganism to an animal such as a non-

20 human animal or a human, followed by monitoring by in vivo imaging. In another embodiment, a microorganism can be screened by administering the microorganism to an animal such as a non-human animal, monitoring by in vivo imaging, and then harvesting the animal. Thus, provided herein are methods for screening a microorganism for desired characteristics by administering the microorganism to an

25 animal such as an animal with a tumor, and monitoring the animal, tumor (if present), and/or microorganism in the animal for one or more characteristics. Also provided herein are methods for screening a microorganism for desired characteristics by administering the microorganism to a non-human animal such as a non-human animal with a tumor, harvesting the animal, and assaying the animal's

30 organs, antibody titer, and/or tumor (if present) for one or more characteristics.

-104-

Provided herein are methods for screening a microorganism for attenuated pathogenicity or reduced toxicity, where the pathogenicity or toxicity can be determined by a variety of techniques, including, but not limited to, assessing the health state of the subject, measuring the body weight of a subject, blood or urine analysis of a subject, and monitoring tissue distribution of the microorganism within the subject; such techniques can be performed on a living subject *in vivo*, or can be performed post mortem. Methods also can include the ability of the microorganisms to lyse cells or cause cell death, which can be determined *in vivo* or *in vitro*.

When a subject drops below a threshold body weight, the microorganism can be considered pathogenic to the subject. Exemplary thresholds can be a drop of about 5% or more, a drop of about 10% or more, or a drop of about 15% or more in body weight relative to a reference. A body weight reference can be selected from any of a variety of references used in the art; for example, a body weight reference can be the weight of the subject prior to administration of the microorganism, the body weight reference can be a control subject having the same condition as the test subject (*e.g.*, normal or tumor-injected), where the change in weight of the control is compared to the change in weight of the test subject for the time period after administration of the microorganism.

Blood or urine analysis of the subject can indicate level of immune response, level of toxins in the subject, or other levels of stress to cells, tissues or organs of the subject such as kidneys, pancreas, liver and spleen. Levels increased above established threshold levels can indicate pathogenicity of the microorganism to the subject. Threshold levels of components of blood or urine for indicating microorganismal pathogenicity are well known in the art, and any such thresholds can be selected herein according to the desired tolerance of pathogenicity or toxicity of the microorganism.

Tissue distribution of a microorganism in a subject can indicate pathogenicity or toxicity of the microorganism. In one embodiment, tissue distribution of a microorganism that is not pathogenic or toxic can be mostly in tumor relative to other tissues or organs. Microorganisms located mostly in tumor

-105-

can accumulate, for example, at least about 2-fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the microorganism accumulate
5 in any other particular organ or tissue.

Provided herein are methods for screening a microorganism for tissue distribution or accumulation, where the tissue distribution can be determined by a variety of techniques, including, but not limited to, harvesting a non-human subject, in vivo imaging a detectable gene product in subject. Harvesting can be accomplished by euthanizing the non-human subject, and determining the accumulation of microorganisms in tumor and, optionally, the accumulation in one or more additional tissues or organs. The accumulation can be determined by any of a variety of methods, including, but not limited to, detecting gene products such as detectable gene products (*e.g.*, gfp or beta galactosidase), histological or microscopic evaluation of tissue, organ or tumor samples, or measuring the number of plaque or colony forming units present in a tissue, organ or tumor sample. In one embodiment, the desired amount of tissue distribution of a microorganism can be mostly in tumor relative to other tissues or organs. Microorganisms located mostly in tumor can accumulate, for example, at least about 2-fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the microorganism
10 accumulate in any other particular organ or tissue.
15
20

Also provided herein are methods of screening for microorganisms that can elicit an immune response, where the immune response can be against the tumor cells or against the microorganisms. A variety of methods for measuring the ability to elicit an immune response are known in the art, and include measuring an overall increase in immune activity in a subject, measuring an increase in anti-microorganism or anti-tumor antibodies in a subject, testing the ability of a
25 microorganism-treated (typically a non-human) subject to prevent later
30

-106-

infection/tumor formation or to rapidly eliminate microorganisms or tumor cells. Methods also can include the ability of the microorganisms to lyse cells or cause cell death, which can be determined in vivo or in vitro.

Also provided herein are methods for determining increased or decreased replication competence, by monitoring the speed of replication of the microorganisms. Such measurements can be performed in vivo or in vitro. For example, the speed of replication in a cell culture can be used to determine replication competence of a microorganism. In another example, the speed of replication in a tissue, organ or tumor in a subject can be used to measure replication competence. In some embodiments, decreased replication competence in non-tumor tissues and organs can be the characteristic to be selected in a screen. In other embodiments, increased replication competence in tumors can be the characteristic to be selected in a screen.

Also provided herein are methods for determining the ability of a microorganism to express genes, such as exogenous gene. Such methods can be performed in vivo or in vitro. For example, the microorganisms can be screened on selective plates for the ability to express a gene that permits survival of the microorganism or permits the microorganism to provide a detectable signal, such as turning X-gal blue. Such methods also can be performed in vivo, where expression can be determined, for example, by harvesting tissues, organs or tumors a non-human subject or by in vivo imaging of a subject.

Also provided herein are methods for determining the ability of a microorganism to express genes toward which the subject can develop antibodies, including exogenous genes toward which the subject can develop antibodies. Such methods can be performed in vivo using any of a variety of non-human subjects. For example, gene expression can be determined, for example, by bleeding a non-human subject to which a microorganism has been administered, and assaying the blood (or serum) for the presence of antibodies against the microorganism-expressed gene, or by any other method generally used for polyclonal antibody harvesting, such as production bleeds and terminal bleeds.

-107-

Also provided herein are methods for screening a microorganism that has two or more characteristics provided herein, including screening for attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity,
5 increased or decreased replication competence, ability to express exogenous proteins, and ability to elicit antibody production against a microorganismally expressed gene product. A single monitoring technique, such as in vivo imaging, can be used to verify two or more characteristics, or a variety of different monitoring techniques can be used, as can be determined by one skilled in the art according to
10 the selected characteristics and according to the monitoring techniques used.

D. Therapeutic Methods

Provided herein are therapeutic methods, including methods of treating or preventing immunoprivileged cells or tissue, including cancerous cells, tumor and metastasis. The methods provided herein include administering a microorganism to
15 a subject containing a tumor and/or metastases. The methods provided herein do not require the microorganism to kill tumor cells or decrease the tumor size. Instead, the methods provided herein include administering to a subject a microorganism that can cause or enhance an anti-tumor immune response in the subject. In some embodiments, the microorganisms provided herein can be administered to a subject
20 without causing microorganism-induced disease in the subject. In some embodiments, the microorganisms can accumulate in tumors or metastases. In some embodiments, the microorganisms can elicit an anti-tumor immune response in the subject, where typically the microorganism-mediated anti-tumor immune response can develop over several days, such a week or more, 10 days or more, two weeks or
25 more, or a month or more, as a result of little or no microorganism-cause tumor cell death. In some exemplary methods, the microorganism can be present in the tumor, and can cause an anti-tumor immune response without the microorganism itself causing enough tumor cell death to prevent tumor growth.

In some embodiments, provided herein are methods for eliciting or
30 enhancing antibody production against a selected antigen or a selected antigen type

-108-

in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause release of a selected antigen or selected antigen type from the tumor, resulting in antibody production against the selected antigen or selected antigen type. The administered

5 microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

10 Any of a variety of antigens can be targeted in the methods provided herein, including a selected antigen such as an exogenous gene product expressed by the microorganism, or a selected antigen type such as one or more tumor antigens release from the tumor as a result of microorganism infection of the tumor (e.g., by lysis, apoptosis, secretion or other mechanism of causing antigen release from the 15 tumor). In at least some embodiments, it can be desirable to maintain release of the selected antigen or selected antigen type over a series of days, for example, at least a week, at least ten days, at least two weeks or at least a month.

Also provided herein are methods for providing a sustained antigen release within a subject, where the methods include administering to a subject a 20 microorganism that can accumulate in a tumor and/or metastasis, and can cause sustained release of an antigen, resulting in antibody production against the antigen. The sustained release of antigen can last for several days, for example, at least a week, at least ten days, at least two weeks or at least a month. The administered microorganisms can possess one or more characteristics including attenuated 25 pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product. The sustained release of antigen can result in an immune response by the microorganism-infected host, in which the host 30 can develop antibodies against the antigen, and/or the host can mount an immune

response against cells expressing the antigen, including an immune response against tumor cells. Thus, the sustained release of antigen can result in immunization against tumor cells. In some embodiments, the microorganism-mediated sustained antigen release-induced immune response against tumor cells can result in complete removal or killing of all tumor cells.

Also provided herein are methods for inhibiting tumor growth in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced as a result of tumor or metastases-accumulated microorganisms can result in inhibition of tumor growth. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Also provided herein are methods for inhibiting growth or formation of a metastasis in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced as a result of tumor or metastasis-accumulated microorganisms can result in inhibition of metastasis growth or formation. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Also provided herein are methods for decreasing the size of a tumor and/or metastasis in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced

-110-

as a result of tumor or metastasis-accumulated microorganisms can result in a decrease in the size of the tumor and/or metastasis. The administered microorganisms can posses one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an 5 immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Also provided herein are methods for eliminating a tumor and/or metastasis from a subject, where the methods include administering to a subject a 10 microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced as a result of tumor or metastasis-accumulated microorganisms can result in elimination of the tumor and/or metastasis from the subject. The administered microorganisms can posses one or more characteristics including attenuated 15 pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Methods of reducing inhibiting tumor growth, inhibiting metastasis growth 20 and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods provided herein include causing or enhancing an anti-tumor immune response in the host. The immune response of the host, being anti-tumor in nature, can be mounted against tumors and/or metastases in which microorganisms have accumulated, and can also be mounted against tumors 25 and/or metastases in which microorganisms have not accumulated, including tumors and/or metastases that form after administration of the microorganisms to the subject. Accordingly, a tumor and/or metastasis whose growth or formation is inhibited, or whose size is decreased, or that is eliminated, can be a tumor and/or metastasis in which the microorganisms have accumulated, or also can be a tumor 30 and/or metastasis in which the microorganisms have not accumulated. Accordingly,

-111-

provided herein are methods of reducing inhibiting tumor growth, inhibiting metastasis growth and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods, where the method includes administering to a subject a microorganism, where the
5 microorganism accumulates in at least one tumor or metastasis and causes or enhances an anti-tumor immune response in the subject, and the immune response also is mounted against a tumor and/or metastasis in which the microorganism cell did not accumulate. In another embodiment, methods are provided for inhibiting or preventing recurrence of a neoplastic disease or inhibiting or preventing new tumor
10 growth, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response, and the anti-tumor immune response can inhibit or prevent recurrence of a neoplastic disease or inhibit or prevent new tumor growth.

The tumor or neoplastic disease therapeutic methods provided herein, such as
15 methods of reducing inhibiting tumor growth, inhibiting metastasis growth and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods, also can include administering to a subject a microorganism that can cause tumor cell lysis or tumor cell death. Such a microorganism can be the same microorganism as the microorganism that can cause or enhance an anti-tumor immune response in the subject. Microorganisms, such as
20 the microorganisms provided herein, can cause cell lysis or tumor cell death as a result of expression of an endogenous gene or as a result of an exogenous gene. Endogenous or exogenous genes can cause tumor cell lysis or inhibit cell growth as a result of direct or indirect actions, as is known in the art, including lytic channel
25 formation or activation of an apoptotic pathway. Gene products, such as exogenous gene products can function to activate a prodrug to an active, cytotoxic form, resulting in cell death where such genes are expressed.

Such methods of antigen production or tumor and/or metastasis treatment can include administration of a modified microorganism described herein or a
30 microorganism having modifications with a functional equivalence to the vaccinia

-112-

virus provided herein containing a modification of the F3 gene and the TK gene and/or the HA gene, for therapy, such as for gene therapy, for cancer gene therapy, or for vaccine therapy. Such a microorganism can be used to stimulate humoral and/or cellular immune response, induce strong cytotoxic T lymphocytes responses
5 in subjects who may benefit from such responses. For example, the microorganism can provide prophylactic and therapeutic effects against a tumor infected by the microorganism or other infectious diseases, by rejection of cells from tumors or lesions using microorganisms that express immunoreactive antigens (Earl *et al.* (1986), Science 234, 728-831; Lathe *et al.* (1987), Nature (London) 326, 878-880),
10 cellular tumor-associated antigens (Bernards *et al.*, (1987), Proc. Natl. Acad. Sci. USA 84, 6854-6858; Estin *et al.* (1988), Proc. Natl. Acad. Sci. USA 85, 1052-1056; Kantor *et al.* (1992), J. Natl. Cancer Inst. 84, 1084-1091; Roth *et al.* (1996), Proc.
15 Natl. Acad. Sci. USA 93, 4781-4786) and/or cytokines (*e.g.*, IL-2, IL-12), costimulatory molecules (B7-1, B7-2) (Rao *et al.* (1996), J. Immunol. 156, 3357-3365; Chamberlain *et al.* (1996), Cancer Res. 56, 2832-2836; Oertli *et al.* (1996), J. Gen. Virol. 77, 3121-3125; Qin and Chatterjee (1996), Human Gene Ther. 7, 1853-1860; McAneny *et al.* (1996), Ann. Surg. Oncol. 3, 495-500), or other therapeutic proteins.

Provided herein, solid tumors can be treated with microorganisms, such as
20 vaccinia viruses, resulting in an enormous tumor-specific microorganism replication, which can lead to tumor protein antigen and viral protein production in the tumors. As provided herein, vaccinia virus administration to mice resulted in lysis of the infected tumor cells and a resultant release of tumor-cell-specific antigens. Continuous leakage of these antigens into the body led to a very high level of
25 antibody titer (in approximately 7-14 days) against tumor proteins, viral proteins, and the virus encoded engineered proteins in the mice. The newly synthesized antitumor antibodies and the enhanced macrophage, neutrophils count were continuously delivered via the vasculature to the tumor and thereby provided for the recruitment of an activated immune system against the tumor. The activated
30 immune system then eliminated the foreign compounds of the tumor including the

-113-

viral particles. This interconnected release of foreign antigens boosted antibody production and continuous response of the antibodies against the tumor proteins to function like an autoimmunizing vaccination system initiated by vaccinia viral infection and replication, followed by cell lysis, protein leakage and enhanced 5 antibody production. Thus, the present methods can provide a complete process that can be applied to all tumor systems with immunoprivileged tumor sites as site of privileged viral, bacterial, and mammalian cell growth, which can lead to tumor elimination by the host's own immune system.

In other embodiments, methods are provided for immunizing a subject, 10 where the methods include administering to the subject a microorganism that expresses one or more antigens against which antigens the subject will develop an immune response. The immunizing antigens can be endogenous to the microorganism, such as vaccinia antigens on a vaccinia virus used to immunize against smallpox. Or the immunizing antigens can be exogenous antigens expressed 15 by the microorganism, such as influenza or HIV antigens expressed on a viral capsid or bacterial cell surface. Thus, the microorganisms provided herein, including the modified vaccinia viruses can be used as vaccines.

1. Administration

In performing the methods provided herein, a microorganism can be 20 administered to a subject, including a subject having a tumor or having neoplastic cells, or a subject to be immunized. An administered microorganism can be a microorganism provided herein or any other microorganism known for administration to a subject, for example, any known microorganism known for therapeutic administration to a subject, including antigenic microorganisms such as 25 any microorganism known to be used for vaccination. In some embodiments, the microorganism administered is a microorganism containing a characteristic such as attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, high immunogenicity, replication competence, and ability to express exogenous proteins, and combinations thereof.

a. **Steps prior to administering the microorganism**

In some embodiments, one or more steps can be performed prior to administration of the microorganism to the subject. Any of a variety of preceding steps can be performed, including, but not limited to diagnosing the subject with a condition appropriate for microorganismal administration, determining the immunocompetence of the subject, immunizing the subject, treating the subject with a chemotherapeutic agent, treating the subject with radiation, or surgically treating the subject.

For embodiments that include administering a subject to a tumor-bearing subject for therapeutic purposes, the subject has typically been previously diagnosed with a neoplastic condition. Diagnostic methods also can include determining the type of neoplastic condition, determining the stage of the neoplastic conditions, determining the size of one or more tumors in the subject, determining the presence or absence of metastatic or neoplastic cells in the lymph nodes of the subject, or determining the presence of metastases of the subject. Some embodiments of therapeutic methods for administering a microorganism to a subject can include a step of determination of the size of the primary tumor or the stage of the neoplastic disease, and if the size of the primary tumor is equal to or above a threshold volume, or if the stage of the neoplastic disease is at or above a threshold stage, a microorganism is administered to the subject. In a similar embodiment, if the size of the primary tumor is below a threshold volume, or if the stage of the neoplastic disease is at or below a threshold stage, the microorganism is not yet administered to the subject; such methods can include monitoring the subject until the tumor size or neoplastic disease stage reaches a threshold amount, and then administering the microorganism to the subject. Threshold sizes can vary according to several factors, including rate of growth of the tumor, ability of the microorganism to infect a tumor, and immunocompetence of the subject. Generally the threshold size will be a size sufficient for a microorganism to accumulate and replicate in or near the tumor without being completely removed by the host's immune system, and will typically also be a size sufficient to sustain a microorganismal infection for a time long

enough for the host to mount an immune response against the tumor cells, typically about one week or more, about ten days or more, or about two weeks or more.

Exemplary threshold tumor sizes for viruses such as vaccinia viruses are at least about 100 mm³, at least about 200 mm³, at least about 300 mm³, at least about 400

5 mm³, at least about 500 mm³, at least about 750 mm³, at least about 1000 mm³, or at least about 1500 mm³. Threshold neoplastic disease stages also can vary according to several factors, including specific requirement for staging a particular neoplastic disease, aggressiveness of growth of the neoplastic disease, ability of the

microorganism to infect a tumor or metastasis, and immunocompetence of the

10 subject. Generally the threshold stage will be a stage sufficient for a microorganism to accumulate and replicate in a tumor or metastasis without being completely removed by the host's immune system, and will typically also be a size sufficient to sustain a microorganismal infection for a time long enough for the host to mount an immune response against the neoplastic cells, typically about one week or more,

15 about ten days or more, or about two weeks or more. Exemplary threshold stages are any stage beyond the lowest stage (e.g., Stage I or equivalent), or any stage where the primary tumor is larger than a threshold size, or any stage where metastatic cells are detected.

In other embodiments, prior to administering to the subject a microorganism, 20 the immunocompetence of the subject can be determined. The methods of administering a microorganism to a subject provided herein can include causing or enhancing an immune response in a subject. Accordingly, prior to administering a microorganism to a subject, the ability of a subject to mount an immune response can be determined. Any of a variety of tests of immunocompetence known in the art 25 can be performed in the methods provided herein. Exemplary immunocompetence tests can examine ABO hemagglutination titers (IgM), leukocyte adhesion deficiency (LAD), granulocyte function (NBT), T and B cell quantitation, tetanus antibody titers, salivary IgA, skin test, tonsil test, complement C3 levels, and factor B levels, and lymphocyte count. One skilled in the art can determine the desirability 30 to administer a microorganism to a subject according to the level of

-116-

immunocompetence of the subject, according to the immunogenicity of the microorganism, and, optionally, according to the immungencity of the neoplastic disease to be treated. Typically, a subject can be considered immunocompetent if the skilled artisan can determine that the subject is sufficiently competent to mount
5 an immune response against the microorganism.

In some embodiments, the subject can be immunized prior to administering to the subject a microorganism according to the methods provided herein. Immunization can serve to increase the ability of a subject to mount an immune response against the microorganism, or increase the speed at which the subject can
10 mount an immune response against a microorganism. Immunization also can serve to decrease the risk to the subject of pathogenicity of the microorganism. In some embodiments, the immunization can be performed with an immunization microorganism that is similar to the therapeutic microorganism to be administered. For example, the immunization microorganism can be a replication-incompetent
15 variant of the therapeutic microorganism. In other embodiments, the immunization material can be digests of the therapeutic microorganism to be administered. Any of a variety of methods for immunizing a subject against a known microorganism are known in the art and can be used herein. In one example, vaccinia viruses treated with, for example, 1 microgram of psoralen and ultraviolet light at 365 nm for 4
20 minutes, can be rendered replication incompetent. In another embodiment, the microorganism can be selected as the same or similar to a microorganism against which the subject has been previously immunized, e.g., in a childhood vaccination.

In another embodiment, the subject can have administered thereto a microorganism without any previous steps of cancer treatment such as
25 chemotherapy, radiation therapy or surgical removal of a tumor and/or metastases. The methods provided herein take advantage of the ability of the microorganisms to enter or localize near a tumor, where the tumor cells can be protected from the subject's immune system; the microorganisms can then proliferate in such an immunoprotected region and can also cause the release, typically a sustained release,
30 of tumor antigens from the tumor to a location in which the subject's immune

-117-

system can recognize the tumor antigens and mount an immune response. In such methods, existence of a tumor of sufficient size or sufficiently developed immunoprotected state can be advantageous for successful administration of the microorganism to the tumor, and for sufficient tumor antigen production. If a tumor 5 is surgically removed, the microorganisms may not be able to localize to other neoplastic cells (e.g., small metastases) because such cells may not yet have matured sufficiently to create an immunoprotective environment in which the microorganisms can survive and proliferate, or even if the microorganisms can localize to neoplastic cells, the number of cells or size of the mass may be too small 10 for the microorganisms to cause a sustained release of tumor antigens in order for the host to mount an anti-tumor immune response. Thus, for example, provided herein are methods of treating a tumor or neoplastic disease in which microorganisms are administered to a subject with a tumor or neoplastic disease without removing the primary tumor, or to a subject with a tumor or neoplastic 15 disease in which at least some tumors or neoplastic cells are intentionally permitted to remain in the subject. In other typical cancer treatment methods such as chemotherapy or radiation therapy, such methods typically have a side effect of weakening the subject's immune system. This treatment of a subject by chemotherapy or radiation therapy can reduce the subject's ability to mount an anti- 20 tumor immune response. Thus, for example, provided herein are methods of treating a tumor or neoplastic disease in which microorganisms are administered to a subject with a tumor or neoplastic disease without treating the subject with an immune system-weakening therapy, such as chemotherapy or radiation therapy.

In an alternative embodiment, prior to administration of a microorganism to 25 the subject, the subject can be treated in one or more cancer treatment steps that do not remove the primary tumor or that do not weaken the immune system of the subject. A variety of more sophisticated cancer treatment methods are being developed in which the tumor can be treated without surgical removal or immune-system weakening therapy. Exemplary methods include administering a compound 30 that decreases the rate of proliferation of the tumor or neoplastic cells without

-118-

weakening the immune system (e.g., by administering tumor suppressor compounds or by administering tumor cell-specific compounds) or administering an angiogenesis-inhibiting compound. Thus, combined methods that include administering a microorganism to a subject can further improve cancer therapy.

5 Thus, provided herein are methods of administering a microorganism to a subject, along with prior to or subsequent to, for example, administering a compound that slows tumor growth without weakening the subject's immune system or a compound that inhibits vascularization of the tumor.

b. Mode of administration

10 Any mode of administration of a microorganism to a subject can be used, provided the mode of administration permits the microorganism to enter a tumor or metastasis. Modes of administration can include, but are not limited to, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intratumor, multipuncture (e.g., as used with smallpox vaccines), inhalation, intranasal, oral, intracavity (e.g.,

15 administering to the bladder via a catheder, administering to the gut by suppository or enema), aural, or ocular administration. One skilled in the art can select any mode of administration compatible with the subject and the microorganism, and that also is likely to result in the microorganism reaching tumors and/or metastases. The route of administration can be selected by one skilled in the art according to any of a 20 variety of factors, including the nature of the disease, the kind of tumor, and the particular microorganism contained in the pharmaceutical composition.

Administration to the target site can be performed, for example, by ballistic delivery, as a colloidal dispersion system, or systemic administration can be performed by injection into an artery.

c. Dosage

The dosage regimen can be any of a variety of methods and amounts, and can be determined by one skilled in the art according to known clinical factors. As is known in the medical arts, dosages for any one patient can depend on many factors, including the subject's species, size, body surface area, age, sex, 30 immunocompetence, and general health, the particular microorganism to be

-119-

administered, duration and route of administration, the kind and stage of the disease, for example, tumor size, and other compounds such as drugs being administered concurrently. In addition to the above factors, such levels can be affected by the infectivity of the microorganism, and the nature of the microorganism, as can be
5 determined by one skilled in the art. At least some of the viruses used in the methods provided herein can be more infectious than the bacteria used herein. Thus, in some embodiments of the present methods, virus can be administered at lower levels than bacteria. In the present methods, appropriate minimum dosage levels of microorganisms can be levels sufficient for the microorganism to survive, grow and
10 replicate in a tumor or metastasis. Exemplary minimum levels for administering a virus to a 65 kg human can include at least about 5×10^5 plaque forming units (pfu), at least about 1×10^6 pfu, at least about 5×10^6 pfu, at least about 1×10^7 pfu, or at least about 1×10^8 pfu. Exemplary minimum levels for administering a bacterium to a 65 kg human can include at least about 5×10^6 colony forming units (cfu), at least
15 about 1×10^7 cfu, at least about 5×10^7 cfu, at least about 1×10^8 cfu, or at least about 1×10^9 cfu. In the present methods, appropriate maximum dosage levels of microorganisms can be levels that are not toxic to the host, levels that do not cause splenomegaly of 3x or more, levels that do not result in colonies or plaques in normal tissues or organs after about 1 day or after about 3 days or after about 7 days.
20 Exemplary maximum levels for administering a virus to a 65 kg human can include no more than about 5×10^{10} pfu, no more than about 1×10^{10} pfu, no more than about 5×10^9 pfu, no more than about 1×10^9 pfu, or no more than about 1×10^8 pfu. Exemplary maximum levels for administering a bacterium to a 65 kg human can include no more than about 5×10^{11} pfu, no more than about 1×10^{11} pfu, no
25 more than about 5×10^{10} pfu, no more than about 1×10^{10} pfu, or no more than about 1×10^9 pfu.

d. Number of administrations

The methods provided herein can include a single administration of a microorganism to a subject or multiple administrations of a microorganism to a subject. In some embodiments, a single administration is sufficient to establish a
30

-120-

microorganism in a tumor, where the microorganism can proliferate and can cause or enhance an anti-tumor response in the subject; such methods do not require additional administrations of a microorganism in order to cause or enhance an anti-tumor response in a subject, which can result, for example in inhibition of tumor growth, inhibition of metastasis growth or formation, reduction in tumor or metastasis size, elimination of a tumor or metastasis, inhibition or prevention of recurrence of a neoplastic disease or new tumor formation, or other cancer therapeutic effects. In other embodiments, a microorganism can be administered on different occasions, separated in time typically by at least one day. Separate administrations can increase the likelihood of delivering a microorganism to a tumor or metastasis, where a previous administration may have been ineffective in delivering a microorganism to a tumor or metastasis. Separate administrations can increase the locations on a tumor or metastasis where microorganism proliferation can occur or can otherwise increase the titer of microorganism accumulated in the tumor, which can increase the scale of release of antigens or other compounds from the tumor in eliciting or enhancing a host's anti-tumor immune response, and also can, optionally, increase the level of microorganism-based tumor lysis or tumor cell death. Separate administrations of a microorganism can further extend a subject's immune response against microorganismal antigens, which can extend the host's immune response to tumors or metastases in which microorganisms have accumulated, and can increase the likelihood a host mounting an anti-tumor immune response.

When separate administrations are performed, each administration can be a dosage amount that is the same or different relative to other administration dosage amounts. In one embodiment, all administration dosage amounts are the same. In other embodiments, a first dosage amount can be a larger dosage amounts than one or more subsequent dosage amounts, for example, at least 10x larger, at least 100x larger, or at least 1000x larger than subsequent dosage amounts. In one example of a method of separate administrations in which the first dosage amount is greater than

-121-

one or more subsequent dosage amounts, all subsequent dosage amounts can be the same, smaller amount relative to the first administration.

Separate administrations can include any number of two or more administrations, including two, three, four, five or six administrations. One skilled in the art can readily determine the number of administrations to perform or the desirability of performing one or more additional administrations according to methods known in the art for monitoring therapeutic methods and other monitoring methods provided herein. Accordingly, the methods provided herein include methods of providing to the subject one or more administrations of a microorganism, where the number of administrations can be determined by monitoring the subject, and, based on the results of the monitoring, determining whether or not to provide one or more additional administrations. Deciding of whether or not to provide one or more additional administrations can be based on a variety of monitoring results, including, but not limited to, indication of tumor growth or inhibition of tumor growth, appearance of new metastases or inhibition of metastasis, the subject's anti-microorganism antibody titer, the subject's anti-tumor antibody titer, the overall health of the subject, the weight of the subject, the presence of microorganism solely in tumor and/or metastases, the presence of microorganism in normal tissues or organs.

The time period between administrations can be any of a variety of time periods. The time period between administrations can be a function of any of a variety of factors, including monitoring steps, as described in relation to the number of administrations, the time period for a subject to mount an immune response, the time period for a subject to clear microorganism from normal tissue, or the time period for microorganismal proliferation in the tumor or metastasis. In one example, the time period can be a function of the time period for a subject to mount an immune response; for example, the time period can be more than the time period for a subject to mount an immune response, such as more than about one week, more than about ten days, more than about two weeks, or more than about a month; in another example, the time period can be less than the time period for a subject to

mount an immune response, such as less than about one week, less than about ten days, less than about two weeks, or less than about a month. In another example, the time period can be a function of the time period for a subject to clear microorganism from normal tissue; for example, the time period can be more than the time period
5 for a subject to clear microorganism from normal tissue, such as more than about a day, more than about two days, more than about three days, more than about five days, or more than about a week. In another example, the time period can be a function of the time period for microorganismal proliferation in the tumor or metastasis; for example, the time period can be more than the amount of time for a
10 detectable signal to arise in a tumor or metastasis after administration of a microorganism expressing a detectable marker, such as about 3 days, about 5 days, about a week, about ten days, about two weeks, or about a month.

e. Co-administrations

Also provided are methods in which an additional therapeutic substance,
15 such as a different therapeutic microorganism or a therapeutic compound is administered. These can be administered simultaneously, sequentially or intermittently with the first microorganism. The additional therapeutic substance can interact with the microorganism or a gene product thereof, or the additional therapeutic substance can act independently of the microorganism.

i. Administration of a plurality of microorganisms

Methods are provided for administering to a subject two or more microorganisms. Adminstration can be effected simultaneously, sequentially or intermittently, The plurality of microorganisms can be administered as a single composition or as two or more compositions. The two or more microorganisms can include at least two bacteria, at least two viruses, at least two eukaryotic cells, or two or more selected from among bacteria, viruses and eukaryotic cells. The plurality of microorganisms can be provided as combinations of compositions containing and/or as kits that include the microorganisms packagd for administration and optionally including instruictions therefore. The compostions can contain the

microorganisms formulated for single dosage administration (*i.e.*, for direct administration) can require dilution or other additions.

In one embodiment, at least one of the microorganisms is a modified microorganism such as those provided herein, having a characteristic such as low pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenic, replication competent, ability to express exogenous proteins, and combinations thereof. The microorganisms can be administered at approximately the same time, or can be administered at different times. The microorganisms can be administered in the same composition or in the same administration method, or can be administered in separate composition or by different administration methods.

In one example, a bacteria and a virus can be administered to a subject. The bacteria and virus can be administered at the same time, or at different times. For example, the virus can be administered prior to administering the bacteria, or the bacteria can be administered prior to administering the virus; typically the virus is administered prior to administering the bacteria. As provided herein, administering to a subject a virus prior to administering to the subject a bacterium can increase the amount of bacteria that can accumulate and/or proliferate in a tumor, relative to methods in which bacteria alone are administered.

Accordingly, the methods provided herein that include administration of virus prior to administration of bacteria permit the administration of a lower dosage amount of bacteria than would otherwise be administered in a method in which bacteria alone are administered or a method in which bacteria are administered at the same time as or prior to administration of a virus. For example, in some embodiments, a bacterium to be administered can have one or more properties that limit the ability of the bacterium to be used, such properties can include, but are not limited to toxicity, low tumor specificity of accumulation, and limited proliferation capacity. A bacterium to be administered that has one or more limiting properties can require administration in lower dosage amounts, or can require assistance in tumor-specific accumulation and/or proliferation. Provided herein are methods of

-124-

administering such a bacterium with limiting properties, where prior to administering the bacterium, a virus is administered such that the limited bacterium can be administered in smaller quantities, can accumulate in tumor with increased specificity, and/or can have an increased ability to proliferate in a tumor.

5 The time period between administrations can be any time period that achieves the desired effects, as can be determined by one skilled in the art. Selection of a time period between administrations of different microorganisms can be determined according to parameters similar to those for selecting the time period between administrations of the same microorganism, including results from monitoring steps, the time period for a subject to mount an immune response, the time period for a subject to clear microorganism from normal tissue, or the time period for microorganismal proliferation in the tumor or metastasis. In one example, the time period can be a function of the time period for a subject to mount an immune response; for example, the time period can be more than the time period for 10 a subject to mount an immune response, such as more than about one week, more than about ten days, more than about two weeks, or more than about a month; in another example, the time period can be less than the time period for a subject to mount an immune response, such as less than about one week, less than about ten days, less than about two weeks, or less than about a month. In another example, the 15 time period can be a function of the time period for a subject to clear microorganism from normal tissue; for example, the time period can be more than the time period for a subject to clear microorganism from normal tissue, such as more than about a day, more than about two days, more than about three days, more than about five days, or more than about a week. In another example, the time period can be a 20 function of the time period for microorganismal proliferation in the tumor or metastasis; for example, the time period can be more than the amount of time for a detectable signal to arise in a tumor or metastasis after administration of a microorganism expressing a detectable marker, such as about 3 days, about 5 days, about a week, about ten days, about two weeks, or about a month. In one example a 25 virus can first be administered, and a bacteria can be administered about 5 days after 30

-125-

administration of the virus. In another example, a virus can be first administered, and a bacterium can be administered upon detection of a virally-encoded detectable gene product in the tumor of the subject, optionally when the virally-encoded detectable gene product is detected only in the tumor of the subject.

5

ii. Therapeutic compounds

The methods can include administering one or more therapeutic compounds to the subject in addition to administering a microorganism or plurality thereof to a subject. Therapeutic compounds can act independently, or in conjunction with the microorganism, for tumor therapeutic affects. Therapeutic compounds that can act independently include any of a variety of known chemotherapeutic compounds that can inhibit tumor growth, inhibit metastasis growth and/or formation, decrease the size of a tumor or metastasis, eliminate a tumor or metastasis, without reducing the ability of a microorganism to accumulate in a tumor, replicate in the tumor, and cause or enhance an anti-tumor immune response in the subject.

10

Therapeutic compounds that act in conjunction with the microorganisms include, for example, compounds that alter the expression of the microorganism or compounds that can interact with a microorganism-expressed gene, or compounds that can inhibit microorganismal proliferation, including compounds toxic to the microorganism. Therapeutic compounds that can act in conjunction with the microorganism include, for example, therapeutic compounds that increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism, and also can include, for example, therapeutic compounds that decrease the proliferation, toxicity, or cell killing properties of a microorganism.

15

Thus, provided herein are methods of administering to a subject one or more therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism. Also provided herein are methods of administering to a subject one or more therapeutic compounds that can act in conjunction with the microorganism to decrease the proliferation, toxicity, or cell killing properties of a microorganism.

20

25

30

-126-

In one embodiment, therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism are compounds that can alter gene expression, where the altered gene expression can result in an increased
5 killing of tumor cells or an increased anti-tumor immune response in the subject. A gene expression-altering compound can, for example, cause an increase or decrease in expression of one or more microorganismal genes, including endogenous microorganismal genes and/or exogenous microorganismal genes. For example, a gene expression-altering compound can induce or increase transcription of a gene in
10 a microorganism such as an exogenous gene that can cause cell lysis or cell death, that can provoke an immune response, that can catalyze conversion of a prodrug-like compound, or that can inhibit expression of a tumor cell gene. Any of a wide variety of compounds that can alter gene expression are known in the art, including IPTG and RU486. Exemplary genes whose expression can be up-regulated include
15 proteins and RNA molecules, including toxins, enzymes that can convert a prodrug to an anti-tumor drug, cytokines, transcription regulating proteins, siRNA, and ribozymes. In another example, a gene expression-altering compound can inhibit or decrease transcription of a gene in a microorganism such as an exogenous gene that can reduce microorganismal toxicity or reduces microorganismal proliferation. Any
20 of a variety of compounds that can reduce or inhibit gene expression can be used in the methods provided herein, including siRNA compounds, transcriptional inhibitors or inhibitors of transcriptional activators. Exemplary genes whose expression can be down-regulated include proteins and RNA molecules, including microorganismal proteins or RNA that suppress lysis, nucleotide synthesis or proliferation, and
25 cellular proteins or RNA molecules that suppress cell death, immunoreactivity, lysis, or microorganismal replication.

In another embodiment, therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism are compounds that can interact with a microorganism-expressed gene product, and such interaction can
30

-127-

result in an increased killing of tumor cells or an increased anti-tumor immune response in the subject. A therapeutic compound that can interact with a microorganism-expressed gene product can include, for example a prodrug or other compound that has little or no toxicity or other biological activity in its subject-
5 administered form, but after interaction with a microorganism-expressed gene product, the compound can develop a property that results in tumor cell death, including but not limited to, cytotoxicity, ability to induce apoptosis, or ability to trigger an immune response. A variety of prodrug-like substances are known in the art and an exemplary set of such compounds are disclosed elsewhere herein, where
10 such compounds can include gancyclovir, 5-fluorouracil, 6-methylpurine deoxyriboside, cephalosporin-doxorubicin, 4-[(2-chloroethyl)(2-mesuloxethyl)amino]benzoyl-L-glutamic acid, acetominophen, indole-3-acetic acid, CB1954, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampotothecin, bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, 1-chloromethyl-5-
15 hydroxy-1,2-dihydro-3H-benz[e]indole, epirubicin-glucoronide, 5'-deoxy5-fluorouridine, cytosine arabinoside, and linamarin.

In another embodiment, therapeutic compounds that can act in conjunction with the microorganism to decrease the proliferation, toxicity, or cell killing properties of a microorganism are compounds that can inhibit microorganismal replication, inhibit microorganismal toxins, or cause microorganismal death. A therapeutic compound that can inhibit microorganismal replication, inhibit microorganismal toxins, or cause microorganismal death can generally include a compound that can block one or more steps in the microorganismal life cycle, including, but not limited to, compounds that can inhibit microorganismal DNA
20 replication, microorganismal RNA transcription, viral coat protein assembly, outer membrane or polysaccharide assembly. Any of a variety of compounds that can block one or more steps in a microorganismal life cycle are known in the art, including any known antibiotic, microorganismal DNA polymerase inhibitors, microorganismal RNA polymerase inhibitors, inhibitors of proteins that regulate
25 microorganismal DNA replication or RNA transcription. In one example, when a
30

microorganism is a bacteria, a compound can be an antibiotic. In another example, a microorganism can contain a gene encoding a microorganismal life cycle protein, such as DNA polymerase or RNA polymerase that can be inhibited by a compound that is, optionally, non-toxic to the host organism.

5

f. State of subject

In another embodiment, the methods provided herein for administering a microorganism to a subject can be performed on a subject in any of a variety of states, including an anesthetized subject, an alert subject, a subject with elevated body temperature, a subject with reduced body temperature, or other state of the 10 subject that is known to affect the accumulation of microorganism in the tumor. As provided herein, it has been determined that a subject that is anesthetized can have a decreased rate of accumulation of a microorganism in a tumor relative to a subject that is not anesthetized. Further provided herein, it has been determined that a subject with decreased body temperature can have a decreased rate o accumulation 15 of a microorganism in a tumor relative to a subject with a normal body temperature. Accordingly, provided herein are methods of administering a microorganism to a subject, where the methods can include administering a microorganism to a subject where the subject is not under anesthesia, such as general anesthesia; for example, the subject can be under local anesthesia, or can be unanesthetized. Also provided 20 are methods of administering a microorganism to a subject, where the methods can include administering a microorganism to a subject with altered body temperature, where the alteration of the body temperature can influence the ability of the microorganism to accumulate in a tumor; typically, a decrease in body temperature can decrease the ability of a microorganism to accumulate in a tumor. 25 Thus, in one exemplary embodiment, a method is provided for administering a microorganism to a subject, where the method includes elevating the body temperature of the subject to a temperature above normal, and administering a microorganism to the subject, where the microorganism can accumulate in the tumor more readily in the subject with higher body temperature relative to the ability of the

-129-

microorganism to accumulate in a tumor of a subject with a normal body temperature.

2. Monitoring

The methods provided herein can further include one or more steps of monitoring the subject, monitoring the tumor, and/or monitoring the microorganism administered to the subject. Any of a variety of monitoring steps can be included in the methods provided herein, including, but not limited to, monitoring tumor size, monitoring anti-(tumor antigen) antibody titer, monitoring the presence and/or size of metastases, monitoring the subject's lymph nodes, monitoring the subject's weight or other health indicators including blood or urine markers, monitoring anti-(microorganismal antigen) antibody titer, monitoring microorganismal expression of a detectable gene product, and directly monitoring microorganismal titer in a tumor, tissue or organ of a subject.

The purpose of the monitoring can be simply for assessing the health state of the subject or the progress of therapeutic treatment of the subject, or can be for determining whether or not further administration of the same or a different microorganism is warranted, or for determining when or whether or not to administer a compound to the subject where the compound can act to increase the efficacy of the therapeutic method, or the compound can act to decrease the pathogenicity of the microorganism administered to the subject.

a. Monitoring microorganismal gene expression

In some embodiments, the methods provided herein can include monitoring one or more microorganismally expressed genes. Microorganisms, such as those provided herein or otherwise known in the art, can express one or more detectable gene products, including but not limited to, detectable proteins.

As provided herein, measurement of a detectable gene product expressed in a microorganism can provide an accurate determination of the level of microorganism present in the subject. As further provided herein, measurement of the location of the detectable gene product, for example, by imaging methods including tomographic methods, can determine the localization of the microorganism in the

-130-

subject. Accordingly, the methods provided herein that include monitoring a detectable microorganismal gene product can be used to determine the presence or absence of the microorganism in one or more organs or tissues of a subject, and/or the presence or absence of the microorganism in a tumor or metastases of a subject.

5 Further, the methods provided herein that include monitoring a detectable microorganismal gene product can be used to determine the titer of microorganism present in one or more organs, tissues, tumors or metastases. Methods that include monitoring the localization and/or titer of microorganisms in a subject can be used for determining the pathogenicity of a microorganism; since microorganismal infection, and particularly the level of infection, of normal tissues and organs can indicate the pathogenicity of the probe, methods of monitoring the localization and/or amount of microorganisms in a subject can be used to determine the pathogenicity of a microorganism. Since methods provided herein can be used to monitor the amount of microorganisms at any particular location in a subject, the

10 methods that include monitoring the localization and/or titer of microorganisms in a subject can be performed at multiple time points, and, accordingly can determine the rate of microorganismal replication in a subject, including the rate of microorganismal replication in one or more organs or tissues of a subject; accordingly, the methods of monitoring a microorganismal gene product can be used

15 for determining the replication competence of a microorganism. The methods provided herein also can be used to quantitate the amount of microorganism present in a variety of organs or tissues, and tumors or metastases, and can thereby indicate the degree of preferential accumulation of the microorganism in a subject; accordingly, the microorganismal gene product monitoring methods provided herein

20 can be used in methods of determining the ability of a microorganism to accumulate in tumor or metastases in preference to normal tissues or organs. Since the microorganisms used in the methods provided herein can accumulate in an entire tumor or can accumulate at multiple sites in a tumor, and can also accumulate in metastases, the methods provided herein for monitoring a microorganismal gene product can be used to determine the size of a tumor or the number of metastases are

25

30

present in a subject. Monitoring such presence of microorganismal gene product in tumor or metastasis over a range of time can be used to assess changes in the tumor or metastasis, including growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, and also can be used to determine the
5 rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases.

Accordingly, the methods of monitoring a microorganismal gene product can be used for monitoring a neoplastic disease in a subject, or for determining the efficacy
10 of treatment of a neoplastic disease, by determining rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases.

Any of a variety of detectable proteins can be detected in the monitoring
15 methods provided herein; an exemplary, non-limiting list of such detectable proteins includes any of a variety of fluorescence proteins (*e.g.*, green fluorescence proteins), any of a variety of luciferases, transferring or other iron binding proteins; or receptors, binding proteins, and antibodies, where a compound that specifically binds the receptor, binding protein or antibody can be a detectable agent or can be
20 labeled with a detectable substance (*e.g.*, a radionuclide or imaging agent).

b. Monitoring tumor size

Also provided herein are methods of monitoring tumor and/or metastasis size and location. Tumor and/or metastasis size can be monitored by any of a variety of methods known in the art, including external assessment methods or tomographic or
25 magnetic imaging methods. In addition to the methods known in the art, methods provided herein, for example, monitoring microorganismal gene expression, can be used for monitoring tumor and/or metastasis size.

Monitoring size over several time points can provide information regarding the increase or decrease in size of a tumor or metastasis, and can also provide
30 information regarding the presence of additional tumors and/or metastases in the

subject. Monitoring tumor size over several time points can provide information regarding the development of a neoplastic disease in a subject, including the efficacy of treatment of a neoplastic disease in a subject.

c. Monitoring antibody titer

5 The methods provided herein also can include monitoring the antibody titer in a subject, including antibodies produced in response to administration of a microorganism to a subject. The microorganisms administered in the methods provided herein can elicit an immune response to endogenous microorganismal antigens. The microorganisms administered in the methods provided herein also can 10 elicit an immune response to exogenous genes expressed by a microorganism. The microorganisms administered in the methods provided herein also can elicit an immune response to tumor antigens. Monitoring antibody titer against microorganismal antigens, microorganismally expressed exogenous gene products, or tumor antigens can be used in methods of monitoring the toxicity of a 15 microorganism, monitoring the efficacy of treatment methods, or monitoring the level of gene product or antibodies for production and/or harvesting.

In one embodiment, monitoring antibody titer can be used to monitor the toxicity of a microorganism. Antibody titer against a microorganism can vary over the time period after administration of the microorganism to the subject, where at 20 some particular time points, a low anti-(microorganismal antigen) antibody titer can indicate a higher toxicity, while at other time points a high anti-(microorganismal antigen) antibody titer can indicate a higher toxicity. The microorganisms used in the methods provided herein can be immunogenic, and can, therefore, elicit an immune response soon after administering the microorganism to the subject. 25 Generally, a microorganism against which a subject's immune system can quickly mount a strong immune response can be a microorganism that has low toxicity when the subject's immune system can remove the microorganism from all normal organs or tissues. Thus, in some embodiments, a high antibody titer against microorganismal antigens soon after administering the microorganism to a subject 30 can indicate low toxicity of a microorganism. In contrast, a microorganism that is

not highly immunogenic may infect a host organism without eliciting a strong immune response, which can result in a higher toxicity of the microorganism to the host. Accordingly, in some embodiments, a high antibody titer against microorganismal antigens soon after administering the microorganism to a subject 5 can indicate low toxicity of a microorganism.

In other embodiments, monitoring antibody titer can be used to monitor the efficacy of treatment methods. In the methods provided herein, antibody titer, such as anti-(tumor antigen) antibody titer, can indicate the efficacy of a therapeutic method such as a therapeutic method to treat neoplastic disease. Therapeutic 10 methods provided herein can include causing or enhancing an immune response against a tumor and/or metastasis. Thus, by monitoring the anti-(tumor antigen) antibody titer, it is possible to monitor the efficacy of a therapeutic method in causing or enhancing an immune response against a tumor and/or metastasis. The therapeutic methods provided herein also can include administering to a subject a 15 microorganism that can accumulate in a tumor and can cause or enhance an anti-tumor immune response. Accordingly, it is possible to monitor the ability of a host to mount an immune response against microorganisms accumulated in a tumor or metastasis, which can indicate that a subject has also mounted an anti-tumor immune response, or can indicate that a subject is likely to mount an anti-tumor immune 20 response, or can indicate that a subject is capable of mounting an anti-tumor immune response.

In other embodiments, monitoring antibody titer can be used for monitoring the level of gene product or antibodies for production and/or harvesting. As provided herein, methods can be used for producing proteins, RNA molecules or 25 other compounds by expressing an exogenous gene in a microorganism that has accumulated in a tumor. Further provided herein are methods for producing antibodies against a protein, RNA molecule or other compound produced by exogenous gene expression of a microorganism that has accumulated in a tumor. Monitoring antibody titer against the protein, RNA molecule or other compound can 30 indicate the level of production of the protein, RNA molecule or other compound by

-134-

the tumor-accumulated microorganism, and also can directly indicate the level of antibodies specific for such a protein, RNA molecule or other compound.

d. Monitoring general health diagnostics

The methods provided herein also can include methods of monitoring the health of a subject. Some of the methods provided herein are therapeutic methods, including neoplastic disease therapeutic methods. Monitoring the health of a subject can be used to determine the efficacy of the therapeutic method, as is known in the art. The methods provided herein also can include a step of administering to a subject a microorganism. Monitoring the health of a subject can be used to determine the pathogenicity of a microorganism administered to a subject. Any of a variety of health diagnostic methods for monitoring disease such as neoplastic disease, infectious disease, or immune-related disease can be monitored, as is known in the art. For example, the weight, blood pressure, pulse, breathing, color, temperature or other observable state of a subject can indicate the health of a subject.

In addition, the presence or absence or level of one or more components in a sample from a subject can indicate the health of a subject. Typical samples can include blood and urine samples, where the presence or absence or level of one or more components can be determined by performing, for example, a blood panel or a urine panel diagnostic test. Exemplary components indicative of a subject's health include, but are not limited to, white blood cell count, hematocrit, c-reactive protein concentration.

e. Monitoring coordinated with treatment

Also provided herein are methods of monitoring a therapy, where therapeutic decisions can be based on the results of the monitoring. Therapeutic methods provided herein can include administering to a subject a microorganism, where the microorganism can preferentially accumulate in a tumor and/or metastasis, and where the microorganism can cause or enhance an anti-tumor immune response. Such therapeutic methods can include a variety of steps including multiple administrations of a particular microorganism, administration of a second microorganism, or administration of a therapeutic compound. Determination of the

-135-

amount, timing or type of microorganism or compound to administer to the subject can be based on one or more results from monitoring the subject. For example, the antibody titer in a subject can be used to determine whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or
5 compound to administer, and the type of microorganism or compound to administer, where, for example, a low antibody titer can indicate the desirability of administering additional microorganism, a different microorganism, or a therapeutic compound such as a compound that induces microorganismal gene expression. In another example, the overall health state of a subject can be used to determine
10 whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or compound to administer, and the type of microorganism or compound to administer, where, for example, determining that the subject is healthy can indicate the desirability of administering additional microorganism, a different microorganism, or a therapeutic compound such as a
15 compound that induces microorganismal gene expression. In another example, monitoring a detectable microorganismally expressed gene product can be used to determine whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or compound to administer, and the type of microorganism or compound to administer. Such monitoring methods can be used
20 to determine whether or not the therapeutic method is effective, whether or not the therapeutic method is pathogenic to the subject, whether or not the microorganism has accumulated in a tumor or metastasis, and whether or not the microorganism has accumulated in normal tissues or organs. Based on such determinations, the desirability and form of further therapeutic methods can be derived.
25 In one embodiment, determination of whether or not a therapeutic method is effective can be used to derive further therapeutic methods. Any of a variety of methods of monitoring can be used to determine whether or not a therapeutic method is effective, as provided herein or otherwise known in the art. If monitoring methods indicate that the therapeutic method is effective, a decision can be made to
30 maintain the current course of therapy, which can include further administrations of

a microorganism or compound, or a decision can be made that no further administrations are required. If monitoring methods indicate that the therapeutic method is ineffective, the monitoring results can indicate whether or not a course of treatment should be discontinued (*e.g.*, when a microorganism is pathogenic to the 5 subject), or changed (*e.g.*, when a microorganism accumulates in a tumor without harming the host organism, but without eliciting an anti-tumor immune response), or increased in frequency or amount (*e.g.*, when little or no microorganism accumulates in tumor).

In one example, monitoring can indicate that a microorganism is pathogenic 10 to a subject. In such instances, a decision can be made to terminate administration of the microorganism to the subject, to administer lower levels of the microorganism to the subject, to administer a different microorganism to a subject, or to administer to a subject a compound that reduces the pathogenicity of the microorganism. In one example, administration of a microorganism that is determined to be pathogenic 15 can be terminated. In another example, the dosage amount of a microorganism that is determined to be pathogenic can be decreased for subsequent administration; in one version of such an example, the subject can be pre-treated with another microorganism that can increase the ability of the pathogenic microorganism to accumulate in tumor, prior to re-administering the pathogenic microorganism to the 20 subject. In another example, a subject can have administered thereto a bacteria or virus that is pathogenic to the subject; administration of such a pathogenic microorganism can be accompanied by administration of, for example an antibiotic, anti-microorganismal compound, pathogenicity attenuating compound (*e.g.*, a compound that down-regulates the expression of a lytic or apoptotic gene product), 25 or other compound that can decrease the proliferation, toxicity, or cell killing properties of a microorganism, as described herein elsewhere. In one variation of such an example, the localization of the microorganism can be monitored, and, upon determination that the microorganism is accumulated in tumor and/or metastases but not in normal tissues or organs, administration of the antibiotic, anti- 30 microorganismal compound or pathogenicity attenuating compound can be

terminated, and the pathogenic activity of the microorganism can be activated or increased, but limited to the tumor and/or metastasis. In another variation of such an example, after terminating administration of an antibiotic, anti-microorganismal compound or pathogenicity attenuating compound, the presence of the

5 microorganism and/or pathogenicity of the microorganism can be further monitored, and administration of such a compound can be reinitiated if the microorganism is determined to pose a threat to the host by, for example, spreading to normal organs or tissues, releasing a toxin into the vasculature, or otherwise having pathogenic effects reaching beyond the tumor or metastasis.

10 In another example, monitoring can determine whether or not a microorganism has accumulated in a tumor or metastasis of a subject. Upon such a determination, a decision can be made to further administer additional microorganism, a different microorganism or a compound to the subject. In one example, monitoring the presence of a virus in a tumor or metastasis can be used in
15 deciding to administer to the subject a bacterium, where, for example, the quantity of bacteria administered can be reduced according to the presence and/or quantity of virus in a tumor or metastasis. In a similar example, monitoring the presence of a virus in a tumor or metastasis can be used in deciding when to administer to the subject a bacterium, where, for example, the bacteria can be administered upon detecting to the presence and/or a selected quantity of virus in a tumor or metastasis.
20 In another example, monitoring the presence of a microorganism in a tumor can be used in deciding to administer to the subject a compound, where the compound can increase the pathogenicity, proliferation, or immunogenicity of a microorganism or the compound can otherwise act in conjunction with the microorganism to increase
25 the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism; in one variation of such an example, the microorganism can, for example have little or no lytic or cell killing capability in the absence of such a compound; in a further variation of such an example, monitoring of the presence of the microorganism in a tumor or metastasis can be coupled with monitoring the
30 absence of the microorganism in normal tissues or organs, where the compound is

administered if the microorganism is present in tumor or metastasis and not at all present or substantially not present in normal organs or tissues; in a further variation of such an example, the amount of microorganism in a tumor or metastasis can be monitored, where the compound is administered if the microorganism is present in
5 tumor or metastasis at sufficient levels.

E. Methods of Producing Gene Products and Antibodies

Provided herein are microorganisms, and methods for making and using such microorganisms for production products of exogenous genes and/or for production of antibodies specific for exogenous gene products. The methods provided herein
10 result in efficient recombinant production of biologically active proteins. In EP A1 1 281 772, it is disclosed that when vaccinia virus (LIVP strain) carrying the light emitting fusion gene construct rVV-ruc-gfp was injected intravenously into nude mice, the virus particles were found to be cleared from all internal organs within 4 days, as determined by extinction of light emission. In contrast, when the fate of the
15 injected vaccinia virus was similarly followed in nude mice bearing tumors grown from subcutaneously implanted C6 rat glioma cells, virus particles were found to be retained over time in the tumor tissues, resulting in lasting light emission. The presence and amplification of the virus-encoded fusion proteins in the same tumor were monitored in live animals by observing GFP fluorescence under a
20 stereomicroscope and by detecting luciferase-catalyzed light emission under a low-light video-imaging camera. Tumor-specific light emission was detected 4 days after viral injection in nude mice carrying subcutaneous C6 glioma implants. Tumor accumulation of rVV-ruc-gfp virus particles was also seen in nude mice carrying subcutaneous tumors developed from implanted PC-3 human prostate cells, and in
25 mice with orthotopically implanted MCF-7 human breast tumors. Further, intracranial C6 rat glioma cell implants in immunocompetent rats and MB-49 human bladder tumor cell implants in C57 mice were also targeted by the vaccinia virus. In addition to primary breast tumors, small metastatic tumors were also detected externally in the contralateral breast region, as well as in nodules on the exposed
30 lung surface, suggesting metastasis to the contralateral breast and lung. In summary

it was shown that light-emitting cells or microorganisms, for example, vaccinia virus can be used to detect and treat metastatic tumors.

Similar results were obtained with light-emitting bacteria (*Salmonella*, *Vibrio*, *Listeria*, *E. coli*) which were injected intravenously into mice and which could be visualized in whole animals under a low light imager immediately. No light emission was detected twenty four hours after bacterial injection in both athymic (nu/nu) mice and immunocompetent C57 mice as a result of clearing by the immune system. In nude mice bearing tumors developed from implanted C6 glioma cells, light emission was abolished from the animal entirely twenty four hours after delivery of bacteria, similar to mice without tumors. However, forty eight hours post-injection, a strong, rapidly increasing light emission originated only from the tumor regions was observed. This observation indicated a continuous bacterial replication in the tumor tissue. The extent of light emission was dependent on the bacterial strain used. The homing-in process together with the sustained light emission was also demonstrated in nude mice carrying prostate, bladder, and breast tumors. In addition to primary tumors, metastatic tumors could also be visualized as exemplified in the breast tumor model. Tumor-specific light emission was also observed in immunocompetent C57 mice, with bladder tumors as well as in Lewis rats with brain glioma implants. Once in the tumor, the light-emitting bacteria were not observed to be released into the circulation and to re-colonize subsequently implanted tumors in the same animal. Further, mammalian cells expressing the Ruc-GFP fusion protein, upon injection into the bloodstream, were also found to home in to, and propagate in, glioma tumors. These findings opened the way for designing multifunctional viral vectors useful for the detection of tumors based on signals such as light emission, for suppression of tumor development and angiogenesis signaled by, for example, light extinction and the development of bacterial and mammalian cell-based tumor targeting systems in combination with therapeutic gene constructs for the treatment of cancer. These systems have the following advantages: (a) They target the tumor specifically without affecting normal tissue; (b) the expression and secretion of the therapeutic gene constructs can be, optionally, under the control of

-140-

an inducible promoter enabling secretion to be switched on or off; and (c) the location of the delivery system inside the tumor can be verified by direct visualization before activating gene expression and protein delivery.

As provided herein, the system described above based on the accumulation
5 of bacteria, viruses and eukaryotic cells in tumors can be used for simple, quick, and inexpensive production of proteins and other biological compounds originating from cloned nucleotide sequences. This system also is useful for the concomitant overproduction of polypeptides, RNA or other biological compounds (in tumor tissue) and antibodies against those compounds (in the serum) in the same animal.
10 As provided herein, after intravenous injection, a microorganism such as vaccinia virus can enter the tumor of an animal and, due to the immunoprivileged state of the tumor, can replicate preferentially in the tumor tissues and thereby can overproduce the inserted gene encoded protein in the tumors. After harvesting the tumor tissues, the localized and overexpressed protein can be isolated by a simple procedure from
15 tumor homogenates. In addition, based on the findings that only 0.2 to 0.3% of the desired proteins produced in the tumor were found in the blood stream of the same animal, a simultaneous vaccination of the mouse and efficient antibody production against the overproduced protein was achieved. Thus, serum from the same mouse (or any other animal) can be harvested and used as mouse-derived antibodies against
20 the proteins or other products overproduced in the tumor.

Thus, provided herein are methods of producing gene products and/or
antibodies in a non-human subject, by administering to a subject containing a tumor,
a microorganism, where the microorganism expresses a selected protein or RNA to
be produced, a protein or RNA whose expression can result in the formation of a
25 compound to be produced, or a selected protein or RNA against which an antibody
is to be produced. The methods provided herein can further include administering to
a subject containing a tumor, a microorganism expressing an exogenous gene
encoding a selected protein or RNA to be produced, a protein or RNA whose
expression can result in the formation of a compound to be produced, or a selected
30 protein or RNA against which an antibody is to be produced. The methods provided

-141-

herein can further include administering to a subject containing a tumor, a microorganism expressing an gene encoding a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced, where such gene expression can be regulated, for example, by a transcriptional activator or inducer, or a transcriptional suppressor. The methods provided herein for producing a protein, RNA, compound or antibody can further include monitoring the localization and/or level of the microorganism in the subject by detecting a detectable protein, where the detectable protein can indicate the expression of the selected gene, or can indicate the readiness of the microorganism to be induced to express the selected gene or for suppression of expression to be terminated or suspended. Also provided herein are methods of producing gene products and or antibodies in a non-human subject, by administering to a subject containing a tumor, a microorganism, where the microorganism expresses a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced, where the subject to which the microorganism is administered is not a transgenic animal. Also provided herein are methods of producing gene products and or antibodies in a non-human subject, by administering to a subject containing a tumor, a microorganism, where the microorganism expresses a selected protein to be produced, where the tumor within the subject is selected according to its ability to post-translationally process the selected protein.

The advantages of the system, include:

- (a) No production of a transgenic animal carrying the novel polypeptide-encoding cassette is required;
- (b) the tumor system is more efficient than tissue culture;
- (c) proteins interfering with animal development and other toxic proteins can be overproduced in tumors without negative effects to the host animal;
- (d) the system is fast: within 4 to 6 weeks from cDNA cloning to protein and antisera purification;

-142-

- (e) the system is relatively inexpensive and can be scaled up easily;
- (f) correct protein folding and modifications can be achieved;
- (g) high antigenicity can be achieved, which is beneficial for better antibody production; and
- 5 (h) species-specific-cell-based production of proteins in animals such as mice, with tumors as fermentors can be achieved.

Depiction of an exemplary method for production of gene products and/or antibodies against gene products is provided in Figure 2.

In one embodiment, methods are provided for producing a desired polypeptide, RNA or compound, the method including the following steps: (a) injecting a microorganism containing a nucleotide sequence encoding the desired polypeptide or RNA into an animal bearing a tumor; (b) harvesting the tumor tissue from the animal; and (c) isolating the desired polypeptide, RNA or compound from the tumor tissue.

15 Steps of an exemplary method can be summarized as follows (shown for a particular embodiment, *i.e.* vaccinia virus additionally containing a gene encoding a light-emitting protein):

- (1) Insertion of the desired DNA or cDNA into the vaccinia virus genome;
- (2) modification of the vaccinia virus genome with light-emitting protein construct as expression marker;
- (3) recombination and virus assembly in cell culture;
- (4) screening of individual viral particles carrying inserts followed by large scale virus production and concentration;
- (5) administration of the viral particles into mice or other animals bearing tumors of human, non-human primate or other mammalian origins;
- (6) verification of viral replication and protein overproduction in animals based on light emission;
- (7) harvest of tumor tissues and, optionally, the blood (separately); and
- (8) purification of overexpressed proteins from tumors and, optionally, antisera from blood using conventional methods.

-143-

Any microorganism can be used in the methods provided herein, provided that they replicate in the animal, are not pathogenic for the animal, for example, are attenuated, and are recognized by the immune system of the animal. In some embodiments, such microorganisms also can express exogenous genes. Suitable 5 microorganisms and cells are, for example, disclosed in EP A1 1 281 772 and EP A1 1 281 767. The person skilled in the art also knows how to generate animals carrying the desired tumor (see, e.g., EP A1 1 281 767 or EP A1 1 281 777).

Also provide is a method for simultaneously producing a desired polypeptide, RNA or compound and an antibody directed to the polypeptide, RNA 10 or compound, the method having the following steps: (a) administering a microorganism containing a nucleotide sequence encoding the desired polypeptide or RNA into an animal bearing a tumor; (b) harvesting the tumor tissue from the animal; (c) isolating the desired polypeptide, RNA or compound from the tumor tissue; and (d) isolating the antibody directed to the polypeptide, RNA or compound 15 from the serum obtained from the animal. This approach can be used for generating polypeptides and/or antibodies against the polypeptides which are toxic or unstable, or which require species specific cellular environment for correct folding or modifications.

In another embodiment, the microorganism can further contain a nucleotide 20 sequence encoding a detectable protein, such as a luminescent or fluorescent protein, or a protein capable of inducing a detectable signal.

Typically in methods for transfecting the microorganisms or cells with nucleotide sequences encoding the desired polypeptide or RNA and, optionally, a 25 nucleotide sequence encoding a detectable protein such as a luminescent or fluorescent protein, or a protein capable of inducing a detectable signal, the nucleotide sequences are present in a vector or an expression vector. A person skilled in the art is familiar with a variety of expression vectors, which can be selected according to the microorganism used to infect the tumor, the cell type of the tumor, the organism to be infected, and other factors known in the art. In some 30 embodiments, the microorganism can be a virus, including the viruses disclosed

-144-

herein. Thus, the nucleotide sequences can be contained in a recombinant virus containing appropriate expression cassettes. Suitable viruses for use herein, include, but are not limited to, baculovirus, vaccinia, Sindbis virus, Sendai virus, adenovirus, an AAV virus or a parvovirus, such as MVM or H-1. The vector can also be a 5 retrovirus, such as MoMULV, MoMuLV, HaMuSV, MuMTV, RSV or GaLV. For expression in mammalian cells, a suitable promoter is, for example, human cytomegalovirus immediate early promoter (pCMV). Furthermore, tissue and/or organ specific promoters can be used. For example, the nucleotide sequences can be operatively linked with a promoter allowing high expression. Such promoters can 10 include, for example, inducible promoters; a variety of such promoters are known to persons skilled in the art.

For generating protein or RNA-encoding nucleotide sequences and for constructing expression vectors or viruses that contain the nucleotide sequences, it is possible to use general methods known in the art. These methods include, for 15 example, in vitro recombination techniques, synthetic methods and in vivo recombination methods as known in the art, and exemplified in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual, 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Methods of transfecting cells, of phenotypically selecting transfected cells, of phenotypically selecting transfectants 20 and of expressing the nucleotide sequences by using vectors containing protein or RNA-encoding DNA are known in the art.

In some embodiments, the protein or RNA to be produced in the tumor can be linked to an inducible promoter, such as a promoter that can be induced by a substance endogenous to the subject, or by a substance that can be administered to a 25 subject. Accordingly, provided herein are methods of producing a protein or RNA in a tumor, where the production can be induced by administration of a substance to a subject, and, optionally, harvesting the tumor and isolating the protein or RNA from the tumor. Such induction methods can be coupled with methods of monitoring a microorganism in a subject. For example, a microorganism can be 30 monitored by detecting a detectable protein. In methods that include monitoring,

-145-

detection of a desired localization and/or level of microorganism in the subject can be coordinated with induction of microorganismal gene expression. For example, when a microorganismally expressed detectable protein is detected in tumor, but not appreciably in normal organs or tissues, an inducer can be administered to the 5 subject. In another example, when a microorganismally expressed detectable protein is detected in tumor, and also in normal organs or tissues, administration of an inducer can be suspended or postponed until the detectable protein is no longer detected in normal organs or tissues. In another example, when a microorganismally expressed detectable protein is detected at sufficient levels in tumor, an inducer can 10 be administered to the subject. In another example, when a microorganismally expressed detectable protein is not detected at sufficient levels in tumor administration of an inducer can be suspended or postponed until the detectable protein is detected at sufficient levels in the tumor.

Also provided herein are methods of producing a protein or RNA in a tumor, 15 by administering a microorganism encoding the protein or RNA, and a suppressor of gene expression. The suppressor of gene expression can be administered for a pre-defined period of time, or until the microorganism accumulated in tumor but not in normal organs or tissues, or until sufficient levels of the microorganism have accumulated in the tumor, at which point administration of the suppressor can be 20 terminated or suspended, which can result in expression of the protein or RNA. As will be recognized by one skilled in the art, methods similar to those provided herein in regard to monitoring a detectable protein and administering an inducer, can also apply for terminating or suspending administration of a suppressor.

In one embodiment, the microorganism is a bacterium, for example, an 25 attenuated bacterium, such as those provided herein. Exemplary bacteria include attenuated *Salmonella typhimurium*, attenuated *Vibrio cholerae*, attenuated *Listeria monocytogenes* or *E. coli*. Alternatively, viruses such as *vaccinia virus*, AAV, a retrovirus can be used in the methods provided herein. In exemplary methods, the virus is *vaccinia virus*. Other cells that can be used in the present methods include

-146-

mammalian cells, such as fibroma cells, including human cells such as human fibroma cells.

Any of a variety of animals, including laboratory or livestock animals can be used, including for example, mice, rats and other rodents, rabbits, guinea pigs, pigs, sheep, goats, cows and horses. Exemplary animals are mice. The tumor can be generated by implanting tumor cells into the animal. Generally, for the production of a desired polypeptide, RNA, or compound, any solid tumor type can be used, such as a fast growing tumor type. Exemplary fast growing tumor types include C6 rat glioma and HCT116 human colon carcinoma. Generally, for the production of a desired antibody, a relatively slow growing tumor type can be used. Exemplary slow growing tumor types include HT1080 human fibrosarcoma and GI-101A human breast carcinoma. For T-independent antibody production, nu-/nu- mice bearing allogenic tumor or xenografts can be used; while for T-dependent antibody production, immunocompetent mice with syngenic tumors can be used. In some embodiments, such as where the compound to be produced is a protein, the microorganism selected can be a microorganism that uses the translational components (*e.g.*, proteins, vesicles, substrates) of the tumor cells, such as, for example, a virus that uses the translational components of a tumor cell. In such instances, the tumor cell type can be selected according to the desired post-translational processing to be performed on the protein, including proteolysis, glycosylation, lipidylation, disulfide formation, and any refolding or multimer assembly that can require cellular components for completing. In some examples, the tumor cell type selected can be the same species as the protein to be expressed, thus resulting in species-specific post-translational processing of the protein; an exemplary tumor cell type-expressed protein species is human.

1. Production of Recombinant Proteins and RNA molecules

The tumor tissue can be surgically removed from the animal. After homogenization of the tumor tissue, the desired polypeptide, RNA or other biological compound can be purified according to established methods. For example, in the case of a recombinant polypeptide, the polypeptide might contain a

-147-

bindable tag such as a his-tag, and can be purified, for example, via column chromatography. The time necessary for accumulation of sufficient amounts of the polypeptide or RNA in the tumor of the animal depends on many factors, for example, the kind of animal or the kind of tumor, and can be determined by the
5 skilled person by routine experimentation. In general, expression of the desired polypeptide can be detected two days after virus injection. The expression peaks approximately two weeks after injection, and lasts up to two months. In some embodiments, the amount of desired polypeptide or RNA in the tumor can be determined by monitoring a microorganismally expressed detectable substance,
10 where the concentration of the detectable substance can reflect the amount of desired polypeptide or RNA in the tumor.

In another embodiment, the desired polypeptide, RNA or other compound can be manufactured in the subject, and provide a beneficial effect to the subject. In one example, a microorganism can encode a protein or RNA, or a protein that
15 manufactures a compound that is not manufactured by the subject. In one example, a microorganism can encode a peptide hormone or cytokine, such as insulin, which can be released into the vasculature of a subject lacking the ability to produce insulin or requiring increased insulin concentrations in the vasculature. In another example, blood clotting factors can be manufactured in a subject with blood clotting
20 deficiency, such as a hemophiliac. In some embodiments, the protein or RNA to be produced in the tumor can be linked to an inducible promotor, such as a promotor that can be induced by increased glucose concentrations. In such instances, the manufacture of the protein or RNA can be controlled in response to one or more substances in the subject or by one or more substances that can be administered to a
25 subject, such as a compound that can induce transcription, for example, RU486. Thus, in some embodiments, the methods provided herein can include administering to a subject having a tumor, a microorganism that can express one or more genes encoding a beneficial gene product or a gene product that can manufacture a beneficial compound.

-148-

2. Production of Antibodies

Also provided are methods for producing a desired antibody, the method comprising the following steps: (a) administering a microorganism containing a nucleotide sequence encoding an antigen into an animal bearing a tumor; and (b) isolating the antibody directed to the antigen from the serum obtained from the animal. The antibodies directed to the antigen can be isolated and purified according to well known methods. Antibodies that are directed against specific contaminating antigens (e.g., bacteria antigens) can be removed by adsorption, and the antibodies directed against the target antigen can be separated from contaminating antibodies by affinity purification, for example, by immuno affinity chromatography using the recombinant antigen as the ligand of the column, by methods known in the art. Antibodies can be collected from the animal in a single harvest, or can be collected over time by collection bleeds, as is known in the art.

F. Pharmaceutical Compositions, combinations and kits

Provided herein are pharmaceutical compositions, combinations and kits containing a microorganism provided herein and one or more components. Pharmaceutical compositions can include a microorganism and a pharmaceutical carrier. Combinations can include two or more microorganisms, a microorganism and a detectable compound, a microorganism and a microorganism expression modulating compound, a microorganism and a therapeutic compound. Kits can include the pharmaceutical compositions and/or combinations provided herein, and one or more components such as instructions for use, a device for detecting a microorganism in a subject, a device for administering a compound to a subject, and a device for administering a compound to a subject.

1. Pharmaceutical Compositions

Also provided herein are pharmaceutical compositions containing a modified microorganism and a suitable pharmaceutical carrier. Examples of suitable pharmaceutical carriers are known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc. Such carriers can be formulated by conventional

methods and can be administered to the subject at a suitable dose. Colloidal dispersion systems that can be used for delivery of microorganisms include macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions (mixed), micelles, liposomes and 5 lipoplexes. An exemplary colloidal system is a liposome. Organ-specific or cell-specific liposomes can be used in order to achieve delivery only to the desired tissue. The targeting of liposomes can be carried out by the person skilled in the art by applying commonly known methods. This targeting includes passive targeting (utilizing the natural tendency of the liposomes to distribute to cells of the RES in 10 organs which contain sinusoidal capillaries) or active targeting (for example by coupling the liposome to a specific ligand, for example, an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods). In the present methods, monoclonal antibodies can be used to target liposomes to specific tissues, for example, tumor tissue, via specific cell-surface ligands.

15 **2. Host Cells**

Also provided herein are host cells that contain a microorganism provided herein such as a modified vaccinia virus. These host cells can include any of a variety of mammalian, avian and insect cells and tissues that are susceptible to microorganism, such as vaccinia virus, infection, including chicken embryo, rabbit, 20 hamster and monkey kidney cells, for example, CV-1, BSC40, Vero, BSC40 and BSC-1, and human HeLa cells. Methods of transforming these host cells, of phenotypically selecting transformants etc., are known in the art.

25 **3. Combinations**

Combinations can include a microorganism and one or more components. Any combination herein also can, in place of a microorganism, contain a pharmaceutical composition and/or a host cell containing a microorganism and one or more components.

Exemplary combinations can contain two or more microorganisms, a microorganism and a detectable compound, a microorganism and a microorganism expression modulating compound, or a microorganism and a therapeutic compound.

-150-

Combinations that contain two or more microorganisms can contain, for example, two or more microorganisms that can both be administered to a subject in performing the methods provided herein, including sequentially administering the two microorganisms. In one example, a combination can contain a virus and a
5 bacterium, where, for example, the virus can first be administered to the subject, and the bacterium can be subsequently administered to the subject.

Combinations provided herein can contain a microorganism and a detectable compound. A detectable compound can include a ligand or substrate or other compound that can interact with and/or bind specifically to a microorganismally expressed protein or RNA molecule, and can provide a detectable signal, such as a signal detectable by tomographic, spectroscopic or magnetic resonance techniques.
10 Exemplary detectable compounds can be, or can contain, an imaging agent such as a magnetic resonance, ultrasound or tomographic imaging agent, including a radionuclide. The detectable compound can include any of a variety of compounds as provided elsewhere herein or are otherwise known in the art. Typically, the detectable compound included with a microorganism in the combinations provided herein will be a compound that is a substrate, a ligand, or can otherwise specifically interact with, a protein or RNA encoded by the microorganism; in some examples, the protein or RNA is an exogenous protein or RNA. Exemplary
15 microorganisms/detectable compounds include a microorganism encoding luciferase/luciferin, β -galactosidase/(4,7,10-tri(acetic acid)-1-(2- β -galactopyranosylethoxy)-1,4,7,10-tetraazacyclododecane) gadolinium (Egad), and other combinations known in the art.
20

Combinations provided herein can contain a microorganism and a
25 microorganism gene expression modulating compound. Compounds that modulate gene expression are known in the art, and include, but are not limited to, transcriptional activators, inducers, transcriptional suppressors, RNA polymerase inhibitors, and RNA binding compounds such as siRNA or ribozymes. Any of a variety of gene expression modulating compounds known in the art can be included in the combinations provided herein. Typically, the gene expression modulating
30

-151-

compound included with a microorganism in the combinations provided herein will be a compound that is a can bind, inhibit, or react with one or more compounds active in gene expression such as a transcription factor or RNA, of the microorganism of the combination. An exemplary microorganism/

5 modulator can be a microorganism encoding a chimeric transcription factor complex having a mutant human progesterone receptor fused to a yeast GAL4 DNA-binding domain an activation domain of the herpes simplex virus protein VP16 and also containing a synthetic promoter containing a series of GAL4 recognition sequences upstream of the adenovirus major late E1B TATA box, where the compound can be
10 RU486 (see, e.g., Yu *et al.*, Mol Genet Genomics 2002 268:169-178). A variety of other microorganism/expression modulator combinations known in the art also can be included in the combinations provided herein.

Combinations provided herein can contain a microorganism and a therapeutic compound. Therapeutic compounds can include compounds that are substrates for microorganismally expressed enzymes, compound that can kill or inhibit microorganism growth or toxicity, or other therapeutic compounds provided herein or known in the art to act in concert with a microorganism. Typically, the therapeutic compound included with a microorganism in the combinations provided herein will be a compound that can act in concert with a microorganism, such as a

15 substrate of an enzyme encoded by the microorganism, or an antimicroorganismal agent known to be effective against the microorganism of the combination.
20 Exemplary microorganism/therapeutic compound combinations can include a microorganism encoding Herpes simplex virus thymidine kinase/gancyclovir, and streptococcus pyogenes/penicillin. Any of a variety of known combinations provided herein or otherwise known in the art can be included in the combinations provided herein.

25

4. Kits

Kits are packaged in combinations that optionally include other reagents or devices, or instructions for use. Any kit provided herein also can, in place of a

-152-

microorganism, contain a pharmaceutical composition, a host cell containing a microorganism, and/or a combination, and one or more components.

Exemplar kits can include the microorganisms provided herein, and can optionally include one or more components such as instructions for use, a device for detecting a microorganism in a subject, a device for administering a compound to a subject, and a device for administering a compound to a subject.

In one example, a kit can contain instructions. Instructions typically include a tangible expression describing the microorganism and, optionally, other components included in the kit, and methods for administration, including methods for determining the proper state of the subject, the proper dosage amount, and the proper administration method, for administering the microorganism. Instructions can also include guidance for monitoring the subject over the duration of the treatment time.

In another example, a kit can contain a device for detecting a microorganism in a subject. Devices for detecting a microorganism in a subject can include a low light imaging device for detecting light, for example emitted from luciferase, or fluoresced from green fluorescence protein, a magnetic resonance measuring device such as an MRI or NMR device, a tomographic scanner, such as a PET, CT, CAT, SPECT or other related scanner, an ultrasound device, or other device that can be used to detect a protein expressed by the microorganism within the subject.

Typically, the device of the kit will be able to detect one or more proteins expressed by the microorganism of the kit. Any of a variety of kits containing microorganisms and detection devices can be included in the kits provided herein, for example, a microorganism expressing luciferase and a low light imager, or a microorganism expressing green fluorescence protein and a low light imager.

Kits provided herein also can include a device for administering a microorganism to a subject. Any of a variety of devices known in the art for administering medications or vaccines can be included in the kits provided herein. Exemplary devices include a hypodermic needle, an intravenous needle, a catheter, a needle-less injection device, an inhaler, and a liquid dispenser such as an

-153-

eyedropper. Typically, the device for administering a microorganism of the kit will be compatible with the microorganism of the kit; for example, a needle-less injection device such as a high pressure injection device can be included in kits with microorganisms not damaged by high pressure injection, but is typically not included in kits with microorganisms damaged by high pressure injection.

Kits provided herein also can include a device for administering a compound to a subject. Any of a variety of devices known in the art for administering medications to a subject can be included in the kits provided herein. Exemplary devices include a hypodermic needle, an intravenous needle, a catheter, a needle-less injection an inhaler, and a liquid dispenser. Typically the device for administering the compound of the kit will be compatible with the desired method of administration of the compound. For example, a compound to be delivered subcutaneously can be included in a kit with a hypodermic needle and syringe.

F. Examples

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Example 1

Generation of recombinant viruses

A Wild type vaccinia virus (VV) strain LIVP (the well known viral strain, originally derived by attenuation of the strain Lister from the ATCC under Accession Number VR-1549, from the Lister Institute of Viral Preparations, Moscow, Russia; see, Al'tshein *et al.*, (1983) Dokl. Akad. Nauk USSR 285:696-699) designed as VGL was used as a parental virus for the construction of recombinant viruses designated RVGLX herein. All vaccinia viruses were purified using sucrose gradient (Yoklik). VVs were propagated and titers were determined by plaque assays using CV-1 cells (ATCC No. CCL-70). Methods for constructing recombinant vaccinia viruses are known to those of skill in the art (see, e.g., Chakrabarti *et al.*, (1985 Mol. Cell Biol. 5:3403 and U.S. Patent No.4,722,848. Table 1 summarizes the recombinant VV strains described in this Example.

Inactivation of VV by PUV treatment

-154-

LIVP VV (3×10^8 pfu/ml) was incubated with 1 μ g/ml psoralen (Calbiochem, La Jolla, CA), suspended in Hank's buffer at room temperature for 10 min, and then irradiated for 5 min in Stratalinker 1800 UV crosslinking unit (Stratagent, La Jolla CA) equipped with five 365 nm long wave UV bulb to 5 produce PUV-VV.

RVGL8: LacZ insertion into F3 of LIVP

Construction of recombinant vaccinia virus RVGL8 containing a lacZ gene inserted the NotI site was prepared as described in Timiryasova *et al.* (2001), BioTechniques 31, 534-540. Briefly it was prepared as follows. The BamHI/SmaI fragment (3293 bp) of pSC65 (see, Chakrabarti *et al.* (1997), BioTechniques 23, 1094-1097; see, also Current Protocols in Molecular Biology, Green Publishing and Wiley-Interscience Supplement 15:16.17.2 (1992); see also SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646) containing the lacZ gene under the control of the vaccinia p7.5 promoter and strong synthetic 15 vaccinia pE/L promoter was isolated by digestion with restriction enzymes, blunted with Klenow enzyme, and cloned into SmaI site of pNT8 plasmid (Timiryasova *et al.* (2001), BioTechniques 31: 534-540) to produce pNZ2 a shuttle plasmid.

To construct pNT8, the NotI region of the wild type VV strain LIVP was amplified using the following primers:

20 Forward: 5'-GGGAATTCTTATACATCCTGTTCTATC - 3' (SEQ ID No. 3); Reverse: 5'-CCAAGCTTATGAGGAGTATTGCAGGGCTAC-3' (SEQ ID No. 4) with the VV as a template. The resulting 972 bp fragment contained flanking EcoRI and HindIII sites at the 5' and 3' ends, respectively. The PCR product was cleaved with EcoRI and HindIII and inserted in pUC28 (Benes *et al.*, (1993) Gene 25 130: 151. Plasmid pUC28 is prepared from pUC18 (available from the ATCC under Accession Number 37253 by introducing a synthetic oligo adaptor using primers: pUC28 I: 5'AATTCAAGATCTCCATGGATCGATGAGCT 3' (SEQ ID NO.6); pUC28 II: 3'GTCTAGAGGTACCTAGCTAC 5' (SEQ ID No. 7) into the EcoRI and SstI sites of pUC18. This introduces BglII, ClaI, and NcoI sites into the 30 polylinker of pUC18.

-155-

Plasmid pNZ2 contains cDNA encoding the *E. coli* lacZ gene under the control of the vaccinia virus early/late promoter p7.5 and a synthetic early/late vaccinia pE/L promoter derived from the plasmid pSC65 (see, Chakrabarti *et al.* (1997), BioTechniques 23, 1094 1097; see, also Current Protocols in Molecular Biology, Green Publishing and Wiley-Interscience Supplement 15:16.17.2 (1992); see also SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646). Plasmid pNZ2 provides for homologous recombination of lacZ into the NotI site of the VGL virus (ATCC VR-1549), to produce in the recombinant vaccinia virus designated RVGL8. The complex of wild type vaccinia virus DNA digested with NotI and not digested plasmid DNA pNZ2 was transfected for in vivo recombination into PUV VV infected cells to produce RVGL8 (see Figure 1A and Figure 1B). RVGL8 and the other recombinant vaccinia viruses described herein are listed in Table 1, below.

Mutant Virus Formation/Transfection

CV-1 African green monkey kidney fibroblasts (ATCC No. CCL-70) grown on 60 mm dishes (Corning, Corning, NY, USA) were infected with PUV-VV (strain LIVP treated with psoralen and UV; see, e.g., Tsung *et al.* (1996), J. Virol. 70, 165-171; Timiryasova *et al.* (2001), BioTechniques 31, 534-540; Timiryasova *et al.* (2001), J. Gene 3 Med. 3, 468-477) at multiplicity of infection (MOI) of 1.

Two hours post-infection, the cells were transfected with a mixture of NotI-digested viral DNA (4 µg) and intact plasmid DNA (4 µg). Lipid-mediated transfection of cells was carried out using 5 µl of GenePORTER reagent (Gene Therapy Systems, San Diego, CA, USA) per µg of the DNA according to manufacturers' instructions. Cells were incubated in transfection mixture for 4 h and then supplemented with a medium containing 20% of fetal bovine serum. Cytopathic effects were monitored daily by light microscopy. Cells were incubated for 5-7 days until formation of the virus plaques and complete cytopathic effect. Then, infected cells were harvested, resuspended in 0.5 ml of medium, and frozen and thawed three times to release the virus. Single virus plaques were selected for

-156-

the preparation of small and large recombinant virus stocks and analyzed for the insertion and expression of the genes.

Confirm Mutant

Viral DNA was analyzed by Southern blots. Briefly, to isolate viral DNA, 5 confluent monolayers of CV-1 cells, grown on 10 cm plates, were infected with the wild type VV (strain LIVP) or VV of the virus stock obtained from a single recombinant plaque. When the cytopathic effect was complete, cells were harvested and the pellet was resuspended in 3 ml of 10 mM Tris-HCl, pH 9.0. Viral particles were lysed, treated with proteinase K, and the virus DNA was isolated by 10 phenol/chloroform extraction, followed by ethanol precipitation. The DNA was resuspended in 100 µl of sterile water. The viral DNA samples were digested by NotI overnight at 37°C, followed by phenol-chloroform treatment, precipitated and 15 10 µg of DNA samples were separated through a 0.8% agarose gel. The DNA was transferred to a positively charged nylon membrane (Roche Diagnostics Corporation, Indianapolis, IN, USA) and fixed to the membrane using a GS Gene Linker (Bio-Rad Laboratories, Hercules, CA, USA). The DIG-labeling of DNA was performed using a nonradioactive DNA labeling and detection kit (Roche Diagnostics Corporation) and incubating for 60 min at 37°C. The membrane was hybridized with a denatured DIG-labeled 3357 bp NotI-NotI DNA fragment of the 20 plasmid pNZ2 encoding the lacZ gene. Hybridization conditions and blot development were performed as suggested by the manufacturer.

The predicted size of the band is 3357 bp. The hybridization of NotI digested viral DNAs with a 3357 bp DNA probe confirmed the integration of the lacZ gene into NotI site of virus genome.

25 Construction of RVGL2 and RVGL23 viruses with a single TK gene mutation

Vaccinia virus LIVP was used for the construction of recombinant virus RVGL2. Vaccinia virus Western Reserve (WR) was used for the construction of recombinant virus RVGL23. The cDNA of *Renilla* luciferase and *Aequorea* GFP fusion (*ruc-gfp*; 1788 bp; see, Wang *et al.*, (1996) Bioluminescence 30 Chemiluminescence 9:419-422; Wang *et al.*, (2002) Mol. Genet. Genomics 268:160-

-157-

168; Wang *et al.* (1997) pp 419-422 in Bioluminescence and Chemiluminescence: molecular reporting with photons, Hastings *et al.*, eds., Wiley, Chichester UK ; see, also U.S. Patent No. 5,976,796; see also SEQ ID No. 8 herein, which sets forth a sequence for a *ruc-gfp* construct) was excised from plasmid pcDNA-*ruc-gfp* (RG), 5 which is described in Wang *et al.*, (1996) Bioluminescence Chemiluminescence 9:419-422 and Wang *et al.*, (2002) Mol. Genet. Genomics 268:160-168 and briefly below, by restriction endonuclease PmeI and inserted into the SmaI site of pSC65 plasmid (see SEQ ID No. 5; see, also herein and SEQ ID No. 57 in PCT International application No. WO 99/32646), resulting in pSC65-RG-1 plasmid 10 DNA.

Briefly to prepare pcDNA-*ruc-gfp*, the *Eco*RI-*Not*I fragment encoding the modified *Renilla* luciferase-ending DNA (see, Wang *et al.* (1997) pp 419-422 in Bioluminescence and Chemiluminescence: molecular reporting with photons, Hastings *et al.*, eds., Wiley, Chichester UK) was cloned into the pcDNA3.1 vector 15 (Invitrogen, Carlsbad, CA), placing expression of the *Renilla* luciferase under control of the CMV promoter. The stop codon at the end of the *Renilla* luciferase ORF was removed, and the resulting plasmid digested with *Not*I. The *Not*I fragment containing the ORF encoindg humanized *Aequorea* GFP (Zolotukhin *et al.*, (1996) *J. Virol.* 70:4646-4654) was excsed from the pTR-β-actin plasmid and 20 inserted into the *Not*I site of the plasmid encoding the *Renilla* luciferase. The resulting plasmid was designated pcDNA-*ruc-* the *ruc-gfp*.

New plasmid pSC65-RG-1 containing *ruc-gfp* fusion under the control of the vaccinia PE/L promoter and *E. coli* β-galactosidase under control of p7.5 promoter of VV was used for the construction of a single TK gene interrupted virus RVGL2 of 25 strain LIVP and RVGL23 of strain WR. CV-1 cells were infected with wt LIVP or wt WR virus at MOI of 0.1, and two hours later, pSC65-RG-1 plasmid DNA was transfected using FuGene6 transfection reagent (Roche). After 24 h of incubation, cells were three times frozen and thawed to release the virus. Recombinant viruses 30 were screened on CV-cells in the presence of substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal, Stratagene, Cedar Creek, TX, USA). After four

cycles of virus purification, all virus plaques were positive for β -galactosidase expression. The expression of the ruc-gfp fusion protein was confirmed by luminescence assay and fluorescence microscopy, respectively. Schematic maps of the viruses are set forth in Figure 1B

5 **Construction of RVGL5 and RVGL9 viruses with single gene mutations**

Recombinant vaccinia virus RVGL5 contains the lacZ gene under the control of the vaccinia late p11 promoter inserted int the HA gene of vaccinia genome (Timiryasova *et al.* (1993) Mol Biol 27:392-402; see, also, Timiryasova *et al.*, (1992) Oncol. Res 11:133-144.). Recombinant vaccinia virus RVGL9 contains a 10 fusion of the Renilla luciferase gene (ruc) and cDNA of green fluorescence protein (gfp) under the control of a synthetic early/late vaccinia promoter (PE/L) inserted into the F3 gene of the VV genome (Timiryasova *et al.*, (2000) pp. 457-459 in Proceedings of the 11th International Symposium on Bioluminescence and Chemiluminescence, Case et al., eds). RVGP5 and RVGLP9 were constructed as 15 described for RVGLP2 and RVGLP23.

Construction of RVGL20 virus with double TK and F3 gene mutations

The cDNA of human transferin receptor (*hTR*) (2800 bp) with polyA sequence was isolated from pCDTR1 plasmid (ATCC Accession No. 59324 and 20 59325) by *Bam*HI, treated with *Klenow* and inserted into *Sal*II site of pSC65 plasmid (SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646), resulting in pSC-TfR and pSC-rTfR. Plasmid pSC-rTfR contains cDNA *hTR* in an orientation opposite to thevaccinia PE/L promoter and *E.coli* β -galactosidase under control of the early/late vaccinia p7.5 promoter flanked by 25 vaccinia sequences for insertion into vaccinia *TK* gene. pSC-rTfR was used for the construction of RVGL20 virus. RVGL9, a recombinant virus with single deletion carrying ruc-gfp fusion in the F3 gene locus, which contains a unique *Not*I site in the LIVP strain (see above, see, also, Timiryasova *et al.*, (2000) pp. 457-459 in *Proceedings of the 11th International Symposium on Bioluminescence and Chemiluminescence*, Case *et al.*, eds) , was used as a parental virus for the creation

-159-

of RVGL20 virus by homologous recombination as described above. A schematic of RVGL20 virus is set forth in Figure 1B

Construction of RVGL21 virus with triple *TK*, *F3* and *HA* gene mutations

5 The cDNA of the β -glucuronidase (*gus*) of *E. coli* (1879 bp) was released from pLacGus plasmid (Invitrogen; see SEQ ID No. 9 herein) with *Xba*I (blunt ended with Klenow fragment) and *Hind*III, and cloned into pSC11 plasmid pSC65 (Chakrabarti *et al.* (1985) Mol. Cell Biol. 5:3403-3409; SEQ ID 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646) digested with *Xho*I (treated with Klenow) and *Hind*III under the control of a vaccinia p11 late promoter, resulting in a plasmid pSC-GUS. The *Sma*I-*Hind*III fragment from pSC-GUS plasmid was inserted into pVY6 plasmid, a vector for inserting antigen genes into the hemagglutinin gene of vaccinia (see, e.g., Flexner *et al.*, (1988) Nature 355:259-262; Flexner *et al.*, (1988) Virology 166: 339-349; see also U.S. Patent No. 15 5,718,902) digested with *Sma*I and *Bam*HI, resulting in pVY-GUS plasmid. The resulting plasmid, designated pVY-GUS plasmid, contains the cDNA encoding *gus* under the control of the vaccinia late promoter p11 flanked by vaccinia sequences for insertion into the hemagglutinin (*HA*) gene. Recombinant virus RVGL20 with double deletions was used as the parental virus for the construction of RVGL21

10 virus. CV-1 cells were infected with RVGL20 virus at MOI of 0.1. Two hours after infection, cells were transected with pVY-GUS plasmid DNA using FuGene6 transfection reagent (Roche). Recombinant virus plaques were selected in CV-1 cells by color screening upon addition of β -glucuronidase substrate 5-bromo-4-chloro-3-indolyl- β -D-glucuronic acid (X-GlcA) (Research Products Int. Co., Mt. Prospect, IL, USA) into agar medium. After eight cycles of purification in agar medium in the presence of X-GlcA pure recombinant virus RVGL21 was selected.

15 RVGL21 virus has interruptions of *TK*, *F3* and *HA* genes and is presented schematically in Figure 1B.

20

25

***In vitro* virus growth**

-160-

CV-1, C6 (ATCC No. CCL-107), B16-F10 (ATCC No. CRL-6475), and GI-101A (Rumbaugh-Goodwin Institute for Cancer Research Inc. Plantation, FL; U.S. Pat. No. 5,693,533) cells were seeded in 24-well plates at the density of 1×10^5 , 2×10^5 , 4×10^5 , and 2×10^5 cells/well, respectively. The next day, the cells were
5 simultaneously infected with 0.001 or 0.01 PFU/cell of a wild type LIVP and its mutants. The virus suspension was added to cell monolayer (0.15 ml/well) and incubated at 37°C for 1 h with brief agitation every 10 min. Then, the virus was removed, appropriate complete growth medium was added (1 ml/well), and the cells were then incubated at 37°C for 24, 48, 72 and 96.h after virus infection. To
10 establish resting cell culture, a confluent monolayer of CV-1 cells was incubated for 6 days in DMEM with 5 % FBS at 37°C. These resting cells were infected and harvested at the same time points after infection as described above. Virus from the infected cells was released by one cycle of freezing and thawing. Viral titers were determined in duplicates by plaque assay on CV-1 cells and expressed as PFU/ml.

15

-161-

Table1
List of recombinant vaccinia viruses (VV)

Designation	Prior Designation	Description	InsertionLocus/loci	Reference
VGL	wt VV	strain LIVP VV	No Insertions	Publicly available
RVGL1	recVV2	(p7.5) Luc-(p11) LacZ of LIVP VV	HindIII-N-Interrupted	Timiryasova TM, Kopylova-Sviridova TN, Fodor I. Mol. Biol. (Russian) 27:392-401 (1993); Timiryasova TM, Li J, Chen B, Chong D, Langridge WHR, Gridley DS, Fodor I. Oncol. Res. 11:133-144 (1999)
RVGL5	recVV8	(p11) LacZ of LIVP VV	HA-Interrupted	Timiryasova TM, Kopylova-Sviridova TN, Fodor I. Mol. Biol. (Russian) 27:392-401 (1993)
RVGL7	rVV-EGFP or rVV-GFP	(PE/L) EGFP-(p7.5) LacZ of LIVP VV	TK-Interrupted	Umphress S, Timiryasova T., Arakawa T, Hilliker S, Fodor I, Langridge W. Transgenics 4:19-33 (2003)
RVGL8	rVV-Not-LacZ or rVV-Not-LZ	(p7.5) LacZ of LIVP VV	NotI (F3)-Interrupted	Timiryasova TM, Chen B, Fodor N, Fodor I. BioTechniques 31:534-540 (2001)
RVGL9	rVV-RG or rVV-ruc-gfp	(PE/L) Ruc-GFP of LIVP VV	NotI (F3)-Interrupted	Timiryasova TM, Yu Ya, Shabahang S, Fodor I, Szalay AA. Proceedings of the 11 th International Symposium on Bioluminescence & Chemiluminescence pp.457-460 (2000)
RVGL12		Same as RVGL7, except that HSV TK is inserted in place of gfp		
RVGL19		(PE/L) Trf-(p7.5) LacZ in Tk locus (PE/L) Ruc-GFP in	TK- and NotI (F3)-Interrupted	Herein

-162-

		F3 locus of LIVP VV		
RVGL20		(PE/L) rTrf-(p7.5) LacZ in TK locus (PE/L) Ruc-GFP in F3 locus of LIVP V	Tk- and NotI (F3)- Interrupted	Herein
RVGL21		(PE/L) rTrf-(p7.5) LacZ in TK locus, (p11) LacZ in HA locus, (PE/L) Ruc-GFP in F3 locus of LIVP VV	Tk-, HA- interrupted and NotI (F3)- Interrupted	Herein
RVGL23		(PE/L) rTrf-(p7.5) LacZ in TK locus of WR VV	Tk- Interrupted	Herein

Example 2

In vitro analysis of virus levels

LacZ

Analysis of *lacZ* expression induced by recombinant vaccinia virus was performed as described previously (Timiryasova *et al.* (2001), BioTechniques 31, 534-540). Briefly, CV-1 cells grown 6-well plates (Corning, Corning, NY, USA) were infected with ten-fold dilutions of the virus stock. The virus was allowed to absorb for 1 h at 37°C with occasional rocking. Then, the virus inoculum was replaced with a complete medium containing 1% of agar, and the incubation was carried out for 48 h. To visualize the virus plaques, 300 µg of X-Gal (Molecular Probes, Eugene, Oregon, USA) per ml and 0.1% of neutral red (Sigma, St. Louis, MO, USA) were added to the second agar overlay, and plaques were counted and isolated after 12 h incubation at 37°C. Levels of vaccinia virus in cells in vitro could also be determined by measuring the plaque forming units (PFU) in the cells.

***In vitro* infectivity of VV's measured by Plaque Forming Units**

-163-

The ability of wt LIVP virus and its mutants to infect and replicate was analyzed in dividing and resting CV-1 cells as well as in three tumor cell lines (C6, GI-101A, B16-F10). The results demonstrate that vaccinia mutants can efficiently infect and replicate in dividing CV-1 cells at an MOI of 0.001. A significant yield
5 of vaccinia virus was obtained from dividing CV-1 cells. The yield of wt VV and its mutants in dividing CV-1 cells was about 10 times higher than in resting CV-1 cells. There was no significant difference in viral recovery between vaccinia mutants and wt virus *in vitro* studies. The interruption of *TK*, *F3* and *HA* genes made no difference to VV mutants replication in the dividing CV-1 cells. Three tumor cells
10 were tested. The relative sensitivities to cytopathic effects at MOI of 0.001 were follows: CV-1 (dividing, highest), CV-1 (resting), C6, GI-101A, B16-F10 (lowest). Mouse B16-F10 melanoma cells were not sensitive to virus infection at MOI of 0.001. Very low viral titer was recovered from melanoma cells infected at MOI of 0.01. Also observed was that wt WR strain was able to infect melanoma cells *in*
15 *vitro* more efficiently compared to LIVP strain and virus recovery was higher compared to LIVP strain.

Example 3

Animal models and assays

Animal Models

20 Athymic nude mice (*nu/nu*) and C57BL/6 mice (Harlan Animal Res., Inc., Wilmington, MA) at 6-8 weeks of age were used for animal studies. Mice in groups of five or four were infected i.v. with 10^7 PFU of VV in a volume of 0.1 ml i.v. Mice were imaged by low-light imager and fluorescence imager for ruc and for gfp expression, respectively. The study was approved prior to initiation by the Animal
25 Research Committee of LAB Research International Inc. (San Diego, CA, USA). All animal care was performed under the direction of a licensed veterinarian of LAB Research International Inc. (San Diego, CA, USA).

Glioma Model

To establish subcutaneous glioma tumor, rat glioma C6 cells (ATCC No.
30 CCL-107) were collected by trypsinization, and 5×10^5 cells/0.1 ml/mouse were

-164-

injected subcutaneously (s.c.) into right hind leg of 6-8 week old male athymic mice. On day 7 after C6 cell implantation when median tumor size was about 150 mm³, viruses at the dose of 10⁷ PFU/0.1 ml/mouse were injected intravenously (i.v.). Mice were sacrificed 14 days after virus injection. In the kinetic studies using of RVGL9
5 virus, mice were sacrificed at 20 min, 1 h, 4 h, 18 h, 36 h, 3 d, 5 d, 7 d and 14 days after virus injection.

Breast Tumor Model

To develop sub cutaneous (s.c). breast tumor, human breast cancer GI-101 A cells (Rumbaugh-Goodwin Institute for Cancer Research Inc. Plantation, FL; U.S.
10 Pat. No. 5,693,533) at the dose of 5 x 10⁶ cells/0.1 ml/mouse were injected s.c. into the right hind leg of 6-8 week old female athymic mice. On day 30 after GI-101A cell implantation, when median tumor size was about 500 mm³, viruses at the dose of 10⁷ PFU/mouse were injected i.v. Mice were sacrificed on day 14 after virus
15 injection. Mice for survival experiments and breast tumor therapy studies were kept for long time periods (more than 100 days after virus injection). Mice that developed tumor with the size about 4000 mm³, and/or lost 50% of body weight were sacrificed.

Melanoma Model

For a melanoma model, mouse melanoma B16-F10 cells (ATCC No. CRL-
20 6475) at the dose of 2 x 10⁵ cells/0.04 ml/mouse were injected into the foot pad of 6-8 week old male C57BL/6 mice. When the tumor was established (median size of tumor about 100 mm³), on day 18 after cell implantation, viruses at the dose of 10⁷/mouse were injected i.v. Mice were sacrificed 10 days after virus injection.

Vaccinia Virus in Animal Models

25 Vaccinia virus recovery from tumor and organs of nude mice

From sacrificed animals blood was collected, and organs (lung, liver, spleen, kidneys, testes, ovaries, bladder, brain, heart) and tumors were harvested and homogenized in PBS containing a mixture of protease inhibitors. Scissors and forceps were changed after each organ dissection or incision to avoid cross-contamination of the tissues. Samples were frozen and thawed, centrifuged at 1,000
30

-165-

g for 5 min. Viral titer was determined in the supernatant diluted in serum-free medium on CV-1 cells by plaque assay and staining them with 1% (wt/vol) crystal violet solution after 48 h incubation. Each sample was assayed in duplicate and viral titer was expressed as mean PFU/g of tissue.

5 **Assay Measurements**

Survival studies were performed on 6-week old nude mice bearing s.c.. human breast tumor. Mice were injected i.v. with 10^7 of vaccinia viruses and followed for survival. Individual body weight was measured twice a week. Gain/loss of body weight after virus infection was calculated as the percentage: body weight (g) - tumor weight (g) on day of virus injection / body weight (g) - tumor weight (g) on day of monitoring $\times 100\%$. Spleens were excised from euthanized animals and weighed. The RSW was calculated as follows: RSW =weight of spleen (g) $\times 10^4$ /animal body weight (g)- tumor weight (g). Mice were euthanized when the mean tumor volume reached 3000 mm^3 or developed the signs of disease. Rapid 10 CO₂ euthanasia was humanely performed in compliance with the *NIH Guide for the Care and Use of Laboratory Animals*.

15 **Reporter genes assays**

20 **LacZ**

E. coli β -galactosidase activity in tissue samples and in the serum of the mice 20 was determined using chemiluminescent Galcto-Light Plus™ Assay system (Applied Biosystems, Bedford, MA, USA) according to the instructions of the kit manufacturer. Briefly, 1-20 μl of the sample was transferred into the tube with 200 μl of 1:100 diluted Reaction Buffer Diluent and incubated at RT for 30 min. A 25 300 μl aliquot of accelerator (-II) was added into the tube with the sample, mixed quickly and the signal was read using luminometer. β -galactosidase activity was expressed as relative light units (RLU) per g of tissue. Purified E. coli β -galactosidase (Sigma) was used as a positive control and to generate a standard curve.

-166-

Luciferase

Renilla luciferase activity was measured in the supernatant of the tissue samples after they had been homogenized using a Turner TD 20e luminometer (Turner Designs, Sunnyvale, CA, USA) as described previously (Yu and Szalay, 5 2002) with some modifications. In brief, 20 µl of the samples was added into 500 µl of luciferase assay buffer (0.5 M NaCl, 1 mM EDTA, 0.1 M potassium phosphate pH 7.4) containing a substrate coelentrazine. Luciferase activity was measured during 10-s interval and expressed as RLU per g of tissue.

Assay Results

10 Tumor-selective replication of vaccinia virus RVGL8.

Recovery of wt LIVP (VGL) and RVGL8 from tumor samples and different organs from six mice and from normal organs. VGL was recovered from tumor, testes, bladder, and liver and as well as from brain. Recombinant virus RVGL8, however, was found mostly in tumor only (in mouse #24 virus was found in testes, 15 bladder and liver; in mouse #22 in testes) and no virus was recovered from brain tissue in six tested animals. This finding demonstrates the safety of RVGL8 with the interruption of the NotI site ,

Presence of RVGL9 over time

A vaccinia virus RVGL9 with a single *F3* gene mutation and carrying ruc-gfp was used to assess the pattern of vector tissue distribution following i.v. 20 administration into immunocompromised athymic mice bearing s.c. glioma tumors. The tissue distribution data using this recombinant virus was showed virus distribution and tumor targeting by this VV strain. Kinetics studies were performed by noninvasive imaging of virus replication in the mice based on ruc and gfp expression. Four to five animals per group bearing s.c. rat glioma C6 tumor were 25 injected with 10^7 of RVGL9 virus via the tail vein. The animals were sacrificed at 20 min, 1,4, 18 and 36 hours, 3, 5, and 14 days after virus injection. No viable viral particles were recovered from brain, bladder or testes at any time point after i.v. injection of virus. Some viral particles were recovered from spleen, heart and lung 30 at early time points after virus injection. After 18 h post-infection, the titer of

RVGL9 virus in these organs decreased. No virus was recovered in the heart tissue after 18 h; around 156.5 and 44 PFU/g tissue was recovered from spleen and lung, respectively, on day 14 as compared to 3221.0 and 3521.9 PFU/g tissue at 20 min after virus injection, respectively. The pattern of virus recovery from liver and kidneys was different from the pattern in the spleen, heart, or lung. No virus in the kidneys and 174.9 PFU/g tissue of virus was recovered from liver at an early time after virus injection. On day 5 after virus injection, the titer of virus in these organs increased and went down on day 14 post virus injection. In tumor tissue virus was detected starting 18 h after virus administration (1.6×10^3 PFU/g tissue), and dramatically increased over the time of observation (1.8×10^8 PFU/g tissue on day 7). Virus in the tumor tissue was detectable for more than 60 days after a single i.v. virus injection. The results demonstrate tumor-specific replication of these vaccinia mutants. A correlation was observed between the virus recovery and the transgene expression in tumors and in organs. Based on the data of RVGL9 virus kinetics, day 10 or day 14 was used for tissue distribution studies of different vaccinia mutants in melanoma and glioma and breast tumor models, respectively.

Presence of various VV in mice bearing a glioma tumor

To examine tissue distribution of vaccinia virus in immunodeficient mice bearing an s.c. glioma tumor, viruses were injected i.v. at a dose of 1×10^7 PFU/0.1 ml/mouse on day 7 after C6 rat glioma cell implantation. Fourteen days after virus injection, mice were sacrificed and virus titer was determined in different tissues. Mice injected with wt WR virus were sick and dying due to viral pathogenicity. Hence, WR-injected mice were sacrificed on day 7 after virus injection. Wild type LIVP virus was recovered from all analyzed tissues as well as from brain. The amount of recovered virus particles from the mice injected with wt LIVP was much lower than wt WR strain of VV. The results presented in Table 1A

Table 1A. Viral recovery from nude mice tissues in glioma model.^a

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR ^b Wt	RVGL23 TK-, WR
Brain	1.2×10^3	1.4×10^3	0	0	0	0	1.4×10^7	1.9×10^6
Kidneys	6.1×10^2	6.7×10^2	1.6×10^2	34.6	33.3	36.6	5.4×10^6	7.9×10^2

-168-

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR ^b Wt	RVGL23 TK-, WR
Lung	2.9×10^3	0	1.6×10^2	1.4×10^4	6.7×10^3	2.4×10^3	1.9×10^6	2.1×10^3
Spleen	1.9×10^2	0	1.8×10^2	1.0×10^3	1.0×10^2	1.7×10^2	1.6×10^6	1.8×10^3
Testes	5.8×10^4	64.3	6.4×10^2	7.5×10^2	0	0	9.8×10^4	1.7×10^3
Bladder	6.4×10^3	0	0	2.9×10^3	0	0	2.8×10^5	1.2×10^3
Liver	3.4×10^4	63.6	4.2×10^2	33.6	96.6	30.8	7.1×10^3	5.6×10^3
Heart	6.0×10^3	0	0	0	0	0	1.4×10^5	0
Serum ^c	0	0	0	0	0	0	6.0×10^2	0
Tumor	5.4×10^7	1.5×10^7	3.8×10^7	2.9×10^7	3.9×10^7	1.9×10^7	1.9×10^8	3.7×10^7

The results demonstrate that 10000-fold more virus was recovered in the brain of mice injected with WR strain versus wt LIVP strain. Wild type WR strain virus was recovered from the serum (600 PFU/20 µl) of mice on day 7 after virus injection.

5 No virus was recovered in the serum of the mice injected with LIVP mutants on day 14. The level of wt LIVP in serum was not tested on day 7. About 1.9×10^6 PFU/g tissue of TK-mutant of WR strain (RVGL23) was found in the brain tissue compared to 1.4×10^3 PFU/g tissue for mice injected with the TK- mutant of LIVP strain (RVGL2).

10 All other mutants of VV strain LIVP were found mostly in tumor only and no virus was recovered from brain tissue of mice injected with a double or triple mutant (Table 1A). Three times as many virus particles were recovered from the tumors of mice injected with WR compared to wt LIVP. The mean of viral recovery in tumor tissue of the mutants of LIVP strain was similar to the wt LIVP and equivalent to TK- mutant of WR strain.

15

Presence of various VV in mice bearing a breast tumor

Data for tissue distribution in immunocompromised mice bearing s.c. GI-101A human breast are presented in Table 1B:

20 **Table 1B. Viral recovery from nude mice tissues in breast cancer model.**

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR ^b Wt	RVGL23 TK-, WR
Brain	0	0	0	0	0	0	7.2×10^6	1.6×10^4
Kidneys	3.6×10^3	38.3	27	3.3×10^2	25.8	0	3.2×10^7	2.8×10^5
Lung	8.6×10^3	5.5×10^2	29.1	1.6×10^3	1.6×10^3	1.0×10^3	2.1×10^6	3.7×10^3
Spleen	5.5×10^3	99.5	0	1.8×10^2	0	0	1.6×10^6	1.8×10^3
Ovaries	1.6×10^3	0	0	0	0	0	8.0×10^7	2.7×10^7

-169-

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR ^b Wt	RVGL23 TK-, WR
Bladder	3.9×10^3	0	0	0	0	0	2.8×10^4	1.2×10^3
Liver	1.2×10^4	0	1.7×10^2	5.2×10^2	1.7×10^2	1.0×10^2	4.0×10^5	4.8×10^5
Heart	1.4×10^2	0	0	58.2	4.6×10^2	0	6.3×10^4	2.2×10^3
Serum ^c	0	0	0	0	0	0	2.4×10^3	0
Tumor	8.6×10^8	1.0×10^9	2.5×10^8	1.1×10^9	5.6×10^8	1.0×10^9	2.9×10^9	6.6×10^8

About 10-fold more viral particles were recovered from breast tumor tissue compared to glioma tumor tissue. No virus particles were recovered from the brain tissue of mice injected with either wt LIVP or its mutants. 7.2×10^6 and 1.6×10^4

5 PFU/g was recovered from brain tissue of mice injected with wt WR and TK-virus
of WR strain VV, respectively (Table). During the dissection of organs from
euthanized mice, it was found that the ovaries from the mice being injected with wt
WR and TK- of WR virus were drastically enlarged as compared to all other groups
of mice. The analysis of viral recovery from ovaries demonstrated high titer of wt
WR and TK- WR strain in ovaries, for example, 8.0×10^7 and 2.7×10^7 PFU/g,
respectively. About 1.6×10^3 PFU/g was recovered from the ovaries of the mice
injected with wt LIVP virus, however no virus particles at all were recovered from
either ovaries or from brain of mice injected with the mutants derived from LIVP
strain (Table 1B).

Presence of various VV in mice bearing a melanoma tumor

The tissue distribution of VV in the immunocompetent mice bearing melanoma tumors on foot pads also were studied. BL/6 mice on day 17 after B16F10 melanoma cell implantation were i.v. injected with the viruses at the dose of 10^7 PFU/mouse via the tail vein. All groups of mice were sacrificed on day 10 after virus injection due to huge tumor size in the PBS-injected control group. The results are set forth in Table 1C:

Table 1C. Viral recovery from C57BL/6 mice tissues in melanoma model.

-170-

^a Mean of viral recovery PFU/g of tissue for 3-5 mice/group.

^b Mice were sacrificed on day 7 after virus injection.

^c PFU/20 µl of serum

^d Mice were sacrificed on day 9 after virus injection.

^e No virus was recovered in all tested tissue.

. No virus was recovered from kidneys, lung, spleen, brain, testes, bladder, liver, heart, and serum of the immunocompetent mice injected with the viruses. Virus was only recovered from the tumor tissue. About 10-fold virus particles were recovered
5 from the tumors of mice injected with wt LIVP, TK- LIVP, wt WR, and TK- WR compared to other groups.

Example 5

Reduction of human breast tumor implanted in nude mice by recombinant vaccinia viruses RVGL7, RVGL9 and RVGL21

10 RVGL7 and RVGL9

Figure 1B shows a schematic representation of the recombinant vaccinia viruses used for these experiments. RVGL7 was prepared as described for the preparation of RVGL9. RVGL7 contains nucleic acid encoding EGFP and lacZ, and includes pE/L and p7.5 regulator regions inserted into the TK gene.

15 Luminescence and fluorescence images of tumors in a nude mouse

Human breast GI-101A cancer cells (5×10^6 cells/mouse) were subcutaneously implanted into the right thigh of the mice. Thirty days after cell implantation RVGL9, the *NotI* (F3)-interrupted virus expressing a fusion of *Renilla* luciferase and green fluorescence protein (RVGL9 = rVV-RG = rVVruc-gfp) was
20 injected intravenously via tail vein at a dose of 1×10^7 PFU/mouse. A fluorescence image of GFP and low-light image of luciferase expression were taken nine days after virus injection, i.e. 39 days post cell implantation showing dissemination of the virus.

25 Reduction of human breast tumor implanted into nude mice by vaccinia viruses RVGL7 or RVGL9

Human breast GI-101A cancer cells (5×10^6 cells/mouse) were subcutaneously implanted into the right thigh of the mice. Mice were injected i.v. with RVGL7=rVV-GFT=TK- or RVGL9-rVV-ruc-gfp=NotI (3) -interrupted viruses

-171-

(1×10^7 PFU/mouse in 0.1 ml) and PBS control on day 30 after cell implantation. Images were taken on day 65 after GI-101A cell implantation and 35 days after virus or PBS injection. The results demonstrate drastic reduction of tumor volume in the mice injected with TK- or NotI (F3) -interrupted vaccinia viruses compared with
5 the tumor in the mice injected with PBS.

GFP in Human Breast Tumor after Viral Administration

Human breast GI-101A cancer cells (5×10^6 cells/mouse) were subcutaneously implanted into right thigh of the mice. Mice were injected i.v. with RVGL7=rVV-GFP=TK- or RVGL9=rVV-RG-rVV-ruc-gfp-NotI (F3) -interrupted viruses (1×10^7 PFU/mouse in 0.1 ml) on day 30 after cell implantation. The data demonstrate GFP expression in tumor area in the mice injected with TK- or NotI (F3) -interrupted vaccinia viruses. No GFP signals were observed in other parts of mice body. The results also showed that expression of GFP can be visualized as early as 48 h after virus injection through tail vein. On day 16 after virus injection
10 very strong signals of GFP which correspond to a tumor volume of about 1300-1620 mm³ for TK- or NotI (F3) -interrupted virus, respectively were observed. Reduced GFP signals were observed on day 25 (1218-1277 mm³ for TK- or NotI (F3) - interrupted virus, respectively) and 32 (514-887 mm³ for TK- or NotI (F3) - interrupted virus, respectively) due to reduction of tumor volume.
15

Time course of Breast Tumor Volume over Time

GI-101A breast cancer cells were implanted subcutaneously into the right thigh of 4-5-week old female athymic (nu/nu) mice in the dose of 5×10^6 cells/mouse. Thirty days after tumor implantation, when the tumor reached about 500 mm³ in volume, a single dose (1×10^7 PFU/mouse in 0.1 ml) of RVGL7 = rVV-GFP = TK- or RVGL9 = rVV-RG = rVV-ruc-gfp = NotI (F3) -interrupted vaccinia viruses or PBS control was injected intravenously (via tail vein). Tumor dimensions were measured with vernier caliper twice a week and volumes were calculated as (LxHxW)/2, where L, H and W represent the length, width, and height of the tumor, respectively and expressed in mm³. The data demonstrate significant (60-80% on
20 day 65) tumor reduction in the mice injected with TK-, NotI (F3) -interrupted
25
30

-172-

vaccinia viruses. In contrast, tumors grew very rapidly in the mice injected with PBS.

Monitoring of tumor regression by light extinction.

Subcutaneous GI-101A breast tumor reduction occurred in 100% of immunocompromised mice treated with a single i.v. injection of wt LIVP, single F3-, single TK-, and double F3-, TK-, mutants of LIVP strain. Some degree of toxicity was seen in the mice treated with above viruses. RVGL21 virus with the triple deletions TK, F3 and HA genes which showed no toxicity in nude mice; hence this virus was used for long-term studies. The difference in antitumor activity and survival between high and low doses of treatment using the triple mutant RVGL21 virus was not significant. GFP expression in tumor area in the mice injected with RVGL21 was monitored. No GFP signals were observed in other parts of mice body. Expression of GFP can be visualized as early as 48 h after virus injection through tail vein. On day 16 after virus injection we observed very strong signals of GFP, which correspond to tumor volume about 1300-1620 mm³ and reduced GFP signals on days 25 (1218-1277 mm³) and 32 (514-887 mm³) due to reduction of tumor volume. Tumor volume reduction also was apparent by visual inspection of the mice.

Example 6

20 : **Reduction of vaccinia virus toxicity and virulence**

Reduction of vaccinia virus pathogenicity by monitoring mouse body weight and survival

The percentage of body weight change in athymic and immunocompetent mice bearing different s.c. tumors after i.v. administration of the viruses was examined. Injection of wt LIVP and wt WR and some mutants at the dose of 10⁷ pfu/mouse via the tail vein led to a progressive vaccinia virus infection within a two week observation period. At one week after challenge, the mice showed typical blister formation on the tail and footpad. Later, weight loss, sometimes accompanied by swelling of the mouth region, in several cases led to death of the mice. In the case of wt WR strain of VV, mice started to die on day 7 after i.v.

-173-

injection of virus. While mice receiving the recombinant LIVP viruses gained weight or remained the same weight over the same time period.

Body weight in glioma model nude mice

Rat glioma C6 cells at the dose of 5×10^5 /0.1 ml/mouse were implanted s.c.
5 into the right thigh of nude mice (5-6 old male mice) on day 0. Vaccinia viruses
were injected i.v. (via tail vein) at the dose of 1×10^7 PFU/0.1 ml/mouse on day 7.
Animals were weighed twice a week. Gain/loss of body weight on day 14 post
infection was calculated as the percentage: body weight - tumor weight on day of
virus injection (g) / body weight-tumor weight on day 14 (g) $\times 100\%$. Injection of
10 VGL (wild type vaccinia virus, strain LIVP) and RVGL5 (HindIII-N-interrupted)
causes toxicity in nude mice: mice continue to lose the weight. Recombinant
vaccinia viruses RVGL5 (HA-interrupted), RVGL7 (TK-interrupted), RVGL8
(NotI(F3) -interrupted), RVGL19 (double, TK- and NotI (F3) -interrupted) were less
toxic in nude mice: after losing some body weight, 10 days post-infection, mice
15 started to gain the body weight .

Nude mice with glioma that were injected with wild type WR strain of VV
lost 31.9% of body weight on day 7 after virus injection. Mice injected with TK-
virus of WR strain lost 22.4% of body weight on day 14 after virus injection
compared to 1.5% in the group of mice injected with TK- virus of LIVP strain of
VV. All mice injected with wild type LIVP strain survived for at least 14 days (the
duration of the experiment). Mice without tumor injected with VGL (wt VV, strain
LIVP) lost 11.23 % of body weight. Mice bearing tumor injected with VGL (wt
VV) or with RVGL1 (HindIII-N-interrupted) lost 15.79% and 10.18% of body
weight, respectively. Mice in the wt LIVP group lost 15.8% of body weight versus
25 9.4% in the PBS injected group. Tumor-bearing mice injected with RVGL2 (TK-),
RVGL5 (HA-), RVGL7 (TK-), RVGL8 (F3-), RVGL9 (F3-), RVGL20 (TK-, F3-),
RVGL21 (TK-, F3-, HA-) on day 14 after virus injection lost only 1.5%, 0.4%,
2.1%, 5.0%, 7.3%, 2.4%, and 3.2% of body weight, respectively. Tumor-bearing
mice injected with virus carrying double gene interruption, RVGL19 (TK- and F3-)
30 demonstrated 0.73% gain of body weight compared to the body weight on day 0.

-174-

Based on the results of body weight, a single interruption of HA, TK, F3 (NotI site) and double interruption of TK, F3 (NotI site) genes in vaccinia virus genome reduces virulence and toxicity of the vaccinia virus strain LIVP.

Injection of wt VV strain WR, however, was extremely toxic to nude mice,
5 which died on day 7 after virus injection. Wild type and mutant VVs of strain LIVP were less toxic in nude mice. Although nude mice injected with various LIVP strains lost some body weight, after day 10-post infection mice started to gain the body weight.

Body weight in breast tumor model athymic mice

10 The body weight change of athymic mice with s.c. GI-101A human breast tumor after i.v. injection of vaccinia viruses was monitored. Mice injected with wt WR strain lost 25.6% of body weight and died due to virus toxicity. Although mice injected with wt LIVP virus survived for longer time, mice lost 26.4% of body weight. Mice injected with TK-WR strain lost 17.8% of body weight, while mice
15 injected with TK- LIVP virus gained 1.9% of body weight. All mice injected with other mutants of LIVP strain were stable; no virus related toxicity was observed in these mice.

Body weight in melanoma model immunocompetent mice

20 The toxicity of the vaccinia viruses in immunocompetent C57BL/6 mice bearing mouse B16-F10 melanoma on their foot pad was studied. Although mice in all groups survived during the experiment, wt WR strain was more toxic in immunocompetent mice compared to wt LIVP and recombinant strains. Mice injected with wt WR strain lost about 11.4% of body weight on day 10 after i.v. injection of virus, while mice injected with wt LIVP strain and its double (RVGL20)
25 and triple (RVGL21) mutants lost only 2.2%, 1.3%, and 0.6% of body weight, respectively, versus to 7.1% of body weight lost in PBS injected mice. Mice administered i.v. with RVGL2 (TK-), RVGL5 (HA-), RVGL9 (F3-), and RVGL23 (TK-WR strain) continued to gain weight over this same period.

Long-term survival after viral infection for breast tumor-bearing mice

-175-

To examine the effect of different mutations on long-term survival, mice bearing s.c. GI-101A human breast tumor received doses of 10^7 virus i.v., and were observed for survival after viral infection. The results showed that there are differences in survival depending upon the virus injected. Injection of the nude mice bearing s.c. breast tumor with wt WR strain (i.v., 1×10^7 /mouse) resulted in 100% mortality: four mice of five died on day 9 and one mouse died on day 11 after virus injection. Mice injected with strain LIVP survived for 35 days. Mice injected with a single mutated virus RVGL9 (F3-) developed the toxicity and 25% of mice died on day 34 after virus injection, however the deletion of F3 gene in LIVP strain prolonged the survival of mice up to 57 days. Mice injected with double mutant virus RVGL20 (F3-, TK-) began to die on day 34 after virus injection, but survived longer than F3- injected mice. The RVGL20 virus injected mice reached 50% survival point on day 65 and showed significantly longer survival time up to 116 days. The single mutant TK-virus of LIVP virus was less pathogenic than the single mutant F3-or double mutant F3-, TK- viruses; all mice were alive on day 80 after injection with TK- virus and 14.3% of the mice survived 130 days. All mice injected with the triple mutant TK-, F3-, and HA-virus (RVGL21) survived 130 days (duration of the experiment) and continued to live without any signs of virus toxicity compared to other groups of mice.

20 Splenomegaly in various mice

Immunocompetent C57BL/6 mice

Several groups of the animals demonstrated enlargement of the spleen; therefore the relative spleen weight (RSW) was calculated. The results are shown in Table 2 as follows:

25 Table 2. Relative spleen weight (RSW) in mice with or without tumors.

Groups	Glioma model nu/nu mice	Breast cancer model nu/nu mice	Melanoma model C57BL/6 mice
No tumor, PBS	43.6 ± 4.1^a	50.5 ± 11.2^d	30.1 ± 2.8^g
No tumor, LIVP	67.2 ± 11.9	48.0 ± 13.1	68.1 ± 9.4
Tumor, PBS	92.4 ± 7.4^b	84.1 ± 14.6^e	106.0 ± 46.1^h
LIVP	98.2 ± 28.2^c	108.4 ± 39.4^f	148.4 ± 44.8^i
RVGL2	96.0 ± 34.9	112.7 ± 15.6	51.9 ± 6.6

-176-

Groups	Glioma model nu/nu mice	Breast cancer model nu/nu mice	Melanoma model C57BL/6 mice
RVGL5	143.8 ± 20.5	169.6 ± 31.7	61.6 ± 2.9
RVGL9	73.9 ± 10.5	151.8 ± 27.9	63.3 ± 34.9
RVGL20	84.9 ± 6.6	159.9 ± 22.7	106.7 ± 36.0
RVGL21	114.4 ± 12.5	117.7 ± 15.3	63.0 ± 24.6
WR	37.3 ± 3.5	57.9 ± 10.9	70.5 ± 1.8
RVGL23	46.9 ± 15.7	73.1 ± 19.3	97.0 ± 43.9

Mean ± SD for n=4-8 mice/group.

RSW = weight of spleen (g) x 10⁴/(animal body weight (g) – tumor weight (g)).

^a p ≤ 0.02 vs. all groups, except no tumor LIVP, WR, RVGL23

^b p ≤ 0.039 vs. no tumor PBS, no tumor LIVP, RVGL5, WR, RVGL23

^c p ≤ 0.046 vs. all groups, except PBS, RVGL2, RVGL20, RVGL21

^d p ≤ 0.006 vs. all groups except no tumor LIVP, PBS, WR, RVGL23

^e p ≤ 0.048 vs. all groups, except no tumor PBS, LIVP, RVGL2, WR, RVGL23

^f p ≤ 0.045 vs. all groups, except PBS, RVGL2, RVGL21

^g p ≤ 0.035 vs. P'BS, LIVP, RVGL20, WR, RVGL23

^h p ≤ 0.049 vs. all other groups, except no tumor LIVP, RVGL20, WR, RVGL23

ⁱ p ≤ 0.049 vs. all other groups.

As shown in the Table 2 above, some degree of splenomegaly was observed in mice. For immunocompetent C57BL/6 mice, a statistically significant difference (p < 0.035) was found in tumorous mice injected with PBS, LIVP, RVGL20, WR and RVG123 compared to non-tumorous mice. In mice injected with wt VV strain LIVP spleen was enlarged greatly (p < 0.049) versus all other groups. In contrast, the smallest spleens were found in the mice without tumor.

Nude mice with a glioma tumor

In nude mice with or without s.c. glioma tumor, mice injected with wt WR or TK- of WR virus had the lowest RSW 37.3 or 46.9, respectively, which was similar to the RSW from the mice without tumor and injected with PBS (43.6). The largest RSW 143.8 and 114.4 was observed in RVGL5 (HA-) and RVGL21 (TK-, F3-, HA-) groups, respectively. No statistically significant difference was found among the groups of mice injected with wt LIVP, RVGL2, RVGL9, RVGL20 versus to PBS injected group.

-177-

Nude mice with breast tumor

The results of RSW in the immunocompromised mice bearing s.c human breast tumor indicate that all mice injected with wt LIVP and its mutants have an enlarged spleen compared to the mice injected with wt WR or TK- WR viruses
5 (p<0.045). The largest spleen was found in the mice injected with single HA-, single F3 -, double F3-, TK- mutants of LIVP strain.

Other results using RVGL21 for injection

Two mice #437 and #458 survived more then 190 days after RVGL21 injection (10^7 and 4×10^5 , respectively, i.v.) without any signs of diseases or virus
10 related toxicities.

On day 30 after GI-101A cell implantation (tumor volume= 594.9 mm^3), 10^7 of RVGL21 was injected i.v. into mouse #437. On day 101 after virus injection (s.c. tumor size= 220.4 mm^3), metastasis (hard tissue) in chest area under the skin was observed. The size of the tumor was 1223.6 mm^3 , which disappeared by day 148.
15 The, s.c. tumor did not disappear, it started to grow back, but the mouse remained metastasis-free.

Mouse #458 had a first s.c. tumor (GI-101A) on the right hind quarter. When the first tumor started to shrink (day 29 after RVGL21 virus injection, tumor size= 1924.3 mm^3), a second syngeneic tumor was implanted s.c. on the left hind quarter. The second tumor grew slowly, reached the size of 1205.7 mm^3 and started to shrink. The mouse was free of first tumor on day 127 post virus injection; the size of the second tumor was 439.6 mm^3 . The tumor continued to shrink and the cells died. The body gradually absorbed remaining tumor tissues that were contributed by the host (such as the tumor vascular skeleton that was coming from
20 the host). Since these remains are not considered foreign, the immune system doesn't destroy them. The tumor cells, on the other hand, were long gone and cleared by the immune system and the virus. Reduction of second syngeneic tumor demonstrates that this mouse developed antibodies against the tumor cells. The
25 antibodies resulted in the reduction of the second syngeneic tumor.

-178-

EXAMPLE 7

Use of a Microorganism or Cell to Induce Autoimmunization of an Organism Against a Tumor

This example shows that the method provided herein and in priority application EP 03 018 478.2 relating to "The production of a polypeptide, RNA or other compound in a tumor tissue" also can be used for the production of antibodies against the tumor tissue. These antibodies provide for autoimmunization of the organism bearing the tumor. Furthermore, these antibodies can be isolated and used for the treatment of tumors in other organisms.

Methods and uses of microorganisms, including cells, which can contain DNA encoding a desired polypeptide or RNA, to induce autoimmunization of an organism against a tumor are provided. Also provided are methods for the production of antibodies against a tumor by: (a) injecting a microorganism, such as a virus or cell, optionally containing a DNA sequence encoding a desired polypeptide or RNA, into an organism bearing a tumor and (b) isolating antibodies against the tumor.

This Example further demonstrates that administration of microorganisms, such as the triple mutant vaccinia virus strain provided herein, which accumulate in tumors, causing them to release tumor antigens for a sufficient time to permit production of antibodies by the host. This is exemplified by showing a reduction and elimination of xenogeneic GI-101A solid breast carcinoma tumors and their metastases in nu-/nu- mice (T cell deficient mice).

Step#1: Female nu-/nu- mice of 5 weeks age were chosen, and the GI-101A cells grown in RPMI1640 medium, supplemented with estrogen and progesterone. The confluence was reached, cells were harvested, washed with phosphate buffered saline. Cells (5×10^6 cells per mouse) were then injected subcutaneously into mice. The tumor growth was carefully monitored every two days.

Step#2: At two stages of tumor growth (at tumor size of $400\text{-}600\text{mm}^3$, and at tumor size of $\sim 1700\text{ mm}^3$), purified vaccinia viral particles (RVGL12) were delivered to each tumorous mice by intravenous injection through tail vein. The colony purified virus was amplified in CV-1 cell line and the intracellular viral particles were

-179-

purified by centrifugation in sucrose gradient. Two concentrations of virus (10^6 pfu/100 μ l and 10^7 pfu/100 μ l resuspended in PBS solution) were injected. The viral replication was monitored externally by visualization of virus-mediated green fluorescence protein expression. The tumor development was monitored by tumor volume determination with a digital caliper.

Vaccinia viruses RVGL12+GCV(gancyclovir), and RVGL12 (RVGL12 is the same as RVGL7, except that the nucleic acid encoding gfp is replaced by herpes simplex virus thymidine kinase (HSV TK; see, SEQ ID Nos. 35 and 36) were injected 67 days after GI-101A cellular implantation. A second administration referred to as RVGL12a, was injected 30 days after cellular implantation.

Step#3: After viral administration , it was determined that first the tumors continued to grow to a size of ~ 900 mm³ (from 400-600 mm³ at the time of viral injection), and to a size of ~ 2400 mm³ (from 1700 mm³). Then the growth rate leveled off for approximately 6-8 days.

Step#4: Approximately 14 days after viral injection, the tumor volume started to decline rapidly. Forty days after viral application, all the treated animals showed more than 60% tumor regression. Sixty-five days after viral treatment and many of the animals had complete regression of tumors.

Step#5: Some of the animals were completely tumor-free for several weeks and their body weight returned to normal. RVGL-12+GCV treatment resulted in 86.3% reduction of tumor size (Day 52 after viral injection) from their peak volumes on Day 13, RVGL-12 treatment resulted in 84.5% reduction of tumor size (Day 52) from their peak volumes (Day 13). RVGL-12a treatment resulted in 98.3% reduction of tumor size (Day 89) from their peak volumes (Day 12). After PBS+GCV control treatment, the average volume of tumors were increased by 91.8% in 38 days

Step#6: The level of immune activation was determined. Sera were obtained from the animals with regressing tumors and the immune titer determined against a foreign protein (e.g. green fluorescent protein), vaccinia viral proteins, and GI-101A

-180-

cancer cell proteins were determined. The following antisera obtained from the following sources were used to analyze the following listed samples.

Samples:

- 1). Mouse cell lysate (control);
- 5 2). Purified and denatured vaccinia viral particles;
- 3). GI-101A tumor cell lysate;
- 4). Purified green fluorescent protein;
- 5). Purified luciferase protein;
- 6). Purified beta-galactosidase protein.

10 Antisera:

- a). Antiserum from nontumorous mouse;
- b). Antiserum from GI-101A tumorous mouse;
- c). Antiserum from GI-101A tumorous mouse 14 days after vaccinia i.v. injection;
- d). Antiserum from GI-101A tumorous mouse 65 days after vaccinia i.v. injection;
- 15 e). Antiserum from tumor-free mouse (after elimination of GI-101A tumor) 80 days after vaccinia i.v. injection.

The results showed that there was enormous tumor-specific vaccinia virus replication in the tumors, which led to tumor protein antigen and viral protein production in the tumors. In addition, the vaccinia virus did lyse the infected tumor cells thereby releasing tumor-cell-specific antigens. The continuous leakage of these antigens into the body led to a very high level of antibody titer (in approximately 7-20 14 days) against foreign cell proteins (tumor proteins), viral proteins, and the virus encoded engineered proteins in the mouse body. The newly synthesized antitumor antibodies and the enhanced macrophages, neutrophils counts were continuously delivered via the vasculature into the tumor and thereby providing for the recruitment of an activated immune system in the inside of the tumor. The active immune system then eliminated the tumor including the viral particles. This interconnected release of foreign antigens boosted antibody production and 25 continuous return of the antibodies against the tumor-contained proteins function as

-181-

an autoimmunization vaccination system, initiated by vaccinia viral replication, followed by cell lyses, protein leakage and enhanced antibody production .

EXAMPLE 8

Production of β -Galactosidase and Anti β -Galactosidase via Vaccinia Virus Delivered lacZ in Tumor Bearing Mice

Thirty five athymic nu/nu mice (5 weeks old, 25g, male) were used to demonstrate the biodistribution and tumor targeting of vaccinia virus (strain LIVP) with different deletions in the genome. Mice were divided into 7 groups with 5 in each group as presented in Table 1

Group	No. mice	Tumor implanted	Virus Injected	Insertion locus
1	5	None	VGL	wtLIVP
2	5	C6, s.c. 5×10^5 cells	VGL	wtLIVP
3	5	C6, s.c. 5×10^5 cells	RVGL1	N-luc, lacZ
4	5	C6, s.c. 5×10^5 cells	RVGL5	HA- lacZ
5	5	C6, s.c. 5×10^5 cells	RVGL7	TK-egfp, lacZ
6	5	C6, s.c. 5×10^5 cells	RVGL8	NotI- lacZ
7	5	C6, s.c. 5×10^5 cells	RVGL19	TK-rTrf, lacZ, NotI-RG

10

C6 gliomas were subcutaneously developed in Groups 2 to 7. Five days after tumor cell implantation (5×10^5 cells/mouse), each animal was treated with 0.1 ml of virus at a multiplicity of infection (MOI) of 1×10^7 via tail vein injection. Two weeks after virus injection, all mice were sacrificed and blood samples were collected. Various 15 organs and tumors also were taken from animals for virus titer and β -galactosidase analysis.

The β -galactosidase analysis was performed using the Galacto-Light Plus system (Applied Biosystems), a chemiluminescent reporter gene assay system for the detection of β -galactosidase, according to the manufacturer's instructions.

20

β -galactosidase Expression Measurements

In non-tumorous mice as well as in tumorous mice injected with wild type vaccinia virus (without reporter genes and without β -galactosidase gene) no β -galactosidase expression was detected in organs, blood and tumor samples. By contrast, in the tumors of mice infected with β -galactosidase expressing virus, high

-182-

levels of β -galactosidase was expressed. β -galactosidase also was detected in blood samples as shown in Table 2, but no virus recovered from blood samples.

Table 2. Production of β galactosidase by vaccinia virus in tumor and blood from tumor bearing mice (day 14 after virus injection)

Group	Virus Injected	β -gal in tumor $\mu\text{g}/\text{mg}$ of total protein	β -gal in serum $\mu\text{g}/\text{ml}$ of total protein	Est. total β -gal/tumor (μg)	Est. total β -gal/5ml blood (μg)
3	RVGL1	1.59 ± 0.41	1.38x10 ⁻² ±1.09x10 ⁻²	489.84	4.00
4	RVGL5	1.51 ± 0.37	1.16x10 ⁻² ±1.08x10 ⁻²	330.21	3.62
5	RVGL7	1.35 ± 0.59	0.95x10 ⁻² ±1.47x10 ⁻²	616.60	1.83
6	RVGL8	1.81 ± 0.42	0.86x10 ⁻² ±0.33x10 ⁻²	962.36	2.38
7	RVGL19	1.30 ± 0.44	0.26x10 ⁻² ±0.16x10 ⁻²	463.75	0.60

5

Anti- β -galactosidase antibody production

To determine whether the amount of β -galactosidase presented in mouse blood was sufficient to elicit antibody production, sera taken from two mice (mouse #116 from Group 5, and #119 from Group 6) were collected and tested for primary antibodies against β -galactosidase in Western analysis. β -galactosidase from *E. coli* (Roche, 567 779) was used as the antigen standard, and the mouse monoclonal anti β -galactosidase from *E. coli* (Sigma, G6282) was used as the antibody positive control. As additional sources of β -galactosidase, total protein was obtained from CV-1 cells 24 hours after infection with RVGL7 at MOI of 1 pfu/cell, and the tumor protein sample from mouse designated #143 (treated with RVGL7) was obtained.

10 The protein samples were prepared in triplicate, each set including a β -galactosidase antigen control, a cell lysate from RVGL7 infected CV-1 cells, and tumor lysate from mouse #143. All protein samples were separated by electrophoresis using a 10% polyacrylamide gel, and transferred to NitroBind 15 nitrocellulose membrane (MSI) using a BioRad semidry blotting system.

20 Immunoblotting was performed with either 1:3000 mouse monoclonal anti β -galactosidase, or 1:3000 mouse serum taken from either mouse #116 or #119, and 1:3000 Goat AntiMouse IgG-HRP (BioRad). An Amplified Opti-4CN Detection Kit (BioRad) was used for detection.

25 The results showed that sera taken from mouse #116 and #119 exhibited similar levels of antibody when compared to a commercial mouse anti- β -

-183-

galactosidase standard , and demonstrated that the tumor bearing mice #116 and #119 produced antibodies against β -galactosidase.

EXAMPLE 9

Mamalian cells for tumor therapy

As shown herein, certain bacteria, viruses, and mammalian cells (BVMC), when administered systemically, again entry and selectively replicate in tumors. Hence, systemically injected mammalian cells and certain bacterial (anaerobic bacteria, such as *Salmonella*, *Clostridium* sp., *Vibrio*, *E. coli*) cells gain entry into solid tumors and replicate in tumor-bearing organisms. Genetically-labeled cells can be used for tumor detection and therapy. In addition to gene expression in tumors through BVMC targeting, tumor-specific gene expression can be achieved by linking transgenes to tissue/tumor-specific promoters. To obtain tumor specific gene expression, a variety of systemic targeting schemes can be employed. These strategies include the use of tissue/tumor-specific promoters that allow the activation of gene expression only in specific organs, such as prostate-specific promoter-directed viral gene expression; the use of extracellular matrix (*i.e.* collagen)-targeted viral vectors; and the use of antibody-directed viral vectors. Conditionally-replicating viruses have also been explored as tumor-specific delivery vehicles for marker genes or therapeutic genes, such as oncolytic adenovirus vector particles, replication-selective HSV, vaccinia viruses and other such viruses.

When light-emitting protein encoded BVMC are injected systemically into rodents, tumor-specific marker gene expression is achieved and is detected in real time based on light emission. Consequently, the locations of primary tumors and previously unknown metastases in animals are revealed *in vivo*. Hence diagnosis can be coupled to therapy and to monitoring of therapy. The impaired lymphatic system in tumors may be responsible for the lack of clearance of bacteria from tumors by the host immunosurveillance after escaping the vascular system.

EXAMPLE 10

Tumor Development is inhibited following *S.pyrogenes* administration

-184-

This Example and following examples demonstrate the use of bacterial cells to colonize tumors, use of reporter in the cells to quantitate colonization; use of the colonized attenuated bacterial cells for tumor inhibition. Co-administration or sequential administration of bacteria and viruses. Administration of virus before 5 bacteria increase tumor colonization by the bacteria. Administer bacteria that expresses an enzyme that will activate a prodrug, thereby targeting colonized cells.

Bacterial Strains

Streptococcus pyogenes M-type 1 T-type 1 (ATCC catalog no. 700294) was transformed with pDC123-luxF plasmid) that contains the bacterial luciferase expression cassette (Lamberton GR, Pereau MJ, Illes K, Kelly IL, Chrisler J, Childers BJ, Oberg KC, Szalay AA. 2002. *Construction and characterization of a bioluminescent Streptococcus pyogenes*. Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence, Case JF, Herring PJ, Robison BH, Haddock SHD, Kricka LJ, Stanley PE (eds). Chichester: Wiley, pp 85-15 88. Luciferase can be detected in the presence of exogenous decanal.

Transformed S.pyogenes were grown overnight in BH1 media in the presence of in the presence of 20 µg/ml of chloramphenicol at 37°C. After overnight growth, the bacteria were counted at OD₆₀₀ and bacteria were resuspended in BH1 media at the indicated density for injection.

Tumor Development and Bacterial Injection

Twenty 5-week old mice were injected subcutaneously in the right lateral thigh. Each mouse was injected with 5 x 10⁵ C6 glioma cells transformed with pLEIN-derived retrovirus (Clontech; see also WO 03/14380). The subcutaneous tumors were developed for 7 days after implantation before bacterial injection.

For bacterial injection, the tumor-bearing mice were anesthetized with isofluorene. The suspensions were injected intravenously with a 1-cc insulin syringe equipped with a 29 ½ -gauge needle through a surgically exposed femoral vein. After the injections, the incisions were sutured.

Tumor growth was monitored on twice a week following bacterial injection 30 using a digital caliper. In addition, fluorescence imaging and photographic images

of the animals were taken at the end time points. The presence of luminescent bacteria was analyzed by intravenously injecting the animals with 30 µl of decanal. Analysis of whole animals for bacterial luciferase activity, followed methods similar to Yu *et al.* (2004) *Nature Biotechnology* 22(3): 313-20. Briefly, anesthetized animals were placed inside the dark box for photon counting (ARGUS 100 low light Iamager, Hamamatsu). Photon collection was for 1 minute from ventral and dorsal sides of the animal and the images were recorded with Image Pro Plus 3.1 software (Media Cybernetics) and/or Lightools® macroimaging system. A light image also was recorded. The luminescent images were superimposed on the light image to localize the luminescent activity on the animal. Total intensity of photon emission in localized regions, *e.g.* in the tumor region, also was recorded. *S. pyogenes* was isolated from removed tumors and ground tissue was plated on LB-chloamphenicol (20 µg/ml) plates. Luminescent bacteria were counted in the presence of decanal vapor.

15 Results

Four groups of mice were tested. Each group contained five mice.

Group	<i>S. Pyogenes</i>
1	None
2	1×10^6
3	1×10^7
4	5×10^7

Tumor volume was measured after 7 days of tumor development and the injection of *S. pyogenes*, through 21 days post-tumor development.

The control group of mice with no *S. pyogenes* had continuous and accelerating tumor growth over the 2-week period. The mice injected with *S. pyogenes* had slower tumor growth. Groups 3 and 4 had the slowest tumor growth rates. Both groups maintained a slower linear rate throughout the monitoring period, whereas the control group, not injected with bacteria, exhibited tumor growth that accelerated at later time periods.

At all time points following bacterial injection, tumor volumes were smaller in Groups 3 and 4 mice than in the control mice (Group 1). At day 21, the average

-186-

tumor volume of the control group was approximately 2.5-3 fold greater than the average tumor volumes in Groups 3 and 4. Group 2, injected with the lowest titer of bacteria, also had a reduced tumor volume from the control group at the later time points, although the tumor volume was larger than Groups 3 and 4.

5 Bacterial colonization and tumor inhibition also is assayed in a fibrosarcoma model. HT1080 fibrosarcoma cells transformed with the pLEIN retrovirus are injected subcutaneously into the right lateral thigh of five week old nude male mice (5×10^5 cells/mouse). *S. pyogenes* transformed with pDC123-luxF is injected into the femoral vein of the animals after 8 or 14 days of tumor growth (5 animals on
10 each day). A group of 5 animals are not injected as serve as a control group. Tumor growth and luciferase activity is monitored at subsequent time points. *S. pyogenes* is isolated from tumors and cultured on BH1 + chloramphenicol (20 µg/ml) plates. Luminescent bacterial colonies are counted in the presence of decanal vapor.

Example 11

15 **Vibrio Cholera localization to tumors**

Plasmids and Bacterial Strains

Attenuated *Vibrio Cholerae*, strain Bengal 2 serotype 0139, M010 DattRS1, was transformed with pLITE201 which contains the luxCDABE cassette (Voisey *et al.* (1998) *Biotechniques* 24:56-58). The transformed strain is a light emitting strain due to the expression of the luciferase genes.

Tumor Development and Bacterial Injection

Groups of nude mice (n>20) were implanted with C6 glioma tumors (500mm^3) as described in the Examples herein. 1×10^8 transformed bacteria (*V.Cholerae*) were suspended in 100 µl of phosphate buffered saline (PBS). The
25 bacterial suspension was injected into the right hind leg of each mouse. The animals were then monitored after injection under a low light imager as described in Example A.

In a separate experiment, for comparison, groups of nude mice (n>20) were implanted with C6 glioma tumors (500mm^3) as described in the Examples herein.

-187-

These mice were injected with 1×10^8 pfu/mouse of rVV-RUC-GFP virus (see Examples 1 and 4).

Results

Titer and luciferase activity

5 Mice from each of the two injected groups were sacrificed at time points after injection. Tumors were excised and homogenized. Bacterial and viral titers and luciferase activities were measured as described in the Examples herein.

10 Both bacterial and viral titer increased following injection. The increase in bacterial growth over time was proportional to luciferase levels in the tumors. A log-log plot of bacterial titer versus luciferase activity in tumors in the mice injected with *V. cholera* demonstrated a linear relationship between bacterial titer and luciferase activity. The groups of mice injected with rVV-RUC-GFP virus, also demonstrated a linear relationship between virus titer and luciferase activity.

	Time after <i>V. Cholera</i> /pLITE injection			
	4 hrs	8 hrs	16 hrs	32 hrs
Bacterial Titer (cfu/tumor)	$3.79 \times 10^4 \pm 2.93$	$3.14 \times 10^6 \pm 2.45$	$1.08 \times 10^8 \pm 1.3$	$5.97 \times 10^8 \pm 4.26$

15

	Time after rVV-ruc-gfp virus injection			
	36 hrs	Day 3	Day 5	Day 7
Viral Titer (pfu/tumor)	$3.26 \times 10^6 \pm 3.86$	$7.22 \times 10^7 \pm 3.67$	$1.17 \times 10^8 \pm 0.76$	$3.77 \times 10^8 \pm 1.95$

The experiments demonstrated a linear relationship between titer and luciferase activity. Thus, luciferase activity of the injected bacteria and/or virus can be used as a correlative measurement of titer.

20 **Localization**

Localization of *V.cholera* was performed as detailed in the Examples herein for virus. Briefly, organs and blood samples were isolated from animals euthanized

-188-

with CO₂ gas. The organs were ground and plated on agar plates with chloramphenicol drug selection for analysis of bacterial titer.

Bacterial titer was assayed in tumor, liver, testes, spleen, kidney, lung, heart, bladder and brain of the injected mice. Samples were taken from mice sacrificed at 5 zero, and subsequent times up to 150 hours following *V.cholera* injection.

At the time point immediately following injection (t=0), *V.cholera* was present in all samples, with the highest levels in the liver and spleen. By 50 hours post-injection, titer of *V.cholera* in all tissues had reduced with the exception of tumor tissue. In contrast, *V.cholera* titer had increased about 4 orders of magnitude 10 as compared to time zero. This level increased slightly and then stayed constant throughout the remainder of the experiment. By 150 hours post-infection, titer in all samples except tumor had decreased. For example, the titer in liver had decreased by approximately 5 orders of magnitude from the time zero point. At the 150 hour point, the *V.cholera* titer in the tumor tissue was about 6 orders of magnitude greater 15 than any other tissue sample.

Example 12

Co-administration and sequential administration of bacteria and virus

V.Cholera/pLITE (see Example B) and vaccinia virus VV-TK-gfp-lacZ (see Example 4) were administered together or sequentially. Groups of nude mice with 20 C6 glioma tumors were injected with bacteria and/or virus as shown in the Table below. Three male mice were injected per group. Bacteria and/or virus were injected on day 11 and day 16 following tumor implantation. Tumor growth, luciferase and GFP activity were monitored as described in the Examples herein.

Group	Day 11 injection	Day 16 injection
1	1×10^7 VV-TK-gfp-lacZ	1×10^7 <i>V.Cholera/pLITE</i>
2	None	1×10^7 <i>V.Cholera/pLITE</i>
3	1×10^7 <i>V.Cholera/pLITE</i>	1×10^7 VV-TK-gfp-lacZ
4	None	1×10^7 VV-TK-gfp-lacZ
5	None	1×10^7 VV-TK-gfp-lacZ and 1×10^7 <i>V.Cholera/pLITE</i>

Results

On day 21 (21 days post tumor implantation) animal were sacrificed. Tumors were excised from each animal and ground. Viral titer was assayed on Groups 3, 4 and 5. Bacterial titer was assed on Groups 1,2 and 5. Titers (colony forming units and plaque forming units) were performed as previously described in the Examples.

A comparison of the bacterial titer in tumors Groups 1, 2 and 5 demonstrated that bacterial titer was highest in Group 1 that had been injected first with vaccinia virus at day 11, and followed by *V.cholera* injection on day 16. Co-injection of bacteria and virus at day 16 (Group 5) gave an intermediate bacterial titer. Group 2, injected only with *V.cholera* at day 16, had a lower bacterial titer in the tumor tissue than either of groups 1 or 5. Thus, tumors were more susceptible to bacterial colonization when first colonized by VV-TK⁻-gfp-lacZ virus.

A comparison of the viral titer in Groups 3, 4 and 5 demonstrated that Group 4, with only virus injection at day 16, had the highest viral titer followed by Groups 5 and 3. The viral titer of Group 5 was slightly higher than Group 3, but not apparently significantly different. One mouse in Group 4 had a viral titerr that was an extreme outlier in comparison to the viral titer of the other 2 mice in Group 4.

When the numbers were reassessed without this mouse, the general trend remained the same. The average viral titer in Group 4 was much closer to the viral titers of Groups 3 and 5. The data from the three groups in this analysis was not significantly different. Thus, pre-administration of bacteria followed by administration of virus did not significantly change the viral colonization of the tumor as compared with viral administration alone.

Example 13

Tumor Inhibition by Administering PNP-expressing bacteria and prodrug

Plasmids pSOD-DeoD contains the bacterial purine nucleoside phosphorylase gene (PNP) (Sorcher *et al.* (1994) GeneTher. 1(4):223-238), under the control of the constitutive SOD (superoxide dismutase) promoter. Plasmid pSOD-DeoD-lux,

-190-

contains the luxCDABE expression cassette (Voisey *et al.* (1998) *Biotechniques* 24:56-58) inserted into pSOD-DeoD.

PNP converts the non-toxic prodrug 6-methylpurine deoxyribose (6-MPDR) to 6-methyl purine which inhibits DNA replication, transcription and translation
5 (Sorcher *et al.* (1994) *GeneTher.* 1(4):223-238).

Tumor Growth inhibition

Nude mice were injected with pLEIN retrovirus transformed C6 glioma cells. The pLEIN retrovirus expresses EGFP under the control of the viral promoter LTR (Clontech; see also WO 03/14380). . *E. coli* DH5 α expressing the bacterial purine 10 nucleoside phosphorylase gene was injected at day 8 following tumor implantation with or without prodrug (6-methylpurine deoxyribose (6-MPDR)). Tumor volume was monitored at subsequent time points (as performed in previous examples).

Group	Administered
1	<i>E. coli</i> /PNP + prodrug
2	<i>E. coli</i> /PNP
3	<i>E. coli</i> control + prodrug

Groups 2 and 3 exhibited equal tumor growth over time points from 8 to 21 days 15 post tumor implantation. Group 1, which received both the *E. coli* expressing PNP and the prodrug exhibited ~20% reduction in tumor size as compared to the control Groups 2 and 3 at the end time points.

To further test bacterial colonization and prodrug effects on tumor growth, a human breast cancer model, GI-101A adencarcinoma in nude mice, was chosen. GI- 20 101A was derived from GI-101. GI-101 originated from a local first recurrence of an infiltrating duct adencarcinoma (stage IIIa, T3N2MX) in a 57 year old female patient by researchers at Rumbaugh-Goodwin Institute for Cancer Research. In the subcutaneous xenograft nude mice model, the tumor consistently metastasizes to the lungs. The GI-101A is a slower growing tumor model as compared to the C6 25 glioma tumor model.

-191-

Fifteen 4 week old female nude mice are each injected subsutaneously in the right lateral thigh with GI-101A cells. Thirty days after tumor development, bacteria are injected. *Escherichia coli* DH5 α is transformed with pSOD-DeoD or pSOD-DeoD-lux. The bacteria are grown overnight in LB media in the presence of 5 20 μ g/ml of chloramphenicol at 37°C. After overnight growth, the bacteria are counted at OD₆₀₀ and bacteria resuspended in BH1 media at the indicated density. The suspensions are injected intravenously with a 1-cc insulin syringe equipped with a 29 1/2 -gauge needle into the animal through a surgically exposed vein or as otherwise indicated. After the injections, the incisions are sutured.

10 Prodrug is administered to groups of mice every four days following injection of bacteria. Tumor growth is monitored twice per week using a digital caliper. Luciferase imaging is performed as described in the Examples herein. At the end point, the animal are sacrificed and organs are assayed as described in Example B. Histological analyses are performed to determine the degree of tumor 15 necrosis due to bacterial colonization and/or drug treatment.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-192-

What is claimed is:

1. A recombinant vaccinia virus, comprising a modified TK and HA gene and optionally a modified F3 gene or locus, wherein the resulting virus does not accumulate to toxic levels in non-targeted organs.

5 2. A recombinant vaccinia virus of claim 1, wherein (a) the F3 gene and (b) the TK gene and/or HA gene are modified.

3. The recombinant vaccinia virus of claim 1, wherein (a) the F3 gene and (b) the TK gene and/or HA gene are inactivated.

4. The recombinant vaccinia virus of claim 1 or 2, wherein at least the
10 F3 gene is inactivated by insertion of heterologous nucleic acid therein..

. 5. The recombinant vaccinia virus of claim 3, wherein the F3 gene and the TK gene are inactivated by insertion of heterologous nucleic acid.

6. The recombinant vaccinia virus of claim 1, wherein the vaccinia virus is a Lister strain.

15 7. The recombinant virus of claim 6, where the strain is the LIVP strain.

8.. The recombinant vaccinia virus of any of claims 1 to 7, wherein the modification of the F3 gene is at the NotI site within the F3 gene or a corresponding locus.

20 9. The recombinant vaccinia virus of claim 8, wherein the modification is at position 35 of the F3 gene or at position 1475 inside of the HindIII-F fragment of vaccinia virus DNA strain LIVP.

10. The recombinant vaccinia virus of any of claims 1 to 9, wherein the TK, HA and/or F3 gene comprises an insertion of heterologous nucleic acid that
25 encodes a protein.

11. The recombinant vaccinia virus of claim 9, wherein the heterologous nucleic acid comprises a regulatory sequence operatively linked to the nucleic acid encoding the protein.

30 12. The recombinant vaccinia virus of claim 11, wherein the regulatory sequence comprises the vaccinia virus early/late promoter p7.5.

-193-

13. The recombinant vaccinia virus of claim 11 or 12, wherein the regulatory sequence comprises an early/late vaccinia pE/L promotor.

14. The recombinant vaccinia virus of any of claims 10 to 13, wherein the heterologous nucleic acid encodes a detectable protein or a protein capable of inducing a detectable signal.

5 15.. A host cell containing a recombinant vaccinia virus of any of claims 1 to 14.

16. A tumor cell, comprising a recombinant vaccinia virus of any of claims 1 to 14.

10 17. A pharmaceutical composition containing a recombinant vaccinia virus of any of claims 1 to 14 in a pharmaceutically acceptable vehicle.

18. The pharmaceutical compositions of claim 17 that is formulated for systemic administration.

15 19. The pharmaceutical composition of claim 12 that is formulated for intravenous administration or is formulated in a delivery vehicle.

20 20. A method for eliminating immunoprivileged cells in an animal, comprising administering the pharmaceutical composition of claim 18 or claim 19 to an animal, whereby the virus accumulates in the immunoprivileged cells, thereby mediating autoimmunization resulting in elimination of the cells or a reduction in their number.

21. The method of claim 20, wherein the immunoprivileged cells comprise tumor cells.

22. The method of claim 20, wherein:
the pharmaceutical composition comprises a vaccinia virus of the Lister strain, w comprising a modified TK and HA gene and optionally a modified F3 gene or locus; and

the resulting virus does not accumulate to toxic levels in non-targeted organs

25 23. A therapeutic method for eliminating immunoprivileged cells or tissues, in an animal, comprising:

30 administering a microorganism to an animal, wherein:

-194-

the microorganism accumulates in the immunoprivileged cells;
the microorganism does not accumulate in unaffected organs and
tissues and has low toxicity in the animal;

5 the microorganism results in leakage of the cell membranes in the
immunoprivileged cells, whereby the animal produces autoantibodies against the
cells or products of the cells.

24. The method of claim 23, wherein the unaffected organs comprise the
ovaries or testes.

10 25. The method of claim 23 or claim 24, wherein the immunoprivileged
cells or tissues comprise tumor cells.

26. The method of any of claims 21-25, wherein the microorganism is an
attenuated bacterium, an attenuated virus or a mammalian cell.

27. The method of claim 26, wherein the microorganism comprises or
expresses a therapeutic product.

15 28. The method of claim 26 or 27, wherein the microorganism comprises
nucleic acid encoding a therapeutic product.

29. The method of any of claims 23-29, wherein the autoantibodies
comprise anti-tumor antibodies.

20 30. Use of a microorganism for formulation of a medicament for
eliminating immunoprivileged cells or tissues, in an animal, wherein:

the microorganism accumulates in the immunoprivileged cells;
the microorganism does not accumulate to toxic levels in organs and
tissues that do not comprise immunoprivileged cells or tissues.

25 31. Use of the pharmaceutical composition of claim 18 or 19 for
eliminating immunoprivileged cells or tissues.

32. A recombinant pox virus, comprising a modified TK and HA gene
and a modified F3 gene or locus that corresponds to the F3 gene in vaccinia.

33. Use of (a) a recombinant virus of any of claims 1 to 14 and 32 or
(b) a recombinant vaccinia virus having a modified F3 gene, TK gene or HA gene,

-195-

for the preparation of a pharmaceutical composition for gene therapy or vaccine therapy.

34. The use of claim 33, wherein the F3 gene, TK gene and/or HA gene are inactivated.

5 35. The use of claim 34, wherein the F3 gene, TK gene and/or HA gene are inactivated by insertion of heterologous nucleic acid.

36 The use of any one of claims 33 to 3, wherein the gene therapy is cancer gene therapy.

37. A method of producing a recombinant vaccinia virus of any one of 10 claims 1 to 14, comprising :

(a) generating (i) a vaccinia shuttle plasmid containing the modified F3 gene inserted at restriction site x and (ii) a dephosphorylated wt VV (VGL) DNA digested at a restriction site;

(b) transfecting host cells infected with psoralen -UV 15 (PUV)-inactivated helper VV (VGL) with a mixture of constructs (i) and (ii) of step a; and

(c) isolating the recombinant vaccinia viruses from the transfectants.

38. The method of claim 37, wherein the host cells are CV-1 cells.

39. A method for production of a polypeptide or RNA or compound, 20 comprising:

(a) administering a microorganism containing nucleic acid encoding the polypeptide or RNA or producing the product compound to tumor-bearing animal, wherein:

25 the microorganism accumulates in the immunoprivileged cells; and the microorganism does not accumulate to toxic levels in organs and tissues that do not comprise immunoprivileged cells or tissues;

(b) harvesting the tumor tissue from the the animal; and

(c) isolating the polypeptide or RNA or compound from the tumor

40. The method of claim 39, wherein the microorganism is a eukaryotic 30 cell, a prokaryotic cell or a virus.

-196-

41. The method of claim 39 or claim 40, wherein the microorganism is a cytoplasmic virus or an attenuated bacterium

42. The method of claim 41, wherein the bacterium is selected from among attenuated *vibrio*, *E. coli*, *lysteria*, salmonella and streptococcus strains.

5 43. The method of any of claims 39-43, wherein the animal is a non-human animal.

44. A method for simultaneously producing a polypeptide, RNA molecule or cellular compound and an antibody that specifically reacts with the polypeptide, RNA molecule or compound, comprising:

10 a) administering a microorganism to a tumor-bearing animal, wherein the microorganism expresses or produces the compound, polypeptide or RNA molecule; and

b) isolating the antibody from serum in the animal.

45. The method of claim 44, further comprising after step a)
15 harvesting the tumor tissue from the animal; and
isolating the polypeptide, RNA molecule or cellular compound from the tumor tissue.

46. The method of claim 44 or 45, wherein the animal is a non-human animal.

20 47.. The method of any of claims 44-46, wherein the microorganism is a bacterium mammalian cell or a virus.

48. The method of any of claims 44-47, wherein:
the microorganism accumulates in the immunoprivileged cells; and
25 the microorganism does not accumulate to toxic levels in organs and tissues that do not comprise immunoprivileged cells or tissues.

49. The method of any of claims 44-47, wherein the microorganism is a virus selected from among pox viruses, herpes viruses, adenoviruses and sindbis virus.

30 50. The method of any of claims 44-47, wherein the microorganism is a cytoplasmic virus.

-197-

51. The method of any of claims 44-47, wherein the microorganism is a eukaryotic cell.

52. The method of claim 41, wherein the cell is an immune cell.

53. The method of claim 52 wherein the cell is a stem cell.

5 54. The method of any of claims 39-53, wherein the microorganism comprises a DNA molecule that encodes a reporter gene construct.

55. The method of claim 54, wherein the reporter gene construct encodes a detectable protein or a protein that induces or produces a detectable signal..

10 56. The method of claim 55, wherein the protein is a luciferase or a fluorescent protein.

57. The method of claim 54, wherein the reporter gene construct encodes a bioluminescence generating system and optionally encodes a fluorescent protein.

58. The method of any of claims 39-57, wherein the microorganism is a mammalian cell.

15 59. The method of any of claims 39-57, wherein the microorganism is a bacterial cell.

60. The method of any of claims 39-57, wherein the microorganism is a virus.

61. The method of claims 60, wherein the virus is a vaccinia virus.

20 62. The method of claim 61, wherein the vaccinia virus is a LIVP strain.

63. The method of claim 59, whereint he bacterium is attenuated *Vibrio cholerae*.

64. The method of any of claims 39-63, wherein the tumor is a solid tumor..

25 65. A method for eliminating immunoprivileged cells or tissues in an animal, comprising:

administering at least two microorganisms, wherein the microorganisms are administered simultaneously, sequentially or intermittently, wherein the microorganisms accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues.

30

-198-

66. The method of claim 65, wherein the immunoprivileged cells or tissues comprises tumor cells.

67. Use of at least two microorganism for formulation of a medicament for elimination of immunoprivileged cells or tissues, wherein the accumulate in the
5 immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues.

68. The use of claim 67, wherein the immunoprivileged cells or tissues comprises tumor cells.

69. A combination, comprising at least two microorganisms formulated
10 for administration to an animal for elimination of immunoprivileged cells or tissues.

70. The combination of claim 69, wherein the immunoprivileged cells or tissues comprises tumor cells.

71. The combination of claim 69, wherein the microorganisms are formulated in separate compositions.

72. A kit comprising the combination of any of claims 69-71, wherein each composition is formulated and packaged for single dosage administration.

73. Use of a microorganism encoding heterologous nucleic acid for inducing autoimmunization against products produced in immunoprivileged cells, wherein, when administered, the microorganism accumulates in immunoprivileged tissues
20 and does not accumulate or accumulates at a sufficiently low level in other tissues or organs to be non-toxic to an animal containing the immunoprivileged tissues.

74. The use of claim 73, wherein the immunoprivileged tissue or cells comprise tumor cells.

75. The use of claim 74, wherein the products produced in the
25 immunoprivileged cells comprise tumor antigens.

76. The use of any of claims 73-75, wherein the microorganism is a eukaryotic cell, a bacterium or a virus.

77. The use of any of claims 73-75, wherein the microorganism is a mammalian cell.

-199-

78.. The use of any of claims 73-75, wherein the microorganism is an attenuated pox virus.

79. The use of any of claims 73-75, wherein the microorganism is a vaccinia virus.

5 80.. The use of claim 79, wherein the virus is a Lister strain.

81. The use of claim 80, wherein the virus is an LIVP strain.

82. The use of any of claims 79-81, wherein the virus contains an insertion in the F3 gene or a locus corresponding to the F3 locus of LIVP (SEQ ID No. 34).

10 83. A method for the production of antibodies against products produced in immunoprivileged tissues or cells comprising:

(a) administering a microorganism containing nucleic acid encoding a selected protein or RNA into an animal containing the immunoprivileged tissues or cells ; and

15 (b) isolating antibodies against the protein or RNA from the blood or serum of the animal.

84. The method of claim 83, wherein the animal is a non-human animal.

85.. The method of claim 83, wherein the animal is a human animal.

86. The method of any of claims 83-85, wherein the immunoprivileged 20 tissues or cells comprise tumor cells.

87. The method of any of claims 83-86 wherein the products produced in the immunoprivileged cells comprise tumor antigens.

88. The method of any of claims 83-87, wherein the microorganism is a eukaryotic cell, a bacterium or a virus.

25 89. The method of any of claims 83-87, wherein the microorganism is a mammalian cell.

90. The method of any of claims 83-87, wherein the microorganism is an attenuated cytoplasmic virus.

91. The method of any of claims 83-87, wherein the microorganism is an 30 attenuated pox virus.

-200-

92. The method of any of claims 83-87, wherein the microorganism is a vaccinia virus.

93. The method of claim 92, wherein the virus is a Lister strain.

94.. The method of claim 93, wherein the virus is an LIVP strain.

5 95. The method of any of ckauns 90-94, wherein the virus contains an insertion in the F3 gene or a locus corresponding to the F3 locus of LIVP (SEQ ID No. 34).

96. A method of inhibiting growth of immunoprivileged cells or tissue in a subject, comprising the steps of:

10 (a) administering to a subject a modified microorganism, wherein the modified microorganism encodes a detectable gene product;

(b) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and

15 (c) administering to a subject a therapeutic compound that works in conjunction with the microorganism to inhibit growth of immunoprivileged cells or tissue.

97. The method of claim 96, wherein growth of immunoprivileged cells or tissue is inhibited by inducing or enhancing an immune response against the 20 immunoprivileged cells.

98. The method of claim 96, wherein the therapeutic compound increases expression of one or more genes encoded by the microorganism that cause cell lysis or apoptosis.

25 99. The method of claim 96, wherein the therapeutic compound is a prodrug that is activated by a protein expressed by the microorganism.

100. A method of inhibiting growth of immunoprivileged cells or tissue in a subject, comprising the steps of:

(a) administering to a subject a modified microorganism that encodes a detectable gene product;

-201-

(b) administering to a subject a therapeutic substance that reduces the pathogenicity of the microorganism;

(c) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and

5 (d) terminating or suspending administration of the therapeutic compound, whereby the microorganism increases in pathogenicity and the growth of the immunoprivileged cells or tissue is inhibited.

101. The method of claim 100, wherein growth of immunoprivileged cells or tissue is inhibited by inducing or enhancing an immune response against the immunoprivileged cells.

102. The method of claim 100, wherein the therapeutic compound decreases expression of one or more genes encoded by the microorganism that cause cell lysis or apoptosis.

15




Figure 1A




Figure 1B




Figure 2

-1-

SEQUENCE LISTING

<110> Genenlux
Szalay, Aladar A.
Timiryasova, Tatyana
Yu, Yong A.
Zhang, Qian

<120> Microorganisms for Therapy

<130> 17248-002w01 (4802PC)

<140> Unassigned
<141>

<150> EP03013826.7
<151> 2003-06-18

<150> EP03018478.2
<151> 2003-08-14

<150> EP03024283.8
<151> 2003-10-22

<160> 36

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 148
<212> DNA
<213> Artificial Sequence

<220>
<223> LIVP F3

<400> 1
aatatagcaa cagtagttct tgctcctcct tgattcttagc atcctcttca ttattttctt 60
ctacgtacat aaacatgtcc aatacgtagt acaacacacc gacgatggcg gccgctacag 120
acacgaatat gactaaaccg atgaccat 148

<210> 2
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> Translation LIVP F3

<400> 2
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu

-2-

35

40

45

Tyr

<210> 3
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer

<400> 3
gggaattctt atacatcctg ttctata

27

<210> 4
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer

<400> 4
ccaagttat gaggagtatt gcggggctac

30

<210> 5
<211> 7252
<212> DNA
<213> Artificial Sequence

<220>
<223> psc65

<300>
<308> GenBank No. AX003206
<309> 2000-08-24

<400> 5
agctttgcg atcaataaat ggatcacaac cagtatctct taacgatgtt ctgcagat 60
gatgattcat ttttaagta ttggctagt caagatgtg aaatcttcattat tatctgat 120
attgcaaatc actcaatatc tagactttctt gttatttatta ttgatccaaat caaaaataaa 180
attagaagcc gtgggtcatt gtatgaatc tcttcagag gaatacagac attgacaaa 240
attcacagac tttcaagatt ttaaaaaactt gtttacaag gtccctatttgc ttacagatgg 300
aagggtcaaa cttataaaag gatatttgtt cgactttgtt attagttga ~~tccatcgat~~ 360
aaaagaatcc tctctagcta ccaccgcaat agatcctgtt agatacatgg ~~ccctcgcc~~ 420
caatatcgca ttttctaaccg tgatggatat attaaagtgc aataaaagtga acaataatta 480
attctttattt gtcatcatga acggcggaca tattcagtttgc ataatcgccc ccatgttttc 540
aggtaaaagt acagaattaa ttagacgagt tagacgttat caaatagctc aatataaattg 600
cgtgactata aaatattcta acgataatag atacggAACG ggactatggc cgcatgataa 660
gaataattttt gaagcattgg aagcaactaa actatgttat cttttggat caattacaga 720
tttctccgtt ataggtatcg atgaaggaca gttttccat gacattgttgc aatttagatcg 780
ataaaaaatttta attaatttacc cgggttaccag gccttagatct gtcgacttcg agtttattta 840
tattccaaaa aaaaaaaaaataa aatttcaat ttttaagctt tcactaattc caaacccacc 900

cgcttttat agtaagttt tcaccataa ataataaata caataattaa tttctcgtaa 960
aagtaaaaa tatattctaa ttattgcac ggtttaggaag tagatcataa ctcgagcatg 1020
ggagatccc tcgtttaca acgtcgac tggaaaacc ctggcggtac ccaacttaat 1080
cgcccttcag cacatcccc ttcgcccagc tggcgtaata gcgaagaggc cgcaccat 1140
cgcccttc aacagttgcg cagctgaat ggcgaatggc gcttgcctg gtttccggca 1200
ccagaagcg tgccgaaag ctggctggag tgcgcatttc ctgaggccga tactgtcg 1260
gtccctcaa actggcagat gcacggtac gatgcgccca tctacaccaa cgtaacctat 1320
cccattacgg tcaatccgccc gtttgttccc acggagaatc cgacgggttg ttactcgctc 1380
acatttaatg ttgatgaaag ctggctacag gaaggccaga cgcaattat ttttgcattgc 1440
gttaactcg cgittcatct gtggcaac gggcgctgg tcgggtacgg ccaggacagt 1500
cgttggcgt ctgaatttga cctgagcgca ttttacgcg ccggagaaaa ccgcctcg 1560
gtgatggtgc tgcgtggag tgacggcagt tatctggaa atoaggat atgtggatgc 1620
agcggcattt tccgtgacgt ctcgttgcg catgttgcctt ctttacgcg ccggagaaaa 1680
catgttgcctt ctcgctttaa tgatgattt acggcgttgcg ttttacgcg ccggagaaaa 1740
atgtgcggcg agttgcgtga ctacacacgg gtaacagtt ctttacgcg ccggagaaaa 1800
caggtcgcca gcccggacccgc gccttcggc ggtgaaatata tcgatgagcg tgggtgttat 1860
gccgatcgcg tcacactacg tctcaacgtc gaaaaccgcg aactgtggag cgccgaaatc 1920
ccgaatctct atcgtgggtt ggttgaactg cacaccggcg acggcacgct gattgaagca 1980
gaagcctcg gatgtgggtt ccggagggcg cggttgcgat atggatgcg tgcgtcgtac 2040
ggcaaggcgt tgctgatcc aggggttaac ctttacgcg ttttacgcg ccggagaaaa 2100
gtcatggatg agcagacgat ggtcggaggat ctttacgcg ttttacgcg ccggagaaaa 2160
gccgtgcgt gttcgattt tccgaaccat gaaacccacg gcatggtgcc aatgaatcgt 2220
ggcctgtatg tgggtggatga agccaatatt atcgttgcg ttttacgcg ccggagaaaa 2280
ctgaccgatg atccgcgtc gctaccggcg atcgttgcg ttttacgcg ccggagaaaa 2340
cgcgatcgta atcaccggcg tggatcatc ttttacgcg ttttacgcg ccggagaaaa 2400
gctaatacag aecgcgtgtc tgcgtggatc ttttacgcg ttttacgcg ccggagaaaa 2460
tatgaaggcg gcccggccga caccacggcc ttttacgcg ttttacgcg ccggagaaaa 2520
gtggatgaaag accagccctt cccggctgtc ttttacgcg ttttacgcg ccggagaaaa 2580
ctacctggag agacgcgcgc gctgatccct ttttacgcg ttttacgcg ccggagaaaa 2640
cttggcggtt tcgctaaata ctggcaggcg ttttacgcg ttttacgcg ccggagaaaa 2700
ttcgtctggg actgggtgga tcagtcgtc ttttacgcg ttttacgcg ccggagaaaa 2760
tcggcttacg ggggtgatt tggcgatcgc ttttacgcg ttttacgcg ccggagaaaa 2820
ctggcttttgc cccggccgcac gccgcatttca ttttacgcg ttttacgcg ccggagaaaa 2880
ttttccagt tccgtttatc cggggaaacc atcgttgcg ttttacgcg ccggagaaaa 2940
catagcgata acgagctcttgc gcaactggatg gtttacgcg ttttacgcg ccggagaaaa 3000
ggtaagtgc ctctggatgt cgctccacaa ttttacgcg ttttacgcg ccggagaaaa 3060
ccgcaggccgg agagcgcggc gcaactctgg ttttacgcg ttttacgcg ccggagaaaa 3120
accgcgttgtt cagaagccgg gcacatcgc gtttacgcg ttttacgcg ccggagaaaa 3180
ctcagtgtga cgctccccgc cgctggccac gtttacgcg ttttacgcg ccggagaaaa 3240
gattttgca tggatgtggg taataagcgt ttttacgcg ttttacgcg ccggagaaaa 3300
tcacagatgt ggattggcga taaaaaacaa ttttacgcg ttttacgcg ccggagaaaa 3360
cgtgcaccgc tggataacga cattggcgta ttttacgcg ttttacgcg ccggagaaaa 3420
tgggtcgaac gtttacgcg ggcggccat ttttacgcg ttttacgcg ccggagaaaa 3480
acggcagata cacttgcgtc tgggtgtcg ttttacgcg ttttacgcg ccggagaaaa 3540
gggaaaacctt tattttatcag cccggaaacc ttttacgcg ttttacgcg ccggagaaaa 3600
attaccgtt atgttgaagt ggcgagcgat ttttacgcg ttttacgcg ccggagaaaa 3660
tgccagctgg cgccaggtagc agagcgggtt ttttacgcg ttttacgcg ccggagaaaa 3720
tatcccggacc gcttactgc cgcttgcgtt ttttacgcg ttttacgcg ccggagaaaa 3780
tataccccgt acgtcttccc gagcgaaaac gtttacgcg ttttacgcg ccggagaaaa 3840
tatggccac accgtggcg cggcgacttc ttttacgcg ttttacgcg ccggagaaaa 3900
caactgatgg aaaccagcca tggccatctg ttttacgcg ttttacgcg ccggagaaaa 3960
atcgacggtt tccatatggg gattgggtggc gtttacgcg ttttacgcg ccggagaaaa 4020
gaatttgcgtt gggccgggt cgttaccatt ttttacgcg ttttacgcg ccggagaaaa 4080
aaccggcag gggggatct tctgtgagcg ttttacgcg ttttacgcg ccggagaaaa 4140
agccgcactc gatgggacat ttcaacgtaa ttttacgcg ttttacgcg ccggagaaaa 4200

-4-

attatctgaa atgggtgtaa aactaactgc tgtgtgtatg aaatgcttta aggaggcttc 4260
 ctttctaaa cgattgggtg agggaaaccga gatagaaaata ataggaggtt atgatatgtt 4320
 tcaatcggtg ttagaaagt gttacatcga ctcataatata tatattttt atctaaaaaaa 4380
 ctaaaaataa acattgatta aattttataa taataacttaa aaatggatgt tgggtcgta 4440
 gataaacccgt ttatgttatt tgaggaaatt gataatgagt tagattacga accagaaaagt 4500
 gcaaatgagg tcgaaaaaaaa actgcccgtat caaggacagt taaaactatt actaggagaa 4560
 ttatttttc ttagtaagtt acagcgacac ggtatattag atgggtccac cgtatgttat 4620
 atagatctg ctccccgtac acatatacgt tatttgagag atcatttcta taatttagga 4680
 gtgatcatca aatggatgtt aattgacggc cgccatcatg atccttattt aaatggattt 4740
 cgtgatgtga ctctagtgac tcgggtcggt gatgaggaat atctacgatc catcaaaaaaa 4800
 caactgcac tttctaaagat tattttaaatt tctgtatgtt gatccaaacg aggagggaaat 4860
 gaaccttagt cggcggattt actaagtaat tacgtctac aaaaatgtcat gattgtattt 4920
 ttaaaccctcg tggcgtctag tcttaaatgg agatgcccgt ttccagatca atggatcaag 4980
 gactttata tcccacacgg taataaaaatg ttacaacatt ttgtctctt atattcagct 5040
 gaaatgagat tattaagttt ttataccggt gagaacatgtt gactgactcg ggccgcgttg 5100
 ctggcggttt tccataggct ccggccccctt gacgagcatc acaaaaaatcg acgtcaagt 5160
 cagaggtggc gaaaccggac agactataa agataaccagg cgtttccccc tggaaagctcc 5220
 ctcgtgcgtc ctccgttcc gaccctgccc ttaccggat acctgtccgc ctttctccct 5280
 tcgggaagcg tggcgcttcc tcaatgtctca cgctgttaggt atctcagttc ggtttaggtc 5340
 gttcgtctca agctgggctg tggcgtacggc ccccccgttc agcccgaccg ctgcgcctta 5400
 tccggtaact atcgtcttgc gtccaaaccgg gtaagacacg acttacgtcc actggcagca 5460
 gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gtttttgaag 5520
 tggtggccta actacgctt cactagaagg acagtatttgc gtatctgcgc tctgctgaag 5580
 ccagttacct tcggaaaaag agttggtagc tcttgcgttcc gcaaacaac caccgcttgt 5640
 agcgggtggtt tttttgttgc caagcagcag attacgcgcgaa gaaaaaaagg atctcaagaa 5700
 gatccttgc tcttttctac ggggtctgac gtcagtggaa acgaaaaactc acgttaagg 5760
 attttggtca tgagattatc aaaaaggatc ttcacctaga tcctttttaaatgaa 5820
 agttttaaat caatctaaag tatatatgtt taaacttggt ctgacagttt ccaatgctta 5880
 atcagtgagg cacctatctc agcgatctgt ctatttgcgtt catccatagt tgcctgactc 5940
 cccgtcggt agataactac gatacgggg ggcatttccat ctggccccc tgcgtcaatg 6000
 ataccgcgag acccacgctc accggctcca gatttatcgtt caataaaacca gccagccgga 6060
 agggccgagc gcagaagtgg tcctgcaact ttatccgcctt ccattccagtc tattatgtt 6120
 tgccggaaag cttagacttgc tagttcgcca gttaatagtt tgcgtcaacgt tggccatt 6180
 gctgcaggca tcgtgggtc acgctcggt tttggatgg ctgcatttcgtt ctcgggttcc 6240
 caacgatcaa ggcgaggatc atgatcccccc atgttgcgtt aaaaaggcggt tagctccttc 6300
 ggtcctccga tcgttgcgtt aagtaagtgg ggcgcgtgtt tatttttttttgcgtcaatg 6360
 gcactgcata attcttttac tgcgtatgcctt tccgttgcgtt gcttttgcgtt gactgggtgag 6420
 tactcaacca agtcatctgc agaataatgtt atgcggcgac cgagttgtc ttgcggggcg 6480
 tcaacacggg ataataccgc gcccacatagc agaactttaa aagtgcgtt cattggaaaaa 6540
 cgttcttcgg ggcgaaaact ctcaaggatc ttaccgtgtt tgagatccat ttcgtatgtt 6600
 cccactcggt cacccaaactg atcttcgttcc tcttttttttgcgtcaatg 6660
 gcaaaaacag gaaggcaaaa tgccgcacaaa aaggaaataa gggcgacacg gaaatgttga 6720
 atactcatac tcttcctttt tcaatattat tgaagcattt atcagggttta ttgtctcatg 6780
 agcgatatac tatttgcgtt tatttttttttgcgtcaatg 6840
 ccccgaaaag tgccacctga cgtctaaagaa accatttattt tcatgcattt aacctataaa 6900
 aataggcgta tcacgaggcc ctttcgttcc cgaataaaata cctgtgacgg aagatcaattt 6960
 cgcagaataa ataaatcctg gtgtccctgt tgataccggg aagccctggg ccaacttttgc 7020
 gcgaaaatga gacgttgcgtt ggcacgttac aggttccac tttcaccata atgaaataa 7080
 atcactaccg ggcgttattttt tggatgttac gatattttca ggagcttacgg aagctaaaat 7140
 ggagaaaaaaa atcactggat ataccaccgt tggatatacc caatggcatc gtaaagaaca 7200
 ttttgcgttcc tttcgttccatg tttcaccata cagaccgttc ag 7252

<210> 6

<211> 28

<212> DNA

-5-

<213> Artificial Sequence

<220>

<223> Primer pUC28 I

<400> 6

aattcagatc tccatggatc gatgagct

28

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer pUC28 II

<400> 7

catcgatcca tggagatctg

20

<210> 8

<211> 1665

<212> DNA

<213> Artificial Sequence

<220>

<223> Renilla luciferase-Aequorea GFP fusion gene

<400> 8

atgacttcga aagtttatga tccagaacaa aggaaacgga tgataactgg tccgcagtgg 60
tgggccagat gtaaacaaat gaatgttctt gattcattta ttaattatta tgattcagaa 120
aaacatgcag aaaatgttgt tatTTTTTA catggtaacg cggcctcttc ttatttatgg 180
cgacatgttg tgccacatat ttagccagta gcgcgggtgtt ttataccaga tcttatttgg 240
atggcAAAT caggcaatc tggtaatggt tcttataggT tacttgatca ttacAAAT 300
cttactgcat ggTTGAact tcttaatttA ccaaAGAAAG tcattttgt cgccatgtat 360
tggggtgctt gttggcatt tcattatAGC tatgagcatc aagataAGAT caaAGCAATA 420
gttcacgctg aaagtgtAGT agatgtgatt gaatcatggg atgaatGCC tgatattgaa 480
gaagatATTG cgTTGATCAA atctGAAGAA ggAGAAAAAA tggttttggA gaataACTTC 540
ttcgtggAAA ccatgttgCC atcaAAATC atgAGAAAGT tagAACCAAGA agaATTtgca 600
gcatatcttG aaccatCAA agacAAAGGT gaagttcgTC gtccAAACATT atcatGGCCT 660
cgtgAAATCC cgTTAGTAAA aggtggtaAA cctgacgttg tacaAAATTG tagGAATTAT 720
aatgcttAtc tacgtgcaAG tGATGATTtA ccaAAATGt ttatGAAAtC ggatCCAGGA 780
ttctttCCA atgctattgt tgaaggcGCC aagaGTTtC ctaataCTGA atttGtCAA 840
gtaaaAGGTC ttcatttttC gcaAGAAAGt gcacCTgtG aaatGGAAA atatAtCAA 900
tcgttcgttg agcgaggTct caaaaAtgAA caAGCGGCCG caccGCatAT gagtaAAAGGA 960
gaagaACTtT tcactggAGT tGtCCCAAtt ctGttGAat tagatGGtGA tGtTAAtGGG 1020
cacAAAtttt ctgtcaGtgg agagggtgAA ggtgtatgAA catacggAAA acttAccCtt 1080
aaatttAtttt gcactactgg AAAActACt GTTCCatGGC caacactgt cactactttc 1140
tcttAtggtg ttcaatgtt ttcaAGAtAC ccAGAtCAtA tGAAACAGCA tgacttttC 1200
aagagtGCCA tggccGAAGG ttatgtACAG gaaAGAAActA tAttttCaa agatgacGGG 1260
aactacaAGA cacgtgctGA agtcaAGtT gaaggtgata cccttGtAA tagatCAGAG 1320
ttaaaaAGGtA ttgattttAA agaAGAtGGA aacatttCtG gacacaAAAtt ggaAtacaAC 1380
tataactcAc acaatgtata catcatggCA gacaAAACAA AgaAtGGAAt caaAGttaAC 1440
ttcaAAAttA gacacaACat tgaAGAtGGA agcgttcaAC tagcAGACCA ttatcaACAA 1500
aatactccAA ttggcgatgg ccctgtcCtt ttaccAGACA accattACt gtcCACACAA 1560
tctgcccTTT cgAAAGAtCC caacgAAAAG agagACCACa tggtcCttCt tgagtTTGtA 1620

-6-

cagtcgggtgg tccggcagta caatggattt cttacgcga aatacggca gacatggct 2700
gcccggttat tattatttt gacaccagac caactggtaa tggtagcgac cggcgctcag 2760
ctggaaattcc gccgatactg acgggctcca ggagtgcgtcg ccaccaatcc ccatatggaa 2820
accgtcgata ttcaaggccatg tgcccttcttc cgctgtcagc agatggcgat ggctggttc 2880
catcagggtgc tggtgactgt agcggctgat gttgaactgg aagtgcgcg gccactggtg 2940
tggggccataa ttcaattcgc gcgtccccca ggcggcggaccg ttttcgtcgg ggaaggacgta 3000
cggggtatac atgtctgaca atggcagatc ccagcggtca aaacaggcgg cagtaaggcg 3060
gtcgggatag ttttcttgcg gccctaattcc gagccagttt acccgctctg ctaccctgcgc 3120
cagctggcag ttcaaggccaa tccggccgg atgcgggtga tcgctgcgca cttcaacatc 3180
aacggtaatc gccatttgcac cactaccatc aatccggtagt gttttccggc tgataaataa 3240
ggttttcccc tgatgctgcc acgcoctgagc ggtcgtaatc agcaccgcatt cagcaagtgt 3300
atctgcgtg cactgcaaca acgtgcgttc ggcctggtaa tggcccgccg cttccagcg 3360
ttcgaaccag gcgttagggt caatgcgggt cgcttcaattt acgccaatgt cgttatccag 3420
cggtgcacgg gtgaactgat cgcgcagcgg cgtcagcagt ttttttttat cgccaatcca 3480
catctgtgaa agaaaggctt actggcggtt aaattgcca cgttattac ccagctcgat 3540
gcaaaaatcc atttcgttgg tggtagatc cgggatggcg tgggacgcgg cggggagcgt 3600
cacactgagg tttccgcca gacgcccactg ctgcccaggcg ctgatgtgccc cggcttctga 3660
ccatgcggtc gcgttcgggtt gcactacgcg tactgtgagc cagagttgcc cggcgctc 3720
cggtcggtt agttcaggca gttcaatcaa ctgtttaccc ttttttttgcg catccagagg 3780
cacttcaccg cttgccagcg gcttaccatc cagcgccacc atccagtgcg ggagctcggt 3840
atcgctatga cggAACAGGTt attcgctggt cacttccatg gtttgcggg ataaacggaa 3900
ctggaaaaac tgctgttgggtt gtttgcgtt cgtcagcgtt ggatgcggcg tgcggcggc 3960
aaagaccaga CCGTTTACATC agaactggcg atcggttgcgtt gtatgcggca aatcaccgc 4020
gtaaaggccac Cacgggttgc cgttttcatc atatttaatc agcgactgtat ccacccagtc 4080
ccagacgaaag CCGCCCTGTA aacggggata ctgacgaaac gcctgcggat atttagcgaa 4140
accgccaaga ctgttaccca tcgcgtgggc gtattcgaa aggttcaggcg ggcggctc 4200
tccaggttagc gaaagccatt ttttgcgtt ccatttcggc acagccggga agggtggc 4260
ttcatccacg cgcgcgtaca tcgggcaaat aatatcggtg gccgtgggtt cggctccgc 4320
gccttcatac tgcaccgggc gggaaaggatc gacagatttgc atccagcgat acagcgcgtc 4380
gtgatttagcg CCGTGGCCTG attcattccc cagcgaccatc atgatcacac tcgggtgatt 4440
acgatcgccgc tgcaccatc gcgttacgcg ttcgttcattc gccggtagcc agcgcggatc 4500
atcggtcaga cgatttatttgcgatc gtcgggttca atattgggtt catccaccac 4560
atacaggccg tagcggtcgc acagcgtgttccacagcgatccatc aatgcgaaca 4620
gcgcacggcg ttaaaagtgt tctgtttcat cagcaggata tcctgcacca tcgtctgtc 4680
atccatgacc tgaccatgca gaggatgtatc ctcgtacgg ttaacgcgttca gaatcagcaa 4740
cggttgcgcg ttcagcggca gcaagaccatttcaatccgc acctcgccgaa aaccgacatc 4800
gcaggcttct gcttcaatca gcgtggcgtc ggcgggtgtc agttcaacca ccgcacgata 4860
gagattcggg atttcggtgc tccacagttt cgggttttcgc acgttcagac gtatgtgac 4920
gcgatcgccgta taaccaccac gtcatcgat aatttcaccg ccgaaaggcg cgggtccgc 4980
ggcggacctgc gtttacccct gccataaaga aactgttacc cgttaggtatc cacgcaactc 5040
gccgcacatc tgaacttcag cttccagtac agcgcggctg aaatcatcat taaagcgagt 5100
ggcaacatgg aaatcgctga ttgtgtatc cgggttatgc agcaacgaga cgtcacggaa 5160
aatccgcctc atccgcaca tatcctgtatc ttccagatata ctgcgcgtc ac tccagcgc 5220
caccatcacc gcgaggccgt tttctccggc gctaaaaat ggcgtcaggat caaattcaga 5280
cgccaaacga ctgtccctggc cgttaaccgc acagcgcggccg ttgcaccacca gatgaaacgc 5340
cgagtttaacg ccatcaaaaa taattcggtt ctggccttcc tttcatcaac 5400
attaaatgtg agcgagtaac aacccgtcg attctccgtg ggaacaaacg gcggttgc 5460
cgtaatggga taggtcacgt tggtgtatc gggcgcatcg taaccgtgc tctgcccagg 5520
tgaggggacg acgacagtat cggcctcagg aagatcgac tccagccagc ttccggc 5580
cgcttcgtgt gccggaaacc aggcaaaacg ccattcgcca ttccaggctgc gcaactgtt 5640
ggaaggccga tcgggtccggg cctcttcgtt attacgcgcg ctggcgaaag gggatgtgc 5700
tgcaaggccg ttaagtcggg aaacctgtcg tgccagctgc attaaatgtatc cggccaaacgc 5760
gcggggagag gcggttgcg tattggccgc cagggtgggtt ttctttca ccagtggac 5820
ggcaacacgc caagctccgg atccgggctt ggcaagctt ggaattccgc acttttcggc 5880
caatggtctt ggttaattcct ttgcgttgcgatca attgaactca ggtacaatca cttcttctga 5940

atgagattta gtcattatag tttttctcc ttgacgttaa agtatacagg tatattaaca 6000
 atttttgtt gatacttta ttacatttga ataagaagta atacaaacg aaaatgttga 6060
 aagtattatg taaagtgggt atgcagttt tgcatttata tatctgttaa tagatcaaaa 6120
 atcatcgctt cgctgattaa ttaccccaga aataaggcta aaaaactaat cgcattatca 6180
 tcccctcgac gtactgtaca tataaccact ggtttatat acagcagtac tgtacatata 6240
 accactgggtt ttatatacag cagtcgacgt actgtacata taaccactgg ttttatac 6300
 agcagtaactg gacatataac cactggttt atatacagca gtcgaggtaa gattagatat 6360
 ggatatgtat atggatatgt atatgggtt aatgcacatgt aatatgatta ttaaacttct 6420
 ttgcgtccat caaaaaaaaa agtaagaatt tttgaaaatt caatataaat gacagcttag 6480
 ttacaaaatgt aaagtacttc taaaattgtt ttgggtacag gtgggtctgg atacattgg 6540
 tcacacactg tggttagagct aattgagaat ggatatgact gtgtgttgc tgataacctg 6600
 tcgaattcca agctcgatc cccgagctcg gatcccccta agaaaccatt attatcatga 6660
 cattaaccta taaaaatagg cgatcacga ggccttcg tctcgccgt ttcggtgatg 6720
 acggtaaaaa cctctgacac atgcagctcc cggagacggt cacagcttg ctgtaaagg 6780
 atgcccggag cagacaagcc cgtcaggccg cgtcagccgg tggtggccgg tgtcggggct 6840
 ggcttaacta tgcggcatca gagcagattt tactgagatg gcaccataac gcatttaagc 6900
 ataaacacgc actatgccgt tcttctcatg tatatatata tacaggcaac acgcagatata 6960
 aggtgcgacg tgaacagtga gctgtatgtg cgcagctgc gttgcattt cggaaaggcgt 7020
 cgtttccgaa aacgcttta agttccattt ccgaagttcc tattcttag ctggaaatgt 7080
 taggaacttc agagcgctt tggaaaccaa aagcgtctcg aagacgcact ttcaaaaaaac 7140
 caaaaaaaaa cccgactgtt acgagctact aaaaatattgc gaataccgt tccacaaaaca 7200
 ttgctcaaaa gtatctctt gctatataatc tctgtctat atccctatata aactaccca 7260
 tccaccttcc gctccttggaa ctgcacatcta aactcgacct ctacatttt tatgtttatc 7320
 tcttagtata ctcttttagac aaaaaattt tagtaagaac tattcataga gtgaatcgaa 7380
 aacaatacga aaatgtaaaatc atttcctata cgtatataat agagacaaaa tagaagaaac 7440
 cgttcataat tttctgacca atgaagaatc atcaacgcta tcacatttcg ttacacaaagt 7500
 atgcgaatc cacatcgta tagaatataa tcggggatgc ctttatcttggggaaatgca 7560
 ccccgagtt cgcttagaat cagtaaacgc gggaaatggg gtcaggctt tttatggaa 7620
 gagaaaaatag acacccaaatg agcccttctt taaccttaac ggacccatcag tgccaaaaagt 7680
 tatcaagaga ctgcattata gagcgcacaa aggaaaaaa aagtaatcta agatgctttg 7740
 ttagaaaaat agcgctctcg ggatgcattt ttgttagaaca aaaaagaatg atagattctt 7800
 tggggtaaa atagcgctctcg cgctgtgcattt ttctgttctg taaaaatgc gctcagattc 7860
 tttgtttgaa aaattagcgc tctcgcttgc cattttgtt ttacaaaaat gaagcacaga 7920
 ttcttcgttg gtaaaaatgc gcttcgttgt tgcatcttcg ttctgtaaaa atgcagctca 7980
 gattttttgtt ttgaaaaattt agcgctctcg cgttgcattt ttgttctaca aatgaagca 8040
 cagatgcttc gttgctccg tggaaagaa cgttacaaac aggtgttgc ctctgaggac 8100
 ataaaaataca caccgagatt catcaactca ttgctggagt tagcatatct acaattcaga 8160
 agaactcgac aagaaggcga tagaaggcga tgcgtgcga atcgggagcg gcgataccgt 8220
 aaagcagcgg gaagcgggtca gcccattcgc cgccaaatgc ttcaagcaata tcacgggtag 8280
 ccaacgctat gtcctgatag cggtccgcga caccacggc gccacagtgc atgaatccag 8340
 aaaagcggcc attttccacc atgatattcg gcaagcaggc atgccttgc gtcacgacga 8400
 gatccctcgcc gtcgggcatttgc ctgccttgc gcctggcgaa cagttccgct ggccggagcc 8460
 cctgatgctc ttctgtccaga tcattctgtat cgacaaagacc ggcttccatc cgagtacgtg 8520
 ctcgctcgat gcgatgtttc gcttgggtgtt cgaatggggca ggtagccgga tcaagcgtat 8580
 gcaagccggc cattgcattca gccatgtatgg atactttctc ggcaggagca agtgagatg 8640
 acaggagatc ctgccccggc acttcgcccata gacgcggc acctgcgtgc aatccatctt 8700
 caacgtcgag cacagctgcg caagggaaacgc cggcgtggc cagccacgat agccgcgtg 8760
 cctcgatcttgc cagttcattt agggcaccgg acaggtcggt tttgacaaaaa agaaccgggc 8820
 gcccctgcgc tgacagccgg aacacggcgg catcagagca gccgattgtc tttgtgccc 8880
 agtcatagcc gaatagcctc tccacccaag cggccggaga acctgcgtgc aatccatctt 8940
 gttaatcat gcgaaaacgt cctcatctcg tcttgcattt agagcttgcattt cccctgcgc 9000
 atcagatctt tggccggcaag aaagccatcc agtttactttt gcagggttc ccaaccttac 9060
 cagagggcgc cccagctggc aattccgggtt cgcttgcgtt ccataaaaacc gcccagtcta 9120
 gctatcgcca tgtaagccca ctgcacatca cctgcatttctt ctttgcgtt ggttttccc 9180
 ttgtccagat agcccaatgt ctgcacattca tccggggatca gcaccgttgc tgccggactgg 9240

-9-

```

ctttctacgt gaaaaggatc taggtgaaga tccttttga taatctcatg accaaaaatcc 9300
cttaacgtga gttttcggttc cactgagcgt cagaccccggt agaaaagatc aaaggatctt 9360
cttgagatcc ttttttctg cgcgtaatct gctgcttgc aaaaaaaaaa ccaccgctac 9420
cagcgggtggt ttgtttggcg gatcaagagc taccacttct tttccgaag gtaactggct 9480
tcagcagagc gcagatacca aatactgttc ttctagtgtt gccgtagttt ggcaccact 9540
tcaagaactc tgttagcaccc cctacatacc tcgcctctgtt aatcctgtt ccagtggctg 9600
ctgcgcgtgg cgataagtgc tgtcttaccg ggttggactc aagacgatag ttaccggata 9660
aggcgagcg gtcgggtga acgggggggtt cgtgcacaca gcccagctt gagcgaacga 9720
cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaaag 9780
ggagaaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgacgagg 9840
agctccagg gggaaacgcc tggttatctt atagtcctgt cgggttgc cacctctgac 9900
ttgagcgtcg atttttgtga tgctcgctcag gggggcggag cctatggaaa aacgccagca 9960
acgcggcctt ttacggttc ctggccttt gctggccttt tgctcacatg atataattca 10020
attgaagctc taatttgtga gtttagtata catgcatttta ttataatac agtttttag 10080
ttttgtggc cgcacatcttcaaataatgt tcccagcctg ctttctgtt acgttcaccc 10140
tctaccttag catcccttcc ctttgcaaat agtcctcttca caacaataat aatgtcagat 10200
cctgttagaga ccacatcatc cacggttcta tactgttgc ccaatgcgtc tcccttgtca 10260
tctaaaccca caccgggtgt cataatcaac caatcgtaac ttcatcttccatg 10320
tctctttag gataaaagcc gataacaaaaa tcttgcgc tcttgcata gtcacacagta 10380
cccttagtat attctccagt agatagggag cccttgcattt acaattctgc taacatcaaa 10440
aggcctctag gttccttgt tacttcttct gccgcctgtt tcaaaccgct aacaataacct 10500
gggcccacca caccgtgtgc attcgtaatg tctgcccatt ctgctattct gtatacaccc 10560
gcagagtaact gcaatttgac tgattacca atgtcagcaaa atttctgtc ttcaagagat 10620
aaaaaattgt acttggcga taatgcctt agcgccttaa ctgtgcctc catggaaaaaa 10680
tcagtcaaga tatccacatg tgtttttagt aaacaaattt tgggacctaa tgcttcaact 10740
aactccagta attccttggt ggtacgaaca tccaatgaag cacacaagtt tggttgctt 10800
tcgtgcatga tattaaatag ctggcagca acagactag gatgagtagc agcacgttcc 10860
ttatatgttag ctttcgacat gatttatctt cgtttgcatt aggttttgc tctgtgcagt 10920
tgggttaaga atactggcga atttcatgtt tcttcaacac tacatatgcg tatataacc 10980
aatctaagtc tgtgctccctt cttcggttct tccttctgtt cggagattac cgaatcaaaa 11040
aaatttcaag gaaaccgaaa tcaaaaaaaaaa gaataaaaaaa aaaatgatga attgaa 11096

```

<210> 10
<211> 150
<212> DNA
<213> Vaccinia Virus/LIVP

<300>
<308> GenBank No. M57977
<309> 2000-04-14

<400> 10
atggtcatcg gtttagtcat attcggtctt gtggcggccg ccatcggtgg tgggttgc 60
aacgtattgg acatgcttat gtacgtagaa gaaaataatg aagaggatgc tagaatcaag 120
gaggagcaag aactactgtt gctatattga 150

<210> 11
<211> 49
<212> PRT
<213> Vaccinia Virus/LIVP

<300>
<308> GenBank No. AAA48282
<309> 2000-04-14

-10-

<400> 11
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 12
<211> 150
<212> DNA
<213> Vaccinia Virus/WR

<300>
<308> GenBank No. AY243312
<309> 2003-04-10

<400> 12
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcattccctttt cattattttc 60
ttctacgtac ataagcatgt ccaatacggtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat 150

<210> 13
<211> 49
<212> PRT
<213> Vaccinia Virus/WR

<400> 13
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 14
<211> 150
<212> DNA
<213> Vaccinia Virus/Ankara

<300>
<308> GenBank No. U94848.1
<309> 2003-04-14

<400> 14
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcattccctttt cattattttc 60
ttctacgtac ataaacatgt ccaatacggtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactaac cgatgaccat 150

-11-

<210> 15
<211> 49
<212> PRT
<213> Vaccinia Virus/Ankara

<400> 15
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 16
<211> 146
<212> DNA
<213> Vaccinia Virus/Tian Tan

<300>
<308> GenBank No. AF095689
<309> 2000-02-14

<400> 16
caatatagca acagtagttc ttgctcctcc ttgattctag catcctcttc attatttct 60
tctacgtaca taaacatgtc caatacgtta gacaacacac cgacgatggc cggcacagac 120
acgaatatga ctagaccgat gaccat 146

<210> 17
<211> 48
<212> PRT
<213> Vaccinia Virus/Tian Tan

<400> 17
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ile Val Gly
1 5 10 15
Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn Asn
20 25 30
Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Tyr
35 40 45

<210> 18
<211> 150
<212> DNA
<213> Vaccinia Virus/Acambis 3000 MVA

<300>
<308> GenBank No. AY603355
<309> 2004-05-15

<400> 18

-12-

tcaatatatgc aacagtagtt cttgctcctc cttgattcta gcatttc 60
ttctacgtac ataaacatgt ccaatacggtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactaaac cgatgaccat 150

<210> 19

<211> 49

<212> PRT

<213> Vaccinia Virus/Acambis 3000 MVA

<400> 19

Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
35 40 45

Tyr

<210> 20

<211> 150

<212> DNA

<213> Vaccinia Virus/Copenhagen

<300>

<308> GenBank No. M35027.1

<309> 1993-08-03

<400> 20

tcaatatatgc aacagtagtt cttgctcctc cttgattcta gcatttc 60
ttctacgtac ataaacatgt ccaatacggtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat 150

<210> 21

<211> 49

<212> PRT

<213> Vaccinia Virus/Copenhagen

<400> 21

Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45

Tyr

<210> 22

<211> 150

<212> DNA

<213> Cowpox Virus

-13-

<300>
<308> GenBank No. X94355.2
<309> 2003-05-09

<400> 22
tcaatatagc aacagtagtt ctgtgcctc cttgattcta gcatcctttt cattattttc 60
ttctacgtac ataagcatgt ccaatacggt agacaacaca ccgacgatgg cggccgcccac 120
agacacgaat atgactagac cgatgaccat 150

<210> 23
<211> 49
<212> PRT
<213> Cowpox Virus

<400> 23
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 24
<211> 150
<212> DNA
<213> Rabbitpox Virus

<300>
<308> GenBank No. AY484669
<309> 2004-03-30

<400> 24
tcaatatagc aacagtagtt ctgtgcctc cttgattcta gcatcctttt cattattttc 60
ttctacgtac ataagcatgt ccaatacggt agacaacaca ccgacgatgg cggccgcccac 120
agacacgaat atgactagac cgatgaccat 150

<210> 25
<211> 49
<212> PRT
<213> Rabbitpox Virus

<400> 25
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

-14-

<210> 26
<211> 150
<212> DNA
<213> Camelpox Virus/CMS

<300>
<308> GenBank No. AY009089
<309> 2002-07-30

<400> 26
tcaatatatgc aacagtagtt cttgctcctc cttaattcta gcataatctt cattattttc 60
ttctacatac ataaggatgt ccaatacggt agacaacaca ccgacgatgg cggccgcccac 120
agacacgaat atgactagac cgatgaccat 150

<210> 27
<211> 49
<212> PRT
<213> Camelpox Virus/CMS

<400> 27
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 28
<211> 150
<212> DNA
<213> Ectromelia Virus/Moscow

<300>
<308> GenBank No. AF012825
<309> 2002-08-06

<400> 28
tcaatatatgc aacaacagtt cttgctcctc cttgattcta gcataatctt cattattttc 60
ttctacgtac ataaggatgt ccaatacggt agacaacaca ccgacaatgg cggccgcccac 120
agacacgaat atgactagac cgaggaccat 150

<210> 29
<211> 49
<212> PRT
<213> Ectromelia Virus/Moscow

<400> 29
Met Val Leu Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
1 5 10 15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu

-15-

Tyr 35 40 45

<210> 30
<211> 146
<212> DNA
<213> Monkeypox Virus/Zaire

<300>
<308> GenBank No. AF380138
<309> 2001-12-13

```
<400> 30
tatagcaaca gtaattcttg ctccctcattt attttagcat cctcttcattt attttcttct 60
acgtacataa gcatgtccaa tacgttagac aacacaccga cgatggtgcc cgccacagac 120
acgaatatga ctagaccgat gaccat 146
```

<210> 31
<211> 48
<212> PRT
<213> Monkeypox Virus/Zaire

```

<400> 31
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Thr Ile Val
   1           5           10          15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
   20          25          30
Asn Glu Glu Asp Ala Lys Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
   35          40          45

```

<210> 32
<211> 150
<212> DNA
<213> Variola Virus

<300>
<308> GenBank No. X69198.1
<309> 1996-12-13

```
<400> 32
tcaatatatacg aacagtagtgtt cttgcttcctc ctttaattctta gcatcttctt cattattttc 60
ttctcacatac ataaggatctt ccaatacggtt agacagcaca ccgatgtatgg cggccgcccac 120
agacacgaat atgactagac tgatqaccat 150
```

<210> 33
<211> 49
<212> PRT
<213> Variola Virus

<400> 33
Met Val Ile Ser Leu Val Ile Phe Val Ser Val Ala Ala Ala Ala Ile Ile
1 5 10 15

-16-

Gly Val Leu Ser Asn Val Leu Glu Met Leu Met Tyr Val Glu Glu Asn
20 25 30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
35 40 45
Tyr

<210> 34
<211> 186854
<212> DNA
<213> Artificial Sequence

<220>
<223> LIVP Complete Genome

<400> 34
ttccactatc tgggtacga acggtttcat cttctttgat gccatcaccc agatgttcta 60
taaacttgtt atccctcgcc gatttcataat cctttgc当地 ccaatacata tagttaact 120
caggcatatg ttccacacat cctgaacaat gaaattctcc agaagatgtt acaatgtcta 180
gatttggaca tttggtttca acccgcttaa catatgagtg aacacaccca tacatgaaag 240
cgatgagaaa taggatttctc atcttgccaa aatatacata gaaaaaaattt atttatcaat 300
tttaaaggta taaaaatac ttattgtgc tcgaatattt tttttttttt ggtatacgga 360
agatttagaaa tttttttttt atcatcaact gattctatgg tttttttttt tttttttttt 420
ttcactattt cttttttttt aatatacata gttttttttt atattttttt ttgttttaac 480
tcataatact cacgttaattc tggatttattt gcatatctat gaataattttt agctccatga 540
tcagtaaata ttaatgagaa catagtatta ccacccatca ttatttttttt catctcattt 600
aattcttaat tgcaaagatc tatataatca ttatagcggtt gactttatgaa ctctggatc 660
tttagacgtatc tacagtcatc tataatcatg gcatatttttaa tacattgtttt tatacgatag 720
tcgttatctt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
ttatgacata atagcattttt cttttttttt tttttttttt tttttttttt tttttttttt 840
atacatgtat atccgttattt tttttttttt tttttttttt tttttttttt tttttttttt 900
gatactagat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 960
tcaatcatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020
caagcataag acatgtcaca aagaccctttt tttttttttt tttttttttt tttttttttt 1080
tccatagttt gatttacata ggtgtccaaat cttttttttt tttttttttt tttttttttt 1140
ggcatctccc ttccctttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200
taaagtatcc gtgtatagcc tttttttttt tttttttttt tttttttttt tttttttttt 1260
cgccgaatgtt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320
atatcaaaga gatggtttcc ttatcattttt tttttttttt tttttttttt tttttttttt 1380
cgtgcggctt tccatttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440
atctataatc actatttttaa taatcagccaa tttttttttt tttttttttt tttttttttt 1500
ctatataatc ataaggcgtt tttttttttt tttttttttt tttttttttt tttttttttt 1560
ctatataatc tgacttaata taatattgaa tttttttttt tttttttttt tttttttttt 1620
acgggttgcattt tccgtgatattt tttttttttt tttttttttt tttttttttt tttttttttt 1680
tatccgactc tgaatacaga tttttttttt tttttttttt tttttttttt tttttttttt 1740
gtagttgata atcatcatac gctgtatcattt tttttttttt tttttttttt tttttttttt 1800
tttctatgaa caaatcaata tttttttttt tttttttttt tttttttttt tttttttttt 1860
aactgaacga tggttttcac tttttttttt tttttttttt tttttttttt tttttttttt 1920
tatcaagtca acgtctatcat tttttttttt tttttttttt tttttttttt tttttttttt 1980
gttgcttaat ccagggttgcattt tttttttttt tttttttttt tttttttttt tttttttttt 2040
tctactattt gtgtattttt tttttttttt tttttttttt tttttttttt tttttttttt 2100
agtgccactg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2160
gtatgcgtgtt aaaggcattat tttttttttt tttttttttt tttttttttt tttttttttt 2220
caacatctgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2280

gactgaatga gctactgtga actctataca cccacacaac taatgtcatt aaatatcatg 2340
tcaaaaactt gtacaattat taataaaaat aatttagtgt ttaaattttt ccagttccag 2400
atttacacc tccgttataa cctccattaa ccccactgga cgatccctt ccccacattc 2460
caccgcacc agatgtataa gttttagatc ctttattact accatcatgt ccatggataa 2520
agacactcca catgccgcca ctacccccct tagaagacat attaataaga cttaaggaca 2580
agttaacaa taaaattat cacgagtacc ctactaccaa cctacactat tatacgat 2640
tagttctat tttagtacta ccttgactaa agtttctat cacaagagca atactaccaa 2700
cctacactat tatatgatta tagttctat tttatagga acgcgtacga gaaaatcaa 2760
tgtctaattt ctaacggtag tggtgataaa cgattgtt ccgcggatac ctccctatc 2820
atgtcgctca ttttcttact ttgttctatt aacttattag cattatata tatttgatta 2880
taaaaacttattt attgcttattt agcccaatct gtaaatatcg gattattaac atatcgtttc 2940
ttttaggtt tatttaacat gtacatctat gtaagcatgt ccttaccatt tatttttaatt 3000
tgacgcatac cgcacatttcc ttttcgca tcggttataa attctatata tcatggatac 3060
atgctacatg ttttacttata atcgactata atgaagtact tgatacatat tttagtac 3120
gatttattat taccacctt gaataagtac ctgtgatcgt cttagtaatc aactgtttt 3180
ttaatacattt cgtgggttgg taatttactc agaataattt ccaatatctt aatataataat 3240
tctgttattt ctgggatata ttatctgccc agtataacac aaatagtaat acatgtaaac 3300
ccatattttt ttttattata aatgtctgcg ccattatcta ttaaccattc tactaggctg 3360
acactatcg actcaataca atgataaaagt atacatcatc catgtttatc tattttgttt 3420
atatcatcaa tatacggctt acaaagttt agtacgtata acacatccaa ctacacgcata 3480
gagaaggtag ggaataatgg cataatattt attaggtt catcattgtc attatctaca 3540
actaagtttcc ttttattata aatatactcg acaactttttag gatctctatt gccaaatttt 3600
tgaaaatattt ttttattatg cttaaatcta tataatgttag ctcccttcatc aatcatacat 3660
ttaataacat ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 3720
gaatctgtat atctttttaag aattgtggat attaggatatt tattacataa actattacac 3780
aattctaaaa tataaaacgt atcacggcgt aataatagtt gatcaactat atattatcg 3840
attttgtgat ttttcttctt aaactgtttt cgttaatagt tagatagaat attcattatgt 3900
tcatgaccac ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 3960
ttgtcaagat aataatagag ttttattatg ttttattatg ttttattatg ttttattatg 4020
tcgtgtgaaa ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4080
gtaataatataat aataatagag aactgttttcc cccattctat catcataatc agtgggtgt 4140
tcgttaatcgtaa ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4200
tgcgttattt ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4260
aataatagtt ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4320
ttaataccat ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4380
tctatattga ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4440
tagtcactg acgacaataaa caaaatcaca acatcgaaaa tgatattattt ttttattatg 4500
gtaacgtatg cccattttttt ttttattatg ttttattatg ttttattatg ttttattatg 4560
tctatcaatg ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4620
atcttattatgt ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4680
cagttatgtt ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4740
gtgtcagtac ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 4800
aggtcagaag ataatgtataat ttttattatg ttttattatg ttttattatg ttttattatg 4860
agatgggttgc atcggtttttt aacgtcaatg gtacaaaattt ttttattatg ttttattatg 4920
tattcgcccc tactataaaa ttttattatg ttttattatg ttttattatg ttttattatg 4980
gtatcaataaa acggagcaca cccattttttt ttttattatg ttttattatg ttttattatg 5040
atcttaacga aagaaggatgt ttttattatg ttttattatg ttttattatg ttttattatg 5100
tatatataatc ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 5160
tttccgaaaga ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 5220
ccttaaaaaaa atacgtataaa ttttattatg ttttattatg ttttattatg ttttattatg 5280
catattatc ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 5340
atgatgtatgt ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 5400
ggtaatagtg ttttattatg ttttattatg ttttattatg ttttattatg ttttattatg 5460
tgttatacag atgttattaca gctctatata ttacgtataa gaacgtgtca ttttattatg 5520
taactttcac cgcataatcc ttttattatg ttttattatg ttttattatg ttttattatg 5580

-18-

accaatctgg gcgtataatg aatctaaact ttaattgctt gtaatcattc gaaataattt 5640
ttagtttgc a tccgttagtta tcccctttat gtaactgtaa atttctcaac gcgatatctc 5700
cattaataat gatgtcaat tcgtgtgtt acccataact gaatggatga acgaataccg 5760
acggcgttaa tagtaattt cttttcatc tttacatatt gggtactagt ttactatca 5820
taagttata aattccacaa gctactatgg aataagccaa ccatcttagt ataccacaca 5880
tgtcttaaag tttattaatt aattacatgt tgtttataat atatcgctac gaatttaaag 5940
agaaaattgt ttaggaagaa aaattatcta tctacatcat cacgtcttg tattctacga 6000
tagagtcta cttaagatg cgacagatcc gtgtcatcaa atatatactc cattaaaatg 6060
attattccgg cagcgaactt gatattggat atatcacaac ctttgttaat atctacgaca 6120
atagacagca gtcggatgg tccataaaca gtgagttat ctttcttga agagatattt 6180
tgttagagatc ttataaaact gtcgaatgac atcgcattt tatcttttagc taaatcgat 6240
atgttaccat cgtaatatct aaccgcgtct atcttaaacg tttccatcgc tttaaagacg 6300
tttccgatag atggtctcat ttcatcagtc atactgagcc aacaaatata atcggttata 6360
acatcttga tagaattcaga ctctaaagaaa aacgaatcgg ctttattata cgcattcatg 6420
ataaaactaa tgaaaaatgt ttttcgtt ttaagtttga tgaatagttt gtcttaataa 6480
ttgttattat ttcattaatt aatattttgt aacgagtaca ctctataaaa acgagaatga 6540
cataactaat cataactagt tatcaaagtg tctaggacgc gtaatttca tatggtagat 6600
atccgttgaag cattgtctgt attctggagc tattttctct atcgcatatg tgagttcaga 6660
atatgttata aatttaaattc gaataacgaa cataacttta gtaaagtctgt ctatattaac 6720
tcttttattt tctagccatc gtaataccat gtttaagata gtatattctc tagttactac 6780
gatctcatcg ttgtcttagaa tatcacatac tgaatctaca tccaattttt gaaattggc 6840
tgttttacat atctcttcta tattattgtt gatgtattgt ctagaaaaac tattacgtt 6900
accattttct ttataaaacg aatataatgt actccaattt tctttaccga tatatttgca 6960
cacataatcc attctctcaa tcactacatc tttaagattt tcgttgc taaattttgc 7020
taaactatata aattcttataa gatcatcaac agaattcagta tatatttttca tagatccaaa 7080
gacgaactct ttggcgtcct ctataatatt cccagaaaaag atattttctgt gttttagttt 7140
atcgagatct gatctgttca tatacgccat gattgtacgg tacgttatga taaccgcata 7200
aaataaaaaat ccattttcat tttaaccaa tactattcat aatttagattt gatgttataac 7260
tttgcgttactt tgaacgtaaa gacagtacac ggatccgtat ctccaacaag cacgttagaa 7320
tcaaaatttgg tgggtttaaa cttcgcaata ttcatcaatt tagatagaaa cttataactca 7380
tcatctgttt taggaatcca tggattttt ccactttcca acttattcattt atcccaggct 7440
atgtttcgtc catcatcgatc ggcgcagatg aataattctt ttgttattogg tagttcaaat 7500
atatgtatcca tgcataagatc ggcaaaagctt ttgttagatgt gatttttctt aaatctaata 7560
taaaaactctt ttactagcaa acactttcctt gatttacatc ccaagacaca tatggtttct 7620
aaatctatca agtgggtgggg atccatagttt atgacgcgtt aacatatttattt attacattct 7680
tgactgtcgc taatatctaa atattttttt ttatcgatc ggattctgcata tatagatggc 7740
ttgtatgtca aagatataaga acacataacc aattttatgtt cgcgcatttac attctcgat 7800
ctaaagttaa gagattttaga aaacattata ttctcgatg atgttattcac tgggttcttgc 7860
gtaggatata tttaaagtctt tacagatttc gtccgattca aataaaatcc taaataataat 7920
cccacattat catctgttag agtagtatca tttaaatctat tatattttt gaaagatata 7980
tcactgtca cctctatatt tcgttacattt tttaaactgtt ttgtataat tctctgtata 8040
caatcagata tatctattgt gtcggtagac gataccgtt catttgaattt aatgggtttc 8100
cattttacaa tttaaacttacaa gttgaccaat tcatttctaa tagtatcaaa ctctccatga 8160
tttaaatattt taatgtatc cattttatatt cactacggac acaaagttagc tgacataaac 8220
cattgtataa tttttatgtt ttatgtttt tagcttacac attttggaaat tccggcttc 8280
catgttattt cttggagagca agtagatgtt gaggaaaccag atagtttata tccgtacttg 8340
cacttaaagt ctacattgtc gttgtatgtt tatgtatctt taaaccgcgtt agacaagtat 8400
ccgtttgtata ttgttaggtt tggacattt acaatctgac acgtgggtgg atcggaccat 8460
tctctctctg aacacaggac actagatgtt ccaatcaacg aatatccactt attgcaacta 8520
taagttacaa cgctccatc ggtataaaaaa ttctcgatc cgttatgtt tccgttggat 8580
atagatggag gggattggca tttaacagat tcacaaatag gtgcctcggg attccatacc 8640
atagatccag tagatcctaa ttccacaatc gatttagattt caccgatcaa ctgatatccg 8700
ctattacaag agtacgttat actagagcca aagtttactc caccaatatc aagttggcca 8760
ttatcgatat ctcgaggcga tggcatctc cgtttaatc attgattttt gagggtccat 8820
ccagtacctg tacatttagc atatataatgtt cccattttt gtttctgtt tccaggttaga 8880

-19-

catagatatt ctatagtgtc tcctatgttg taatttagcat tagcatcagt ctccacacta 8940
ttcttaaatt tcatattaat gggtcggtgac ggaatagtac agcatgatag aacgcaccc 9000
attcccaaca atgtcaggaa cgtcacgctc tccacccctca tatttttattt tccgtaaaaa 9060
tgttatcctg gacatcgatc aaataataaa aagcccatat atgttcgcta ttgttagaaat 9120
tggtttcac agttgcctaa aaacgatggc agtgcattt gagttacgat acactttgga 9180
gtctcatctt tagtaaacat atcataataat tcgatattac gagttgacat atcgaacaaa 9240
ttccaagttt attgattttgg ataataattcg tattttgcat ctgctataat taagatataa 9300
tcaccgcaag aacacacgaa catcttcct acatggtaa agtacatgta caattctatc 9360
catttgcctt ccttaactat atatttgcatt agataattac gagtctcgat agtaattcca 9420
gtaattacat agatgtcgcc gtcgtactct acagcataaa ctatactatg atgtcttaggc 9480
atgggagact tttttatcca acgattttt gtgaaacatt ccacatcgat taataactaca 9540
tatttctcat acgtggataa aactccaccc attacatata tatcatcgat tacgaatacc 9600
gacgcgcctg aatatctagg agtaattaaat tttggaaatc ttatccattt cgaagtgcgg 9660
tggttcaaat attctgccac acccggtgaa atagaaaatt ctaatccccc tattacatata 9720
aacttccat cgtaacaca agtactaact tctgattttt acgacgacat attagtaacc 9780
gtttccatt tttcggttt aagatctacc cgcgatacgg aataaaacatg tctattgtta 9840
atcatgcccgc caataatgtt tagacaattt tgtaaaaacat ttgcattata gaattgtcta 9900
tctgtattac cgactatcgat ccaatattct gttcttaggag agtaatgggt tattgtggat 9960
atataatcag agtttttaat gactactata ttatgtttt taccatttcg tgcactggc 10020
ttttagatt tggatataatg taatcccaac aatgatatacg cattgcgcattt atgtatccac 10140
ataaaacttgg gatgtaaaat gttgatgata tctacatcgat ttggattttt atgtatccac 10200
tttaataataa tcatagctgt aacatccctca tgatttacgt taacgtcttc gtggataaag 10260
atagttgtca gttcatccct tgataatttt ccaaattctg gatcgatgt caccgcagta 10320
atattgttga ttatccctga catcgacgca ttatataatg ttttaattcc atatctttt 10380
gaaaagttaa acatccctat acaatttgcg aaattaatata tatgaatcat agtttttaca 10440
catagatcta ctacaggcg aacatcaattt attatggcag caactatgat catttctaca 10500
ttgtttatgg tgatgtttt ctcttcccg cgcatatagt ctaatagcga ttccaaacgcg 10560
tgatagtttta taccatttca tataatcgat tcattccctt gatggatgcgat ctgaatgcgt 10620
ttaaaaaaaat tatacggaga cgccgtataa atttccctt tcaacttgcgtt aatttcccc 10680
ttgatagaaa atattacgat ttccatttctt aaagtactat aagtaattat agtataatgt 10740
aaacgtttat atattcaata tttttataaa aatcattttt acattaattt ctttttaaat 10800
ttccgtctat catctataga aacgtattt atgaattttt aaaatgcctt tacgtgtcct 10860
atcgtaggcg atagaaccgc taaaaaggct atcgaatttc tacaatggaa tctgttat 10920
ggatagggaa ggtataaaaa cattaaatgt ccgtactttaaagtttccat agtagccat 10980
ccttaacttcc tcgaataactt attaatggct ttgttctgt acgaatctat tttttgaac 11040
aacggaccta gtggatatac ttgttctatg tatctaaaat aatgtctgac tagatccgtt 11100
agtttaatat ccgcagtcat ttgtctaga atggcaatc taactgcggg ttaggcgtt 11160
agtttagttt ctatatctac atctatgtct ttatctaaca ccaaaaatataat aatagctaat 11220
attttattac aatcatccgg atattctt acgatctcactt taactatgt ttctttgggtt 11280
atacttagat agtcaactatc ggacaaataa agaaaatcag atgatcgatg aataatacat 11340
ttaaattcat catctgtttaaattttt gatgttgcattt gaatattttt agggttagta 11400
ctcattatca ttccggcagct attacttattt ttattttt tcaccatata gatcaatcat 11460
tagatcatca aaatatgtttt caatcatctt aaagagtatg gtaaatgact ctcccatct 11520
aatttctgaa cgttcaccaa tgcgttctatg cactttggca ctaatagcga tcattcgctt 11580
agcgtcttct atattattaa ctgggttattt caatctatct agcaatggac cgtcggacag 11640
cgtcattctc atgttctttaa tcaatgttaca tacatcgccg tcatttacca attcatccaa 11700
caacataagc tttttaaaat catcattata ataggtttga tcgttgcattt tccatccaaag 11760
aatatatactt ataagttagat tcctcatgtt tagtttacaa ctatccatgtt tgcataatca 11820
atttagtacac cgctatgtttt aatacttattt catattttt ttttttagat tgagaatcaa 11880
tacaaaaattt aatgcacatcat taattttttaga aatacttagt ttccacgttgcac 11940
atttgaactc atcgtaggtt acgttctcgat acaggacgtt actataaaacc ggtttatattt 12000
tgttcaagat agataaaaat cogataactt tttttacggaa ttctacggat tccactttaa 12060
aagtgtcata cccgggttctt ttatccatgtt taaacagatc aatgggtgttgc 12120
gtcttttacg aatttgcattt agaatacgat ttacatccatgttccatccatgg tcaatgcgg 12180
tttgcgttgcata tgcataatcatgtt tgcataatccatgttccatccatgg tcaatgcgg 12180

-20-

tgttcattgt taggaatcta tccaaaatgg caattatact agaactatacg gtgcgttgta 12240
tacacatatt gatgtgtctg ttatatacat caatgtact accttcgggt aaaattgttag 12300
catcatatac catttctagt acttttaggtt cattattatc cattgcagag gacgtcatga 12360
tcgaatcata aaaaaatata ttatTTTtat gttatTTTgt taaaataat catcgaatac 12420
ttcgtaaagat actccttcat gaacataatc agttacaaaaa cgTTTtatATg aagtaaagta 12480
tctacgattt ttacaAAAGT ccggatgtcat aagtacAAAG tacgcgataa acggaataat 12540
aatagattt tctagtctat ctTTTctat agcttcatc gttagatACA tggTctcaga 12600
agtaggatta tgtaacatca gttcgataa aatgactggg ttatTTTgtc ttacacattc 12660
gctcatacat gtatgaccgt taactacaga gtctacacta aaatgattga acaataagata 12720
gtctaccatt gtttgcgtatt cagatgtac agcgtatgtac atggcatctt cacaattat 12780
atcattgtct aatagatatt tgacgcatct tatggatccc acttcaacag ccattttaaa 12840
atcggtagaa tcatattgtct ttccTTTtattc attaataatt tctagaacat catctctatc 12900
ataaaaagata caaatattaa ctgtttgatc cgtaataaca ttgcttagtgc atagcaattt 12960
gttaataaga tgcgtgggc tcaatgtctt aataagaagt gtaagaggac tatctccgaa 13020
tttggTTTgt ttatTAACAT ccgttgcgtgg aagtaaaAGA tctataatgt ctacattctt 13080
gactgtttt gacgatACAA tatggagagg tGTatTTCCA tcatgtatcG gttttgaggg 13140
actaattcct agtttcatca tccatgtatc tGtagaAGt tttggattgt ctgacataag 13200
atgtctatga atatgatttt tgccaaattt atccactatc ctggcttgcg atccgatgg 13260
cattatTTTt ttaaacatc tttctgcagg atctgtacac gccaacaacg gaccacatcc 13320
ttcttcatca accgaggTTTgt taatcttggc tccatactgt accaataat ttattctctc 13380
tatgacttca tcattgttc ccgagagata atatagaggc gttttatgtc gttttatcaca 13440
cgcgtttggc ttcgtgcggcgt ggcgtcggcgt catcgcgact attctattat tattatTTT 13500
agaagctata tgcaatggat aatttccatc atcatccgtc tcatttggag agtacctct 13560
atgaagaagt tcttcgacaa atcgttcatc tagtcTTTta attccacaat acgcatgtag 13620
aatgtgataa ttatTTCCAG aaggTTTcgat agcttgcgtc atattcctaa atacatctaa 13680
atTTTacta ttatTTTgg cataaAGAGA tagataatac tcggccgaca taatgttgc 13740
cattgtatGA taaaaattaa tatttctatt tctgtatatt tgcaacaatt tactctctat 13800
aacaatatac ataacttagt tctttatgt caagaaggc ctggTTTtagt tcattctataa 13860
atgtcacGCC ataactacca cgcattgcatt actcagaatt atgataaaaga tatttattcct 13920
tggggTgtAG gtaatggggA ttaatTTTt tggatcagt ctctaaagtta acacatgtca 13980
cacatgatcc atttatagtt atatcacacg atgatgattt atgaattgtatccggaaagat 14040
cgctatcgta ttttgcgttt ccacaattca ttccatACA tgTTTattgtc acactaatat 14100
tatgatgaac ttatCTAGC cgctgagtgg taaacaacag aacagatagt ttattatctt 14160
taccaacacc ctcagccgcgt gccacaaatc tctgtatccgt atccatgtatc gtcgttta 14220
tttctagtcc gtagccatc aacactatgt tagcatttct gtcgtatatacg ctTTCactca 14280
tatgacactc accaataata gtagatTTAAT tgTCgtatTT tacaccaata gtaggttccg 14340
cgGcaaAGTA ccaatACCGG taatcttgcg gaggaggaca tatagtattc ttgtattct 14400
ccgaaataccC gagagatgcg atacaAAAAGA gcaagactaa ttgtAAACC atcttactca 14460
aaatatgtaa caatagtacg atgcaatgag taagacaata ggaatctat ctatataca 14520
cataattattt ctatcaattt tccaatttag ttatgttaat gttacaaaaa atgtgggaga 14580
atctaatttag ttttcttta cacaatttgcg gtacatgtatc ctgagttctt tgTTTtgc 14640
aattatttca tccaattttat tattcttgcg gatatcgaga tctttgtat aggagtcaaa 14700
cttgatttca acatgcTTTt ctataatcat tttagtattt tcggcatcat ccaatagtac 14760
atTTTccaga ttagcagaat agatattaaat gtcgtatTTG aacagagcct gtaacatctc 14820
aatgtcttta ttatctatAG ccaatTTAAT gtcggaaatg aagagaaggg aattattgg 14880
gtttgtcgac gtcataatgt cgagcaagag aatcatcata tccacgtgtc cattttttat 14940
agtgtatgtGA atacaactaa ggagaatAGC cagatcaaaa gtagatggta tctctgaaag 15000
aaagttaggaa acaataactta catcattaaAG catgacggca tgataAAATg aagtTTTcca 15060
tccagTTTc ccatagaaca tcagtctcca atTTTctta acaaACAGT ttaccgtttg 15120
catgttacca ctatcaACCG cataatACA tgCGGTGTTT cccttgcatt caaattgtga 15180
atcatccagt ccactgaata gcaaaatctt tactatTTG gtagatTTCA atgtggctgc 15240
ctgatgtat gggaaatttcat tctctagaAG atTTTcaat gtcggcgt tcaacaacgt 15300
acataactaga cgcacgttat tattcgtat tgcataatac aaggcactat gtcacatggac 15360
atccgccttA aatgtatTTTt tactagagAG aaagctttc agctgcttag acttccaatg 15420
attaattcgT gacagatcca tgcgtgaaac gagacgtcaa ttatgttattt 15480

-21-

ttttataatt ttgtcatatt gcaccagaat taataatatac ttaatagat ctgatttagta 15540
gatacatggc tatcgaaaaa caacatatac acattaataa aaaataatat ttattaagaa 15600
aattcagatt tcacgtaccc atcaatataa ataaaataat gattccttac accgtaccca 15660
tattaaggag attccacctt acccataaac aatataaatac cagtaatatac atgtctgatg 15720
atgaacacaa atggtgtatt aaattccagt ttttcaggag atgatctcgc cgtagctacc 15780
ataatagtag atgcctctgc tacagttcct tggcgatcgatc catctatott tgcatctga 15840
aacattttat aaatataaa tgggtcccta gtcataatgtt taaacgacgc attatctgga 15900
ttaaacatac taggagccat catttcggct atcgacttaa tattccctt attttcgata 15960
gaaaattttag ggagtttaag attgtacact ttattcccta attgagacga ccaatagtct 16020
aattttgcag ccgtgataga atctgtgaaa tgggtcatat tattccctat tgccaggtac 16080
atactaataat tagcatcctt atacggaagg cgtaccatgt catattctt gtcatcgatt 16140
gtgattgtat ttccctgcaa ttttagtaact acggtcatca tgggaaccgt tttcgatccg 16200
tacttattag taaaacttagc attgcgtgtt ttagtgatatac caaacggata ttgccatata 16260
cctttaaaat atatagtatt aatgattgcc catagagtat tattgtcgag catattagaa 16320
tctactacat tagacatacc ggatctacgt tctactatag aattaatttt attaaccgca 16380
tctcgctcaa agttaatct atataggccg aatctatgtt attgttgata atacgacgg 16440
ttaatgcaca cagtattatc tacgaaactt tgataagtta gatcgtgtt cgtatattta 16500
gatgtttca gcttagctaa tcctgatatt aattctgtaa atgctggacc cagatctt 16560
tttctcaaat ccatagttt caataattct attctagtat tacctgatgc aggcaatagc 16620
gacataaaaca tagaaaacga ataacccaaac ggtgagaaga caatattatc atcttgaata 16680
tttttatacg ctactatacc ggcattggta aatccttgta gacgataggc ggacgctgaa 16740
cacgctaacg atagtatcaa taacgcaatc atgattttat ggttataata attaacccta 16800
tttttatgtt cggtaaaaaa aaattattgtt tgtctacaca tccttttgta attgacatct 16860
atataccctt ttgtataatc aactctaatc actttaactt ttacagttt ccctaccagt 16920
ttatccctat attcaacata tctatccata tgcatcttaa cactctctgc caagatagct 16980
tcagagttag gatagtcataa aagataaaata tatagagcat aatcattctc gtatactctg 17040
cccttttata catcacccgc attgggcaac gaataacaaa atgcaagcat cttgttaacg 17100
ggctcgtaaa ttgggataaa aattatgttt ttattgtctt atatctattt tattcaagag 17160
aatattcagg aatttcttt tccgggttgc tctcgatcgatc gtatataatca ttgtacatt 17220
gtttcatatt ttttaatagt ttacaccctt tagtaggact agtacgtac aattcatagc 17280
tgtatTTGA attccaatca cgatccccaa tatctccaa ttgttgacga agacctaatc 17340
catcatccgg tgaatattt atagatgctc cacatgtatc cgtaaagatc ttccctgtcc 17400
aatttgaggt acctatatacg gccgtttat cggttaccat atatttgca tggtttaccc 17460
tagaatacgg aatgggagga tcagcatctg gtacaataaa tagctttact tctatattta 17520
tgTTTTAGA ttttagata gcgatagatc taaaagtt tctcatgata aacgaagatc 17580
gttgccagca actaatcaat agcttaacgg atactgtct gtctatagcg gatcttctta 17640
attcatcttca tataaaggc caaaacaaaa tttaaccgc cttcgatataa ataataaggga 17700
taaagttcat aacagataca taaacgaatt tactcgatc tctaatacat gacaataaaag 17760
cggttaaattt attggttctt tccatagatc atagttgtt cgggtcagaa gcaataaaata 17820
cagagtgtgg aacgcccgtt acgttaatac taagaggatg atctgtatc taatacgacg 17880
gataaaagtt ttccaattt tatggtagat tgtaactcc aagataccag tatacctcaa 17940
aaatttgagt gagatccgt gcaagttcc tattattgaa gatcgatataa cccaaattctt 18000
tgacctgagt tagtgatctc caatccatgt tagcgatcc taaaataataa tttgttattat 18060
cagatatacca aaattttgtt tgaagaactc ctccttaggtt atttgtatataa tctatgtatc 18120
gtacttcaac tccggccatt ttgtatctt caacatccctt taatggttt ttagatttt 18180
taacggctac tctaactcgat acccctctt tgggtatcg tacaatctcg ttaatattta 18240
tcgtggcggaa attcgatccc acttcatccg ataaactcca ataaaaagat gatataatcta 18300
gtgtttttgtt ggttggat agaatttccc tccacatgtt aatgttagac aaatataactt 18360
tatcaaatttgcatacata ggaatagttt ctgtatcactc tgcatgtt ttagatttt 18420
tcattttattt ttttttttttataatccat atcacttccatc tcttattttttt atccaagttt 18480
ctatttctt catgactgat ttttttttttataatccatc tccatgtt cttatgttgg tttttttttt 18540
cacccatata aattttttt tctctattac aatttgcgtt ttttttttttataatccatc tttttttttt 18600
ctaaaacatc gctaatttca ttttttttttataatccatc tccatgtt gatgtccgg ggggtttttt 18660
tcttggaaat ttttttttttataatccatc accttgcgtt ttttttttttataatccatc tttttttttt 18720
ccttaattttt ttttttttttataatccatc tccatgtt gatgtccgg ggggtttttt 18780

-22-

-23-

attctataacc catcatgtaa cactcgacac aatattcctt tctaaaatct cgtaagataa 22140
agtttataca agtgttagatg ataaaattcta cagaggttaa tatagaagca cgtaataaaat 22200
tgacgacgtt atgactatct atatatacc ttccagttata cgagtaaata actatagaag 22260
ttaaactgtg aatgtcaagg tctagacaaa ccctcgtaac tggatctta ttttcgtgt 22320
attttgacg taaatgtgtg cgaaagtaag gagataactt tttcaatatc gtagaattga 22380
ctattatatt gcctccatg gcatcaataa ttgtttgaa tttcttagtc atagacaatg 22440
ctaatatatt ctacagtag acagtattga caaatatcgg catttatgtt tctttaaaag 22500
tcaacatcta gagaaaaatg attatcttt tgagacataa ctcccattt ttgttattca 22560
cccacacgtt ttgcgaaaaa attagtttt ctttccaatg atatatttc catgaaatca 22620
aacggattgg taacattata aattttttt aatcccaatt cagaaatcaa tctatccgcg 22680
acgaattcta tatatgtttt catcatttca caattcattc ctataagtt aactggaaga 22740
gccgcagtaa gaaattcttg ttcaatggat actgcattcg ttataataga tctaacgggtt 22800
tcttcactcg gtggatgca aataatgttta aacatcaaac atgcgaaatc gcagtgcaga 22860
ccctcgcttc tactaattag ttctgtggaa aacgtgagtc cgggcattag gccacgcctt 22920
ttaagccaaa atatggaaagc gaatgatccg gaaaagaaga ttcccttctac tgcagcaaag 22980
gcaataagtc tctctccata accggcgctg tcattgtatcc acttttgagc ccaatcgccc 23040
ttctttttt cacaaggcat cgtttctatg gcattaaaga gatagtttt ttcttacta 23100
tcttaacat aagtatcgat caaaagacta tacatttccg aatgaatgtt ttcaatggcc 23160
atctgaaatc cgtagaaaca tctagcctcg gtaatctgtt cttctgtaca aaatcggttcc 23220
gccaaattttt cattcactat tccgtactg gctgaaaaaa acgccaatac atgttttata 23280
aaatattttt cgtctgggtg tagtttattt caatcattga tatctttaga tataatctact 23340
tcttcactg tccaaaatga tgccctcgcc ttttataca tggccagat gtcatgat 23400
tggattggga aaataacaaa tctatttggg tttgggtgaa ggatgggttc cataactaaa 23460
ttaacaataa caataaattt ttttcagtt atctatatgc ctgtacttgg atttttgtt 23520
catcgatatc gcccgaatca ctacaataat tacaagtatt attgatagca ttgttattag 23580
tactatcata attaaattat ctacattcat gggtgctgaa taatcgat tatcatcatt 23640
atcatttgt aattgtgaca tcatactaga taaatcgat ttccatgtt gcgagatgt tggggaaagc 23700
gggcatggag gatgcattat cattatttt taacgccttc catttggatt cacaatgtt 23760
acgcacattc aacattttt gggaaactata attttgtgaa aacaataaac aagaaaactc 23820
gtcatcgttc aaatttttaa cgatagtaaa ccgattaaac gtcgagctt tttctaaccgc 23880
tagcgactct gttggatatg ggtttccaga tatatatctt ttccatgttcc ctacgtatct 23940
ataatcatct gttagaaatg gaagatattt ccatttatct actgttccca atatcatatg 24000
tgggtgtta gttagaaccat taagcgcgaa agatgttatt tcgcattgtt ttttaacttc 24060
gcaataattt ctggtagat aacgcactt accagtcaag tcaatgat tagcctttac 24120
agatataattc atagtagtcg taacgatgac tccatctttt agatgcgata ctcctttgtt 24180
tgtaccagaa tcttcgtacc tcaaactcga tatattttaa caagttatg agatattaac 24240
gcgtttatg aatgatgata tataaccaga agtttatcc tcgggtggta gcgctataac 24300
cttacatcata taataccaac tagtgtgatt aatatgtgac acgtcagtgt gggtacaaat 24360
atgtacatca tcgtctacgt cgtattcgat acatccgcattt acagccaaaca aatataaaat 24420
gacaatatact ctaacgcctt tcgttacccat ttgtatgcgg tttataaaat gtttgattt 24480
caatttattt gaaaaaaaaa ttccgtttt tactgttca tattcttattt gcttataattt 24540
tcattatca tctccacaca gtcaaattccg tggtagcat gcacccatc aaccggtaaa 24600
agactatcggtt actcttttat cattataact cttagaatattt taatttgcattt attattaatc 24660
aagtcaattt tcttattttt aacaaaacgtt agtattttac tcattttttttaaaaaacttt 24720
tagaaatata cagactctat cgtgtgtcta tatcttctt ttatatccaa tgtattttatg 24780
tctgatattt tttcattttt cattatataat ggtccaaattt ctacacgttc ttccgattca 24840
tccagatcat taaggttctt ataattgttta catccttctc ttcccttcc tacatcttcc 24900
ttcttatttct tattcttagc gtcacagaat ctaccacagc aggatcccat gacgagcgatc 24960
atattaaactt aatccatattt caattataat atatgattttt gatgaccat taaaataaaa 25020
aatattcttc ataaccggca agaaagtggaa aagttcacat tgaaactatg tcagtagtat 25080
acatcatgaa atgatgatattt atatataactt tattttgggtt gaggattata tgatataatt 25140
cgtggataat catttttaag acacatttct ttattcgtaa atcttttcac gttaaatgag 25200
tgtccatattt ttgcattttt ttcattatgat ggcgggttac gtggacgagg ctgctcctgt 25260
tcttgggttgc gtcgcgcact gtcgtgtctg cgtttagatc cttccattat cgcgattgcg 25320
tagatggagt actattttt accttgaat taaattttt tattaattaa acgtataaaa 25380

-24-

acgttccgta tctgtattta agagccagat ttgcgtcta at agaacaata gctacagta 25440
aaataactag aataattgct acacccacta gaaaccacgg atcgtataac ggcaatcggt 25500
tttcgataat aggtggaacg tatattttat ttaaggactt aacaattgtc tgtaaaccac 25560
aatttgcctc cgccggatcct gtattaacta tctgtaaaag catatgtga ccgggcggag 25620
ccgaacatcc tccgatatact aatttctgtat tatctataat attattaacc tccgcatacg 25680
cattacagtt cttttcttagc ttggataccg cactaggtac atcgtctaga tctattccta 25740
tttcctcagc gatagctctt ctatccttt ccggaaagcaa tgaatactt ctaataaaatg 25800
attcaaccat gagtgtaaaa ctaagtgcag aattactcat gcatttgtt gttattcgg 25860
gcfgcattt tttaaactgt cctataaccc tccctatata gatagcacaa gtgacattag 25920
tagggataga atgttgagct aattttgtt aataactatc tataaaaaga ttatacaaag 25980
ttttaactc ttttagttcc gccatttattc cagtcgtt gaaatgtctt cataataaaat 26040
tttccaaga aactaattgg gtgaagaatg gaaacctttt atctatattt atcacagtct 26100
gttttggtagt acatgtatgaa ttcttccat gccgtactaa attcgtatc ttttcgatt 26160
tctggatatg ttttaataa agtatgaaca aagaaatgga aatcgtatc ccagttatgt 26220
ttaactttga aattgtttt tattttctt ttaatgattt cagccactt gaaaaagtca 26280
aagtgcgtt aatgccgattt aatacggttca ttaaaaacaa actttttatc ctttagatga 26340
attattattt gttcatgtt aatcaaaaagt aagatattt cgggtttaag atctgcgtgt 26400
aaaaagttgt cgcaacaggg tagttcgtt atttatgt ataacagagc catctgtaaa 26460
aagataaaact ttatgtattt taccaaaagat ttaaattccta atttgatagc taactcggt 26520
tctactttat ctggcaata cagtcgttgg gaaaaaattt taatgtttcc tctttcatat 26580
tcgttagttt tagttttttc atgttgcggaa aagtggaaaca tgcgggtttaa atagtttata 26640
acattaatat tactgttata aactgcccga taaaagtggg atagtaattt cacgaatttg 26700
atactgtcct ttctctcggtt aaacgcctt aaaaaaactt tagaagaata tctcaatgag 26760
agttccgtac catccatagt ttgtatcaat aatagcaaca tatgaagaac acgtttatac 26820
agagtatgtt aaaaatgtt aatccatgg cccacgcaca cacgattaat 26880
ttttttcat ctcccttttag atgttgtat agaaatttgg gtactgttga ctccgcccgt 26940
gttccatgg gactatataa ttttggcc tcgaatacaa attttactac atagttatct 27000
atcttaaaga ctataccata tccctctgtt gatatgtt gat aaaaatgtc gtttatagga 27060
taaaaatcggtt tatttttttgg tttggaaaaag gatgatattt tgaatcattt ctcttctatc 27120
tttagtagtg tttcccttattt aaaaattcttta aaataatttta acaatctaac tgacggagcc 27180
caatttttgtt gtaaattctaa ttggggacattt atattgtt aatacaaaaca gtctccta 27240
ataacagttt ctgataatct atggggagac atccattgtt attcaggggta tgaatcattt 27300
gcaacaccca tttattgttac aaaaagcccc aatttacaaa cggaaagtccca ggtttgatag 27360
agacaaacaa ttaactattt tgcgttgcgtt tttaacaccc ccacagttt taatttcttt 27420
agtaatgaaa ttattcacaat tattcgttcc ttctttatctt accagagattt ttactaactt 27480
gataaccttg gctgtctcat tcaatagggtt agtaatattt gtatgtgttga tattgatatc 27540
tttttgaattt gtttcttttta gaagtgttcc ttgtatgtt ccagcatacg aattacaata 27600
atgcagaaac tcggtaaca tgcaggaaattt atagtaagcc aattccaaattt gttgcctgt 27660
ttgttatttga gtgtcaatattt gggcaatgggtt gtccttgcgt ttctctgata gaatgcgagc 27720
agcgatttttgc gctgttcat ttgtacgatattt ttcttggatg acgaatctt gtttactaa 27780
ctttttggta ggacaaagtgtt aacaatcaa gaagatagct tctcctcttta tttgtggaaag 27840
aaatttgaactt cctcttagatg atctactgttcc gatagtttcc ctttgcacaga tattggaccg 27900
aatttacagaa gtacctggaa tggaaagcccc tggaaacccccc tcatttttttta agcagattgt 27960
tgccgttaat cctgcactat gcccacatata gggatgttcc ttgtgttgc tatttctatc 28020
tttcagtttta accaagaaac agtgcgttcc ttcttttttcc ccatctctt ctaatacagc 28080
atctaacttg atgtcaggaa ctatgaccgg tttaatgtt aatgttacat tggtaatcc 28140
cttaagttca taatcatcact tgcgttccgtt tatgttacgtt ccaaaacatc ttttaccgg 28200
catagtggat acgaagatgc tatttccatcgtt aatgtttccctt tgattttat ttttctatata 28260
gctattttcc tttaaaccat tttccaaatc agtaactatg ttcatttttt taggatgtt 28320
acgccttagcc agtatgaaag aggattttctt agatcctctt tcacacatctt gatctgttgc 28380
tggaaatgcaaa aaccccatag tggaaacaacc aacgataaaa aataatattgt ttttccattt 28440
ttataattttt accatctgttcc tcatggattt attaataatctt ttataagagc tactaacgtt 28500
taatttcttta taactgttactt gagatataa caccggatctt atggtttccca taatttgatgtt 28560
aatgaatgttca cggcaataac taatggcaaaa tggatgttgc aacgaaatata tactagatgtt 28620
gtttaaagtta atattttcttca tgatgttgc caataaaatata tttgttgc tgcgttcaa 28680

-25-

gtcataaaatc atcttgatac tatccagtaa accgtttta agttctggaa tattatcatc 28740
 ccattgtaaa gcccctaatt cgactatcga atatctgtc ctgatagcag tttcaataatc 28800
 gacggacgtc aatactgtaa taaagggtgt agtattgtca tcatcgat aaactacggg 28860
 aatatggtcg ttagtaggtt cggtaacttt acacaacgcg atatataact ttccctttgt 28920
 accatttta acgttagttgg gacgtcctgc agggatttgt tttgaagaaa tgatatcgag 28980
 aacagatttg atacgatatt tttggatc ctgatttattc actataat aatctagaca 29040
 gataatgtat tcgataataa gagaaggat atcggttgc ggataataca tccccattcc 29100
 agtattctcg gatactctat tgatgacact agttaagaac atgtcttcta ttctagaaaa 29160
 cgaaaacatc ctacatggac tcattaaaac ttctaacgct cctgattgtg tctcgaatgc 29220
 ctctgacaag gatttcaagg atgcccata gtttttgcacc aacgatttag aattgcgtt 29280
 agcatctgtat ttttttata aatcgaatgg tcggctctc ggtttgcac cccaatgata 29340
 acaatagtct tggtaaagata aaccgcaga aaatttatac gcatccatcc aaataaccct 29400
 agcaccatcg gatgatattt atgttattt atagattttc catccacaat tattggcca 29460
 gtatactgtt agcaacggta tatcgaatag attactcatg taacctacta gaatgatagt 29520
 tcgtgtacta gtcataataat ctttaatcca atctaaaaaa ttttttttattt gattttttac 29580
 actgttaaag ttaacaaaag tattaccggg gtacgtggat atcatatatg gcattggtcc 29640
 attatcgtt atagctccat aaactgatac ggcgatggtt ttatatgtg ttttatctaa 29700
 cgaggaagaa attcggcccc acaatttcatc tctagatatg tttttatataa caaacggtaa 29760
 cacatcaatt tcgggacgcg tataatgttcc taaatttttta atccaaat aatgatgacc 29820
 tataatccctt attatcatac tgcactat agtacaccta gggacttac gatacatctg 29880
 ttccctataa tgcgttattt ttacaaatct ataacatgct aaacctttt acgacagcc 29940
 ttccattaatt tctgatatgg aatctgtatt ctgcataccg ttcgttcta aagccagtgc 30000
 tataatctccc tggcggtggg aacgctttcg tataatatcg atcaacggat aatctgaagt 30060
 ttttggagaa taatatgtact catgatctat ttccgtccata aacaatctag acataggaat 30120
 tggaggcgat gatcttattt ttgtgcattt agtgcgtcaat cctataactt ctaatcttgc 30180
 aatatttcatc atcgacataa tactatctat gtttcatcg tatattatg taccatgacc 30240
 ttcttcattt cgtgcacaaa tgatatacag tcttaatag ttacgcataa tctcaatagt 30300
 ttccataattt ttagctgttt tcatcaaggat ttgtatctt ttttacatga tggcggttcta 30360
 taacgtctctt attttctattt ttttattttta acaatcttactt acgattttact gtggctagat 30420
 acccaatctc tctcaaatat ttttttagcc tcgttacaa gctgttttac tataacttata 30480
 aaactgacga, atccgtgatt ttggtaatgg gttccgtcga aatttgcgcg agtgcgtatga 30540
 acatatttgcg cgtcgactat caacaattttt gtattatttctt gaatgtgaa aacccttcaca 30600
 gatagatcat ttgtacaca caacgcacatc agactttgg cggttgcac agaatataacg 30660
 tcgttcttat cccaaatacc aacttagaagt ctgatcttaa ctcccttattt aatggctgct 30720
 tctataatgg agttgttaat gtcggggccaa tagtagctat taccgtcgac acgtgtatgt 30780
 ggaactatgg ccaaatttttc aatatctata ctgtttagt ctgaccttgcg tttatcaata 30840
 actacatcggt tatcttagat totagaatat cccaaataggt gttccggaga atcagtaaag 30900
 aacactccac ctataggatt cttaaatatga tacgcagtgc taactggca acaacaagcc 30960
 gcagagcata aattcaacca tgaattttttt ggcctttaaa aggctttttttaa agtacatcaa 31020
 ctcttacgaa gatctgtggc cagcggggggtaa taaatcagaat atacaccctaa cgttttatc 31080
 gtatgtatag atccctcgtt aaatgcacgcg ttccctacat aacatcttcc atcatctgac 31140
 acccaaaaac aaccgagtag tagtcccaca ttattttttt tatctatattt aacggttata 31200
 aaattttatat ccgggcagtg actttgttagc totccctat gatcccttttttttttttcc tcgttcatct 31260
 agcaaaaactt ttatattttat ccctttttca gatcccttttcc ttatgtttatc aaaaataaagc 31320
 gctcccttag tcgtactcg aggattacaa caaaaagatg ctatgtatattt atatttctta 31380
 gctagatgtt taatttgcgtt aaaaacattca aatgttgcgtt aatgatcgga tctaaaatcc 31440
 atattttctg gtagtgtttt taccaggccta cattttgcgc cccgacggatc cgatgcacat 31500
 ggcacacatc agttaacata aaaaacttata catccgttgc tatcaacgcg tctagaatat 31560
 catcgctat atcgctaaaa ttccatcaaa agtgcacatc acaacctaacc tcaatcttca 31620
 tattaaagaag ttccatcgatc tcatcttgcgt ctatttctat atccgtatcc attgttagatt 31680
 gttgaccgat ttagtgcgtt aaatcattac taatactca tccctcagaa tacaatctgt 31740
 gtttcatgtt aaatttataat gccgggtgtttaa ttagtgcgtt gattttcaat tatgttattaa 31800
 tatagcaaca gtagttcttg ctccctccttgc attcttagcat cctcttcttatttatttcttct 31860
 acgtacataa acatgtccaa taatgttagac aacacaccga cgatggccgc cgctacagac 31920
 acgaatatga cttaaaccatc gaccatttaa aaacccttcttcttca cttaaactgt 31980

-26-

attaataaacg tgctcattag gcagttatg gcagcttgat aatttagatat agtatattcc 35340
agtccatatt tattagatac cgcattgcc agattttgat attctatgaa ttctctcgaa 35400
aataaatcca aaataactag acattctatt ttttggat tagtgtactc tcttcctct 35460
atcatgttca ctactgggt ccacgatgat aaatatctag agggaatata atatagtcca 35520
taggatgccat atctagaat gtcgaataac tgtaattttt ttcttcgctc ttcatattga 35580
attgattctt gaggtataaa cctaacaacaa attatattat tagactttt gatatgtatg 35640
tcttcatgt tataagttt taatcctgga atagaatcta tttttagag gcttttaaac 35700
gcagagttct ccaacgagtc aaagcataat actctgttgc ttttcttata tacgatgtta 35760
cgattttctt cttgaatgg aatagggttt tgaatttagtt tataattaca acataataga 35820
taaggaagtg tgcaaatagt acgcggaaaa aacataatag ctccccgtt ttcatccatg 35880
gtttaagta aatgatcact ggcttccttta gtcaatggat attcgaacat taaccgttcc 35940
atcatcattg gacagaatcc atatttctta atgttaaagag tgatcaaactt attgtgttta 36000
ttgtaccatc ttgtgtaaa tggttattcg gttatcgat ctgctccccc ttcttattaa 36060
gtatcgatgt caatctcgatc taagaattca actatatcgat catatttcat ttgtatacac 36120
ataaccatta ctaacgtaga atgtatagga agagatgtaa cgggaacagg gtttggat 36180
tcgcaaacta ttctaataca taatttcttta gttataacgtt ctgcacgta atctattata 36240
gatgccaaga tatctatata attattttgtt aagatgtatgt taactatgtg atctatataa 36300
gtatgtataat aattcatgtt ttttggatata ttgttcaactt ctgttcttgc gatgtctagt 36360
ttcgtaatat ctatagcatc ctcaaaaaat atattcgat atattcccaa gtcttcagtt 36420
ctatcttcta aaaaatcttc aacgtatggat atataataat ctatatttacc tcttctgata 36480
tcattaatga tatagtttt gacactatct tctgtcaattt gatttttattt cactatatct 36540
aagaaaacgga tagcgtccctt agacgaaactt actgcatttta atatctctat tatagttct 36600
ggacataattt catctattat accagaatttta atgggaactt ttccgtatctt atctaacata 36660
gttttaagaa agtcagaatc taagacttgc ttgttcatata ttgggttcatata catgaaatga 36720
tctctattgt ttagtgcatttgc tctgaaaattt ggttacttcat tcttattatgt 36780
cttcccttgc ttagtgcaggat tagaataat tcaatagaat ttgttaccaat aaactgttct 36840
cttatgaatc gtatatcatc atctgaaata atcatgttgc gcatatcattt aacaatttgc 36900
gacttgtctc ctgttatcaa tatactatttgc ttgttataat ttatgtgtgc ggcaatatttgc 36960
tccacgttctc ttaattttgtt tatagttagat atcaatccat atggagatctt agtttgc 37020
ttaaacagat atagttttc tggaaacaaat tctacaacat tattataaag gactttgggt 37080
aaataagtgg gatgaaatcc tatttttattt aatgcgatag ctttgccttc gtgcagatatt 37140
ccaaacgctt ttgttgcatttgc atggcattca ttgttgcatttgc aacgttcaatc aatatctgt 37200
acagatatca tcttttagaga atataactgtt cgcgtttaata gtactacaat ttgttattttt 37260
taatctatctt caataaaaaa attaataatgtt atgattcaat gtataactaa actactaact 37320
gttattgtataacta gaatctatgc atgacgttacc caagaaggat ttctactgccc 37380
aatttagctg cattattttt agcatctcgat tttagtgcatttgc catctgcctt atcgaataact 37440
cttccgtcga tatctacaca ggcataaaaat gtaggagatgt tactaggccc aactgattca 37500
atacgaaaatcc accaatctctt ctttagtttgc tggcgttactt cattaataac ggtgacaggg 37560
tttagcatctt tccaatcaat aatttttttgc gcccggatata catcatcaaa agacttatga 37620
tcctctctca ttgttgcatttgc gcccggatata tcatcttata ttgttgcatttgc cataacatca 37680
gcatccggct tatccgcctc cgttgcatttgc aaccaacgat gggatatac gtcggagctg 37740
tacaccatag cactacgttgc aagatctcgat agacttttgc taacttctcg cttccatata 37800
ttaagttgtc tagttgttgc tgcagcgttgc gctccttcgat ttccatggat tttaatagcc 37860
tcacacacaa tctctgcatttgc agaacgttgc tgcattatgc tttagagatgc tttagagatgc 37920
aactaacaacaa accagcaataaaatc aactgttgcatttgc ttttttttttgc catcatccctc 37980
ttgttgcatttgc tgcatttgcatttgc caaatgttgc tctgatataac cctgttcatcttgc taggtgatgc 38040
ttgttgcatttgc gattctggat gatggatatttgc attatcttgc aagatctcttgc ttatccctt 38100
tttttgcatttgc atcgatttgcg ttgttgcatttgc aagatcttgc aatgttgcatttgc ttgttgcatttgc 38160
cttaaagtgttgc ttgttgcatttgc ctctacacgc gtttgcatttgc agtggagatgc cgtcagctgc 38220
tcttagttgttgc atcatcttgc gctgttgcatttgc cttacttttgc cttacttttgc agtggagatgc 38280
gttattctcg tgcggatataatc ttgttgcatttgc aatgttgcatttgc ttgttgcatttgc agtggagatgc 38340
attgttgcatttgc atcccttgcatttgc taatgttgcatttgc ttttttttttgc atcacaatgttgc 38400
tttttgcatttgc cctgttcatcttgc cttacttttgc atcacaatgttgc ttgttgcatttgc agtggagatgc 38460
ggcaatagac gtttgcatttgc tatacgatgc ttgttgcatttgc gatcccttgc agtggagatgc 38520
accaatatttgc ttcttcgatc cttacttttgc atcacaatgttgc ttgttgcatttgc ttttttttttgc 38580

-29-

agatctctca ttataaaaaag tgatcacgag tttgtaaagc tatgtaaaaa tcacgcggag 41940
aaaagttctc cagaaacgc acaaattgatt atcaaacaca tatacgaaaa atatcttatt 42000
ccagtatctg aagtactatt aaaacctata atgtccatgg gtgacataat tacatataac 42060
ggatgtaaag acaatgaatg gatgcttagaa caactctca ccctaaactt taacaatctc 42120
cgcacatgga actcatgttag cataggcaat gtaacgcgtc tgttttatac atttttttagt 42180
tatctgtatga aagataaact aaatatataa gtataatccc attctaatac tttaacctga 42240
tgtatttaga tcatttttata aatattaacct aactaaaaaga cataacataa aaactcatta 42300
catagttgt aaaaagcggt aggtataaaa tattatggct gccaccgttc cgcggtttga 42360
cgacgtgtac aaaaatgcac aaagaagaat tctagatcaa gaaacatttt ttagtagagg 42420
tctaagttaga ccgttaatga aaaacacata tctatttgat aattacgcgt atggatggat 42480
accagaaaact gcaatttggg gtagtagata cgcaaactt gatgcaagtg actattatcc 42540
catttcgttg ggattactt aaaagttcgat gtttctcatg tctctatata aaggtcctat 42600
tccagtatac gaagaaaaag taaatactga attcattgtc aatggatctt tctccggtag 42660
atacgatatac tatcttagaa agtttctgc tcttccaaca aacgagttt ttagttttt 42720
gttactgact tccattccaa tctataatattt cttgttctgg tttaaaaata ctcagtttga 42780
tattactaaa cacacattat tcagatacgt ctatacagat aatgcacaa acctggcggt 42840
ggcttaggtat atgtatcaaa caggagacta taagcccttgg ttagtgcgtc tcaaagagaa 42900
ttatataattt accggtcccc ttccaaatatg tatcaaagat atagatcacc ctaatcttag 42960
tagagcaaga agtccatccg attatgagac attagctaat attagacta tattgtactt 43020
taccaagtat gatccggat taatgtttt attgttttac gtacctgggt attcaattac 43080
tacaaaaatt actccagccg tagaataatct aatggataaa ctgaatctaa caaagagcga 43140
cgtacaactg ttgtaaatattt tttatgtctt cgtaaaatgt aggttttggaa ccaaacattc 43200
tttcaaagaa tgagatgcat aaaactttat tatccaaatag attgactatt tcggacgtca 43260
atcgtttaaa gtaaacttcg taaaatattt tttgatcact gccgagttt aaacttctat 43320
cgataattgt ttcatatgtt ttaatattta caagttttt ggtccatggc ccattaggac 43380
aaatataatgc aaaataatat cgttctccaa gttctatagt ctctggattt ttttatttt 43440
attcagtaac caaatacata ttagggttat ctgcggattt ataattttgag tgatgcattc 43500
gactcaacat aaataattct agaggagacg atctactatc aaattcggat cgtaaatctg 43560
tttctaaaga acggagaata tctatacata cctgattaga attcatccgt ctttcagaca 43620
acatctcaga cagtctgtt ttgtacatct taatcatatt ctatgaaac ttggaaacat 43680
ctcttctagt ttcaactagta ccttattaa atgctgatc ttctctcagg tacagatttt gaattcgacg 43740
atgctgatc ttcatcgat gtatatttct tcttcgattt cataatcaga ttcttatata 43800
ccgcctcaaa ctctattttt aaattattaa acaataactt attattaatc agtgcgttcta 43860
actcttcgc tattttataa gacttatcta agtctgttactt catcttgcgt gtcstatctc gtaaacacgg 43920
agtcgttatac tccatacagc ctacgaaaac gaaatctgtt atctataggg aacgatgttt 43980
tcacaatcggtt attaataatct ctatcgatccataataatgg attacttaat ggattggcaa 44040
accgttaacat accgttagat aactctgtcc ttcacgtcc tatggatgtg caactcttagt ccgaagcgta tgagtataga gcactatttc 44160
taaattccat cagaccatattt actgagttgg ctactatctt gtacgttatat tgcatggat 44220
catagatggc cttttcagtt gaactggtag cctgttttag catctttttat tatctggctc 44280
tctctgccaat aaatgttctt aatagtcttagt gaatgggtcc ttctatcgat ctatcgaaaa 44340
ttgctatttc agagatgagg ttcggtagtcc taggttccata atgaaccgta atatatcttag 44400
gagggtggata tttctgaagc aatagctgat tatttttttcc ttcttccaaat ctattttgtac 44460
taacaacgac accgactaat gtttccggag atagatttcc aaagatacac acatttaggt 44520
acagactgtt ataatcaaaat attaataatct tattactaaa cattttttgt tttggagcaa 44580
ataccattacc gccttcataa gggaaactttt gtttttttgc ttagtctaact aagatagttt 44640
tagtttccaa caatagctt aacagtggac ctttgcgt gttactcgct ctatattcgat 44700
ataccatggc ttgaggaagc acatatgtt acgcacccgc gttctttttt gtttctactc 44760
cataatactc ccacaaatc tgacacaaac aagcatcatg aatacagtat ctacccat 44820
ctaaagctat gtttagatataa taatccattt acatctgacg taaatcaacg tcacccat 44880
cgaaagataa ttatataatgtt tcatttagtta aagttaggaca taatgtacg actttaaatc 44940
cattttccaa aatataatctt cgaattactt tacatataat atccatcatca acagtcacat 45000
aattacctgt ggttaaaaacc tttgcaatgc cagcggctt gcctttcgcc tctgtatgt 45060
cgtcaccgat gaacgtcatt tctctaaactc ctctattaa tacttttaccc atgcaactga 45120
acgcgttctt ggatataaaaaa tccaaatggat acaatccaa tttttcaaat ttttgaatga 45180

-30-

atgaatatag atcgaaaaat atagttccat tattgttatt aacgtgaaac gtagtattgg 45240
ccatgccccc tactccctta tgacttagact gatttctctc ataaatacag agatgtacag 45300
cttcctttt gtccggagat ctaaagataa ttttctctcc tgttaataac tctagacgat 45360
tagtaatata tctcagatca aagttatgtc cgtaaagggt aacgacgtag tcgaacgta 45420
gttccaacaa ttgttagct attcgtaaca aaactatttc agaacataga actagttctc 45480
gttcgttaatc catttccatt agtgactgtc tcctcaaaca tcctctatcg acggcttctt 45540
gtatccctg ttccgttaac atctcttcat taatgagcgt aaacaataat cgtttaccac 45600
ttaaatcgat ataacagtaa cttgtatgcg agattgggtt aataaataca gaaggaaact 45660
tcttatcgaa gtgacactct atatctagaa ataagtacga tcttggata tcgaatctag 45720
gtatcccccc agcgaacag ttacgtggat cgtcacaatg ataacatcca ttgttaatct 45780
ttgtcaaata ttgctcgcc aacgagtaac atccgtctgg agatatcccg ttagaaatat 45840
aaaaccaact aatattgaga aattcatcca tggtggcatt ttgtatgctg cgtttctttg 45900
gctttctat caaccacata tctgcgacgg agcattttct atcttaata tctagattat 45960
aacttattgt ctcgtcaatg tctatagttc tcatcttcc caacggcctc gcattaaatg 46020
gaggaggaga caatgactga tatatttcgt ccgtcactac gtaataaaaag taatgaggaa 46080
atcgataaaa tacggctca ccatttcgac atctggattt cagatataaa aactctgttt 46140
caccgtgact ttcaaaccaa ttaatgcacc gaacatccat ttatagaatt tagaaatata 46200
tttcattta aatgaatccc aaacattggg gaagagccgt atggaccatt attttatag 46260
taccccgca agcgggtta gacggcaaca tagaagcgtg taaacgaaaa ctatatacta 46320
tagtttagcac tcttccatgt cctgcgtat gacggcacgc gactatcgct atagaggaca 46380
ataatgtcat gtctagcgat gatctgaatt atatttatta tttttcatc agattattta 46440
acaatttggc atctgatccc aaatacgcga tcgatgtac aaaggttaac cctttataaa 46500
cttaacccat tataaaactt atgatttagtc acaactgaaa taaccgcgtg attatTTT 46560
ggtataattc tacacgcgt ggttctgtg actatgaatt caaccccgat tacatttagt 46620
aaatctttaa caaacagcaa gggttcgtca aagacataaa actcattgtt tacaatcgaa 46680
atagaccccc tatkacactt aaaataaaaa atatccttac cctttaccac caaataaaat 46740
tctgatgggt caatgtaat gtattcactt aacagttcca caaatttatt tattaactcc 46800
gaggcacata catcgtcggg attttttatg gcaaacttta ctctccagc atccgtttct 46860
aaaaaaatat taacgagttc catttatatc atccaatattt attgaaatga cgttgatgga 46920
cagatgatac aaataagaag gtacgggtacc tttgtccacc atctcctcca attcatgctc 46980
tattttgtca ttaacttta tttatggaaa cgtacgcca catgcttcca tgacagtgtg 47040
taacactttg gataaaaaat gtttgcattt agtataattt ttcaagactg tcaatctata 47100
atagatagta gctataatattt attctatgtt ggtattgtt aagatgacaa ccttggcata 47160
ttgatcattt aacacagaca tttatggaaa agatagctt aatgaaagag aatcagtaat 47220
tggaaataagc gtcttctcgta tagagtgtcc gtatccaac atgtctgata ttttgatgta 47280
ttccattttt ttatggat ttttctttt attctcgat tttatggat tttatggat tttatggat 47340
accccaacat cggtgaccga ttaagttttt attgatggat ccgtgttcaagg cgtatcttagt 47400
cagatcgat agcctatcca ataatccatc atctgtcgat agatcacatc gtacactttt 47460
taattctcta tagaagagcg acagacatct ggagcaatta cagacacaa tttctttatt 47520
ctctacagat gtaagataact tgaagacatt cctatgtat gtcgaaat tggataacac 47580
ggtattgtat gtatctgtt ccataattcc tttatggat gatagtgtca gagcacaaga 47640
tttccaaatct ttgacaattt ttagcaccat tttatggat tttatggat tttatggat 47700
catggcgat ctgacaacac agggatggaa acggaaagat gaaatgatcc tctcaacatc 47760
ttcaatagat accttgcattt ttttctggc attatctata tttatggat tttatggat 47820
agaatcgat tttatggat tttatggat tttatggat tttatggat tttatggat 47880
tattctatca ccagatgca tttatggat tttatggat tttatggat tttatggat 47940
aaattcatcg gcaaaatgtc tatatctaaa atcataatat gagatgttta cctctacaaa 48000
tattctatcg tccaaatgtt tttatggat tttatggat tttatggat tttatggat 48060
aacggattta attttatattt cctctatcaa gtcctcgatc atataaacag aatgttagata 48120
atcatttaat ccattcgatc tttatggat tttatggat tttatggat tttatggat 48180
gatgaagggtg ggactatatc taacatcttgc attatggat tttatggat tttatggat 48240
atacttgcgtt actatgttta tacacatcttgc tttatggat tttatggat tttatggat 48300
aacagggtgtt atattatattt catcgatcatc acgaagaaca atgtccaaat tttatggat 48360
taatataatata tttatggat tttatggat tttatggat tttatggat tttatggat 48420
ttcatcaacc gttatcgatc tttatggat tttatggat tttatggat tttatggat 48480

-31-

tgttagccttg actacattct cattaattaa ccattccaag tcactgtgtg taagaagatt 48540
atattctatc ataagcttga ctacatttg tcccgatacc attaaagaat tcttatgata 48600
taaggaaaca gcttttaggt actcatctac tctacaagaa ttttgagag ccttaacgat 48660
atcaagtgacg tttatttattt caggagggaa aaacctaaca ttgagaatat cgaaattaat 48720
agcttcaga tacagtgatt ttggcaatag tccgtgtat ccataatcca gtaacacgag 48780
ctggtgcttg ctagacacctt ttcaatgtt taattttttt gaaataagct ttgataaagc 48840
cttcctcgca aattccggat acatgaacat gtcggcgaca tgattaagta ttgtttttc 48900
attatttctt caataccccca atagatgata gaatatcacc caatgcgtcc atgttgtcta 48960
tttccaacag gtcgtatata ccaccaatag aagttttcc aaaaaagatt ctaggaacag 49020
ttctaccacc agtaatttgc tcaaaaatagt cacgcaattc atttcggtt ttaaattctt 49080
taatatcgac aatttcatac gtcctcttt tgaaactaaa cttatTTAGA atatccagtg 49140
catttctaca aaaaggacat gtatacttga caaaaattgt cactttgtt ttggccaacc 49200
tttgggtgtac aaattcctcg gccattttaa tatttaagtg atataaaact atctcgactt 49260
atthaactct ttagtcgaga tatatggacg cagatagcta tatgatagcc aactacagaa 49320
ggcaaacgct ataaaaaaca taattacgac gagcatattt ataaatattt ttattcagca 49380
ttacttgata tagtaatattt aggcacagtc aaacattcaa ccactctcga tacattaact 49440
ctctcatttt cttaacaaa ttctgcaata tcttgcgtaaa aagattcttgg aaactttta 49500
gaatatctat cgactctaga tgaatagcg ttctgtcaaca tactatgttt tgtatacata 49560
aaggcgccca ttttaacagt ttcttagtgc aaaatgttag cgatcctagg atccctttaga 49620
atcacataga ttgacgattc gtctctctta gtaactctag taaaataatc atacaatcta 49680
gtacgcgaaa taatatttac ctgacttgc ggagatctaa acaatctagt ttgagaaca 49740
tcgataagtt catcggaat gacatacata ctatcttta tagaactctt ttcatccagt 49800
tgaatggatt cgtccttaac caactgatta atgagatctt ctatTTATC atttccaga 49860
tgatatgtat gtccattaaa gtaaaattgt gtacgcgttc tttagtct agcagccat 49920
actttaacat cactaatac gatatacataa ggagatgatt tatctatgtt attaagaatt 49980
cgttttcga catccgtcaa aaccaattcc ttttgcctg tatcatccag tttccatcc 50040
tttgtaaaga aattatTTTC tactagacta ttaataagac tgataaggat tcctccataa 50100
ttgcacaatc caaactttt cacaacta gactttacaa gatctacagg aatgcgtact 50160
tcaggtttt tagcttgc tttttcttt tgccgacatt ttcttgcac caactcatct 50220
accatttcat tgattttgc agtggaaataa gctttcaatg cacgggcact gatactattt 50280
aaaacgagtt gatcttcaaa ttccgcccatt taagttcacc aaacaactt taaataacaaa 50340
tatatacaata gtagtagaaat aagaactata aaaaaataaa taattaacca ataccaaccc 50400
caacaaccgg tattattgt ttagtgcact gtttctcat cacttagaac agatttaaca 50460
atttctataa agtctgtcaa atcatcttcc ggagacccca taaatacacc aaatatacg 50520
gcgtacaact tatccattt tacattgaat attggctttt cttagtgcct atcttcatca 50580
tattcatcat caatataac aagtcccaga ttacgagcca gatcttcttcc tacatTTCA 50640
gtcattgata cacgttcaact atctccagag agtccgataa cgtagccac cacttctcta 50700
tcaatgatta gtttcttgag cgcgaaagta atttttgtt ccgttccgga tctatagaag 50760
acgatagggtg tgataattgc ctggccaaat tgcctttctc tttagtgc gatattctagt 50820
tcaccttcta tagatctgag aatggatgat tctccagtcg aaacatattc taccatggat 50880
ccgttttaatt tggatgaa gatggattca tccttaatg ttttctctgt aatagttcc 50940
accgaaagac tatgcaaaaga atttggaaatg cgttccttgc gcttaatgtt tccatagacg 51000
gcttcttagaa gttgatacaat cataggacta gccgcggtaa cttttatttt tagaaagttat 51060
ccatcgcttc tatcttgcgtt agatttattt ttataaaagtt tagtctctcc ttccaacata 51120
ataaaagtgg aagtcatatg actagataaa ctatcagtaa gttttataga gatagacgaa 51180
caatttgcgt attgagaagc atttagtgc acgttattcga tacatttgc attagattta 51240
ctaatcgatt ttgcataactc tataacaccc gcacaagtct gtagagaatc gctagatgca 51300
gtaggtcttg gtgaaggttt aactctcttc ttgattacat tactcatgat taaacctaaa 51360
taatttgcgtt ttgtatata atgatataata ttcttacttt atctcatatg agaataaaaa 51420
tgcgttgcgtt taaccactgc atgatgtaca gatttgcgaa tcgcaaaacca ccagtgggtt 51480
tattttatcc ttgtccatgc tgaattgaat gggagcggat gcccgggttgc tacatTTAGA 51540
gtacattccc gtttttagac cgagactccaa tccgtaaaaa tgcatactcg ttagtttgg 51600
ataactcgga tctgtatata ggtatattcat agattgactt tgatcgatga aggctccct 51660
gtctgcagcc atttttatga tcgtcttttggaaatttcc caaatagttt tataaactcg 51720
cttaatatct tctggaaaggat ttgtattctg aatggatcca ccattctgcca taatcctatt 51780

-32-

-33-

attatgcatt cgtttaaaga tatcacctca tctgacggag acaattttt gtaggttt 55140
agagactttg aagctacttg tttaacaaag ttattcatcg tcgtctacta ttctatcaa 55200
ttttagtta aatttatcac atatcacatt aattgacttt ttggccatt ttccatacg 55260
tttatattct tttaatccgt cgttatccgt ttccgttata tccaggata gatcttgca 55320
gttaaataga atgctcttaa ataatgtcat ttcttatcc gctaaaaatt taaagaatgt 55380
ataaacctt ttcagagatt taaaactctt aggtgggtc ctatcacaca atatcataaa 55440
caaactaata aacattccac attcagattc caacagctga ttaacttcca cattaataca 55500
gcctatttc gctccaaatg tacattcgaa aaatctgaat aaaacatcg tgcacaatt 55560
tgttattatcc aatacagaat gttgtgatt cgtttaaaa ccatcgagaa aggaatagaa 55620
ataaaaatta ttatagtggt ggaattcagt tggatatattc cctccggagt cataaaagga 55680
tactaaacat tggttttat cattaaattac acatttccaa tgagacaat aacaaaatcc 55740
aaacattaca aatcttagagg tagaactttt aattttgtct ttaagtatat acgataagat 55800
atgtttattc ataaacgcgt caaatttttca atgaatcgct aaggagttt agaatctcat 55860
gtcaaattgt cctatataat ccacttcgga tccataagca aactgagaga ctaagttctt 55920
aatacttcga ttgctcatcc aggctcctct ctcaggctt attttcatct tgacgacett 55980
tggattttca ccagtatgtt ttcccttacg tgataaaatca tcgatttca aatccattt 56040
tgagaagtct atgcgccttag atacttttcc cctgtatcgaa gttttaaaaa aatacgctaa 56100
cggtatacta gtaggttaact caaagacatc atatataaaaa tggtaacgcg tcttaactc 56160
gtcggtaac tctttttt gatcgagttc gtcgctacta ttgggtctgc tcaggtgccc 56220
cgactctact agttccaaaca tcataccgat aggaatacaa gacacttgc cagcgggtgt 56280
agatttatca tatttctcca ctacatatcc gttacaattt gttttaaaaa tagatacatc 56340
tatattgcta cataatccag ctatgtatc tatatgacat aataaaattgg taaatcttag 56400
ttctggatt ttactaatta ctaaatctgt atatcttcc atttcatcg gaaaagaatt 56460
taccagatattt cttttttt ccaaactgcg ttaatgtatt ctcttacaaa tattcacaag 56520
atgaatttcg taatatgagt aaaacggAAC gtgatagttt ctcatggcc gtgtttccag 56580
ttataaaaca tagatggcat aacgcacacg ttgttttttca taaaggaata tacaaggat 56640
gtacagaagc acgtggaaaa aaagtatctc ctccatcaact aggaaaaccc gcacacataa 56700
acctaaccgc gaagcaatataatatacgta aacacacaat aagcttggaa tttttatgt 56760
ttctaaaatg tataacaaat acagaaatca attcgatcg ttagtataata ttaagaggac 56820
tattagaagc tggtaatagt ttacagatatttccattt ctaggtttt cgaacagata 56880
ctatagggtt actaggaat aagtatccat tttagaaaaat tccattggcc tcattactc 56940
ctaaagcaca acgagagata ttttcagcg ggatttctca tagacctgta gttttactg 57000
gaggaactgg agtggtaag acgtcacagg taccatggattt attgttttgg ttttatttt 57060
tatttgggg attctctact ctagataaaa tcactgactt tcacggaa ccagtcatc 57120
tatcttcc taggatagct tttagtttagat tgcatacgaa taccattttt aaatcattgg 57180
gatTTAAGGT actagatggc tctccttattt ctttacggta cggatctata ccggaaagaa 57240
taataaaacaa acaaccaaaa aaatatggaa ttgttttcc taccatcaat ttatctctaa 57300
caaaactatt tagttatggc actcttattt tagacgaaat tcatgagcat gatcaaata 57360
gagatattat tatacgatc gcgagaaagc atcatacgaa aatagattct atttttttaa 57420
tgactgccac gtttagggat gacagggaaac ggctaaaatg atttttacct aatcccgcat 57480
ttatacatat tcctggagat acactgttta aaatttagcg ggtattttt cataataaga 57540
taaatccatc ttccagaatg gcatacatag aagaagaaaa gagaaattt gttactgcta 57600
tacagatgtt tactccctt gatggatcat ccggatcgat ctttggca tccggc 57660
agtgtcacga atataaatca tatttagaaa aaagattacc gtatgatatg tatattttt 57720
atggtaaggt tttagatata gacgaaatata tagaaaaatg gtattcatca cctaatgtat 57780
cgataattat ttctactcc tatttggaaat ccagcgatc tatacgcaat gttacacaca 57840
tttatgatatt gggtagagtt ttgtcccccg ctccctttgg agatcgaa caattttttt 57900
ctaaatctat gagagatcaa cggaaagaa gagtaggaag agttaatccct ggtacatacg 57960
tcttatttctt ttagtctgtt tatttgcattt ctatacagcg aatagattca gaatttctac 58020
ataatttat attgtacgct aataagttt atctaacact ccccgaaagat ttgtttataa 58080
tccctacaaa ttggatattt ctatggcgta caaaggaata tatacgatcg ttcgatattt 58140
gtacagaaac atggaaataaa ttattatccatttatttattt gaaatgata gatgtgcta 58200
aactttatgt actaagtcctt attctcgctt aggagttggtaaactttgag aggacgggag 58260
aatttaacttag tattgtacga gaagccattt tatctctaaa ttacaaattt aagattttaa 58320
attttaacaa taaagatgtt gatacgatata tacactttt gttttttttt ttcgggtgtct 58380

-34-

ataacggaac aaacgctact atatattatc atagacctct aacgggatat atgaatatga 58440
tttcagatac tataattgtt cctgttagata ataactaaaa atcaaactct aatgaccaca 58500
tctttttta gagataaaa attttccaca tctccttttgc tagacacgac taaacatttt 58560
gcagaaaaaa gtttattagt gtttagataa tcgtatactt catcagtgt aatgatataat 58620
gtgaacagat aaaaggattt cttgctcaat agattggtaa attccataga atatattaat 58680
ccttcttct tgagatccca catcattca accagagacg ttttatccaa tgatttacct 58740
cgtactatac cacataaaa actagattt gcagtgcgt cgtaccttgtt attccatcca 58800
aacaaaattt tacttttagt tcttttagaa aattctaagg tagaatctctt atttgccaat 58860
atgtcatctc tggaaattacc actagcaaaa aatgatagaa atatataattt atacatcgca 58920
gctggttttg atctactata cttaaaaac gaatcagatt ccataattgc ctgtatata 58980
tcagctgaaa aactatgtt tacacgtt ccttcggcat ttcttttaa tgatataatct 59040
tgtttagaca atgataaaatg tattcatgtcc atgagagacg cgtctccgtc tcgtataaaat 59100
atttcatttag atgttagacg cttaatttgcg ggtatacttc tataaggattt cttaatcagt 59160
ccatcattgg ttgcgtcaag aactactatc ggatgttgcg ggtatctctt agtgcac 59220
atggccttac taaagtttgg gtaaataact atgatatactc tattaattt agatgcata 59280
atttcattcg tcaaggatat tagtacgcac ttgctatcg tattaatacg tgtaatgtaa 59340
tcatataaat catgcgatag ccaaggaaaa tttaataga tgttcatcat ataatcgctg 59400
ctataattca tattaatacg ttgacattga ctaatttgc atatagccctc gccacgaaga 59460
aagctctcgat attcgtttc atcgataaaag gataccgtt aatataactg gttgccata 59520
gtctcatagt ctattaatgt gtaagttcg tacaataca gaatccctaa aatattatct 59580
aatgttggat taatcttac cataactgtt aaaaatggag acggagtcat aactatttt 59640
ccggtttgtac ttactggat agatgaagga ataactccg gacatgctgg taaagacc 59700
aatgtctgtt tgaagaaatc caatgttcca ggtcctaattc tcttaacaaa aattacgata 59760
ttcgatcccg atatccttgc cattctattt accagcatat cacgaactat attaagatta 59820
tctatcatgt ctattctccc accgttataat aaatcgccctc cgctaaagaaa cgtagtata 59880
tccataacaat ggaataacttc atttctaaaa tagtattcg tttctaattc tttaatgtg 59940
aatcgtatac tagaaaggaa aaaattatct ttgagtttc cgtagaaaaa gaaccacgaa 60000
actaatgttc tgattgcgtc cgattccgtt gctgaattaa tggatttaca ccaaaaactc 60060
atataacttc tagatgtaga acattcgct aaaaatttag tagaatcaaa ggatataagt 60120
agatgttcca acaagtggc aattcccaag atttcatcta tattcatctc gaatccgaaa 60180
tttagaaattt ccaagtagat atcccttttc atccgatcg ttagaaaaat acgaacttta 60240
ttcggtaaga caatcatttt ctaaggagta aaataggaag taatgttgcg atgtcggtat 60300
catcgtaaa attaaagggtg ttttttttac cattaaatgtt cattataattt ttaccaat 60360
tggaaattata atataagggtt attgcgcac tcgcgacggg ttagatgcattt gtaaatatag 60420
ctgtatctaa tggatcgatc ggtatttcat catttcgtc tctaataata gcgttttctc 60480
tatctgtttc cattacagct gcgtgaagtt tattggcgtt ataatatgtt aaataataag 60540
aaatacatac gaataacaaa aataaaaataa gatataataa agatgccatt tagagatcta 60600
attttggatc atttgcgttcaaa attcctactt acagaagatg aggaatcggtt ggagatagtg 60660
tcttccttat gtagaggatt tgaatataatct tataatgact tgataactt cttccagat 60720
aggaaatacc ataaatataat ttataaaatgtt ttgaacatg tagatttac ggaggaatta 60780
agtatggat tccatgatac aactctgaga gatttagtct atcttagatt gtacaagtat 60840
tccaagtgtt tacggccgtg ttataaaatgtt ggagataatc taaaaggcat agtggatata 60900
aaggacagga atatttataat tagggaaagca aatgatgact tgatagaata tctcctcaag 60960
gaatacactc ctcagatttacatattt aatgagcgcg tccccataac tgggtcaaaa 61020
ttaattcttt gtggattttca tcaaggatcatttttgcgtt atacaacgtt cgcataataaca 61080
acaacaaaaaa aggtatgtt tctcggttcc aaaaatgtt tagatgaact agtgcgttcca 61140
ataaaattatc aaatacttca aaatttattt gataaaggaa gcggaaacaat aaacaaaata 61200
ctcaggaaga tattttatttgcgtt ggttgcgtt ggccaaactc cataggtac ttttcttatt 61260
tcggattttca gatattccaa attcaccaggc gatttgcgtt ttttggat ttttggat 61320
ttatataatgtt ccacaaatgc cattttgtttt gtcgtggat ttttggat ttttggat 61380
atgtatgtttag atagatgcgc tggatgtttt cctttaggg ttttgcgtt cacgtcaccc 61440
agcataacttgc aatcaccatc cttaaaaaaa aatgataaga tatcaacatg gagatata 61500
tactcggtttag ttaattcttc tactgcatttgcgtt cacaatact acaatacggt 61560
ttaccggaaaaaa taatcacttgcgtt ttttggat ttttggat 61620
gctggaaaaat aaatcacttgcgtt cgtatatttttgcgtt ttttggat 61680

-35-

atttgtggat acaatgagta tttatatacg cgtcgccaat tgcgtcagaa acttagaaga 61740
gtttaactacg gtattcataa aatacgtaaa cggatggta aaaaaggagg ggcattgtaac 61800
ccttttatac gatagaggaa gtataaaaaat taaacaagac gtttagagaca agagacgtaa 61860
atattctaaa ttaaccaagg acagaaaaat gttagaatta gaaaagtgt aatccgaaat 61920
acaatgtt accggattta tggagaaga aataaaggca gaaatgcaat taaaatcg 61980
taaactcaca ttcaaatat atttatctga ttctgataac ataaaaatcatgtaa 62040
gatactaaca cattcaaca ataatgagaa tgtagcatttttatttgat atgaacgaga 62100
cgcagaattc gttatgtgtc tcgaggctaa aacacatttc tctaccacag gagaatggcc 62160
gttataata agtaccgatc aggataactat gctatttgc tctgctgata atcatcctaa 62220
gatgataaaa aacttaactc aactgtttaa atttggcccc tcggcagagg ataactattt 62280
agcaaaatta acggcgtag tgaatggatg tgatttctt cctggactct atggggcattc 62340
tataacaccc accaacttaa acaaaaataca attgtttagt gattttacaa tcgataat 62400
agtactagt ttggcaatta aaaattatta tagaaagact aactctaccg tagacgtgc 62460
taatattgtt acgttataaa acgattacgc taatttagac gatgtctact cgtatattcc 62520
tcctgtcaa tgcactgttc aagaatttat attttccgca ttagatgaaa aatggatga 62580
attnaatca tcttatttag aaagcgtgcc gttaccctgc caattatgt acgcgttaga 62640
accacgcaag gagattgtat tttcagaatg taaaacttta tcatcttata tagatttgc 62700
aaatactaaa tcagatatcg atgttataaa atctatatecc tgcattttcg gatattctaa 62760
cgaaaactgt aacacgatag tattcggcat ctataaggat aatttactac tgagtataaa 62820
taattcatt tactttaacg atagtctgtt aataaccaat actaaaagtg ataataataat 62880
aaatataagg t tactagatta aaaatgggtt tccaactctgt gtgctctaca tgcggtaaag 62940
atatttctca cgaacgatataatttgcatt tacgaaaaaa atcattaaag gatgtactcg 63000
tcagtgtaaa gaacgaatgt tgcgtttaa aatttctac acaaataagaa cctcaacgt 63060
acttaacagt gcaacctcta ttggatataa actaatatgg atccgggttaa ttttatcaag 63120
acatatgcgc ctagaggccc tattttttt attaattata ccatgtcatt aacaagtcat 63180
ttgaatccat cgatagaaaa acatgtgggtt attttttatg gtacgttatt atcggAACAC 63240
ttggtagttg aatctaccta tagaaaagga gttcgaatag tcccatttgg tagttttttt 63300
gaagatatac tttagtgcataa agtatacatg tttagagaata ttcaagttat gaaaatagca 63360
gctgatacgt cattaactttt attgggtatt ccgtatggat ttggcataa tagaatgtat 63420
tgtttaaat tggtagctga ctgttataaa aatgcggta ttgatacatc gtctaaacga 63480
atattggca aagatattt tctgagccaa aacttcacag acgataataag atggataaaag 63540
atataatgatt ctaataatattt aacattttgg caaattttgtt accttaaagg gtgagttat 63600
atgcataact actcctccgt tttttttcc ctcgttctt ttcttaacgt tgtttgcatt 63660
cactctcata atgtaaagat attctaaaat ggtaaacttt tgcataatcg acgoagaaat 63720
tggtataaat tggtaattt tattttcc cgtcaatggc ttagtcacag ctccatcagt 63780
tttatatcct tttagtgtt tctcactctgt gtctaaacat cttagcattt ccatgatctg 63840
tttatcggtt atattggccg gaaagataga tttttttttt ttatttataat tactatttgc 63900
aattttagat ataacttctg gtaatattt ttctacctt tcaatctttt ctatttca 63960
gccggctata tattctgta tattttgtt agtataaca ctttttctgg ctaagaagtc 64020
atatgtggta ttcaactatatac ttttttttttcc attagccctt ccacttctgc 64080
agaataatca gaaattgggtt ctttaccaga aaatccagct actataataag gtcaccgat 64140
gatcattggc aaaatccat attgtaccag attatgtt gcatatttca tttccaataa 64200
ttctgctgt tcttgagaca ttgattttt tgcgttattt tgcgttattt tgcgttattt 64260
taccatttct gccgcataaca ataaacttgcgtt agataaaatc aggggttatca aagtgttttag 64320
cgtggctaga atagtggct tgcgttattt aaagaatgcg tgcgttattt taaaccgttt 64380
taacgaattt tatacttcc agaaatctgt ggcgttacat acatgagccg aatgacatcg 64440
aagattgtcc aatatttttta atagctgtt tttgttccattt atttctatataat ttgactcgca 64500
acaattgttag ataccattaa tcaccgatc ttttttgcattt ggcggacaat agcacaattt 64560
tttagcttgc gactctatgt attcagaattt aatagatataat tctctcaata cagattgcac 64620
tatacatttt gaaactatgt caaaaattgtt agaacgacgc tgcgttatttccat 64680
ttaaataatt taaaatggatc atccgtataa aaatcgataa actgcgcacaa 64740
attgtggcat atttttccaga gttcagtggaa gaagtatcta taaaatgttgc tgcgttatttccat 64800
gagttaatgt atatttttgc cgccttggcc ggcgttattt ggcgttatttccat 64860
ctcagtgcatt cagtgttttccat cgcggccat gaaatatttgc tgcgttatttccat 64920
aaggtaaaaat cgtgttttgc tgcgttatttccat aatgatgcata tgcgttatttccat 64980

-36-

ctggaaaata atctagtaaa actttctagt tatcatgttag taagtgtcga ttgtaacaag 65040
gaactgatgc ctattaggac agatactact atttgcataa gtatagatca aaagaaatct 65100
tacgtgttta attttcacaa gatatgaaaa aaatgttggtg gtagaaccgt cattcattaa 65160
gtgacattat aattttacca atatttggat tataatatacg gtgtatttgc gcacttgcga 65220
cggttgcgc atcggtaaat atagctgtat ctaatgttct agtccgtatt tcattcatttc 65280
gctgtctaat aatagcggtt tctctatctg tttccattac agctgcctga agtttattgg 65340
tcggataata tgtaaaaataa taagaaatac atacgaataa caaaaataaa ataagatata 65400
ataaaagatgc catttagaga tctaattttt ttaacttgtt ccaaattcct acttacagaa 65460
gatgaggaat cggtggagat agtgcatttc ttatgttagag gatttggaaat atcttataat 65520
gacttgataa cttactttcc agataggaaa taccataaat atatttataa agtatttgaa 65580
catgttagatt tattcgagga attaagtatg gaattccatg atacaactct gagagatata 65640
gtctatcttta gattgtacaa gtattccaag tgtatcacggc cgtgttataa attaggagat 65700
aatctaaaag gcatagttgt tataaaggac aggaatattt atatttaggaa agcaaatgtat 65760
gacttgatag aatatctcct caaggaatac actcctcaga ttttatacata ttctaatgag 65820
cgcgtccccca taactgggtt aaaaattaatt ctttggat tttctcaagt tacattttagt 65880
gctgtatacaa cgtcgcataat aacaacaaat aaaaaggtag atgttctcgt ttccaaaaaaa 65940
tgtatagatg aactagtcga tccaataaat tatcaaatac ttcaaaaattt atttgataaa 66000
ggaagcggaa caataaaca aataactcagg aagatattt attcggttaac aggtggccaa 66060
actccatagg tagcttttc tatttccggat ttttagaattt ccaaattcac cagcgattta 66120
tcggttttgg tgaaatccaa ggatttatta atgtccacaa atgcccattt tttgtctgt 66180
ggattgtatt tgaaaatggaa aacgatgtag ttagatagat ggcgtgcgaa gtttccattt 66240
agggttccgc gcttcacgat acccagcata cttgaatcac catcctttaa aaaaatgtat 66300
aagatatacaa catggagtat atcatactcg gattttaaatt ttctactgc atcactgaca 66360
ttttcacaata tactacaata cggttaccg aaaataatca gtacgttctt catttatggg 66420
tatcaaaaac ttaaaatcgt tactgctgga aaataatca ctgacgataat tagatgataa 66480
tttatacaaa gtatacaatg gaatattttt ggatataatg agtatttata tagccgtcgc 66540
caattgtgtc agaaacttag aagagttaac tacggatttc ataaaatacg taaacggatg 66600
ggtaaaaaag ggagggcatg taaccctttt tatcgataga ggaagtataa aaattaaaca 66660
agacgttaga gacaagagac gtaaaatattt taaattaacc aaggacagaa aaatgctaga 66720
attagaaaag tgtacatccg aaatacaaaa tggttaccgga tttatggaaag aagaatataa 66780
ggcagaaaatg caattaaaaa tcgataaact cacatttcaa atatatttctt ctgattctga 66840
taacataaaa atatcattga atgagataact aacacatttc aacaataatg agaatgttac 66900
attattttat tgtgtatgaaac gagacgcaga attcggtatg tgcgtcgagg ctaaaacaca 66960
tttctctacc acaggagaat ggcgttcat aataagtacc gatcaggata ctatgctatt 67020
tgcattctgt gataatcatc ctaagatgt aaaaactta actcaactgt taaaatatgt 67080
tccatctgcg gaggataact atttagcaaa attaacggcg ttatgtgaatg gatgtgattt 67140
ctttcctggc ctctatgggg catctataac acccacaac tttaaaaaaaa tacaattgtt 67200
tagtgatttt acaatcgata atatagtacat tagttggca attaaaaattt attatagaaa 67260
gactaactct accgttagacg tgcgtatataat tggttacgtt attaaacgatt acgctaattt 67320
agacgtgtc tactcgatg ttccctccttg tcaatgcact gttcaagaat ttatattttc 67380
cgcatttagat gaaaatggaa atgaatttta atcatcttattt ttagagaccg tgccgttacc 67440
ctgtcaatta atgtacgcgt tagaaccacg taaggagatt gatgtttcag aagttaaaac 67500
tttatcatct tatatagatt tcgaaaatac taaatcgat atcgatgtt taaaatctat 67560
atcctcgatc ttccggatatt ctaacgaaaa ctgtAACACG atagtattcg gcatctataa 67620
ggataattta ctactgagta taaataattt attttactttt aacgatgtc tggtaataac 67680
caatactaaa agtgataata taataaataat aggttacttag attaaaaatg gtgttccaaac 67740
tcgtgtgctc tacatgcggtaa aagatattt ctcacgaaacg atataaattt attatacgaa 67800
aaaaatcatt aaaggatgtt ctcgtcagtg taaagaacga atgttggtagg taaaatattt 67860
ctacacaaat agaacctcaa cgttaacttac cagtgcaccc tctattggat ataaactaat 67920
atggatccgg ttaattttat caagacatataat ggcgtttagg gttctattt ttttatttt 67980
tataccatgt cattaacaag tcatttgcattt ccattcgatag aaaaacatgt gggattttat 68040
tatggatcgat tattatcgga acacttggta gttgaatcta cctatagaaa aggagttcga 68100
atagtcccat tggatagttt ttttggaaat tatcttagtgc caaaaatgtata catgttagag 68160
aatattcaag ttatgaaaat agcagctgat acgtcattaa ctttatttggg tattccgtat 68220
ggatttggtc ataatagaat gtattgtttt aaatttggtag ctgactgtta taaaatgcc 68280

ggtattgtata catcgcttaa acgaatattg ggcaaaagata tttttctgag ccaaaaacttc 68340
acagacgata atagatggat aaagatatat gattctaata atttaacatt ttggcaaatt 68400
gattaccta aagggtgagt taatatgcata aactactcct ccgttgtttt ttccctcggt 68460
cttttctta acgttgtttgc ccatcactct cataatgtaa agatattcta aaatggtaaa 68520
cttttgcata tcggacgcag aaattggat aaatgttgc attgtattat ttccatatta 68580
ttatgaagac tcctggtaat actgtatggcg tttccaggg aatattctat gactgaatgt 68640
tctcaagaac tacaaaagtt ttcttcaaaa atagctatct cgtctctcaa caaactacga 68700
ggattcaaaa agagagtcaa tgttttgaa actagaatcg taatggataa tgacgataaac 68760
attttaggaa tggtgtttc ggatagagtt caatcctta agatcaacat ctttatggcg 68820
tttttagatt aatacttca atgagataaa tatgggtggc ggagtaagtg ttgagctccc 68880
taaacgggat ccgcacccgg gagtacccac tgatgagatg ttattaaacg tggataaaat 68940
gcatgacgtg atagctcccg ctaagctttt agaatatgtg catataggac cactagcaaa 69000
agataaaagag gataaaagtaa agaaaagata tccagagttt agattagtca acacaggacc 69060
cgggtgtctt tcggcattgt taagacaatc gtataatggc accgcaccca attgctgtcg 69120
cacttttaat cgtactcatt attggaagaa ggatggaaag atatcagata agtataaaga 69180
gggtgcagta tttagaatcgt gttggccaga cgttcacgac actggaaaat gcgtatgtga 69240
tttattcgcac tggtgtcagg gggatacgtt cgatagaaac atatgccatc agtggatcgg 69300
ttcagcctt aataggagta atagaactgt agagggtaa caatcgttaa taaatctgt 69360
taataagatg caaaacattat gtagtaaaga tgctagtgt 69420
gcattattta cgcgcacaca atacagaaga tagcaaagag atgatcgatt atattctaag 69480
acaacagtct gcggacttta aacagaaata tatgagatgt agttatccca cttagagataa 69540
gttagaaagag tcattaaaat atgcggAAC tcgagaatgt tgggatccag agtgttcgaa 69600
tgccaatgtt aatttottac taacacgtaa ttataataat ttaggactt gcaatattgt 69660
acgatgtaat accagcgtga acaacttaca gatggataaa acttcctcat taagattgtc 69720
atgtggatta agcaatagtg atagattttc tactgttccc gtcaataagag caaaagttagt 69780
tcaacataat attaaacact cgttcgacct aaaattgtat ttgatcaatttattatctct 69840
cttggtaata tggatactaa ttgtagctat tttaatgggt gccgcggcaa gcatacagac 69900
gacggtgaat acactcagcg aacgtatctc gtctaaattttaa gaacaagaag cgaacgctag 69960
tgctcaaaca aaatgtgata tagaaatcgg aaatttttattt atccgacaaa accatggatg 70020
taacctcact gttaaaaata tggctctgc ggaogcggat gctcagttgg atgctgtgtt 70080
atcagccgct acagaaacat atagtggtt aacaccggaa caaaaggcat acgtgccagc 70140
tatgtttact gctgcgttta acattcagac gagtgtaaac actgttggta gagattttga 70200
aaattatgtg aaacagactt gtaattcttag cgccgtcgatc gataacaaat taaagataca 70260
aaacgttaatc atagatgaat gttacggagc cccaggatct ccaacaaatttggat 70320
taatacagga tctagcaaag gaaattgtgc cattaaagcg ttgatcaat tgacgactaa 70380
ggccactact caaatagcac cttagacaatgt tgctggtaca ggagttcaat tttatatgt 70440
tgttatcggt gttataatat tggcagcgtt gtttatgtac tatgccaagc gtatgtt 70500
cacatccacc aatgataaaa tcaaacttat tttagccat aaggaaaacg tccattggac 70560
tacttacatg gacacattct ttagaacttc tccgatgggtt attgctacca cggatatgca 70620
aaactgaaaa tatattgtata atattttat agattaacat ggaagttatc gctgatcgatc 70680
tagacgatata agtgaacaa aatatacggg atgaaaaattt tttttttttt gttatacagc 70740
gtcttagagca tcaatgcctt gctatacttc gaccattat taggttggattt attgatatac 70800
tattttttgt tatagtaattt tatttttttta cggtagtct agtaagttaga aattatcaaa 70860
tgttgttgggt ggtgctagtc atcacaattaa ctatttttta ttactttata ctataatagt 70920
actagactga cttctaaacaa acatctcacc tgccataat aaatgctga tattaaagtc 70980
ttcttatttct aacactattc catctgtgga aaataatact ctgacattat cgctaaattga 71040
cacatcggtg agttagatgc ctataaaagta ataattttctt ttgggcacat ataccagtgt 71100
accaggttct aacaacccat ttactggtgc tcctgttagca tacttttttctt ttaccttgag 71160
aatatccatc gtttgcttgg tcaatagcga tatgtgattt ttatcaacc actcaaaaaaa 71220
gtaattggag tggcatatc ctctacgggc tattgtctca tggccgtgtt tggccgtgtt 71280
gtaacacgac tggtagat ttgttctata gagccgattt ccgcaaaatag atagaactac 71340
caatatgtct gtacaaatgt taaacattaa ttgattaaaca gaaaaaaacaa tggccgttct 71400
gggaatagaa accagatcaa aacaaaattt gtttagaataat atgcccacgtt tatacatgga 71460
atataaaata actacagttt gaaaaataac agtattcattt aaacattaa cttgcggggt 71520
taatctcaca actttactgt ttttgaactt tttttttttt agcatcgatc cgtgagaaat 71580

acgtttagcc gccttaata gaggaaatcc cacgcctt ctggatctca ccaacgacga 71640
tagttctgac cagcaactca ttcttcattc atccacctgt tttAACATAT aatAGGcagg 71700
agatagatat ccgtcattgc aatattcctt ctcgtaggca cacaatctaa tattgataaa 71760
atctccattc ttctctgc atttattatc ttgtctcggt ggctgattag gctgtggct 71820
tggtttaggc cttggctat cttgttcaa tctatTTGG tcattaatc tttcatTTCT 71880
tcctggata ttctatcac ctcgttggg tggatTTTG tctatTTAT cgTTTGTaac 71940
atcggtacgg gtattcattt atcacaAAAAA aaactctct aatAGGAGT actGCTAGAA 72000
aacctcatcg aagaagatac catatTTTT gcaggaaAGT tatCTGAGT tgATGATTa 72060
caaATGGTTA ttGCCGCGC AAAATCCAAA tttccaAGAT ctatGCTTC tATTTTAAT 72120
atagtaccta gaacgatgtc AAAATATGAG ttggAGGTGA ttCATAAcGA aaATATCACA 72180
ggagcaatgt ttaccacaat gtataatata agaaACAAAT tgggtctAGG agatgataAA 72240
ctaactattg aagccattga aaACTATTTC ttggatCCTA acaatGAAGT tatGCTCTT 72300
attattaata atacggatAT gactGCCGTC attCCTAAAA aaAGTGGTAG gagaAAGAA 72360
aagaACATGG ttatCTCCG tcaaggatca tcACCTATCT tGTGCACTT CGAAACTCGT 72420
aaaaAGATTA atatttataa agaaaATATG gaATCCGCGT CGACTGAGT tacACCTATC 72480
ggagacaaca aggCTTGTAT atCTAAATATG gCggGAATTa ATGTCCTGAA TGTGTATTCT 72540
cCTTCCACAT CCATAAGATT GAATGCCATT tacggattca ccaataAAAAA taaACTAGAG 72600
aaACTTAGTA CTAATAAGGA ACTAGAAATCG TATAGTTCTA GCCCTCTCA agaACCCATT 72660
aggTTAAATG atTTTCTGGG ACTATTGGAA TGTGTTAAAAA agaATATTC tCTAAACAGAT 72720
attCCGACAA aggATTGATT ACTATAAATG gagaATGTTC CTAATGTAT CTTAAATCCT 72780
gtgtttatAG agcccacgtt taaACATTCT ttATTAAGTG tttATAAAACA cAGATTAATA 72840
gttttatttg aagtattcgt tGATTTCATT CTAATATATG TATTTTTAG ATCTGAATTA 72900
aatatgttct tcatgctaa acgaaaaata cccgatCCTA ttGATAGATT acgACGTGCT 72960
aatCTAGCGT gtGAAGACGA TAAATTAAATG atCTATGGAT tACCATGGAT gacaACTCAA 73020
acatCTGCgt TATCAATAAA TAGTAAACCG AGATGTATA aAGATTGTGc AAAGCTTTG 73080
cgatcaataa atggatcaca accAGATATCT cttAACGATG TTCTCGCAG ATGATGATTc 73140
atTTTTAAG tatttgctA gtcAAGATGA tgaATCTCA ttATCTGATA tattGCAAAT 73200
caCTCAATAT CTAGACTTC tGTTATTATTt ATTGATCCAA TCAAAAAATA AATTAGAAC 73260
tGTTGGTCA tGTTATGAAT CTCCTTCAGA ggaATACAGA CAATTGACAA AATTCAACAGA 73320
cttTCAGAT tttAAAAAAAC tGTTTAACAA ggtCCCTATT GTTACAGATG gAAGGGTCAA 73380
acttaataaa ggatATTGT TCGACTTTG GATTGTTG ATGCGATTCA AAAAGAATC 73440
ctctCTAGCT ACCACCGCAA TAGATCCTGT TAGATACATA GATCCTCGTC GTGATATCGC 73500
atTTTCTAAC gtGATGGATA TATTAAGTC GAATAAAGTG AACATAATA ATTCTTTAT 73560
tGTCATCATG AACGGCGGAC ATATTCACTT GATAATCGG CCCATGTTT CAGGTTAAAG 73620
tacagaatta attAGACGAG ttAGACGTTA tcaAAATAGCT CAATATAAAT GCGTGACTAT 73680
aaaATATTCT aACGATAATA GATACGGAAc gggACTATGG ACGCGATGATA AGAATAATT 73740
tGAAGCATTG gaAGCAACTA AACTATGTG TGTCTGGAA TCAATTACAG ATTCTCCGT 73800
gatAGGTATC gatGAAGGAC AGTTCTTC AGACATGTT TAATTCTGT AGCGTATGGC 73860
aaACGAAGGA AAAATAGTTA TAGTAGCCGc ACTCGATGGG ACATTCAAC gtaAAACCGTT 73920
taataatatt ttGAATCTTA ttCCATTATC tGAAATGGTG gtaAAACTAA CTGCTGTGT 73980
tatGAAATGC ttTAAGGAGG CTTCCTTTTCAAAAGATTG ggtGAGGAAA CGAGAGATAGA 74040
gataATAGGA ggtAAATGATA TGTATCAATC ggtGTGTAGA aAGTGTtACG TCGGCTATA 74100
atatttatTTT ttttatCTAA AAAACTAAAA AtAAACATTG AtAAATTTT AATATAATAc 74160
ttAAAAATGG atGTTGTGTC GTTAgATAAA CGGTtATGT ATTtTGAAGGA AATTGATAAT 74220
gagTTAGATT acGAACCAGA aAGTGCAAAT gagGTGCGAA AAAAActGCC GtATCAAGGA 74280
cAGTTAAAC TATTACTAGG AGAATTATTt TTtCTTAGA AGTACAGCG ACACCGTATA 74340
ttAGATGGTG CCACCGTAGT GtATATAGGA TCGGCTCTG GtACACAT ATCGTTATTG 74400
agAGATCATT tCTATAATTt AGGAGTGTAC AtCAAATGGA TGCTAATTGA CGGCCGCCAT 74460
catGATCCTA ttttAAATGG ATTGCGTGT GtAACTCTAG TGAATCGGTT CGTTGATGAG 74520
gaATATCTAC GATCCATCAA AAAACAACTG CATCCTCTA AGATTATTt AATTCTGT 74580
gtaAGATCCA AACGAGGAGG AAATGAACCT AGTACGGCGG ATTtACTAAAG TAATTCTGCT 74640
ctacAAATG tCATGATTAG TATTTAAAC CCCGTGGCAT CTAGTCTAA ATGGAGATGC 74700
ccGTTTCCAG ATCAATGGAT CAAGGACTTT TATATCCCAC ACgGTAATAA AATGTTACAA 74760
cCTTTGCTC CTTCATATTC AGCTGAAATG AGATTATTAC GtATTtATAc CGGTGAGAAC 74820
atGAGACTGA CTGAGTTAC CAAATTAGAC GCTGTTAAATT ATGAAAAAAT GATGTACTAC 74880

-39-

cttaataaga tcgtccgtaa caaagttagtt gttaactttg attatcctaa tcaggaatat 74940
gactatttc acatgtactt tatgtctgagg accgtgtact gcaataaaaac atttcctact 75000
actaaagcaa aggtactatt tctacaacaa tctatatttc gtttcttaaa tattccaaca 75060
acatcaactg aaaaagttag tcatgaacca atacaacgta aaatatctag caaaaattct 75120
atgtctaaaa acagaaatag caagagatcc gtacgoggta ataaatagaa acgtactact 75180
gagatatact accgatatacg agtataatga tttagttact ttaataaccg ttagacataa 75240
aattgattct atgaaaactg tgggtcaggat attaacgaa tcatccataa attatactcc 75300
ggttgatgat gattatggag aaccaatcat tataacatcg tatcttcaaa aaggtcataa 75360
caagttcct gtaaatttc tatacataga tgtggtataa tctgacttat ttcctagctt 75420
tgttagacta gatactacag aaactaatat agttaatagt gtactacaaa caggcgatgg 75480
taaaaagact ctgcgtcttc cccaaatgtt agagacggaa atagttgtca agattctcta 75540
tcgccctaat ataccattaa aaattgttag attttccgc aataacatgg taactggagt 75600
agagatagcc gatagatctg ttatttcagt cgctgattaa tcaatttagta gagatgagat 75660
aagaacatta taataatcaa taatatatct tataatctt atcttatatc ttatatcttg 75720
tttagaaaaa tgctaattt aaaaatagcta acgctagtaa tccaatcgga agccatttga 75780
tatctataat agggtatcta attcctgtat ttaaatagcg gacagctata ttctcggtag 75840
ctactcggtt ggaatcacaa acattattt catctaattt actatctgta atgaaacagt 75900
ttcccaatga aatggtacaa tccgatacat tgcattttgt tataattttt tttaaagagg 75960
ctggtaacaa cgcacgcgtt cgtttacatg gctcgatcca acaataatag ggtaatcttg 76020
tatctattcc tattccgtact atgctttat caggataaaat acatttacat cgtatatcg 76080
ctttgttagc atcacagaat gcataaaattt gttcgtccgt catgataaaaa attaaagtg 76140
taaatataac tattatttt atagttgtaa taaaaaggaa aatttgattt gatactttcg 76200
gttcttaaa agaaaactgac ttgataaaaaa tggctgtat ctctaaggat acgtatagtc 76260
tatatgatca aaaagagatt aatgtctacag atattatcat tagtcatgtt aaaaatgacg 76320
acgatatcg taccgtaaa gatggtagac taggtgctat ggatggggca ttatgtaa 76380
cttggggaa aacggattt gaatgtttcg gtcactgggg taaagtaagt attataaaaa 76440
ctcatatagt taagcctgaa ttatttcag aaattattcg ttactgaat catatatgt 76500
ttcactgcgg attattgcgt tcacgagaac cgtattccga cgatattaac ctaaaagagt 76560
tacgggaca cgctcttagg agattaaagg ataaaatattt atccaagaaa aagtcatgtt 76620
ggaacagtga atgtatgca cctgtatcaa aaattacttt ttcaaaagaaa aagttttgtt 76680
tcgtcaacaa gttggatgat attaacgttc ctaattctct catctatcaa aagttatTTT 76740
ctattcatga aaagttttgg ccattattag aaattcatca atatccagct aacttatttt 76800
atacagacta ctttcccattt cctccgttga ttatttagacc ggctatttagt tttggatag 76860
atagtatacc caaagagacc aatgaattaa ttacttattt aggtatgatc gttaaagaatt 76920
gtaacttgaa tgctgtatc cagggttatcc agaaggcggt aatagaatac gatgatatta 76980
aaattatttc taataacact accagtatca atttacatca tattacatcc ggcaaaaata 77040
atatgattag aagttatattc gtcgccccgac gaaaagatca gaccgctaga tctgtatTTT 77100
gtcccagtac atctatcacc gtaatgagg taggaatgcc cgcataatattt agaaatacac 77160
ttacagaaaaa gatattttt aatgccttta cagtggataa agttaaacaa ctattagcg 77220
caaaccaagt taaattttac ttaataaaac gattaaacca attaacaaga atacgccaag 77280
gaaagtttat taaaaataaa atacatttt tgcctggta ttgggtagaa gtagctgttc 77340
aagaatatac aagtattttt ttggaagac agccgtctct acatagatac aacgtcatcg 77400
cttcatctat cagagctacc gaaggagata ctatcaaaat atctcccgaa attgccaact 77460
ctcaaaatgc tgatttcgac ggggatgagg aatggatgat attagaacaa aatccctaaag 77520
ctgtattttt acaaagtattt ttatgtatc cgacgacgtt actcaaacac gatattcatg 77580
gagccccgtt ttagggatctt atcaagatg aaatcgtagc agcgtattca ttgttttagga 77640
tacaagatctt ttgttttagat gaagtattga acatcttggg gaaatatggaa agagagttcg 77700
atccctaaagg taaatgtaaa ttacgggtt aagatatcta tacttactt ataggtgaaa 77760
agattaatta tccgggtctc ttaaaaggatg gtgaaattat tgcaaacac gtagatgtta 77820
attttggatctt ggctatgagg catctgtcat tggctggact cttatccgtt cataagtgc 77880
acgtggaaagg tatcaactttt attatcaagt catcttattgt tttaagaga tatctatcta 77940
tttacgggttt tgggttgcata ttcaaaagatc tgagacccaa ttgcacgttc actaataaaat 78000
tggaggccat caacgttagaa aaaaatagaac ttatcaaaga agcatacgcc aaatatctca 78060
acgatgtaaag agacggaaaa atagttccat tatctaaagc ttttagaggcg gactatgtgg 78120
aatccatgtt atccaaactt acaaatactt atatccgaga gatagaagaa catatgagac 78180

-40-

aaacgctgat agatgatcca gataataacc tcctgaaaat ggccaaagcg gggtataaaag 78240
taaatcccac agaactaatg tatattctag gtacgtatgg acaacaagg attgatggtg 78300
aaccagcaga gactcgagta ttgggttagag ttttaccta ctatcttcca gactctaagg 78360
atccagaagg aagaggttat attctaatt cttaacaaa aggattaacg gggtctcaat 78420
attactttc gatgctgggt gcaagatctc aatctactga tatcgctgt gaaacatcac 78480
gtaccggAAC actggctaga aaaatcatta aaaagatgga ggatgtgt gtcgacggat 78540
acggacaagt agttataaggt aatacgctca tcaagtagcgc cgccaattat accaaaattc 78600
taggctcagt atgtaaaacct gtagatctt tctatccaga tgagtccatg acttggatt 78660
tggaaattag tgctctgtgg aataaaataa aacagggatt cgttactct cagaaacaga 78720
aacattgcaaa gaagacattt gcgcgcgttta atttcttagt attcgtaaaa cccaccactg 78780
aggataatgc tattaaagggtt aaggatctgt acgatatgtat tcataacgtc attgatgtat 78840
tgagagagaa atacttctt acggtatcta atatagattt tatggaggtat atattcttga 78900
cgcatcttaa tccttcttaga attagaattt caaaagaaac ggctatcaact atctttgaaa 78960
agttctatga aaaactcaat tatactctag gtggtggAAC tccttatttga attatttctg 79020
cacaggtatt gtctgagaag ttacacaaac aagccctgtc cagttttcac actactgaaa 79080
aaagtggtgc cgtcaaaacaa aaacttgggt tcaacaggtt taataacttg actaatttga 79140
gtaagaataa gaccgaaattt atcaactctgg tatccatgtatctctaaa ctcaatctg 79200
ttaagattaa ttctgaattt gtatgtttgg gagaattaaa tccaaacatc actcttcgaa 79260
aagaaaacaga taggtatgtt gtagatataa tagtcaatag attatacatc aagagagcag 79320
aaataaccga attagtcgtc gaatatatgtt ttgaacgattt catctccctt agcgtcattt 79380
taaaggaatg gggtatggag acattcattt aggacgagga taatatttga ttactgtct 79440
acctaaattt cgttgaaccg gaagaatttga atcttagttaa gtttatgtat gttttccgg 79500
gggcagccaa caagggaaaag atttagtaaaat tcaagattcc tatctctgtc tatacgggat 79560
atgacgactt caatcaaaca aaaaagctca ataagatgac tgtagaactc atgaatctaa 79620
aagaatttggg ttctttcgat ttggaaaacg tcaacgtgtt ccctggagta tggaaatacat 79680
acgatatctt cggtatcgag gcgcgtcggt aatacttggt cgaagccatg ttaaacacact 79740
atggagaagg gttcgattt ctgtatcagc cttgtatct tctcgctagt ttactatgtg 79800
ctagttacga accagaatca gtgaataaaat tcaagttcgg cgcagctagt actcttaaga 79860
gagctacgtt cggagacaat aaagcattgtt taaacgcggc ttttcataaaa aagtcagaac 79920
ctattaacga taatagtagc tgccactttt ttagcaaggt ccctaataa ggaactggat 79980
attacaataa ctttatcgac ttgggtcttc tcatgagaat gggaaaggaaa ctatctgata 80040
agatatctt tcaaaagatc aaggaaatgg aagaaacaga agacttttaa ttcttatcaa 80100
taacatattt ttctatgtatc tgccttttaa acgatggattt ttccacaaat ggcctctca 80160
agtcctcat agaatgatac acgtataaaa aatatacgat aggcaatgac tccttatttt 80220
tagacattag atatgcaaaa atcatagccc cgcttctatt tactcccgca gcacaatgaa 80280
ccaaacacggg ctcgttcgt tgatccatc tagataaaaaa ggcggttacg tcgtcaaaaat 80340
atttactaat atcggtagttt gtagatctca ccaacggat atgaataata ttaatatttag 80400
agtttaggtaa tgcatttttca aattttaaaac atatttgaac ttaacttcag 80460
atgtggtgc atccatagca tttttataat ttcccaataa cacattattt gttacccttg 80520
tcattatagt gggagattt gctctgtgca tatctccagt tgaacgtagt agtaagtatt 80580
tatacaaact ttcttatcc atttataacg tacaatggaa taaaactact ttatcggtaa 80640
acgctgttaa tttagaaataa gtttagggaaa aggctatagt aggctacaa gcagccaaaa 80700
catcaacact tatattcttt gttattatattt tggcaatttgc tgcgtatcattt ctctgggttc 80760
agacgtctga taatccagtc tttaatgtatc taacgagata tatgcgaattt aaaaatacgg 80820
ttaacacgtt gaaatcatta acggatagca aaacaaaattt agaaaagtgtt agaggttagac 80880
ttctagccgc tggtaaggat gatataattcg acttcaatg tgcgttgc ggcgcctatt 80940
ttatagctat gcgattggat aagaaaacat atctggcgca agcttatttgc cgaggtactg 81000
gagacgcgtg gatggtaaaa aaggccggcaa aggtcgatcc atctgctcaaa caattttgtc 81060
agtatttgcgaaaacaaat gaaatcatttgc gagtagttaaa cgcgtacata actcctggat 81120
aatttaggtta tagcggttat ttatgtcactt cgcattttgc ttccgatattt agtaatatgg 81180
aataggtta gataaatgcg gtaacgatgtt ttcctgttaag gaaccataac agcttagatt 81240
taacgttaaa gatgagcata aacataataa acaaaaatttac aatcaaactt ataaacattaa 81300
tatcaaaacaa tccaaaaat gaaatcatttgc gagtagttaaa cgcgtacata actcctggat 81360
aacgttttagc agctgcgcgtt cctattcttag accaaaaattt cgggttcatg ttttcgaaac 81420
ggtattctgc aacaagtcga ggcattttgc ttccgatattt ggcggcattt tccagtatct 81480

-41-

gcctattgtat cttcatttcg ttttcaattc tggctatttc aaaataaaaat cccgatgata 81540
gacccctcaga ctttataatt tcatactacga tgttcagcgc cgtagtaact ctaataatat 81600
aggctgataa gctaacatca tacccttcctg tatatgtgaa tatggcatga tttttgtcca 81660
ttacaagctc ggtttttaact ttattgcctg taataatttc tctcatctgt aggatatcta 81720
ttttttgtc atgcattgcc ttcaagacgg gacgaagaaa cgtaatatcc tcaataacgt 81780
tatcgtttc tacaataact acatattcta ccttttatt ttctacttcg gtaaaaaaat 81840
tagaatccca tagggctaaa tgtctagcga tattttttt cgtttccctc gtacacatag 81900
tgttacaaaaa ccctgaaaag aagttagtat acttgcattc atttctaattg tttccctcag 81960
tccactgtat aaacgcataa tccttgcata gatctggatc atccttgcact accacaacat 82020
ttctttttc tggcataact tcgttgtcc ttacatcatc gaacttctga tcattaatat 82080
gctcatgaac attagggaaat gtttctgatc gaggtctatc aataactggc acaacaataa 82140
caggagttt caccgcgc catttagttt tgaaattaaat catatacaac tctttaatac 82200
gagttatatt ttctgtatc cattgtttca cattgacata tttcgacaaa aagatataaa 82260
atgcgttattc caatgcctt ctgtttaaatg aattactaaa atatacaaac acgtcaactgt 82320
ctggcaataa atgatatctt agaatattgt aacaatgtaa ggaaccataa cagtttagat 82380
ttaacgtttaa agatgagcat aaacataata aacaaaatta caatcaaacc tataacatta 82440
atatacaaaca atccaaaaaaa tgaaatcagt ggagtagtac acgcgtacat aactcctgga 82500
taacgttttag cagctgccgt tcctattcta gacaaaaat ttggtttcat gttttcgaaa 82560
cggtatttcg caacaagtcg gggatcgtgti tctacatatt tggcggcatt atccagatc 82620
tgcctattga tcttcatttc gttttcgatt ctggctattt caaaataaaa tcccgatgat 82680
agacctccag actttataat ttcatctacg atgttcagcg ccgttagtaac tctaataata 82740
taggctgata agctaacatc ataccctccgt gtatatgtga atatggcatg atttttgc 82800
attacaagct cggttttaac ttatttcgtt gtaataattt ctctcatctg tagatatact 82860
attttttgt catgcattgc cttcaagacg ggacgaagaa acgtatatac ctaataacg 82920
ttatcgttt ctacaataac tacatatttc acctttttt tttctactc ggtaaaaaaaa 82980
ttagaatccc atagggctaa atgtctagcg atatttcctt tcgtttcctc tgtagacata 83040
gtgttacaaa accctgaaaaa gaagttagta tacttgcatt catttctaatt gtttcctcca 83100
gtccactgtt taaacgcata atccattgtaa tgatctggat catccttgac taccacaaca 83160
tttctttttt ctggcataac ttctgtgtcc tttacatcat cgaacttctg atcattaata 83220
tgctcatgaa cattagaaaa ttgttctgtt ggaggcttat caataactgg cacaacaata 83280
acaggagttt tcaccgcgc catttagtta ttgaaattaa tcataataac ctctttaata 83340
cgagtttat tttcgctat ccattgtttt acatttacat atttcgacaa aaagatataa 83400
aatgcgtatt ccaatgcctc tctgtttaaat gaattactaa aatatacaaa cacgtcaactg 83460
tctggcaata aatgatatct tagaatattt taacaatttta tttgtattt cacatgttcg 83520
tgatctatga gtttcttcga gaatggcata ggatctccga atctgaaaac gtataatag 83580
gagtttagat aataatattt gagagtattt gtaatataata aactcttttag cggtataatt 83640
agttttttt tctcaatttc tatttttaga tggatggaa aaatgactaa tttttagca 83700
tttagtatcat gaactctaattt caaaatctt atatcttcgt cacacgttag ctcttgaag 83760
ttttaagag atgcattcgt tggttctaca gatggagtag gtcaacaaat ttttgc 83820
acacatgtat gtactggagc cattgttttta actataatgg tgcttgatc gaaaaacttt 83880
aatgcagata gcggaaagctc ttccgcgcga ctttctacgt cgtaattggg ttcttaacgccc 83940
gatctctgaa tggataactag ttttctaaatg tctaatgtga ttctctgaaa atgaaatcc 84000
aattccctccg gcattataga tggatgtaca tcggtaataa aaactataatg atccaacgat 84060
cccttcctcgc aaattcttagt cttaaacccaa aaatcgtata taaccacgga gatggcgat 84120
ttaagagtgg attcttctac cgttttgcattt ttggatgtca tataggaaac tataaagtcc 84180
gcactactgt taagaatgtat tactaacgcg actataatgt taaaatttaag cattttggaa 84240
acataaaaata actctgtaga cgataacttga ctttgcata agtttgcaga caaacgaaga 84300
aagaacagac ctctcttaat ttcaagaa aactttttt cgtattctgt acgtcttagag 84360
tttatataatca taagaatgtt aagaatttagt cggttaatgt tggatgtca taccctaaatg 84420
tgagatttca taatattatc aaaagacatg ataattatc agataaagcg ctgactatga 84480
acgaaaatagc tataatggatc gctcaagaat atagttttgt taaacgtggaa aacgataact 84540
gtatTTTAA tcacgtcagc ggcattctaa taaaatataatg gtatatttcat tccacacact 84600
ctacaatatg ccacaccatc ttccataataa ataaattcgt tagccaaattt attaattttta 84660
gtgaaaatagt tagcgtcaac ttccatagct tccttcaatc taatttgatg ctccacacgg 84720
gcgaatttcca ctcttaacatc cctttccat gcctcaggtt catcgatctc tataatatact 84780

-42-

agtttttgc gtttcacaaa cacaggctcg tctctcgca tgagatctgt atagtaacta 84840
tgtaaatgat aactagatag aaagatgtag ctatatacat gacgatccct taagagaggt 84900
ataataactt taccccaatc agatagactg ttgttatggc cttcgaaaaa agaattttta 84960
taaattttc cagtatttc caaatatacg tacttaacat ctaaaaaatc cttaatgata 85020
ataggaatgg ataatccgtc tattttataa agaaatacat atcgcacatt atacttttt 85080
ttggaaatgg gaataccgat gtgtctacat aaatatgca agtctaaata ttttttagag 85140
aatcttagtt ggtccaaatt ctttccaag tacggtaata gattttcat attgaacgg 85200
atcttcttaa tctctggtc tagtccgca ttaaatgatg aaactaagt actattttt 85260
taactaacga ttacatcacc tctaacatca tcatttacca gaataactgat cttctttgt 85320
cgtaaataca tgtctaatgt gttaaaaaaa agatcataca agttatacgt catttcattct 85380
gtggatttct tgtcattgaa ggataaaactc gtactaatct cttctttaac agcctgttca 85440
aatttatatc ctatatacga aaaaatagca accagtggtt gatcatccgc gtcaatattc 85500
tgttctatcg tagtgtataa caatcgta tcttcttctg tgatagtgcg tacgttataa 85560
aggttgataa cgaaaatatt tttatttgc gaaataaaagt catcgtaga ttttgactt 85620
atattcgcgt ctagtagata tgcttttatt tttggaatga tctcaattag aatagtctct 85680
ttagagtcca tttaaagtt caaacaacta ggaaattggg ttatgatgta taatttttt 85740
agttttata gattctttat tctatactta aaaaatgaaa ataaatacaa aggttcttga 85800
gggttgggtt aaattgaaag cgagaaataa tcataaatta tttcattatc gcgtatccg 85860
ttaagtttgc atcgtaatgg cgtggtaat tacgaataaa gcggataacta gtatgttcc 85920
aaagatggct gaaatcagag ctcatctaaa aaatagcgct gaaaataaag ataaaaacga 85980
ggatattttc ccggaagatg taataattcc atctactaag cccaaaacca aacgagccac 86040
tactccctcgtaaaccaggccg ctactaaaag atcaacccaa aaggaggaag tggaagaaga 86100
agtagttata gaggaatatc atcaaaacaac tgaaaaaaat tctccatctc ctggagtcc 86160
cgacattgtgta gaaagcgtgg ccgctgtaga gctcgatgat agcgacgggg atgatgaacc 86220
tatggtacaa gttgaagctg gtaaagtaaa tcatagtgct agaagcgatc tctctgacct 86280
aaaggtggct accgacaata tcgttaaaga tcttaagaaa attattacta gaatctctgc 86340
agtatcgacg gttctagagg atgttcaagc agctgtatc tctagacaat ttacttctat 86400
gactaaagct attacaacac tatctgatct agtcaccggg gaaaaatcta aagttgttgc 86460
taaaaaagtt aaaacttgcgta agaagtaaaat gcgtgcactt ttttataaag atggtaaact 86520
cttaccgat aataattttt taaatccgt atcagacgat aatccagcgt atgaggtttt 86580
gcaacatgtt aaaattccta ctcatttaac agatgttaga gtatataacaa aacgtggga 86640
ggagggcgtta actagattaa ttttgggg aagcgattca aaaggacgta gacaataactt 86700
ttacggaaaa atgcgtgtac agaatcgca cgtaaaaga gatcgatattt ttgttagagt 86760
atataacgtt atgaaacgaa ttaattgttt tataaacaaa aatataaaga aatcgccac 86820
agattccaat ttcagggtgg cgtttttat gttatggaa actatgttt ttattagatt 86880
tggtaaaatg aaatatctta aggagaatga aacagtaggg ttatatacac taaaaataaa 86940
acacatagaa ataagccccg atgaaatagt tatcaagttt gtaggaaagg acaaagttc 87000
acatgaattt gttgttcata agtctaatag actatataaa ccgctattga aactgacgga 87060
tgattctagt cccgaagaat ttctgttcaa caaactaagt gaacgaaagg tatacgaatg 87120
tatcaaacag tttggtatta gaatcaagga tctccgaacg tatggagtca attatacggtt 87180
tttatataat ttttggacaa atgtaaagtc catatctcct cttccgtcact caaaaaaaaagtt 87240
aatagcgtta actatcaaac aaactgctga agtggtaggt catactccat caatttcaaa 87300
aagagcttat atggcaacga ctattttaga aatggtaaaag gataaaaatt ttttagatgt 87360
agtatctaaa actacgttgc atgaattccat atctatagtc gtatgcacg ttaaatcatc 87420
tacggatgga tgatatacat ctttacacaa ataattacaa gaccgataaa tggaaatgga 87480
taagcgtatg aaatctctcg caatgacagc tttctcgga gagctaagca cattagat 87540
tatggcattt ataatgtcta tattttaaacg ccatccaaac aataccattt ttctcgtgg 87600
taaggatggc cagtttatga ttgatgttgcg atacgataat tataaggctt ctcataattt 87660
ggatctgacc ctcactccga tatctggaga tgaatgcacg actcaccgc acgtatagc 87720
cgaacaattt gcgtgtgtgg atattattaa agaggatatt agcgaatata tcaaaaactac 87780
tccccgtttaa aacgattta taaaaaaaata ccgcaataga tcagatactc gcatcagtcc 87840
agatacagaa aagcttaaaa tagctctagc taaaggcata gattacgaa atataaaaaga 87900
cgcttgcattaa taagtaaatg aaaaaaaact agtcgtttat aataaaaacac gatatggatg 87960
ccaaacgttagt atcatcttct actattgcga cgttatataca cgctttagcg aagaatgctt 88020,
cagaatttgcgtaa acagaggctt accgcatacg aaataaataa tgaattggaa ctatgttta 88080

-43-

ttaagccgcc attgattact ttgacaaaatg tagtgaatat ctctacgatt caggaatcgt 88140
ttattcgatt taccgttact aataaggaag gtgttaaaat tagaactaag attccattat 88200
ctaaggtaa tggtagat gtaaaaaatg tacagttgt agatgtata gataacatag 88260
tttggaaaaa gaaatcatta gtgacggaaa atcgcttca caaagaatgc ttgttgagac 88320
tatcgacaga ggaacgtcat atattttgg attacaagaa atatggatcc tctatccgac 88380
tagaattagt caatcttatt caagcaaaaa caaaaaactt tacgatagac ttaagctaa 88440
aatatttct aggatccggt gccaaatcta aaagttctt gttgcacgct attaatcata 88500
caaagtcaag gcctaataca tctctggaaa tagaattcac acctagagac aatgaaacag 88560
ttccatataa tgaactaata aaggaattga cgactctctc gcgtoatata tttatggctt 88620
ctccagagaa tgtaattctt tctccgccta ttaacgcgc tataaaaacc tttatgttgc 88680
ctaaacaaga tatagttagt ttggatctgg aaaatctata tgccgtaact aagactgacg 88740
gcattcctat aactatcaga gttacatcaa acgggttgc ttgttatttt acacatcttgc 88800
gttatattat tagatatcct gtaagagaa taatagattc cgaagtagta gtcttgggt 88860
aggcagttaa ggataagaac tgaccgtat atctcattaa gctaatacgcccgtgaatg 88920
ctatcagtga tagactagaa gaaagtaagt atgttgaatc taaacttagt gatatttgc 88980
atcgatagt attcaagtca aagaaatacg aaggccgtt tactacaact agtgaagtcg 89040
tcgatatgtt atctacatata ttaccaaagc aaccagaagg ttttattctg ttctattcaa 89100
agggacctaa atctaaccatt gattttaaaa taaaaaagga aaatactata gaccaactg 89160
caaatgtatg attttagtac atgtccagtg aaccaattat ctittggagaa tcgtctatct 89220
ttgttagagta taagaattt agcaacgata aaggcttcc taaagaatata ggttctggta 89280
agattgtgtt atataacggc gtaattatc taaataatata ctattgttt gaatataat 89340
atacacataa tgaagtgggt attaagtccg tgggttgc tattttttt atagcagaat 89400
tcttagttaa tggagaaata cttaaaccta gaattgataa aaccatgaaa tatattaact 89460
cagaagatata ttatggaaat caacataata tcatacgca acatttaaga gatcaaagca 89520
tcaaaatagg agatatctt aacgaggata aactatcgca tggggacat caatacgcca 89580
ataatgataa attttagatta aatccagaag ttagttattt tacgataaaaa cgaactagag 89640
gaccgttggg aattttatca aactacgtca agactcttct tatttctatg tattgttcca 89700
aaacatttt agacgattcc aacaaacgaa aggtattggc gattgatttt gaaacgggt 89760
ctgacctgga aaaatacttt tatggagaga ttgcgttatt ggtagcgcacg gatccggatg 89820
ctgatgctat agctagagga aatgaaagat acaacaaatt aaactctgca attaaaacca 89880
agtactacaa atttgactac attcaggaaa ctattcgatc cgatacattt gtctctatgt 89940
tcagagaagt attctatattt gaaaaagttt atatcatcgca ctggcagttt gctatccatt 90000
attctttca tccgagacat tatgctaccg tcatacgataa cttatccgaa ctaactgctt 90060
ctggaggcaa ggtattaaatc actaccatgg acggagacaa attatcaaaa ttaacagata 90120
aaaagacttt tataattcat aagaatttac ctagtagcga aaactatata tctgttagaaa 90180
aaatagctga tgatagaata gtggtatata atccatcaac aatgtctact ccaatgactg 90240
aatacattat caaaaagaac gatatagtca gagttttaa cgaatacgga tttgttctt 90300
tagataacgt tgatttcgt acaattatag aacgaagtaa aaagttttt aatggcgcat 90360
ctacaatgga agatagaccg tctacaaaaa acttttcga actaaataga ggagccatta 90420
aatgtgaagg ttttagatgtc gaagacttac ttagttacta tttttttt gtctttctt 90480
agcggttaat aataatatgg tatggttct gatatccccg ttctaaatgc attaaataat 90540
tccaaatagag cgattttgt tcctatagga ctttcaact gtggataactc tttttttt 90600
atagatataat taatactttt gtcggtaac agaggttcta cgtcttctaa aaataaaaatg 90660
tttataacat ctggcgtt cataaataaa aacttggcga ttctatataat actcttattt 90720
tcaaatactt ccattgttcc atagatgtga gctactgttag gtgttaccatt tttttttt 90780
tctaatactt tatatttctc tcgaaagat tcttgcacat catctggaa taaaataacta 90840
ctgtttagta aatcagttat tttttttata tcgatattga tggacatttt tatagtttaag 90900
gataataagt atcccaaagt cgataacgac gataacgaag tttttataact ttttaggaaat 90960
cacaatgact ttatcgatt aaaattaaca aaattaaagg agcatgtatt tttttctgaa 91020
tatattgtga ctccagatac atatggatct ttatgcgtcg aattaaatgg gtctagttt 91080
cagcacgggtg gtatgatata agaggtggag gaatttatac atgctggaaag acaagttaga 91140
tggtgttcta catccaatac tatacttataa gatatacccg aagatatgc aactgataaa 91200
tttgtcattt atgatataata cacttttgc gcttcaaga ataaaacgatt ggtattcgta 91260
caggtacctc cgtcgtagg agatgatagt catttgacta atccgttatt gtctccgtat 91320
tatacgtaatt cagtagccag acaaatacgca aataatatga tttttatca agattcattt 91380

-44-

taaaatatt tattagaactctgattaga agccactata gagtttctaa acatataaca 91440
atagtttagat acaaggatac cgaagaatta aatctaacga gaatatgtta taatagagat 91500
aagtttaagg cgtttgatt cgcttggg aacggcggtt cgaaaaatga aaaggtacta 91560
gatacgata aaaaggatc taatttgcata taatgaattc agtgactgtc tcacacgcgc 91620
cataactat tacttatcac gatgattggg aaccagtaat gagtcaattt gtagagtttt 91680
ataacgaagt agccagttgg ctgctacgag acgagacgtc gcctattcct gataagttct 91740
ttatacagtt gaaacaaccc cttagaaata aacgagatgt tggtgtcggt atagatccgt 91800
atccgaaaga tgaactggt gtaccgttcg aatcaccaaa ttttacaaaaaa aatcaatta 91860
aggagatagc ttcatctata tctagattaa ccggagtaat tgattataaa gggttataacc 91920
ttaatataat agacgggggtt ataccctggaa attatcaacg aaaaagtca cgcgatctac tgggataaga 91980
aacacgttag tggctttat tgtttggta tttccaagtt actgctgcag catataacta 92040
tagaatcccc ggttaactacc atagtcggat aaacagattt ctgcataata cgggcaaagt 92100
agaaagatag atcatttgcata attatcaacg taaattggc tcaagggtttt atttattaaat 92160
atggatgcgg ctattagagg taatgtgtt atcatccagc ggctagagac cgccaattcg 92220
tcagcgtgca gacaaaatga agatccaaga tttactggat gcttttagtga aattttaact tggttctaa 92280
gaaagatata ttgagaataa tccagaatgt gatcgttatc ttttactggat aatccatgtt 92340
gcatactcta tagtcagaat tttcatggat gattattaa cggctattca agatttttatt 92400
gctgttacag aatgcgggtgc cattcatgaa tttactggat gtagatttag acgcgtgtct 92460
tcattgacta agtctacaaa tagagataaa aacacgaaatc ttttactggat aatccatgtt 92520
tataccacta tggatacatt gatagctatc tctgaaaatc cactaacaag atcgatagac 92580
cgggtttagt gtaactaggaa aatccaaat tttactggat atcgaggtgt caaactgtgt 92640
catgataata tagaagatata cctattcaact aatgtataatc ttttactggat aatccatgtt 92700
ttttctctac aacaacgatt ggaggattta aatgtataatc ttttactggat aatccatgtt 92760
atttcattcg aagacgctat aaaaagagtt ttttactggat aatccatgtt aacaaacttctt 92820
ttaatgatc tcgatgaaaaa taattttaca ccttgtcat tatgtaaaaaa acgatcgcatt 92880
ggtgcttattttaaacttccat aactggtaat ttttactggat aatccatgtt aacaaacttctt 92940
ttggatggta ataaactgtt taatattgca ttttactggat aatccatgtt aacaaacttctt 93000
ttaaccgaac gaggagacca tatagttgg aacatccgc atcaactatc gttggaaaat 93060
gaacccttga taacaaaact aattttgtca agcgaattac tctgtccgag gaaacgaaag 93120
gttagatttag tggagacca tacctatccg aacatccgc atcaactatc gttggaaaat 93180
gaccttggtag acggaatgtt ttactctggat ccacatccgc atcaactatc gttggaaaat 93240
tcaaccggat ttaaatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 93300
ttaatgaata tcattaaacgcata ttttactggat aatccatgtt aacaaacttctt 93360
ctatatgaaa aaacattatc tagtggatc ttttactggat aatccatgtt aacaaacttctt 93420
ttttttggag aaactgcaac tggaaagtgc ggtgacctgt ttgttgcata cgtacaaaact 93480
aatccatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt aacaaacttctt 93540
tttgcatgtatc ttttactggat aatccatgtt aacaaacttctt 93600
tgtgtcatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt aacaaacttctt 93660
attatcgata ctaattacaa acctgttttttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 93720
attgccgtcg tgcattcgtatc ttttactggat aatccatgtt aacaaacttctt 93780
aataatgacg cgtacgataa agtcaaaacta aacacactttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 93840
aataatagat atagattcgc atttctatac gataggatag ataaacgcatt aatgagaaga 94080
gttccttatttgcata cgtacaaaact aacacactttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 94140
aaaataggtatc ttttactggat aatccatgtt aacaaacttctt 94200
tccaaaaagg gatataatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 94260
cagaaaaatatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 94320
aatagacata agaaatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt 94380
gatatttcat ctccgtaaat atatgtctcatc ttttactggat aatccatgtt aacaaacttctt 94440
atattttagtgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt aacaaacttctt 94500
tttagacgagg gtttagatgg taaaatacaa ttttactggat aatccatgtt aacaaacttctt 94560
tttgttggtag aatggatcag aaaaatcatc ttttactggat aatccatgtt aacaaacttctt 94620
gaagagatttgcata cgtacaaaact aactgtgtatc ttttactggat aatccatgtt aacaaacttctt 94680

gaataccgga atcatagatt tatttgataa tcattgttgc agtataccaa ctatattacc 94740
tcattcaggta gctactctag attatctagt tagaactatc atagatgaga acagaagcgt 94800
gttattgttc catattatgg gatcaggtaa aacaataatc gctttgttgc tcgccttgg 94860
agcttccaga tttaaaaagg ttacatctc agtgcgaac atcaacatct taaaaatttt 94920
caattataat atgggtgttag ctatgaactt gttaatgac gaattcatag ctgagaatat 94980
ctttattcat tccacaacaa gttttattt ctttaattt aacgataacg tcattaatta 95040
taacggatta tctcgctaca ataactctat ttttacgtt gatgaggcac ataataatctt 95100
tgggaataat actggagaac ttatgaccgt gataaaaaat aaaaacaaga ttccttttt 95160
actattgtct ggatctccca ttactaacac acctaataact ctgggtcata ttatagattt 95220
aatgtccgaa gagacgatag attttggtaa aattttatgt cgtggtaaga aagtaattca 95280
gacacttctt aacgaacgcg gtgtgaatgt acttaaggat ttgcttaaag gaagaatatc 95340
atattacgaa atgcctgata aagatctacc aacgataaga tattcacggac gtaagtttct 95400
agataactaga gtagtatatt gtcacatgtc taaacctcaa gagagagatt atatgattac 95460
tagacgacag ctatgttac atgaaatgtt tgataaaaat atgtataacg tgtcaatggc 95520
agtattggaa caacttaatc tgatgaataa ttttagatact ttatccagg aacaggataa 95580
ggaattgtac ccaaacttgcg aaataaataa tggcgttta tacggagaag aattggtaac 95640
gttaaacatt agttccaaat ttaaataactt tattaatcgg atacagacac tcaacggaaa 95700
acattttata tacttttca attctacata tggcggattt gtaattaaat atatcatgtc 95760
cagtaatgga tattctgaat ataatggttc tcaggaaact aatccacata tgataaacgg 95820
caaaccaaaa acatttgcta tcgttactag taaaatgaaa tcgtctttt aggatctatt 95880
agatgtgtat aattctcctg aaaacgtgaa tggttagtca ttgatgtttt tgtttcatc 95940
aaacattatg tccgaatcct atactctaaa agaggtaagg catattttgtt ttatgactat 96000
cccagatact ttttctcaat acaacccaaat tcttggacga tctttagaa aatttcttta 96060
cgccgatatt tctgaaccag ttaatgtata tcttttagcc gccgtatatt ccgatttcaa 96120
tgacgaagtg acgtcattaa acgattacac acaggatgaa ttaattaatg ttttaccatt 96180
tgacatcaaa aagctgttgt atctaaaatt taagacgaaa gaaacgaata gaatataactc 96240
tattctcaa gagatgtctg aaacgtattc tcttccacca catccatcaa ttgtaaaagt 96300
tttattggaa gaattggtca gacaattttt ttataataat tctcgttata agtataacga 96360
taccaagttt cttaaaatgg ttacatcgt tataaaaaat aaagaagacg cttagaatta 96420
catagatgtat attgtaaacg gtcacttctt tttatcgtt aaagtatttgc ataaatctct 96480
tttataaaaa tacgaaaaacg attatattac agtaccgttt agactttctt acgaaccatt 96540
tggttggaa gttaactttc gtaaagaata taacgtggta tcttctccat aaaactgtat 96600
agatataataa agaaataaaat gtcgagctt gttaccatg gataccttgc cggtacattt 96660
gaacccatcg agctgacgtt agacataaaa actaatatta ggaatgccgt atataagacg 96720
tatctccata gagaattttt tggtaaaatg gccaagaaaa tagaaattcg tgaagacgtg 96780
gaattacctc tcggcgaaat agtaataat tctgtgttta taaacgttcc gttgttaata 96840
acctacgcgt attatcacgt tggggatata gtcagaggaa cattaaacat cgaagatgaa 96900
tcaaataatg tattcaatg tggagatata atctgttac taagtagaga ttcgggtact 96960
gtatcatttgc gcgattcaaa gtactgtttt tttcgaaatg gtaatgcgtc tgacatggc 97020
agcgaagtca ctggcgatctt aatggaggct caacaaggta tcgaatctag ttttgggg 97080
ctcgcaataa tcgtcgactc ataaaaaaga gaatagcggt aagtataaaac acgaataacta 97140
tggcaataat tgcgaatgtt ttattctttt cgatattttt ttgataataat gaaaaacatg 97200
tctctctcaa atcgacaaac catctcataa aatagtctc ggcgcgttgg gaggtagtt 97260
ccgctcgat aatctctcca gaataatata cttgcgttgc gtcgttcaat ttatacggat 97320
ttctatagtt ctctgttata taatgcgggtt tgccctcatg attagacgac gacaatagt 97380
ttctaaatgg agatagtgttca gagaatgaa tggattttgg cgttggaaaa attatccata 97440
cagcgtctgc agagtgggtt atagttgttc ttagatatgt aaaataatcc aacttactag 97500
gcagcaattt gtctagataa aataactgaat caaacgggtc agacgttattt gcggtatcaa 97560
tggaaatccaa ttgattaact atctttgaa aatatacatt ttatgatcc aataactgtt 97620
agaatataaga aataatgata agtccatcat cgtgtttttt tgcccttca taagaactat 97680
atttttctt atccaaatgtt acaagattaa tctctccaga gtattttgtac acatctatca 97740
agtattggaa tccataatcg tcttccttc cccaaatataat atgttagtgc gataacacat 97800
attcattggg gagaacccctt ccacttataat atcctctttt aaaaatttac cttacttagtt 97860
ttccagtgtt ctggatagtgtt gttggtttgc actcattata atgtatgtt aacggcttca 97920
atcgccgtt agaaattgtt ttttttagttt ctatattaaat aggagatagt tggcgccca 97980

tagaaaaat gaaatgataa ctgtttaaaa atagcttta gtatggaat tacaatggat 98040
 gaggaagtga tatttggaaac tcctagagaa ttaatatcta ttaaacgaat aaaagatatt 98100
 ccaagatcaa aagacacgca tgggttgct gcgtgtataa caagtgcacgg atatccgtt 98160
 ataggagcta gaagaacttc attcgcgttc caggcgat tatctcaaca aaattcagat 98220
 tctatctta gagtatccac taaactatta cggttatgt actacaatga actaagagaa 98280
 atcttagac gggtgagaaa aggttctatc aacaatatcg atcttcactt tgaagagtt 98340
 atattattgg gtggtaaact agataaaaaag gaatctatta aagattgtt aagaagagaa 98400
 ttaaaagagg aaagtgtatga acgtataaca gtaaaaagaat ttggaaatgt aattctaaaa 98460
 cttacaacac gggataaattt attaataaa gtatataaa gttattgtat ggcgtgttt 98520
 attaatcaat cggtggagga tttatcgcat actatgtt acaatgtaga aattagaaaag 98580
 attaaatcat taaatgattt tattaacgc gataaatacg aatatctgtc ttatatttt 98640
 aatatgctag ttaatagtaa atgaactttt acagatctag tataattgt cagattatta 98700
 agtataatag acgactatct aagtcttta ttgcgagga tgactctcaa attattacac 98760
 tcacggcatt cgtaaccac tgccatggt gtcataaaccg agtatccgtg tccgttattt 98820
 tattaactac tgataacaaa atattatgt gtaacagacg agatagttt ctctattctg 98880
 aaataattag aactagaaac atgttttagaa agaaacgatt atttctgaat tattccaatt 98940
 atttgaacaa acagggaaaga agtatactat cgtcattttt ttctcttagat ccagctacta 99000
 ctgataatga tagaatagac gctatatttc cgggtggcat accccaaaagg ggtgagaatg 99060
 ttccagagtg ttatccagg gaaattaaag aagaagttaa tatagacaat tctttgtat 99120
 tcatalogcac tcggttttt attcatggca tcatalogaaga taccattatt aataaatttt 99180
 ttgaggtat cttcttgc ggaagaatat ctctaaccg tgatcaaatc attgatacat 99240
 ttaaaagtaa tcatgaaatc aaggatctaa tattttttaga tccgaattca ggtatggac 99300
 tccaatacga aattgcaaaa tatgtcttag atactgc当地 actttaatgt tacggccata 99360
 gaggatgtt ttatgaatca ttaaaaaaaat taactgagga tgattgatta aaaaatataa 99420
 attaatttac catcggttat ttttataacg ggattgtccg gcatatcatg tagatagtt 99480
 ccgtctacat cgtaactcg accatctacg cttttaatc ctcttattt tgacatttaat 99540
 ctattagaat tggatcacca aatatttagt cccctcaatta gtttatttgtt aatattttt 99600
 ttagacgata gatcgatggc tcttggaaacc aagggtttcc aaccggactc attgtcgatc 99660
 ggtgagaagt cttttcatt agcatgaatc cattctaattg atgtatgttt aaacactcta 99720
 aacaatttggaa caaattctt tgatttgctt tgaatgattt caaataggjc ttctgttaca 99780
 gtaggcatac cattagataa tctagccatt ataaagtgcg cgtttacata tctacgttct 99840
 ggaggagtaa gaacgtgact attgagacga atggcttcc ctactatctg acgaagagac 99900
 gcctcggtcc atgtcatatc taaaatgaag atatcattaa ttgagaaaaa actaatacc 99960
 tcgcctccac tagaagagaa tacgcattt ttaatgcattt ctccgttagt gtttattct 100020
 tggtaaact cagccaccgc ctgttatttca gtatctttt ttcttagatga gaactctata 100080
 ttagagatac caaagacttt gaaatatagt aataagattt ctattcctga ctgattaaca 100140
 aatggttcaa agactagaca tttaccatgg gatgctaata ttcccaaaca tacatctata 100200
 aatttgcacgc ttttctctt taattcattt aatagagaga tatcagccgc actagcatcc 100260
 ctttcaata gttctccctt tttaaaaggta tctaattgcgg atttagaaaaa ctctctatct 100320
 cttaatgaat tttaaaatc attatatagt gttgctatct ctgcgcgtt ttcccccgg 100380
 tcacgatttt gtcttcagg aaagctatcg aacgttaaccg tagtagccat acgtctcaga 100440
 attctaaatg atgatataacc tgtttttattt tcagcgattt tagcctttt ataaatttct 100500
 tcttgcattt tcgacatattt aacgtatcgc attaatactg ttttcttagc gaatgatgca 100560
 gacccttcta cgtcatcaaa aatagaaaaac tcgttattaa ctatatacga acatagtcc 100620
 cctagttgg agactaattc ttttcatcg actagacgtt tattctcaaa tagtatttt 100680
 tggtgtttaagg atccctggc tagtaagtta accaaccatgg tgaattcttgc acactattt 100740
 acgataggtg tagccgataa acaaattatc ttatgggtt ttaacgc当地 ggtcttagat 100800
 aaaaaattat atactgaacg agttaggacgg atcttaccat ctcttttgc taatgatatt 100860
 gaaatgaagt tatgacattc atcaatgtg acgcatttc tactcttggg attaataatgtt 100920
 ttgatattt taaaaattt atttctaaaa ttgtatcat cgtatattt aaaaatacaa 100980
 tccttcgttta tctctggagc gtatctgat agtggatca tccaggatc ttctatcaaa 101040
 gccttttca ccaataagat aatagccaa ttctgtataaa tattcttaag atgtttgaga 101100
 atatatacag tagtattt tttaccgaca cccgtttcat ggaacaataa aagagaatgc 101160
 atactgtcta atccataagaa aactcttgcg acaaaatgtt gataatccctt gaggcgact 101220
 acgtccgacc ccatcatttc aacggccata ttagtagttc tgcgttgc当地 ataatcgata 101280

taggccgcgt gtgatttact catttatgag tgataagtaa taactatgtt taaaaaatca 101340
 cagcagtatg ttaacttagtc ttctctgatg tttgtttcg atacttttg aatcagaagt 101400
 catactagaa taaagcaacg agtgaacgta atagagagct tcgtatactc tattcgaaaa 101460
 ctctaagaac ttattaatga attccgtatc cactggattg tttaaaatac taaattgaac 101520
 actgttcaca tccttccaag aagaagactt agtgcggac ttaacatgag acataaataa 101580
 atccaaattt ttttacaaa catcaactg caccataatg ggcgttatc tcaaccagct 101640
 atcgottacg cattttagca gtctaacatt tttaaagaga ctacaatata ttctcatagt 101700
 atcgattaca cctctaccga ataaaagttgg aagtttaata atacaatatt tttcgttac 101760
 aaaatcaaat aatggtcgaa acacgtcgaa ggtaacatc ttataatcgc taatgtatag 101820
 attgtttca gtgagatgat tattagatt aatagacatc cggtcacgtt tgaacagttt 101880
 attgcgtcg 0tggaggtcg 0aactacggc gtccgctta gtactcctcc cataataactt 101940
 tacgctatta atctttaaaa tttcatagac tttatctaga tgcgtttctg gtaacatgat 102000
 atcatgtgt aaaaagtttta acatgtcggt cggtttctt ttttagatcat taactctaga 102060
 aatctgaaga aagtaattag ctccgttcc cagacttagt aatgggctt tacctagaga 102120
 cagattaagt tctggcaatg tttcataaaaa tggagaagg acatgcgttc cctccggat 102180
 attttttaca atttcatcca tttacaactc tatagtttg tttcattatt attagttatt 102240
 atctccata atcttggtaa tacttacccc ttgatcgtaa gatacctt acagtcatt 102300
 acatacaact accaatttgg tttgtacata atagattgga tggttgacat ccattgggaa 102360
 ataaaactact cgaacagata gtttatctt cccccatagat acattagccg taatagtgt 102420
 cggcctaaag aatatctttg gtgtaaagtt aaaagtttagg gttctgttc cattattgct 102480
 ttttgtcagt agttcattat aaattctcg 0atgggtccg ttctctgaat atagaacatc 102540
 atttccaaat ctaacttca gtctagaaat aatatcggtc ttattcttaa aatctattcc 102600
 cttgatgaag ggatcgtaa tgaacaaatc ttggcctt gattcggctg atctattatc 102660
 tccgttatac acgttacgtt gactgtcc 0aacttaca ggaatagatg tattcgtatg 102720
 gttgatacta tgtgatatgt gagaaagat tttcttta gtggcatcac tataatgtcc 102780
 agtaatggcg gaaaactttt tagaaatggtt atatataaaa gaatttttc gtgtccaaa 102840
 cattagcaga ttagtatgaa gataaacact catattatca ggaacattat caattttac 102900
 atacacatca gcatcttca tagaaacgat accatcttct ggaacctcta cgatctcggc 102960
 agactccgga taaccagtcg gtggccatc gctaacaata actagatcat ccaacaatct 103020
 actcacatat gcatctatataatctttt atcttgcgtt acgttgcgtt acgaaataaaa 103080
 tttattatcc gtatttccat aataagggtt agtataaaca gagagagatg ttgccgcatg 103140
 aacttcagtt acgtcgccg ttgttgggtt tatttgcacct attactctcc taggttctc 103200
 tataaacatg ggttaattt gtacattctt aaccatatac ccaataaagc tcaattcagg 103260
 aacataaaaca aattctttgt tgaacgttcc aaagtgcac gaagagtcac gaataacgat 103320
 atcgataact ggattgaagg ttacgttac ggttaattttt gaatcggtt gtttaagact 103380
 gctgaatgta tcttccacat caaacggagt ttaatataa acgtataactg tagatggttc 103440
 ttaatagtg tcatttaggag tttaggcaat agaaatatca ttaagttcac tagaatatcc 103500
 agagtgtttc aagcaattt tatttgcgtt acattttata tataattctt cgccctcaat 103560
 ttcccaaata acaccgttac acgaagagat agatacgta ttaatatacatt tatatccaac 103620
 atatgttacg taactgaatc ttccctatcc tttaacttct ggaagttcca aactcagaac 103680
 caaatgatta agcgcagtaa tatactgtc ctaatctcg aagctagcga tagcctgatt 103740
 gtctgacca tgcgttgc taaatccgg tagagaaata tattgcggca tatataaagt 103800
 tggaaatttga ctatcgactg cgaagacatt agaccgttta atagagtcat cccaccgat 103860
 caaagaatta atgatagttt tatttgcattt tattttaaa tggaaaaaagc ttacaataaa 103920
 ctccgttagag aataatctt aatttgcgtt tttcccttaa agtaacagct tccgtaaacg 103980
 ccgtctttat ctcttagtag gtttattgtt ttatgcacct ttcccttac ttcatagaat 104040
 actaaaggca acaaagaaat ttttgcgtt tctctaaagag ctacgtgaga cttaccata 104100
 gaagccaacg aatccctaca tattttgcgtt cagaatacc ctacttcacc accctgttat 104160
 gtctcaatac taataggtct aaaaacccaa tcttgcattac aaaaccaaca cttatcaatt 104220
 acactatttgc tcttaataga cacatctgcc atagattat aatactttgg tagtatacaa 104280
 gcgagtgctt cttcttttagc gggcttaaag actgcgttagt gtcgtgaaat aaccacatct 104340
 ggaaggctt ctcgtttagc catttaatca cggaaacttatt tttttataact tctaatgagc 104400
 aagtagaaaa cctctcatat acaaaaaacgt actcggtgtcc ataatccctc accatagtt 104460
 cacgtttttt agatctcata tgcgttaaaa agttttccca tactaattgg ttactattat 104520
 tttcgtata attttaaca gtttgagggtt ttagattttt agttacagaa gtgatatcga 104580

atattttatc caaaaagaat gaataattaa ttgtcttaga aggagtgtt tcttggcaaa 104640
agaataccaa gtgcttaaat atttctacta cttcattaaat ctttctgtt ctcagattca 104700
gtttctcatc ttttacttga ttgattattt caaagactaa cttataatcc tttttattta 104760
ttctctcggtt agccttaaga aaactagata caaaatttgc atctacatca tccgtggata 104820
tttgattttt ttccatgata tccaagagtt ccgagataat ttctccagaa cattgatgag 104880
acaataatct ccgcaataca ttctcaaataat gaataagttt attagacacg tggaaagttt 104940
acttttttg tacctttgta cattttgaa ataccgactc gcaaaaaata caatattcat 105000
atccttggtc agatactata ccgttatgtc tacaaccgct acataatcgt agattcatgt 105060
taacactcta cgtatctcggtt cgtccaaataat tttatataaa aacattttat ttctagacgt 105120
tgccagaaaa tcctgtataa ttttagttt tttgggtgtt gaataaagta tcgcccataat 105180
attgttaccg tcttcogcca atatagtagt taaattatcc gcacatgcag aagaacacccg 105240
cttaggcgga ttcaatcataa ttttatattt ttctgtaccaaa ctcatttaaa tatcataatc 105300
taaaaatagtt ctgtatataatg tctagcgcta atatattgtat cataatccgt tgcatataatt 105360
aagataacaac aatgtctcgaa aatcatcgac atggcttctt ccatagttt aagatcgctg 105420
tcaaagtttag caacgtgatt catcaacatt tgctgtttt aggtagccaa tactgaacccg 105480
tcgcccattca accattcata aaaaccatcg tctgaatcca ttgataattt ottgtactgg 105540
tttttgagag ctgcgtatcaa tctagcattt ctgcgtcccg gattgaaaaac agaaagagga 105600
tcgtacatcc agggccattt ttctgtaaat agaatcgat aatgtccctt caagaagata 105660
tcagacgatc cacaatcaaa gaattggctt ccgagtttgc aacaaactgc ggactttaac 105720
ctatacatga taccgttttag cataatttctt ggtgatacgt caatcgagttt atcatctatt 105780
agagatctaa agccgggtgtt acattctcca ccaaacatataat tcttattctg acgtcggtt 105840
acataaaaaca tcattgtcc attaacgata acagggaat gaacagcact acccatcaca 105900
tttagttccca atggatcaat gtgtgttaact ccagaacatc ttccatagcc tatgttagga 105960
ggagcgaaca ccactcttcc actattgcca tcgaatgcca tagaataaaat atccctggaa 106020
ttgatagaaa tcggactgtc ggtatgttgc atcatcttca taggattaac aactatgtat 106080
ggtgccgcctt gaagtttcat atcgtaactg atgccgttta taggtctagc cacagaaacc 106140
aacgttaggtc taaatccaaac tatagacaaa atagaagccaa atatctgtt ctcattctgtc 106200
ataacttgag agcatccagt atgaataatc ttctttagat gggatctac cgcattatca 106260
tcgttacaat aaaaaattcc cattctaaatg ttctataattt ctttcttaat catgttatgc 106320
atgtttgtcc tctgaatctc tttggaaattt agatctgata cacctgtat cactatcgga 106380
ttatcctccg taagacgatt aaccaacaac atataattt aagacttttac ttttcttaat 106440
tcataaaatgtt gctggatttag gctataggtt tctccatgtt catacgcgtt ctgcagcgtc 106500
ggaagtttaa taccgaatag tccatcaga ataggatgaa tatagtaattt agtttctgtt 106560
tttctataaa taaaagacaa atcttgttga ctagacatataat cggtaaaatg catggattgg 106620
aatcgtgttag tcgacagaag aatatgttga tttagatggag agtataattt atctaactct 106680
ttgagttggc caccgattctt aggacttagt cgagaatgaa taagtactaa agatgagta 106740
catttcacag aaacacttagc attgttcaat gtgtcttta catggtaag gagttgaaat 106800
agctcggttcc tatttggatc gacaatattt agtttatttca taatgttaag catatccgt 106860
atagtaaaatgt tagatgtgtc atacttgttta gttagttttagt atttagcaat tgcattccca 106920
tcatttctca atctcgactt ccaatcatgtt gttagtgcata ttcgtcgat ggaaaccata 106980
caatcctttt tgatagctgtt tgagatttga tcatttctgtt cacgtttagg tttgttacgt 107040
tgatttcttag cccctgcggaa tataaagtca tcgtctacaa tttgggacaa tgaattgcatt 107100
acactacaag acaaagattt atcagaagtg tgaatatgtt cttcatctac caaagaaaaga 107160
gtttgatttag tataactaga ttttagtccctt gctttagatg tttttttttt atcgctattt 107220
accacggctt ccatttatttta tatttctgtt ttttactcgaa aagcgtgattttaatatcca 107280
atcttatttac ttttggaaatc gtccaaaacc tttgacttagt tttttttttt gatctattgc 107340
cctacgcgtt tactcccttg catcatatac gttcgccacc agatcggtt tttggccctg 107400
aagggtgtcc atatctctt caacattcgaa catgagatcc ttaaggccaa tttttttttt 107460
attttggatc gatgtgtctc ctggattttgg attttggatgtt gctgttgcataactgttacc 107520
accagtaggtt gttaggttac atacagtggc cacaatagga ggttggaaaa gtgtaaaccgt 107580
tggagtagta caagaaatac ttccatccga ttgttgcata catgttagtttgc ttgttaacgt 107640
ctgagaaggtt tgggttagatg gccccgtcggtt cgttttttttgc tttttttttt atttagagat 107700
aatatcctgtt acagcattgc tcggcgtaa cgctggagg agtgaactcg ccggccatc 107760
agtatcttca gacagccaaat caaaaagattt agacatatac gatgtatgtt tagtttgc 107820
tcgtgggtttt ggtgttaggatc cgtactactt aggttggaaat taggagccg attagactgt 107880

-49-

-50-

atcatcacgg tatcgccgtc gctagataac gctaattgtac catccaagtc ccaaattggag 111240
agatttaact gttcatcggt tagaataaaa tgattaccgg tcataattaat aaagtgttca 111300
tcgttatctag ataacaacga ctataatta atgtccaagt cttgaactcg ctgaatgatc 111360
tttttaacc cagttagtt tagattggta cgaaatatat tggtaaaacctt tgattctaca 111420
gtaatgtcca aatcttagtt tgaaataact tccatcaaca ttgtttcaaa cttgataata 111480
ttattatcta catcttcgtc cgatccaaat tccggatag atgtatcgca cgctctggcc 111540
acccagataa ccaaaaagtc acacgctcca ggatatacat tgtataaaaa gctatcgtt 111600
tttagtaggg ttttttctg cgtgtatacg aagggattaa aaatagtatt atcaacgtaa 111660
ctatattcca aattattctt atgagaatacg ataataatat cgtcottaat atctaacaaa 111720
tttccttaat atcccttaa ttgagtcatt cgaagcgtca atagaatatg tctcttaact 111780
attcccgct gttgtatatt taaatgactt cgtaaaaaat aatatatggg cgacttctca 111840
tctatgtaat catatgggt gagatataagg gctcggtcta cctccctggcc cttacccacc 111900
tgtaataccca attgcggact tactatatac cgcattttt tattcggtggg taaagtgaaa 111960
atctactacc gatgatgtaa gtcttacaat gttcgAACCA gtaccagatc ttaatttgga 112020
ggcctccgta gaacttaggg agttaaatat agatcaaaca acacctatga taaaggagaa 112080
tagcggtttt atatccgca gttagacgtct attcgcccat agatctaagg atgatgagag 112140
aaaacttagca ctacgattct ttttacaaag actttatttt ttagatcata gagagattca 112200
ttatttggtc agatgcgtt acgctgtaaa agacgtcaactt attaccaaaa aaataaacat 112260
tacgtggcg ccttatatacg cacttttaac tatcgcatca aaaggatgca aacttacaga 112320
aacaatgatt gaagcattct ttccagaact atataatgaa catacgtaaga aattttaaatt 112380
caactctcaa gtatccatca tccaagaaaa actcggatac cagtttgaa actatcacgt 112440
ttatgatttt gaaccgtatt actctacagt agctctggct attcgagatg aacattcatc 112500
tggcattttt aatatccgtc aagagagtt tctggtaagt tcattatctg aaataacata 112560
tagattttat ctaattaatc taaaatctga tcttggtaaa tggagtgtca gtacgggcgc 112620
tgtaattat caaatgtaa atactgtatt gattacagtg tatgaaaagt tacaactggt 112680
catagaaaaat gattcacaat ttacatgttc attggctgtg gaatcaaaa ttccaataaa 112740
attacttaaa gatagaaatg aattatttac aaaatttattt aacgagttaa aaaagaccag 112800
ttcattcaag ataagcaaac gcgataagga tacgctacta aaatattttt ctttaggactg 112860
gagttagaat ttatagacga ctcatttcgt ttatcattgt tactattattt actattacta 112920
tcattattag tggcattt attagtttc ttcttgcattt cttgttcaga aatatacagc 112980
aatgctatac ctaataactaa atacattatc atgctcgaa tggctctaac aacaacgaac 113040
caaaatgaat ttggcgttag ctttgttca caaaaataca taaagaaatg tctacataaaa 113100
tctatggcgc cattggctac ttgaaatagc gccagtcctc ctacagattt taatatacg 113160
gtataacatg acatttattt atcatcaaaa gagacagagt caccatctgt catattttaga 113220
tttttttca tggttcaaa gtatccctca ctcatttcatttataatagtt tattttactt 113280
agaatttttag gacggatcaa tggtaagac ttgactagat cgtcagtagt aatttggca 113340
tcgtcttattc tgcattccgtc tcgtcgaata atgtatagca tcgcttttagg attctccata 113400
gctatcaagt ctttatacaa tgacatggaa atatctgtca atactttata cttctccaaac 113460
atcgatgcct taacatcatc gcctacttta gcattggaaa tacgttctat tggtagatg 113520
gatgtaccaa gattttaaa caacaatgcc atcttacacg atgattgcct caagtctcca 113580
atcgtttggtt tagaacgatt agtacagag tccaatgtt ggctgactag catatttata 113640
tctttagaaa ttgtattctt caatggggc tttatcattt ctgtgatttc gtttgtcata 113700
ttacagtctg actgggttgt aatgttatcc aacatatcac ctatggatc ggtacacgt 113760
ccagcatttg taataatcct atctaagatg ttgtatggca ttgcgcagaa aatatcttct 113820
cctgtaataat ctccactctc gataaatcta ctcagattt tcttaatgc cttattctct 113880
ggagaaaaaga tgcgtgtc catcatttca ttaatagttt acgcagaaaa gataaccacga 113940
gtatcaattc tatccaagat acttatcggt tccgagtcac agataatggt ttctctccct 114000
tcgggagatc ctgcataaaaa atatcttagga caatagttt tataactgtct gtaactctga 114060
taatctctaa agtcactaac tggataccatg aaatttggaa gatcaaacgc tgaagtaatt 114120
aatttttctg ctcgtttt actacaacta gtttcatca atgtatgtac gatgtattgt 114180
ttagttactt ttggtctaat actgtatgata gagatattat tgcttcccat aatggatctt 114240
ctagtagtca ctttaagcc cattgtatgcg aatagcagat agataaaagtc ttggatgac 114300
tccttctaa tatagtacgg actacccttt tcacccaaact ttataccac ataagccata 114360
acaacctctt taatagccgt ttcattgaggt ttatcagccca tgaggctgag tagttggaa 114420
aatctcatga atccccgtctc agaaagtccct atatgcata tagatttatac tttcctggga 114480

aacttcgtatgtcataga tggaaataactc
gtcttaccccgactactct aggttaacaaa
ataatatcaaaaggataga gcaataagta
taacaggttag aatttataaa catcatgtcc
tccataccgt cccaaaacat ggatttggta
gccaacaggt taaagaaatt aataaagaat
acgttggaa ggcacgggt tacattcact
acgatgttat tgtttactgg tataatctgga
tgatatcgca tagaaatagt aaagttata
ttgtataaaa tatccactct gtcatatgt
tgtttatatg ttggcatagt agtgagatcg
actccataat gtctagcagc atctgcgt
tgtattgttataattgtct aacacctata
ccgttaacaa ttttgcctt gaattcttt
atgttaaaca aataagtgtt atcaaagtt
tccattggat cggagccatc tggttata
gtatccgtca atctaattt aagaagggt
tgagtattaa tgataggatt agttccgaa
atattccatcgtaatgtt aacattaaac
aaataattaa tgcccaattt ggatata
cctaatttggat tattaagcaa tatatcgac
catacttgcattt aatctagaca tagatcg
tcagagtctt ctaattgatc aagagtaact
ttaaatgacg accgtaccatc tgacggat
agataattt ccattctaaca aaaattatga
tcacgttaaac acgtggtag atagagaaca
aatatccgtca caacttaatg aagatctt
cgaacggatc caacccata ctactattat
agagtttataatccgttac aacgtcaaca
gaaaaatgtctt gaaagcaataa tggaaatct
accatcccttggatgtttt atgataaaaga
ggatctt aaaaatcaac gatctaata
caaaatactat tttggtaaga ctccgtac
cgtaattat gcaaatttgc acgggtcccc
ggaggatgaa atagatagaa tctataaaac
aaaaattatcgttcaactaacc tgattattat
aaaactccgat tttgaagaaa tcaaaggact
tgtggagatc ggagatgact gcgatgt
ggttcttaat attgtattgt ttatactcaa
attnaataca ttcccataatc cagacaacaa
ataccggacg acatattat cttttatta
ccagcattaa ctgagtcgat acctagaaga
acttcttaat gcccgtctc gacggat
tggacaatctt gaccatccat cgcattgt
ggagcaccag aagtattttt ggagccctt
gattttggtt tacatgtat acatttgc
gtcacatctg tttgagaatt aagatttgc
attngcgtat gtagattttt aagctgt
tcgttaactgc ttcttaacggc taaattttt
ttatttatgc agaagattt actagattat
tatttacaaa ctggatattt tttggat
tcggatattt taagttctt atcttattat
ctacacaaat accgatcaaa agaagaata
gatcaagtat gcaatataatc atctttc
tcgagatata tggacgatata taatttagt

ttaaaagttt ctgaaataag attagtaaca 114540
caaactctaa taggtgtttt ctctgcggag 114660
gtattattgtt gattataaag accgaataca 114660
tgaaggttt tagactgtt ttcctctgtaa 114720
actttgatag ccgtagatct ttgttccttc 114780
ttgttgcattt tatttatgtc cacaattgc 114840
gcagcatattt gaggatcgat agtatgaagt 114900
aagaatctt ccagtcttgg aataagagat 114960
atctcatcat cgaagagcat tttgttacca 115020
taaatgaagt actgttcaaa catgtgaga 115080
acgttgttataatgtt atggcaatgtt attaagatta 115140
ttataaggctt cgtcaaaagcg gggtcgtt 115200
agattatcaa aatcttgcgtt gcttaataca 115260
atgggtgcatttaatcattt cttatagagg 115320
agatctggat atttcttttgcgtt gcttagaaca 115380
taaccacccgtaaaatcttgcgtt tctgttattt 115440
tgagtgaagatg tggaaagatc gtaaaagctg 115500
ctaattgttataatgtt ttgggttattt aataatatct 115560
agttttaaatcgtt cactgttgcgtt ggtatcaatt 115620
gcctgaagctt catcttgcgtt agttacggat 115680
ggatgaacgaaatgtt aagttggatc 115740
agaacggatc aactataacg aaataaataat 115800
attgacttaatggatcatcat ttatttagt 115860
acaaaacatc ttaatttacag agtttccaga 115920
aataacttccgtcaatgtt ctattcttcaac 115980
tcacgttacaaac acgtggtagttaatgcgtt cttccagagga 116040
aatatccgtca caacttaatg aagatcttattat 116100
cgaacggatc caacccata ctactattat 116160
agagtttataatccgtt aaaaatcaac gatctaata
gaaaaatgtctt gaaagcaataa tggaaatct
accatcccttggatgtttt atgataaaaga
ggatctt aaaaatcaac gatctaata
caaaatactat tttggtaaga ctccgtac
cgtaattat gcaaatttgc acgggtcccc
ggaggatgaa atagatagaa tctataaaac
aaaaattatcgttcaactaacc tgattattat
aaaactccgat tttgaagaaa tcaaaggact
tgtggagatc ggagatgact gcgatgt
ggttcttaat attgtattgt ttatactcaa
attnaataca ttcccataatc cagacaacaa
ataccggacg acatattat cttttatta
ccagcattaa ctgagtcgat acctagaaga
acttcttaat gcccgtctc gacggat
tggacaatctt gaccatccat cgcattgt
ggagcaccag aagtattttt ggagccctt
gattttggtt tacatgtat acatttgc
gtcacatctg tttgagaatt aagatttgc
attngcgtat gtagattttt aagctgt
tcgttaactgc ttcttaacggc taaattttt
ttatttatgc agaagattt actagattat
tatttacaaa ctggatattt tttggat
tcggatattt taagttctt atcttattat
ctacacaaat accgatcaaa agaagaata
gatcaagtat gcaatataatc atctttc
tcgagatata tggacgatata taatttagt

-52-

gactccgcta actctgtggg gtgcgcagtg ctttccccac atagaataaa ttagcattcc 117840
 gactgtgata ataataccaa gtataaacgc cataataactc aataacttcc atgtacgagt 117900
 gggactggta gacttactaa agtcaataaa ggcaagata cacgaaagaa tcaaaaagaat 117960
 gattccagcg attagcacgc cgaaaaata atttccaatc ataagcatca tgtccattta 118020
 actaataaaa attttaaatac gccgaatgaa caaagtggaa tataaaccat ataaaaacaa 118080
 tagttgtac tgcaaaaata atatcttattt ttgtttcga agatatgta aaattaaata 118140
 gtagtacaca gcatgttata actaacagca gcaacggctc gtaattactt atcatttact 118200
 agacgaaaag gtggtggat attttcttc tcaaataata cgaatatatac accatccat 118260
 tttatgcgt gttatatac tctaatactt aatagatcta tagacgacgg gtttaccaac 118320
 aatatagatt ttatcgattt atctaattt aacccttcct taaacgtgaa tgatctatta 118380
 tctggcataa cgatgaccct acctgtatgaa tcggacaatg tactgggcca tftagaataa 118440
 attatcaacg aattatcgtc tacgaacattt tatatcattt gttttatattt taggacgcga 118500
 ataaatggat ataaaataga aaataaacaga tattacaacc agtgttatgg ccgcgcccaa 118560
 ccaggttaggc agtttattt tatcttttac tacaggctt cctggatgta cgtcaccaac 118620
 ggcggacgta gttctagtagt aatttagacgt aagttccgct tgggatattt ttaacgctaa 118680
 agagttAACG ttaatcgatc acccaacgta tttacatcta gtcgttgcg catcttgatt 118740
 ataataatac cattttctat ctctagattt gtcagtgcac tcatgttacc aacataaccct 118800
 aggtcctaaa tatttatctc cgaatttataa ttttgatataa ttctggcacc aacaatttct 118860
 atttccctta tgatcgatc aaaagacgta taatccgta tccccaaaag taaaataatc 118920
 aggacgaata attctaataa actcagaaca atatctcgca tccatatgtt tggagcaaat 118980
 atcggataaa gtagacatag ccggtttccg ttttgcacgt aaccattcta aacaatttggg 119040
 gtttccagga tcgttctac aaaatccagt catgaaatcg tcacaatgtt ctgtcttgta 119100
 attattatta aatatttttgc gacagtgtt ggtatttgc tttagaacaac attttgcac 119160
 gctatcacta tcgcccagga gataatcctt ttttataaaa tgacatcgat gcccggatgc 119220
 tatataatca gtagcgtgtt taaaatcctt aatataattca ggagttacact cgttctgata 119280
 atagattaat gatccaggac gaaatttggaa agaactacat gtttctccat gaattaatac 119340
 atattgtta gcaaatttcg gaactataaa actactacaa tgatctatcg acataccatc 119400
 tatcaaacaa aacttgggtt taatttctcc cggagatgtt tcataatagt acgtataact 119460
 ttcttcgtca aacttaacag ctctattata ttccaggatata taaaatccat attccatata 119520
 tttgtctcgt atatctgcta ttctggatc tattttgatt ctatataagag taacagctgc 119580
 cccatttctt aataatcgatc agtatttataa ctgtttaatg ttggatatac aacatctacc 119640
 ttatttcccg cagtataagg tttgttgcag gtataactgtt caggaatggat tacatttata 119700
 cttcttctat agtcctgtct ttctgatgtt acacatatg caaagaacag aataaacaaa 119760
 ataatgttaag aaataatatt aaataatctgt gaattctgtaa atacattgtat tgccataata 119820
 attacagcag ctacaataca cacaatagac attccacag tggatccatt acctccacga 119880
 tacatttgcg ttactaagca ataggtataa actaagcttag taagaggccaa tagaaaagat 119940
 gagataataa tcatcaatata agagatttgc ggagggtat atagagccaa gacgaacaaa 120000
 atcaaaccga gtaacgttct aacatcattt ttttggaaat tccccaaata atcatttatt 120060
 cctccataat cggtttgcataccttca tctttaggcataa cgttgcattt ctgtgttcc 120120
 tctgtaaata aatctttatc aagcacttca gcaccgcgcg agaagtgcgc aagcatattt 120180
 taatatactt aataactcat ttatataattt aaaaatgtca ctatataaga tggatataa 120240
 tctttatgcc gaaactaaaaaa aaatgacttgc tggatcaccctt ctaagtctt ttaacgaa 120300
 cggggatttc gtagaaggatc aaccgggatc atcctttaag tttctgatc ttaaggatc 120360
 ttacgcctct cttccgtaa agacgacttgc agtatttgcg acatataacaa cgacccgat 120420
 taaaatctt aatgtcaatc caacaaatgc gccaaggatc tttcttccat aacgcaaaatg 120480
 cgtatctgaa gtagtttctt atatgaggaa aatgtatcgaa tcaaaaacgtc ctctatacat 120540
 tactcttgc ttggatcgttgc gatttggatc gacttattacc acgtgttatac ttatggatc 120600
 acacggtaga aaaaccgtca tttgcgttacc caataaaatg ttaatacatc aatgaaagac 120660
 acaggttagat gcagtcggat tggaaatataa gatatccata gatggatgaa gtagtctt 120720
 aaaggaaacta aagactcaaa gtcggatgtt attatagta gtcagttagac atctgacaaa 120780
 cgatgcctt tgtaaatata tcaataagca ttatgatccat ttcatttttgc atgaatcaca 120840
 tacgtataat ctgtatcaca atacagcgtt tacaagatccat ttagcgttattt atccctccat 120900
 gatgtgttat tttttaactg ctacacccat accatctaac cgaatttattt gtaacagttat 120960
 tattatataat gccaaggatc tcaataatccat aaaaactatac tatgcgttag atagttttt 121020
 tgagccatataat tccacagata atattagaca tatggtaaaa cgactagatg gaccatctaa 121080

tagagatatt tgagagggaa aagtcatctc ttgtatcata tattaaaact accaataaga 124440
agagaaaggt caattacggc gaaataaaaga aaactgttca tggaggcact aatgcaaatt 124500
actttccgg taaaaagtct gacgagtatc tgagtactac agttagatcc aacattaatc 124560
aaccttggat caaaaccatc tctaagagga tgagagtta tatcattaat cactctatag 124620
taacgcgtgg aaaaagctct atattacaaa ctatagaaat tattttact aatagaacat 124680
gtgtgaaaat attcaaggat tctactatgc acattattct atccaaggac aaggatgaaa 124740
aggggtgtat acacatgatt gacaaattat tctatgtcta ttataattt tttctgttg 124800
tcgaagatat catccaaaac gagtactta aagaagtagc taatgttga aaccacgtac 124860
tcacggctac ggcattagat gagaattat tcctaattaa gaaaatggct gaacacgtat 124920
tttatggagt tagcaatttc aaaataggaa tgtttaacct gacatttatt aagtcgttg 124980
atcataccgt tttcccctct ctgtagatg aggatagcaa aataaagttt ttaagggga 125040
aaaagctcaa tattgttagca ttacgatctc tggaggattt tataaattac gtgactaat 125100
ccgagaatat gatagaaatg atgaaggaaa gatcgactat tttaaatagc atagatata 125160
aaacggaaatc ggtagatcg taaaagaat tgctctaaa atgaaaaaaaaa acactaattc 125220
agaaaatggat caacgactag ggtataagtt tttggtgctt gatcctaaag ccggagttt 125280
ttatagaccg ttacatttcc aatatgtatc gtattctaat ttatatttgc atcgattgc 125340
tgaardtctt accgtcaagc ggccactctt atcggttaag aataatacag aacgaattat 125400
gatagaaattt agcaatgtt aagtgactcc tccagattac tcacctataa tcgcgagtt 125460
taaaggttaag agttatgacg cattagccac gttcactgta aatatcttta aagaggtaat 125520
gaccaaagag ggtatatatcoa tcactaaaat aagtagttt gagggaaaaag attctcattt 125580
gataaaaaattt ccgctactaa taggatacgg gaataaaaaat ccacccgtata cagccaaatg 125640
tcttgcctt aatgtcatag gtggagtctt tatcaataaa caatctgtcg aaaaagtagg 125700
aattaatcta ttagaaaaaaa ttacaacatg gccaaaattt agggttgtt agccaaactc 125760
attcacccctc tctttttccct ccgtatcccc tcctaatttttta ttaccgacaa gatatcgcca 125820
ttacaagata tctctggata tatcacaattt ggaagcgtt aatataatcat cgacaaagac 125880
atttataacg gtcaatattt ttttgcgtc tcaatattt tctagagtga gtctagaatt 125940
cattagacgt agtttatcat acgatatgcc tccagaagtt gtctatctt taaacgcgt 126000
aatagatagt gctaaacgaa ttactgaatc tattactgac tttatatttgc atacatacat 126060
taatgacctg gtggaaagctg aacacattaa acaaaaaatct cagttaacga ttaacgagtt 126120
caaataatgaa atgctgcata actttttacc tcataatgcac tatacaccgg atcaactaaa 126180
gggattttat atgatatctt tactaagaaaa gtttctctac tgtatcttcc acacttctag 126240
atatccagat agagattcga tggtttgtca tcgcattctt acgtacccggc aatattttga 126300
gacgttggca catgatgaat tagagaatta cataggcaac atccgaaacg atatcatgaa 126360
caatcacaag aacagaggca cttacccggc aaacatttcat gtactaacaa cttccggact 126420
taatcaccgc tttcttagct tattgagtgg aaagtccaaa aagtccagacg gtatgtatcg 126480
aacacatccct cactattcat ggatgcagaa tatttctatt cctaggagtg ttggattttt 126540
tccggatcaa gtaaaagattt caaagatgtt ttctgtcaga aaataccatc caagtcataa 126600
tctttacttt tggatcatcg acgttccggaa aagaggctt caggttaggtt tagtatctca 126660
attgtctgtc ttgagttcca ttacaaatat actaacgtct gagtatttgg atttggaaaa 126720
gaaaatttgt gagtatatac gatcatatta taaagatgtt ataaatgttact ttgaaacagg 126780
atttccaaatc actatagaaa atgctcttagt cgcattctt aatccaaata tgatatgtga 126840
ttttgttaact gacttttagac gtagaaaaacg gatgggattt ttcggtact tggaggtagg 126900
tattacttta gtttagggatc acatgaatga aatttcgtt aatattggag cgggaagatt 126960
agtcagacca ttcttgggtt tggataacgg agagctcatg atggatgtgt gtccggagtt 127020
agaaaagcaga ttagacgaca tgacattctc tgacatttcgaa aagagtttccgcatgtcat 127080
cgaaaatggta gatatagaac aatttacttt tagtaacgtt tggatgttccgg ttcaaaaatt 127140
tagaatgtatc tcaaaggatg aaagaaaagca atacgatttta tggatgttccggcatgtcat 127200
tagagatgga tatgttagcat cttcactagt gggaaatcaat cacaattctg gacccagagc 127260
tattcttggta tggatgttcaag cttaaacaatc tatctcttgc tggatgttccgg atatacgaaa 127320
taaaatagac aatggaaattt atttgtatgtt tccagagagg ccaatcgatc tttagttaggc 127380
tttagaaact tcaaaggatg cggcttattt cttccggccaa catgttacta tagcattaaat 127440
gtcgtacaaa ggtatcaatc aagaggatgg aattatcatc aaaaaacaat ttatttcagag 127500
aggccgtctc gatattgtt cagccaaagaa acatcaagta gaaattccat tggaaaactt 127560
taataacaaa gaaagagata ggtctaacgc ctattcaaaa tttagaaagta atggattatgt 127620
tagactgaat gttttcttgg aatccggaga cgctatggca cgaaaatatct catcaagaac 127680

tcttgaagat gattttgcta gagataatca gattagcttc gatgttccg agaaatatac 127740
cgatcatgtac aaatctcgcg ttgaacgagt acaagttagaa cttactgaca aagttaagg 127800
acgagtatta accatgaaag aaagaagacc cattctagga gacaaatcca ccactagaac 127860
gagtc当地 ggaacagtcg cgtatgtcgc ggatgaaacg gaacttccat acgacgaaaa 127920
tggatcacca ccagatgtca ttattaattc tacatccat ttctctagaa aaactatatac 127980
tatgttgata gaagtttattt taacagccgc atattctgct aagccgtaca acaaataagg 128040
agaaaaccga cctgtctgtt ttctctagtag taacgaaaca tccatcgata catatatgca 128100
attcgctaaa caatgttatg agcattcaaa tccgaaatttgc tccgatgaaag aattatcgga 128160
taaaatctt tggaaaaga ttctctatga tcctgaaacg gataaggcctt atgcattcaa 128220
agtatTTT ggaccaattt attacttgcg tctgaggcat ttaactcagg acaaggcaac 128280
cgtagatgt agaggtaaaa agacgaagct cattagacag gcgaatgagg gacgaaaacg 128340
tggaggaggt atcaagttcg gagaaatgga gagagactgt ttaatagcgc atggcag 128400
caactattt acagaagttt tggaaagattc ggaagaagat tatcaagatg tggatgttt 128460
tgaaaattgt ggagacatag cagcacaat caagggtatt aatacatgtc ttagatgtt 128520
aaaacttaat ctctctcc tcctaacaat aattgatacc acgcacgtat ctaaagtatt 128580
tctactcaa atgaacgccca gaggcgtaaa agtcaaatta gatttgcac gaaggcctt 128640
ttcgTTTaaaccatttag ataaagtgtt tctcaagccg tctttctgg tgtaatatto 128700
tagtttggta gtagatacat atcaatatac tcaaattcga gatccgaatttataatggg 128760
cgtagattgt taactataga atcggacgtc tgatattcga aaatctgtgg agtggcagg 128820
tttggggag gtgttaactgc tacttggat actgaagtct gatattcaga aagctgtgg 128880
tgttctgggtt cggcatccac cgatgggtgc acatcaactaa tcgggttcggg aacgtctgt 128940
gatggaggtg ctacttctac agaacctgtt gcctcagttg tcaacggaga tacattttt 129000
atgcgagaaa atgtataatt tggtaatggt ttcttatgtt gatctgaaga agaggttaaga 129060
tatctacttag aaagataccg atcacgtttt agttctttt tggtaaactt aactttttt 129120
ttctccgcatttctatgttatac ttcacgttac tacgttcaga ttcaattca 129180
cgtagcgtat ggttacttcc gcaatTTTTTt ctagccgtt cacgttcagg cttcatgcgt 129240
ctctccctct ctctatcgat tttatcgat cagtttttctt gatccatccata 129300
aatttctcca acgttttgc ttttccata gatttccgaa gttcagttt tagactgtg 129360
attctttttt tttcgaattt acagctggat gtacaaccgt ttccattacc gccatctcta 129420
agtttctttt ttagatccgc aadatttcat ccccatgcct tttacattcc tcgagtctac 129480
tgtcgtcgaa atatcgatcc agtccctttt ctagatcaat aacttttagca cgttgcgtt 129540
caagctctct tttgtatgtt tctgattccc tggcacgtt aagatcttca tgcaatttgag 129600
tcagctctta acttcccttc ttgtttcttc gtcatagttac ggcacatcac tggagatcc 129660
attgttacca cgtctacact cggcgagctc ggcgtttaaga gattcaattt cccgtttgtt 129720
tttgtccatg tttccattgc taccaccatt agatttacag gctgttagtt gtgttcgag 129780
atcagaatata cgggttttct tggaaattgtt ttcgtcgatg tacttggat cggaaacactt 129840
attaagttct ttttccattt ctagatgtttt atttctttcg ctagtcaattt ccctcctgtt 129900
gtaaactatct gtttgcgtt attcacgttc tctacgttac ctttcttgc agtactaat 129960
ttgttcccta gcacgtccga gtttagttt atatcgatgaa tagatgttgc attcatccctt 130020
tgagcagatc tctagcgatc gtttaagatt cctaatttca gtcttttagcc tatttacctt 130080
ctcagaagat gttccgttac cgttgcgtt acactcgat agtctgttat caagatccat 130140
gattctatct ctaagacgtt gatctcttcc ttccatatca gcatgttccatttac 130200
tctcgagtca ctcaactgtc tttcaatattc tgagatttca tctctaaagac gtgcgttcc 130260
tctctgtttc ggcattgggtt tatttattac gtctacgtc gttcaactgt ctttcaagat 130320
ctgatattct agattggatgt ctgctaatct ctgttagattt ttcacggat tcaactcgat 130380
gtctttcaag atctgaaattt ttagattggat gtcgttcaat ctctgttgc tttccctctt 130440
cgctctcgat gcaatcggtc aacttatttct ctagttctctt aatacgccaa cgcagtcgt 130500
caacttcttg cgtgtttcc tggttgcgtt tacatttca gacttcaat tggatcttc 130560
taacgcgtcg tgcgttcc tcaagttcttcc tgcgttactac agaaaggctg tcccttatctt 130620
gttgatattt agcaatttctt gatttcttagat tactgatttt gcttacgttag ttactaat 130680
ttgtcttggc ttatcaaga tcccttgcgtt atttgcgtt tcccttgcata tccctacgaa 130740
gtctggacag ttcccattcg acatttacgac gtttacgtt ttcagctcg agatcgatct 130800
cgcgTTTttt tagccacata cgtactgatgtt caagttctcg ttgacaagat ccattctactt 130860
ttccatttcc aatagatatcc agttccctttt ttagttctga acgcatttctt cgttcccttat 130920
caagcgattc tctcaatttctt cggatagtc tcttataat tctgaaccat 130980

-56-

catctgtccc attttgaata tccctgtgtt ctttgatctc ttttgaagt cggtcgattc 131040
tttcgggttt ataaacagaa tcaccttcca aagtctaat cttactgagt ttatcaactaa 131100
gttctgcatt caattcggtg agttttctct tggctcttc caactctgtt ttaaactctc 131160
caactattcc gcattctcc tcgcatttat ctaaccattc aattagttt ttaataacta 131220
gttggtaatc agcgattcct atagccgttc ttgttaattgt gggAACATAA ttaggatctt 131280
ctaattggatt gtatggcttg atagcatcat ctttatcatt attaggggga tggacaacct 131340
taattgggtt gtcctcatct cctccagtag cgtgtggttc ttcaataccca gtgttagtaa 131400
taggtttagg caaatgttg tcgtacgcgg gcacttcctc atccatcaag tatttataat 131460
cgggttctac ttcagaatat tctttctaa gagacgcgac ttccggagtt agtagaaagaa 131520
ctctgtttct gtatctatca acgctggaaat caatactcaa gttaaggata gccaataacct 131580
catcgtcatc atccgtatct tctgaaacac catcatatga catttcatga agtctaacct 131640
attgataaaat agaatcagat ttagtattaa acagatcctt aacctttta gtaaacgcatt 131700
atgtatattt tagatctcca gatttcataaa tatgatcaca tgccttaaat gtcagtgttt 131760
ccatgatata atctggaaaca ctaatgggtt acgaaaaaga tacagcacca tatgctacgt 131820
tgataaataa atctgaacca ctaagtagat aatgattaat gttaagaaaag agggaaatatt 131880
cagtgtatag gtatgtcttgc ggcgtcatatc ttgtactaaa cacgctaaac agttgtttaa 131940
tgtgtatcaat ttccaaataga ttaatttagag cagcggaaat accaacaac atattaccac 132000
atccgtattt tctatgaata tcacatatac tgtaaaaaaa tcttgataga agagcgaata 132060
tctcgtctga cttaatgagt ctagtttcag cagcaacata agtcataact gtaaatagaa 132120
catactttcc ttagtggttt attctagact ccacatcaac accattatta aaaatagttt 132180
tatatacattt ttaatctgc tctccgttta tcgtogaacg ttctagtata cggaaacact 132240
ttgatttctt atctgttagtt aatgacttag tgatatcacg aagaatatta cgaattacat 132300
ttcttggttt tcttgagaga cctgatttcag aactoaaactc atcggtccat agttttctta 132360
cctcagtggc gaaatcttgc gagtgtttgc tacatttttca aataagggtt cgtgacctcca 132420
tttattataa aaaattttt caaaacttaa ctacaatcgg gtaattataa aatcgttagat 132480
ctcccatgtg gcggaaataact accatctatc gcatgtggat ggacagtagg taatggccat 132540
gggaaacagta atgtttgcattttt cttgccagta ttactgcata ttgtcccaat 132600
gtttcgatgt gatgttctaa cctatcaact gccgctgtat cacaacaata gtgtcccgatg 132660
aaattaagat tatgatccaa tgggttttaat atatgattat caagtcttat acgatccgcg 132720
tctttttgaa caggatcagg ttcttctaca ggaagaagtt tcggccttctt atgatattca 132780
tgtctggaa acgggtgttctt agggtgaggc tccggtatcg gagtgggttt tggattataa 132840
tcatcatcgat ctatgacatc atcttcgact tcgatattta ttttgcatttc ttgtatgtt 132900
cctgtatcgat ttgcattttc agcacttcgac tgaatattag cgcatttcatt gtctattt 132960
accatatttc taaaccaaa atgtatgtgt tgaacatcag tactatcgat gatgagtcctt 133020
atagcatgaa ttcgcttatac gttatcggtt ttatcttctg tcaccttagc aatccctttt 133080
ttattaaact ctacataatc atatccattt ctattgtttt ttctaatata aacgagttata 133140
gcatcattgc taaattttc aatagttatca aaaacagaat atcctaaacc atataatata 133200
tattcaggaa cactcaaact aaatgtccag gatttcctta aatacgtaaa ctttaatagt 133260
gcgaaatcat tcaaaaatctt accacttata gatagatagt acataaaatgc gtatagtagt 133320
ctacctatct ctttattatg aaaacccggca ttacgatcat atatgtcgat atataccctgt 133380
gatccgttta cgttaaaccat taaatacatg ggtgtatcata taaacatgaa ttatatttctta 133440
attctcagag ctatagttaa ttgaccgtgt aatatttgc tacatgcata ctggatacgc 133500
ttattaaataa gattttatc attgctcgat atttcagaat cgtatataatc aggagttacca 133560
tcgtgattct taccagatata tataaaaaat actatataatc aaatatatttgc acccacgtt 133620
gtaatcatat aaatgtttaa cgtttttaaat ttgttattca atgatccattt atcatacgat 133680
atcatggatc tggatatttc attctttaaa atataatattt ggtttagcca ttgcatttgg 133740
gctcctaattt gagattttctt attctcatcc atttttaggtt aggctttcat aaagtccctt 133800
ataacttcgtt gaataatgtt tctatgtttt ctactgtatgc atgtatttgc ttgcattttt 133860
ttatccccatg tttcatctt catagattt aacgcagttaa tgctcgcaac attaacatct 133920
tgaaccgttg gtacaattcc gttccataaa tttataatgt tcgccttata tataactcat 133980
tttttgaata tacttttaat taacaaaaga gttaagttac tcataatggac gccgtccagt 134040
ctgaacatca atcttttttag ccagagatata catagccgtt ctttaggttt cagcgtgatt 134100
ttccaaccta aatagaactt catcggttgcg tttacaacac ttttcttattt gttcaaaactt 134160
tgggtttaca ttagtaatct tttttccaa attagttac cgttgggttga gagtttcctc 134220
attgtcgatct tcatacgatcc ttgcgttta gcctctggct ttttagcagc 134280

cttttagaa aaaaattcag ttgctggaaat tgcacatcg tcatactccgg ggaaaaagagt 134340
tccgtccatt taaagtacag attttagaaa ctgacactct gcgttattta tattttgtac 134400
aacacatgga ttataaatat tgatgttaat aacatcagaa aatgtaaaatg ctatacatgg 134460
ttgcacatcg ttaaattttc taatggatct agtattattg ggtccaactt ctgcctgaaa 134520
tccaaatatg gaagcggata caaaaccgtt tcctggataa accacacatc tccactttt 134580
ctttacatca gaaaattgtgt cggtgacatc ttgactctc ctatctaattg ccgggttcc 134640
acctataatgt tttgaatatt cgaatgctgc atgagtagca ttaaatttcct taatattgccc 134700
ataattttca tatatttgagt aaccctggat aaaaagtaaa cacaccgcag ccgtcgctac 134760
cacaataaaa aaaattgata gagagttcat ttataatcta ttagaagctg aaaaaatttt 134820
tttacacgca tcaagacaatg cttaataaa tagtcaaca tctactttt tcataatcgaa 134880
ccgatggtat gattctaacc tagaattaca tccgaaaaag ttgactatgt tcataatgtcat 134940
taagtcttta acaaacaaca ttccagactc tggattataa gacgatactg ttcgtcaca 135000
attacctacc ttaatcatgt gattatgaat attttaaaatc aaaccacgaa tatacttcta cgaagaaatg 135060
tataatatact ttgaaacacg attttttttca taggatctaa aataaaaaat ccggatctat 135120
tagtttaccc ataggagaaa taactataaa gatgttttta acattattat attctctatt tggagatcta aataaaaaat 135180
gatgttttta taaaactatg tcttcgttta ttaccgtacc ttatctttaa acatctaaaat atgttaattt 135240
agaactctt aaacgatatt ctggaaatac ttatctttaa tgaactaaac gctataagct ctattgttt 135300
tttatctacc atagttacag aattttgttca tggagatcta aataaaaaat 135360
taaagtata taattatcgc gttcagattt ggtatcttca aatcccttgc ttgataatgt tagccaatga 135420
ttctcttagta agtatactt gtatgtttt gtagatgttca aatcccttgc ttgataatgt tagccaatga 135480
taccgcagtt agccattctt cattgacagc ggtatgttca aatcccttgc ttgataatgt tagccaatga 135540
gtttaacaag ggccattttt cggattttt aatgtgagaa gttgcctcg ttaaggctt 135600
gggttcgagt tcaacgacga ttgaattctc ttcccgccg tgctgcattga tgaacgacgg 135720
gatgttgttc gattgatttg gaatttttt tcgactttt gtttatatta aatattttaa 135780
aattttatagc ggatagcaat tcatgtacca cggataatgt agacgcgtat tgcgcattca 135840
tatcttttattt attagataaa ttatcaata aatgtgagaa gttgcctcg ttaaggctt 135900
ccattttaat attatataaa catttgcatt tgtaacttt tcgtctttt tggatagtt 135960
ttttacttagt aaagctgcaa ttacacactt tgcgttcaaa acataaatat aaacaccagc 136020
ttttatcaat cgttccaaaaa agtcgacggc ggacattttt aacatggcat ctattttaa 136080
tacactttagg ttttggaaa aaacatcatt ttataattgt aacgattcaa taactaaaga 136140
aaagatataag attaaacata agggaaatgtc atttgcattt tataagccaa agcattctac 136200
cggttgtaaa tacttgtctg gaggaggat atatcatgt gatttgcattt tattttggaa 136260
ggttaacaatt aataatctaa agatgtatgtt attttacatg gatttgcattt atcatggagt 136320
gacaagtagt ggagcaattt acaaattttttt atcgcttac gatagacttt ctctaaatag 136380
gactatgtt aaaaaagttt ataattatgt tgatacattt ttgcacgacg atgattgtac 136440
gctattgcac aattttgttt ttgtactttc taatataatgt ttttaggttct ttttcatatg 136500
agaatattgtt ttactaaaaa tatctatgtt taactttgt tctatgcacgt ctttatcgcc 136560
ggtatcgta catatacgta attcaccttc aaaaaatacg gagtcttcga taataatagc 136620
caatcgatattt tttccctt acaggcatcg atcgtagcat atttccgcg tctgatatgg aatgtttaaa 136680
actacaaaaa tgcgtatgt tagccgtcc taatattgtt acgtgtctat aagtttggca 136740
tagtagataa atagacgtgt ttaaatgcct tccaaagttt aagaattcta tttagagtatt 136800
gcattttgtt agtttatcgat ctacatcatc aaaaataatgtt aaaaagttgtg ctgattttt 136920
atgattttgtt ggcacagcaa tacatttttca tttttttttt ttagttcgta tcagattata 136980
ttcttagagat tctgtactac taacgaaattt aatatgattt ggcacatgtt atccatcata 137040
atctgggtt aaaaacgggtt aaaaacaaagaa tttttttttt tttttttttt ttagttcgta 137100
aaacagagat agtaaataga tagtttttcc agatccagat cttctgtta aaaccattct 137160
aaacggcatt ttaataaaat tttcttgc tttttttttt tttttttttt ttagttcgta 137220
tatatttaca gttactaaat taatttgcata aaaaatcaaa atatggaaaaa ctaagggtt 137280
tagtagggag gagaacaaag aaggcacatc gtgtatataaa taacattttat tttttttttt 137340
acaccagaaaa acgacgaaga gcagacatct gtgttctccg ctactgtttt cggagacaaa 137400
attcaggaa agaataaaacg caaacgcgtg attggcttat gtattttttt ttagttcgta 137460
atttcactac tatctatgtt tttttttttt tttttttttt ttagttcgta 137520
atgtctgcta acgaggctgc tttttttttt tttttttttt ttagttcgta 137580

actcatagaa aggttgcgtc tagcaactaca caatatgatc acaaagaagg ctgtaatgg 137640
tttatattacc agggttcttg ttatataatta cattcagact accagttatt ctccggatgct 137700
aaagcaaatt gcactgcgga atcatcaaca ctacccaata aatccgatgt cttgactacc 137760
tggctcattt attatgttg ggatacatgg gnatctgatg gtaatccaaat taaaaaaact 137820
acatccgatt atcaagattc tgatgtatca caagaaggta gaaagtattt ttgtgttaaa 137880
acaatgaact aatattttattt ttgtacatt aataaaatgaa atcgcttaat agacaaactg 137940
taagtaggtt taagaagttt tcgggtccgg ccgctataat gatgatactc tcaaccatta 138000
tttagtggcat aggaacattt ctgcattaca aagaagaact gatgcctagt gcttgcgcca 138060
atggatggat acaaatacgat aaacattgtt atttagatac taacattaaa atgtctacag 138120
ataatgcggt ttatcagtgt cgtaaattac gagctagatt gcctagacct gatactagac 138180
atctgagagt attgttttagt attttttata aagattattt ggttaagttt aaaaagacca 138240
atgataaaatg gttagatatt aataatgata aagatataga tatttagtaaa ttaacaaatt 138300
ttaaacaact aaacagtagc acggatgctg aagcgtgtt tatatacaag tctggaaaac 138360
tggttaaaac agtatgtaaa agtactcaat ctgtactatg tggtaaaaaaa ttctacaagt 138420
gacaacaaaa aatgaattaa taataagtcg ttaacgtacg ccgccatgga cgccgcgtt 138480
gttattactc caatgggtgt gttgactata acagatacat tttatgtatg tctcgatata 138540
tcaatcatgg actttatagg accatacatt ataggttaaca taaaaactgt ccaaataagat 138600
gtacgggata taaaatattt cgacatgcaaa aatgtctact ttagctataa gggtaaaata 138660
gttcctcagg attctaataa ttggctaga ttcaacattt atagcaittt tgccgcatac 138720
agatcaaaaa ataccatcat catagcatgc gactatgata tcatgttaga tatagaagat 138780
aaacatcagc cattttatctt attcccatctt attgtatgtt ttaacgtac aatcatagaa 138840
gcgtataacc tgtatacagc tggagattat catctaataa tcaatcctt agataatctg 138900
aaaatgaaat tgcgtttaa ttcttcattt tgcataatcag acggcaatgg atggatcata 138960
attgtatgggaa aatgcaataag taattttta tcataaaaatg tgtaaaagtaa ataataaaac 139020
aataaaatattt gaacttagtag tacgtatattt gagcaatcag aatgtatgtt ggtacccctt 139080
atcacgggtga cctgtatgtt gggacaataa ttagttagttt atatattata tattttgtagg 139140
aaaaagatac gtactgtcta taatgacaat aaaattatca tgacaaaattt aaaaagata 139200
aagagttcta attccagcaa atctagtaaa tcaactgata gcaatcaga ctgggaggat 139260
caactgtatgt ctatggaaaca aaacaatgac gtagataataa ttcttaggaa tgagatattt 139320
gacgatgata gcttcgctgg tagttataa tgggataacg aatccaatgt tatggcgcct 139380
agcacagaac acattttacga tagtggatgtt ggaagcacgc tgctaataaa taatgatcgt 139440
aatgaacaga ctatattatca gaacactaca gtagtaatta atgaaacggg gactgttgaa 139500
gtacttaatg aagataccaa acagaatcctt aactattcatt ccaatcctt cgtaaaattat 139560
aataaaaacca gtatattgtat caagtcaaat ccgttttattt cagaacttaa caataaattt 139620
agtgagaata atccgtttatg acgagcacat agcgatgattt atcttaataa gcaagaacaa 139680
gatcatgaac acatgtatattt agaatcatcg gtcgtatcat tgggtgtattt agtttccctt 139740
ttataaaattt gaagtaataat ttagtattat tgctccgtc acgttgtaca aatggagata 139800
ttccctgtat tggcatttc taaaattatca aattttattt ctaataatga ctgtagatatt 139860
tatatagata cagaacatca aaaaattataa tctgatgaga tcaatagaca gatggatgaa 139920
acggtacttc ttaccaacat cttaaagcgta gaagttgtaa atgacaatga gatgtaccat 139980
cttattccctc atagattatc gacgattataa ctctgtatca gttctgtcg aggatgtgtt 140040
atctctatag ataatgacat caatggcaaa aatattctaa ctttcccat tgatcatgct 140100
gtaatcatat cccccactgag taaatgtgtc gtagtttagca agggtcctac aaccatattt 140160
gttgttaaaag cggatataacc tagcaaacga ttggtaacat cgtttacaaa cgacatacta 140220
tatgtaaaca atctgtcact gattaattat ttggcgttgtt ctgtattcat tattagacga 140280
gtcaccggact atttggatag acacatatgc gatcagatattt ttgctaataa taatgtgtat 140340
tcccttataa coatcgacga taagcaataat cctattccat caaactgtat aggtatgtcc 140400
tctgccaagt acataaaattt tagcatcgag caagatactt taatccatgt ttgttaacctc 140460
gagcatccgt tgcactcagt atacaaaaaa atgcagtcgt acaattctct acctatcaag 140520
gaacaaatat tgcgtatgtt aattgataat ataaatatga gcatttagt ttctgtggat 140580
taatagattt ctgtatggg gatcattat catctctaattt ctctaaatac ctcataaaac 140640
gaaaaaaaaag ctattatcaa atactgtacg gaatggattt attctcttctt ctttttatga 140700
aactctgttg tataatctact gataaaaactg gaagcaaaaaa atctgataga aagaataaga 140760
ataagatcaa ggattatatg gaacacgattt attataaaaat aacaatagtt cctgggtcct 140820
cttccacgtc tactagctcg tggattataa cacatgccta gtaatagtct ctttgcgttg 140880

acggaaagca gactagaataat aacaggctaa aatgttcaga caccataata gttcccaacc 140940
 cagataataa cagagtcca tcaacacatt cctttaaact caatccaaa cccaaaaccg 141000
 ttaaaatgtt tccggccaat tgatagtaga taatgaggtg tacagcgcat gataatttac 141060
 acagtaacca aaatgaaaaat actttatgtt ttataagaaa tatagacggt aatgtcatca 141120
 tcaacaatcc gataaatatgc ctgagagttt acatttgacgg ataaaacaaa aatgctccgc 141180
 ataactctat catggcaata acacaaccaa atacttgtt gattcctaaa ttagtagaaa 141240
 atacaacgaa tattcgatgtt taatgtatct cgagaaaaataa taagaataaa gtaatgcccgg 141300
 taaagataaa catcaacattt gttggtaat cattaaacca attagtatga agttaacta 141360
 atttcacatg agatttttt ccagtgttat cctcgcatgt ataagtacctt ggttagat 141420
 ctttatattt cataatcaat gagacatcac tatctgtt gaaatgaaatg ctagcactag 141480
 tatgccattt acttaatattt gtctgtttt aagtttttataaataatcatgtt 141540
 tatccaattt ccatctaata tactttgtcg gattatctat agtacacgga ataatgatgg 141600
 tattcattaca tgctgtatac tctatggctt ttgttagttgt tataacaacc aacgtataga 141660
 ggtatataaa cgatatttca actcttgaca ttttttattt attttaaaatg atacctttgt 141720
 tatttattttt attctattttt gctaacggta ttgaatggca taagtttggaa acgagtgaaag 141780
 aaataatttc tacttactta tttagacgacg tattatacac ggggtttaat ggggcggtat 141840
 acacattttc aaataataaaa ctaaacaacca ctggtttaac taataataat tatataacaa 141900
 catctataaa agtagaggat gcccggataagg atacattatgtt atgcggaaacc aataacggaa 141960
 atcccaaattt ttggaaaaataa gacgggtttagt acggacccaaa acatagaggat agaggatacg 142020
 ctccttatac aaatagcaaa gtaacgatata tcagtcacaa cggatgtgtt ctatctgaca 142080
 taaacatatac aaaagaagga attaaacgtt ggagaagatt tgacggacca tgggtttagt 142140
 atttatttcac ggccggataaac gtaattccaa aagatggttt acgaggagca ttctgtcgata 142200
 aagacgggtac ttatgacaaa gtttacattt ttttactgtt tactatcgcc tcaaaagagaa 142260
 ttgtcaaaaat tccgtatata gcacaaaatgtt gcttaacacg cgaagggtgtt ccattcatcat 142320
 tgtctagtca tagatggctcg acgtttctca aagtcaattt agaattgtat atcgacggaa 142380
 gaagttatag acaaattttt cattcttagaa ctataaaaac agataatgtt acgataactat 142440
 atgtattttt cgtatgttctt tatttcaatgtt ccgcattatgt tacctattttt atgaataacca 142500
 ttaaacaatc tttttctacg tcaaaaattgg aaggatatac aaagcaattt ccgtctccag 142560
 ctcctggat atgttttacca gctggaaaag ttgttccaca taccacgtt gaagtcata 142620
 aacaatataa tgtacttagat gatattataa agcctttatc taaccaaccc atcttcgaag 142680
 gaccgtctgg ttgttaatgg ttcgatataa aggagaagga aatgaacat cgggaatata 142740
 gaatataactt cattaaagaaa aattctatgtt attcggttca tacaaaatctt aaacaaactc 142800
 gtagctcgca agtctgtcg cgacttattt cagtaatgtt aactgcggaa ccgttattta 142860
 tagcagatatac agggatagga gttagaatgc cacaatgaa aaaaataactt aaaatgtat 142920
 cttaatcgag tacaccacac gacaatgaaac aaacataaga cagattatgc tggttatgtt 142980
 tgctcgtaa tatgcggctt aattgtcggtt atttttttta cagcgacactt attaaaatgtt 143040
 gtagaacgtt aatttagtca tacaccatta atagataaaa cgataaaaaga tgcataatatt 143100
 agagaagatgtt gtcctactgtt ctggataagg tataataata aatgtatcca tttatctact 143160
 gatcgaaaaa cctggggagga aggacgttacat gcatgcaaaatg ctctaaattt aaattcggat 143220
 ctaattaaaga tagagactcc aaacggttacat agttttttaa gaagccttag acgaggctat 143280
 tgggttaggaa aatccggaaat attaaaccacg acaaccccatt ataaattttt agctaagaat 143340
 gccacgaaga atggaaactaa aaaaacggaaa tatatttgc gacacaacggaa tactccaaa 143400
 ctgcattcgtt gttacactat ataaacattt cactacattt ttatcataacc actacttcgg 143460
 ttagatgtttt tagaaaaaaaaaa taaatatcgcc cgtaccgtt ttgtttttttaa aaaaataaca 143520
 attaacaattt atcaaattttt ttcttttataa tttaacgtgg ttgaccatcc ttgggtgtt 143580
 aataatctct tagtgggttggaa atggaaatgtt gtttaatgtt tccacactca tcgtatattt 143640
 tgacgtatgtt agtcacatcg tttacgttacat agtcagactg tagttctatc atgccttccta 143700
 catcagaagg aggaacagttt ttaaagtctt ttgggtttaa tctattaccg ttgttttca 143760
 tgaaatccctt tgggtttatcc acttcacattt ttaaataaaaatgtt cttccactata cattttttt 143820
 ttaatttttac tagatcgca tgggtcatgtt aattttatgg ttccgttagtccatgatcc 143880
 aactagcaaa cttcgcgttat acgttatcgcc gattgtgtt tacaccaactt gtatgaaaat 143940
 taagaaaaaca gtttaataaaa tcaacagaaa tatttaatcc tccgtttgtt acagatgcgc 144000
 catattttatg gatttcggat tcacacgtt gttgtctgtt gttgttgcgtt agtggcgtt 144060
 ctacgtaaac ttgcatttttccatatttttca tattgtcaga atcgcatacc gattttatcat 144120
 catacactgtt ttggaaaacta aatgggtatac acatcaaaaat aataaataat aacgagtgaca 144180

actccaaacgc atttatgtgg gcataacaaca agtcattact aatggaatat tccaagagtt 147540
ttagttgtct agtatttaac aagagaagag atttcaacag actgtttatg aactcgaatg 147600
ccgcctcatt gtcgcttata ttgatgatgt cgaattctcc caatatcatc accgatgagt 147660
agctcatctt gttatcgggc tccaagtttt ctaaaagatgt cattaaaccc tcgatcatga 147720
atggatttat catcatcggt tttatgttgg acatgagctt agtccgttt tccacatcta 147780
tagaagatga tttctgaatt atttcataata tctctctt taactccagg aacttgtcag 147840
gatggctcac ttaaatatgt tctcgctcaa gagataaaaa tcttggatg gttcacgcg 147900
actttctct aaaggatgac gttgcccaag atcctctttaa atatgaatcc atcttaccc 147960
tggacaagat ggacagtcta tttccttag catatatta ttttcagttt tattatacgc 148020
ataaaggtag acctaatcg tctcgatgac aaaaatgtc gtggggcatt aatcgaaaa 148080
ataaattgt aaaaatgt tagtttaca caatgtatga acatcatgga atcttaccc 148140
gaaggattgg acaaactctgg aaaaacaaca cagagatcca ctgtcactgg aaaaatgata 148200
gcaaaccacga taaaatatct taacttcct gatgactatc taactcgtaa aaaaacctat aatgatcata tagttatctt attatgtt 148260
gcaaataagat gggagttgc atctttata caagaacaac tagaacaggg aattacttta 148320
atagttgata gatacgcatt ttctggatg gctgtatggc ccgtctaaagg cgctcaatg 148380
actctoagta agagttatga atctggattt cctaaacccg acttagttt attcttgaa 148440
tctggtagca aagaaaattaa tagaaacgta ggcgagggaaa tttatgaaga tgttacattc 148500
caacaaaagg tattacaaga atataaaaaaa atgattgaag aaggagatat tcattggcaa 148620
attattctt ctgaattcga ggaagatgta aagaaggagt tgattaagaa tatagttata 148680
gaggctatac acacggttac tggaccagt gggcaactgt ggatgtataa gtgaaattac 148740
atttttata aatagatgtt agtacagtgt tataatgtaa tgaagcatat tactctggca 148800
acttggaaatc agtactcgga tacgtgtccg atatgcatac cgaactcgca tcaatatctc 148860
aattagttt tgccaagata gaaactatag ataatgatataatgata attaaacaag gacattgtaa 148920
attttatcat gtgttagatca aacttggata atccatttat ctcttccta gatactgtat 148980
atactattaa aaataactag ttataagttt gaatccgtca attttgattt caaaattgaa 149040
tggactgggg atggcttata caatatacc cttaaaaattt atggcatcaa gacgtggcaa 149100
acaatgtata caaatgtacc agaaggaaca tacgacatat ccgcattttcc aaagaatgat 149160
ttcgtatctt tctgggttaa atttgaacca ggcgattata aagtggaaaga gtattgtacg 149220
ggactatgcg tgcgaaataaa aattggacca ccgactgtaa cattaactga atacgacgac 149280
catacaatt tgcacatcg gcatccgtat gctactagag gtagcaaaaaa gattccatt 149340
tacaaacgcg gtgacatgtg tgatatctac ttgttgataa cggctaaactt cacattcgga 149400
gattctaaag aaccagtacc atatgatatac gatgactacg attgcacgta tacaggttgc 149460
agcatagact ttgcacaaac agaaaaaagtg tgcgtgacag cacagggagc cacagaaggg 149520
tttctcgaaa aaattactcc atggagttcg aaagtatgtc tgacacctaa aaagagtgt 149580
tatacatgcg caatttagatc caaagaagat gttcccaatt tcaaggacaa aatggccaga 149640
gttatcaaga gaaaatttaa tacacagtct caatcttatt taactaaatt tctcggtac 149700
acatcaatg atgttaccac ttttcttagc atgcttaact tgactaaata ttcataatta 149760
tttttattt atgatacaaa aacgaaataa aactgcataatataactgg ttaacgccc 149820
tataggctct aaccatttc aagatgaggt ccctgattt agtccttctg ttccccctca 149880
tcatctactc catgtcttatt agacgatgtg agaagactga agagggaaaca tggggattga 149940
aaatagggtt gtgtataatt gccaaagatt tctatcccgaa aagaactgtat tgcaagtgttc 150000
atctcccaac tgcagaatgaa ggattgataa ctgaaggcaa tggattcagg gatataacgaa 150060
acaccgataa attataaaaaa aagcaatgtg tccgctgtt ccgttaataa tactattttc 150120
gtaactggcg gattattcat aaataactct aatagcacga tcggtggacat ttataaagac 150180
aaacaatggc cgattataga aatggctagg gtatatcagc gcatcgactc gacatttgg 150240
atgttatatt ttgcggagg tctatccgtt accgaacaat atgtaattt agagaaaaac 150300
aacgagatat ctgttacaa tcctagaacg aataagtggt ttgatatttc atataactatt 150360
tataagatat ccatatcatc attgtgtaaa ctaaataacg tcttctatgt atttagtaag 150420
gacattggat atgtggaaaa gtatgttgc gcatggaaatg tagtacatga tcgtctcccc 150480
gctataaagg cattatcaac ttctcttata tgattgaaaa tgaaaaatata aatagtttt 150540
atgtatagca gtattaccct atagtttat tgcttactac taacatggat acagatgtt 150600
caaatgtaga agatatcata aatgaaatag atagagagaa agaagaaata ctaaaaaatg 150660
tagaaattga aaataataaa aacattaaca agaatcatcc caatgaatattagagaag 150720
cactcggtt taataccagt agtaatagtg attccatttgaaatggat atagaatgt 150780

-62-

tcagtcacga	tgttaggaata	tagatcatat	ctactaat	ttataatcg	tacaaaacat	150840		
aaaaaaacaac	tcgttattac	atagcaggca	tggaaatc	caagtattgt	tttgataacg	150900		
atggcaagaa	atggattatc	ggaataactt	tatattctgg	taattcaata	ctctataagg	150960		
tcagaaaaaaaa	tttcaactgt	tcgttctaca	atta	gaagatagat	cacaatcac	151020		
acaagccatt	gttgtctgaa	atacgattct	atata	attggatcct	ttgactatcg	151080		
acaactggac	acgggaacgt	ggtataaaagt	atttggctat	tccagatctg	tatggattg	151140		
gagaaaccga	tgatttatgt	ttcttcgtt	taaagaattc	gggaagagta	ttcgccccaa	151200		
aggatactga	atcagtcttc	gaagcatgcg	tcactatgtat	aaacacgtt	gagtttatac	151260		
actctcgagg	atttacccat	ggaaaaatag	aaccgaggaa	tatactgatt	agaaataaac	151320		
gtctttca	aattgactat	tctagaacta	acaactata	caagagtgg	aactcacata	151380		
tagattacaa	cgaggacatg	ataacttcag	aaaatata	ttatatgtgt	gtagacaatc	151440		
atcttggagc	aacagttca	agacgaggag	atttagaaat	gttgggat	tgcataat	151500		
aatggttcgg	tggcaaactt	ccatggaaaa	acgaaatgt	tataaaagta	ataaaacaaa	151560		
aaaaagaataa	taaaaaattt	atagctactt	tcttgagga	ctgtttcct	gaaggaaatg	151620		
aacctctgga	attagttaga	tatata	tagtata	gttagattat	tctcaaactc	151680		
ctaattatga	cagactacgt	aaactgttta	tacaagattt	aaattatatt	cttttttta	151740		
tagagtgtgg	tagtgttacg	gatata	attaatatta	gactatctt	atcgcgctac	151800		
acgaccaata	tcgattacta	tgatata	ctatgaaagg	agagaatgt	tttatttctc	151860		
cagcgtcaat	tcgtcagta	ttgacaatac	tgtatata	agctaatgg	tccactgctg	151920		
aacagctatc	aaaatatgt	gaaacggagg	agaacacgg	taagggttag	gctcagaata	151980		
tctcattcaa	atccatgaat	aaagtata	ggcgatattc	tgccgtgtt	aaagattcct	152040		
ttttgagaaa	aattggcgat	aagtttcaaa	ctgttgactt	cactgattt	cgcactatag	152100		
atgaatcaa	caagtgtgt	gatata	ctgaggggaa	aatcaatcca	ctattggat	152160		
aaccattgtc	tccttagcaat	tagtgcgt	tactttaaag	aaaaatgg	gacgccattc	152220		
gaaaaagaaat	ttaccagtga	ttatccc	tacgtatctc	cgacggaaat	ggtagacgt	152280		
agtatgtgt	ctatgtacgg	caaggcattt	aatcacgc	ctgtaaaaga	atcattcg	152340		
aactttcaa	tcatagaact	gccatatgtt	ggagatact	gtatgtgt	cattcttcca	152400		
gacaagattt	atggatttga	atccatagaa	caaaatctaa	cagataaaaa	tttaagaaa	152460		
tggtgtact	ttatggatgc	tatgttata	gatgttcaca	ttcccaagtt	taaggtaa	152520		
ggctctata	atctggtgg	tactctagta	aagtcaagg	tgacagaggt	ttcggttca	152580		
actggagatt	atagcaat	gtgtat	gatgtgatgt	tcgacgctat	gatccacaaa	152640		
acgtatata	atgtcaat	agagtata	gaagcagct	cagcaactt	tgtactatgt	152700		
gcagactgt	catcaacaat	tacaaat	ttctgtgcag	atcatccgt	catctatgt	152760		
attaggcat	ttgatggaaa	aattctt	gttggtagat	attgtctctc	gacaactaat	152820		
tgttaaccat	ttttttt	aaaaacaat	ggtgatgg	acactt	gtataatgt	152880		
gaatgaacgc	gatgtttctg	taagcg	caccgaaata	ctattcatgg	aatgtttt	152940		
ccgttacaat	aaaaatagta	tcaacaat	actaatgtat	gatataatta	atagcgtatc	153000		
tataagtgt	gctaattata	gata	ctgtttt	cgacgtat	atatacatcc	153060		
gtagaaat	gattaacaag	ttgtacggat	acgcac	tct	ggcacatcg	153120		
ctggagggtgt	ttgttattat	ctgtt	atct	tagtt	tttgtataaa	taatttattc	153180	
aatatactag	ttaaaat	aagattttaa	atgtataaa	aactaataac	gttttattt	153240		
gtaataggtg	cattagcatc	ctatt	aatgag	taca	ctccgtt	taaactgagt	153300	
gtaaaaactct	atata	agtagataat	atagaa	att	catata	tgataataat	153360	
gaattgggtgt	taaattttaa	agat	acaca	attt	cttac	atcagagtc	153420	
ggat	ccatagat	agat	ttata	aac	gactata	aaattt	tatgtataacc	153480
attgactgt	ctactatt	acgc	ca	cac	gtgt	aat	ttatctac	153540
tgccattat	ata	gttac	ttat	at	gtgt	gag	cgacat	153600
attactgcag	agg	aaaat	ctat	aa	ttt	ttt	at	153660
gatactat	tg	aaaaca	tact	ttt	at	ttt	at	153720
ggacat	at	aca	ttt	ttt	at	ttt	at	153780
ttcagt	gt	aaat	ttt	ttt	aa	ttt	aa	153840
ttgttcatt	at	gtt	ttt	ttt	aa	ttt	aa	153900
gattccaaaa	tt	gaat	ttt	ttt	aa	ttt	aa	153960
atcaagacgt	gg	caaaca	at	ttt	aa	ttt	aa	154020
tttccaaaga	at	gat	ttt	ctt	ttt	ttt	ttt	154080

gaagagtatt gtacgggact atgcgtcgaa gtaaaaaattg gaccaccgac tgtaacattg 154140
actgaatacg acgaccatat caatttgtac atcgagcatc cgtatgctac tagaggtagc 154200
aaaaagattc ctatttacaa acgcgggtac atgtgtata tctacttgtt gtatacggct 154260
aacttcacat tcggagattc taaagaacca gtaccatatg atatcgatga ctacgattgc 154320
acgtctacag gttcagcat agacttgc acaacagaaa aagtgtcgt gacagcacag 154380
ggagccacag aagggttct cgaaaaatt actccatgaa gttcggaaagt atgtctgaca 154440
cctaaaaaga gtgtatatac atgcgcaatt agatccaaag aagatgttcc caatttcaag 154500
gacaaaatgg ccagagttt caagagaaaa tttaatacac agtctcaatc ttatthaact 154560
aaatttctcg gtagcacatc aaatgatgtt accactttc ttagcatgct taacttgact 154620
aaatattcat aactaatttt tattaatgtat acaaaaaacga aataaaaactg catattatac 154680
actggtaac gcccttatag gctctaaccat tttcaagat gaggtccctg attatagtcc 154740
ttctgttccc ctccatgtct attagacgt gtgagaagac tgaagaggaa acatggggat 154800
tggaaatagg gttgtgtata attgccaaag atttttatcc cgaaaagaact gattgcagtg 154860
ttcatctccc aactgcaagt gaaggattga taactgaagg caatggattc agggatatac 154920
gaaacaccga taaattataa aaaaagcaat gtgtccgctg tttccgttaa taatactatt 154980
ttcgttaactg gcggttatt cataaataac tctaatacgca cgatcggttga catttataaa 155040
gacaaaacaat ggtcgattat agaaaatggct agggatatac acggcatcgta ctcgacattt 155100
ggaatgttat attttgcgg aggtctatcc gttaccgaac aatatggtaa tttatagaaa 155160
aacaacgaga tatcttgcataa caatcctaga acgaataagt gtttgcataact 155220
atttataaga tatccatatac atcattgtgt aaactaaata acgtcttcta tgtatttagt 155280
aaggacattt gatatgtgga aaagtatgtt ggtgcatttga agtttagtaca tgatcgctc 155340
cccgctataa aggccatttcc aacttctccct tattgattga aaatgaaaat ataaatagtt 155400
tttatgtata gcagtattac cctatagttt tattgcattac tactaacatg gatacagatg 155460
ttacaatgtt aagaagatatt ataaatgaaa tagatagaga gaaagaagaa atactaaaa 155520
atgtagaaat tggaaataat aaaaacattt acaagaatca tcccaatgaa tatatttagag 155580
aagcactcgt tattaaatacc agtagtaata gtgattccat tgataaagaa gttatagaat 155640
gtatcgtca cgatgttagga atatacgatc tatctactaa ttttataat cgatacaaaa 155700
cataaaaaac aactcggtt tacatagcag gcatggatc cttcaagttat tggtttgata 155760
acgatggcaa gaaatggatt atcgaaaataa ctttatattc tggttaattca atactctata 155820
aggtcagaaa aaatttcaact agttcggtt acaattacgt aatgaagata gatcacaat 155880
cacacaagcc attgttgcataa gaaatacgat tctatataatc tgtattggat cctttgacta 155940
tcgacaactg gacacgggaa cgtggatataa agtattttgc tattccagat ctgtatggaa 156000
ttggagaaac cgatggatta tatgttctt gttataaaga attcgggaaag agtattcgcc 156060
ccaaaggata ctgaatcgtt cttcgaaagca tgcgtaacta tgataaacac gttagagttt 156120
atacactctc gaggatttac ccatggaaaa atagaacccgaa ggaatataat attaaaactt 156180
accacgtaaa acttaaaatt taaaatgata tttcatttgc agatagatca cacattatga 156240
actttcaagg acttgcgtt actgacaattt gcaaaaaatca atgggtcggtt ggaccattaa 156300
tagggaaaagg tggattttgtt agtattttata ctaatacgat caataattat gtgtaaaaaa 156360
tagagccaa agctaacggta tcatttattt ccgaacaggc attttataact agagtactta 156420
aaccatccgt ttcgaagaa tggaaaaaat ctcacaatat aaagcacgta ggtcttatca 156480
cgtcgaaggc atttggtcta tacaatcca ttaatgtgga atatcgattc ttggtaatta 156540
atagattagg tgcagatcta gatgcgggtca tcagagccaa taataataga ctacaaaaaa 156600
ggtcgggtat gttgatcgga atcgaaatct taaataccat acaattttatc cacgagcaag 156660
gatattctca cgagatattt aaagcgagta atatgtctt agatcaaata gataagaata 156720
aatttatatct agtggattac ggattttgtt ctaaatttcat gtctaattggc gaacatgttc 156780
catttataag aatccaaat aaaatggata acggtaactt agaatttaca cctatagatt 156840
cgccataaagg atacgttgcataa tctagacgtg gagatctaga aacacttggaa tattgtatga 156900
tttagatggtt gggaggatattt ttaaccatgga ctaagatatac tgaaacaaag aattgtgcat 156960
tagtaagtgc cacaacaaacag aaatacgat tcaataactgc gactttgtta atgaccagtt 157020
tgcaatatgc acctagagaa ttgcgtcaat atattaccat ggtttaactt ttgacatatt 157080
ttgaggaacc caattacgac aagtttgcgc acatattaat gcagggtgta tatttataag 157140
tgtgggttt ggtcgataaa aattaaaaaaa taacttaatttatttgc ttcgtgtgta 157200
caaccgaaat catggcgatc tttaacgcac acgctctcg gggtaacgac gagaatctt 157260
atgcctttcc tgaatatac tcgactgtt ccaatgtatc cagggaaat tctgtgtgt 157320
cagttataaa taacaagttt gacattgtaa aagacaaata tatgtgtgtt tacagtcagg 157380

tgaacaagag atatattgga gcactgctgc ctatgttga gtgcaatgaa tatctacaaa 157440
ttggaaatcc gatccatgat caagaaggaa atcaaatttc tatcatcaca taticccaca 157500
aaaactacta tgctctaagc ggaatcggtt acgagagtct agacttggt ttgaaaggag 157560
tagggattca tcatacgtt cttgaaacag gaaacgctgt atatggaaaa gttcaacatg 157620
attattctac tatcaaagag aaggccaaag aaatgagtgc acttagtcca ggacctatca 157680
tcgattacca cgtctgata ggagattgtt tctgtcaagt tactgtgtg gacgtacatg 157740
gaaaggaaat tatgaaaatg agattcaaaa agggtgcggt gcttccgatc ccaaattctgg 157800
taaaagttaa acttggggag aatgatacag aaaatcttc ttctactata tcggcgacac 157860
catcgaggta accaccttc tggaaagacag cgtgaataat gtactcatga aacgtttgg 157920
aactatacgc catatgtgtt ctgttgtata tgatcattt gatattgtt atgtaaaaaga 157980
atgctgttat gtgcatacgc atttgcataa tcaaaatctt ataccgatc ctgtaaaaac 158040
aaatttgcac atgaagacta tggatcatg cattcaaatg gattccatgg aagctctaga 158100
gtatcttagc gaactgaagg aatcaggtgg atggagtccc agaccagaaa tgcaggaatt 158160
tgaatatcca gatggagtgg aagacactga atcaatttgg agattggtag aggagttctt 158220
caatagatca gaacttcagg ctggtgaatc agtcaaattt ggtatctt ttaatgtttaa 158280
acatacatct gtttcagcta agcaactaaag aacacgtata cggcagcgc ttccttctat 158340
actctcatct tttaccaaca caaagggtgg atatttggc atggaggtt ataataatac 158400
acacaaagta tttggattca cgggtgggta cgactaccc agactgatag agaatgatata 158460
agaaaagcat atcaaaagac tttgtgttggt gtatttctgtt gagaagaaaag aggacatcaa 158520
gtacgcgtgt cgattcatca agttatataa acctggggat gaggctacct cgacatacgt 158580
gtgcgctatc aaagtggaaa gatgtgttgg tgctgtgtt gcagattggc cagaatcatg 158640
gtatatggat actaatggta tcaagaagta ttctccagat gaatgggtt cacatataaa 158700
attttaatta atgttaactat agagaacaaa taataagggtt gtaatatcat atagacaata 158760
actaacaatt aatttagtaac ttttatctt ttttaatta accaactaac tatataccta 158820
ttaatacatc gtaattatag ttcttaacat ctattaatca ttaattcgct tcttaattt 158880
tttataaaact aacattgttta atgaaaagg gataacatgt tacagaatataaatttata 158940
tggatttttt taaaaaggaa atacttgact ggagtatata tttatctttt cattatata 159000
cacgcgtgtt ttccaaatttt tccacatccc atataataca ggattataat ctcgttcgaa 159060
catacgagaa agtggataaa acaatgttgg attttttac taggttgcac aatttattcc 159120
atattttaga atatggggaa aatatttac atatttttac tatggatgtat gctaatacga 159180
atattataat ttttttctt gatagagtat taaaatattaa taagaacggg tcatttatac 159240
acaatctcggtt gttatcatca tccattaata taaaagaata tttatctt ttagttaata 159300
atgatcatcc agataatagg ataagactaa tgcttgaaaa tggacgttga acaagacatt 159360
ttttgtccta tatatcagat acatgttata tctatatag ttttaataa aatcatggat 159420
tttatataga tgccgaagac agttacgggtt gtacattt acatagatgtt atatatact 159480
ataagaaatc agaatcagaa tcatacatgtt aatttattaa gatattgtt aataatggat 159540
cagatgttaga taaaaaaagat acgtacggaa acacaccttt tttatctt tttatctt 159600
atatcaacaa cgtggattt tttgagatgtt gtttagagaa tgctaatataa gactctgttag 159660
actttatag atatacacactt ttcttatttgc tttatctt gtttagatgtt gtttagatgtt 159720
agttattat ttcttaaaagga gcaaatgttta atgcgtgtt taaaattcggtt actactccat 159780
tttattgtgg aatttatacac ggtatctcgat tttatctt atatttggaa tttatctt 159840
agtttagaaat agataatgtt gtttagatgtt gtttagatgtt gtttagatgtt 159900
cttttagatta tttatctt gtttagatgtt gtttagatgtt gtttagatgtt 159960
aaacatctat ttacgacgct gtttagatgtt gtttagatgtt gtttagatgtt 160020
acaaaaatgg tgattttggac gtttagatgtt gtttagatgtt gtttagatgtt 160080
tcgcaaaacaa caacaaaata ataatggaa gtttagatgtt gtttagatgtt 160140
ttatgatataa gtctatgtata gtttagatgtt gtttagatgtt gtttagatgtt 160200
aaatgtgtat aaaatataact gtttagatgtt gtttagatgtt gtttagatgtt 160260
cgctacagca atataaaatgg tttatctt gtttagatgtt gtttagatgtt 160320
gatgttataat aaaaataaaaactt gtttagatgtt gtttagatgtt gtttagatgtt 160380
ctttaatgtt gtttagatgtt gtttagatgtt gtttagatgtt gtttagatgtt 160440
gaagtcgtgt acgtatatac atagcatctt tttatctt gtttagatgtt gtttagatgtt 160500
tatccaagaa gtttagatgtt gtttagatgtt gtttagatgtt gtttagatgtt 160560
aaatatttggaa aacttttac gtttagatgtt gtttagatgtt gtttagatgtt 160620
tattaaaata taaaatctt gtttagatgtt gtttagatgtt gtttagatgtt 160680

tcgcacagtgtatacttatttttaacgctcaaaaataaaaaaatgaaaacgtttccgttggtt 160740
acgttgttatgcgtactaccgtctgttttcaacatgttcaatgatcttggatccaaatgtgtct
aacgctaaataacgtctaccgaaacatcgaaaatcatgcaaaaaaatgtgcacaatgtgtct
tgtgatcaggatatcatttttgatccaaatgtgtcttccaccatgtttctgttgcatactaaat
tacgaaaatcatgcaaaaaaatgtgcacaatgtgtcttccaccatgtttctgttgcatactaaat
aaaccgctatacgaagtgaaatccaccatgtttctgttgcatactaaatgtgtcttccaccatgt
tttcgttgcgaaagaaaaatgtgtcttccaccatgtttctgttgcatactaaatgtgtcttccaccatgt
gctggatgtcaacctcttcaattagaacacggatctgtcaaccagttaaatgtgtcttccaccatgt
tcatttgggaaatataatgttatcaactgttatcttggatgtgttgatatgtcttgcatactaaat
tacataagttgtacagcttaatccaccatgtttctgttgcatactaaatgtgtcttccaccatgt
atgccgttcctatctaacggattaatttccggatctacatgttctatcggttccgttataatgttgcatactaaat
catcttagttgtaaaatgtttacactacgggggtctccatcatccacatgtatcgac
ggtaaatggatcccataactcccaatatgttatcttggatgtgttgatatgtcttgcatactaaat
gatgatggtccegacgatgagacgattttgatctacatgttctatcggttccgttataatgttgcatactaaat
gaacaagaaaaatagaatcgtagaagcaactatggggctcaatttttaatctccgttata
gaccaatataatgttccataattgttacccgatctatgttttgcataataatatacaggct
tttaataaacaacaatgttacaaaagattaaatcttggatgttacgttacatgttgcata
taacaagagatttttgcgttataatgttgcataatgttgcataataatatacaggct
atttacaagaatgcgccccgttataccgttgcataatgttgcataatgttgcataataatatacaggct
acgtgttaaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
ttctgttaagcttggcacccgatctatgttttgcataatgttgcataataatatacaggct
tagtatacaacatcaactaaatgttgcataatgttgcataatgttgcataataatatacaggct
tgagagatataatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
caagttgtacggatctacatgttgcataatgttgcataatgttgcataataatatacaggct
ttatctgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
tttaaagattttaaatgttataatgttgcataatgttgcataatgttgcataataatatacaggct
catcctatttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
atggagtagataatgttgcataatgttgcataatgttgcataataatatacaggct
ttaaagagttttaaatgttgcataatgttgcataatgttgcataataatatacaggct
atataatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
ttcaacgcagatgtcacacgtgttagatataatgttgcataatgttgcataataatatacaggct
acccttatattcaacaaatataatgttgcataatgttgcataatgttgcataataatatacaggct
aatgtataaaatgttgcataatgttgcataatgttgcataataatatacaggct
aacataactctttaaatgttgcataatgttgcataatgttgcataataatatacaggct
attattcaaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
aaataacaaaatgttgcataatgttgcataatgttgcataataatatacaggct
tacatgttacatgttgcataatgttgcataatgttgcataataatatacaggct
ggactgggatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
caatgttacaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
tgcgtatctttctgggttataatgttgcataatgttgcataatgttgcataataatatacaggct
gactatgtgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
ataaaacagaaatgtgtgcgtacgacatgttgcataatgttgcataatgttgcataataatatacaggct
tactccatggatgtgcataatgttgcataatgttgcataatgttgcataataatatacaggct
tagatccaaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
attnaataatcatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
taccactttcttagcatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
tacaaaaacgaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
attnaataagatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
tctttagacatgtgtgagaaatgttgcataatgttgcataatgttgcataataatatacaggct
ataattgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
agtgaaggatgtataactgatgttgcataatgttgcataatgttgcataataatatacaggct
taaaaaaaatgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct
attcataatcatgttgcataatgttgcataatgttgcataataatatacaggct
gactatgtgttgcataatgttgcataatgttgcataatgttgcataataatatacaggct

taaaagacaaa caatggtcga ttatagaataat gcctatggct agggtatatac acggcattga 164040
 ctcgacattt ggaatgttat attttgccgg aggtctatcc gttaccgaac aatatggtaa 164100
 ttttagagaaaa aacaacgaga tatcttgtt caatcctaga acgaataagt ggtttgat 164160
 ttcatatact atttataaga tatccatatac atcattgtgt aaactaaata acgtcttcta 164220
 tgtattttatg aaggacattt gatatgtgga aaagtatgtat ggtgcatttga agttatgtaca 164280
 tgatcgctc cccgctataa aggccattatc aactcttcc tattgtatga aaatataat 164340
 agttttatg tatagcagta ttaccctata gttttattgc ttactactaa catggatata 164400
 gatgttacaa atgtagaaga tatcataat gaaatagata gagagaaaga agaaaatacta 164460
 aaaaatgtag aaattgaaaa taataaaaaac attaacaaga atcatcccaa tgaatataatt 164520
 agagaagcac tcgttattaa taccagtagt aatagtgatt ccattgataa agaagttata 164580
 gaatgtatca gtcacgatgt aggaatatacg atcatatcta ctaattttta taatcgat 164640
 aaaacataaa aaacaactcg ttattacata gcaggcatgg aatccttcaa gtattgttt 164700
 gataacgtat gcaagaaatg gattatcgaa aatactttat attctgttta ttcaataactc 164760
 tataaggcata gaaaaaattt cactagttcg ttctacataa acgtatgtaa gatagatc 164820
 aaatcacaaca agccattgtt gtctgaaata cgattctata actctgttatttggatcttcc agatctgtat 164940
 actatcgaca actggacacg ggaacgtgtt ataaagtatt ggaattggag aaaccgtatgaa ttatatgttc ttcttataa 165000
 gcccggaaagg atactgaatc agtcttcgaa gcatgcgtca ctatgataaa cacgttagag 165060
 tttataactc ctgcaggatt tacccatgaa aaaatagaac cgaggaatai actgatttaga 165120
 aataaacgtt tttcaactat tgactattct agaactaaca aactatacaa gagtgaaac 165180
 tcacatatacg attacaacgaa ggacatgata acttcaggaa atatcaatta tatgtgtgt 165240
 gacaatcato ttggagcaac agtttcaaga cgaggagatt tagaaatgtt gggatattgc 165300
 atgatagaat ggttcgggtt ccaaacttcca tggaaaaacg aaagtatgtat aaaaatgtaata 165360
 aaacaaaaaaa aagaatataa aaaattataa gctactttct ttgaggactg tttcctgaa 165420
 ggaatgaac ctctggatt agttagat atagaatttag tatacacgtt agattattct 165480
 caaactccta attatgacag actacgtaaa ctgtttatac aagattgaaa ttatattctt 165540
 tttttatag agtgtggtag tttacggat atctaataatt aatattagac tatctctatc 165600
 gcgctacacg accaataatcg attactatgg atatcttcta tgaaaggaga gaatgtat 165660
 attatccatcg cgtcaatctc gtcagtattt acaatactgtt attatggagc taatggatcc 165720
 actgctgaac agctatcaaa atatgttagaa acggaggaga acacggataa ggttagcgct 165780
 cagaatatact cattcaaatc catgaataaa gtatatggc gatattctgc cgtgtttaaa 165840
 gattcctttt tgagaaaaat tggcgataag tttcaacttgc ttgacttcac tgattgtcgc 165900
 actatagatg caatcaacaa gtgtgttagat atctttactg aggggaaaat caatccacta 165960
 ttgatgaac cattgtctcc tagcaattt tagccgtatac tttaaagcaa aatggttgac 166020
 gccattcgaa aaggaattt ccagtgatta tcccttttac gtatctcga cggaaatgg 166080
 agacgttaagt atgatgtcta tgcgtggcaaa ggcatttaat cacgcacatcg taaaagaatc 166140
 attccggcaac tttcaatca tagaactgccc atatgttggaa gatactagta tgcgtgtcat 166200
 tctccagac aagattgtat gattagaatc catagaacaa aatctaacag atacaaat 166260
 taagaaatgg tgcgttttgc tggatgttat gtttataat gttcacattc ccaagttaa 166320
 ggttaacaggc tgcgtataatc tggatgttatc tctgttttttgc tcaaggactga cagaggtgtt 166380
 cgggtcaact ggagattata gcaatatgtg taattttagat gtgagtgctg acgctatgtat 166440
 ccacaaaacg tatataatgtg tcaatgaaatc gtatagatcc gcaagctgcg caacttctgt 166500
 actagtggca gactgtgcattt caacaatttcc aatgagttc tgcgtcgcattt atccgttcat 166560
 ctatgtgatt aggcatgtt atggaaaaat tctttcgat ggttagatatt gctctccgac 166620
 aactaattgtt taaccatttt tttttttttt aatagaaaaa acatgtgttta ttagtgcagg 166680
 tcgttgcattt tccaatgtca attggtaaga tgacggccaa cttttagtacc cacgtctttt 166740
 caccacagca ctgtggatgtt gacagactga ccagtttgc tgacgtcaaa caatgtttga 166800
 ctgaatataat ttattgttgc tccatgtcat accgcaacag gcaatgcgt ggacaattgt 166860
 attccacact cctctttttt agagatgtat ccgttatttgc tttcatcgac attcgcgagc 166920
 tggtaaaaaaa tatggcgatgg gatgtatgtca aagattgtac agaaatcatc cgtgtttata 166980
 taccggatgtt gcaaaaaacc atcagagaga ttccggccat catcgactt tgcgtat 167040
 ctgctactta ctggggaggtt gaaagaccatc ccactgttca cagtctgttca acgttgcgt 167100
 tgatgcttgc gatgttgcattt tacgtggattt ataaatcatcat attccggcgt atgaattgtat 167160
 gagttgtaca ttttgacatt ttctttcttcc ttcttccctt ttcttcttctt ctcccttcc 167220
 ccctcttctc cctttccccag aaacaaactt ttttaccacataaaaataa aatgagtata 167280

ctacctgtta tattttttt tatatttttt tattttcat tcgttcagac ttttaacgcg 167340
tctgaatgtt tcgacaaaagg gcaatatttt gcatcattca tggagttaga aaacgagcca 167400
gtaatcttac catgtcctca aataaatacg ctatcatccg gatataatat attagatatt 167460
ttatggaaa aacgaggagc ggataatgtt agaattatac cgatagataa tggtagcaat 167520
atgctaattc tgaaccgcac acaatcagac tctggtattt atatatgtt taccacgaac 167580
gaaacacttact gtgacatgtt gtcgttaaat ttgacaatcg tgcgtctc agaatcaa 167640
atagattttt tctcgatcc acaaatacgta aatgagagat ctactggcga aatggtatgt 167700
cccaatattt atgcatttt tgcttagtaac gtaaacgcag atattatatg gagcggacat 167760
cgacgcctt aaaaataagag acttaaaca 2gacacacccg gaattattac catagaagat 167820
gttagaaaaa atgatgttgg ttattttatac tgcgttttag aatataatata cggggcaaa 167880
acatataacg taaccagaat tgtaaaaatta gaggtacccc ataaaataat accttctact 167940
atgcaatttac cagatggcat tgtaacttca ataggtagta atttgactat tgcattgtt 168000
agacctccca caacggatgc agacgtctt tggataagta atggatgtt ttacgaagaa 168060
gatgatgggg acggaaacgg tagaataagt gtagcaataa aaatctata gaccgataag 168120
agacgtgtt ttacatccc gttaaacatt aatccgttca aggaagaaga tgctacaacg 168180
tttacgttga tggcggttac tatttttagc atcagcaaaa cagttactgt tagtataacg 168240
tgaatgtatg ttgttacatt tccatgttca ttgagttt aagaattttt atacatttac 168300
ttccaacaaa caatttgcga acgtattgtt atgatataact cccacgatac tgcattt 168360
attaatcatt aacttgcaga ctatcacccat tgcttattttt acataactcat gttcttgcgt 168420
aatttgcgtt tctatattt taaaatgtt aaatctatgtt atagttttt tattttat 168480
tagataatattt accgtcttcc tattttt aatttgcaca tcccttattt aatcatgtt 168540
gggaaattttt atgtcatgtt tagtataattt tgaacaacaa gagcagatata ctataggaaa 168600
gggtggaaatg cgatacattt atctatgtt tttttttttt cacgcgaact ttgaaagaatt 168660
tatataaattt attccatcgat tacatccccc tatgttgcgtt tgcgttatatac caggaatttcg 168720
tttattttata tggggaaatg tataaactaa aacatttcccc gaaagcgggtt cctctatctt 168780
cgttatattcc gttcttactt tacaaaatgtt aaccaatacc tttgcatttttgcgtt 168840
cgccaaacgtt agttttttttt tgacgaatgg attaatttaca atagcatgtt ccgcgcattct 168900
attaagttttt tttactttttt cggcccttgcgtt ttttttttttca gagactttt tttttttttt 168960
agtgttgcgtt tgcgttataa atataaacggg atatagaacc gaatcaccta ccttagatac 169020
ccaaatttacat tttatcagat ccagataata aacaaattttt gtcgccttca ctaatttctat 169080
attgttataat tttttttttt tggttatgtt atcatgttataa aacttggagt ctaacgcgc 169140
tcgtcgatcg tttatcataat tgcgttttttgcgtt ttttttttttca gagactttt tttttttttt 169200
actatagttat tctggacttag tgataaaactt atcgttataat ttttttttttca tgaacttcatc 169260
gagatatttgc tctctgttcat attcatacacc ctgcataaaac ttttttttttca ttttttttttca 169320
cggttattttt taggatcata tttttttttt ttttttttttca ttttttttttca ttttttttttca 169380
aatgggaatc gtctataata atgaatattt aacaaattttt tgaggactttt ttttttttttca 169440
catcataaaaaa atgagtcgtt gtcgttattttt ttttttttttca atcaaccgc 169500
taaaatcacaa gagaatggaa tatatacata ttttttttttca ttttttttttca ttttttttttca 169560
tacagaactt gattttttttca ttttttttttca ttttttttttca ttttttttttca 169620
gtatactgca ctacactgtt atttgttataa taatttttttca ttttttttttca ttttttttttca 169680
attatttttttca catggagtgg atgttacgtt gaaaaccagt agcggacgtt ttttttttttca 169740
tatattgtttt actagatgtt gtaatatttttca acatgttacgtt gtttttttttca ttttttttttca 169800
agataaaaaac cacttatttttca atagagactt ttttttttttca ttttttttttca ttttttttttca 169860
tcgtttacatg ttatttttttca aagaggatattt ctttttttttca ttttttttttca ttttttttttca 169920
taagggaaatc gatccttactt ttttttttttca ttttttttttca ttttttttttca ttttttttttca 169980
gtgtctcgca ctttttttttca aaccagggtt gtttttttttca ttttttttttca ttttttttttca 170040
caagcgaattt atttttttttca ttttttttttca ttttttttttca ttttttttttca ttttttttttca 170100
tggtaatataa ccatttttttca ttttttttttca ttttttttttca ttttttttttca ttttttttttca 170160
taaaatgttgc ttgttttttca atccgaattt ttttttttttca ttttttttttca ttttttttttca 170220
tataactatgtt ttttttttttca ttttttttttca ttttttttttca ttttttttttca ttttttttttca 170280
tcactatgtt acaaatacgat gtttttttttca ttttttttttca ttttttttttca ttttttttttca 170340
gtttatcaaa acatatttttca ctttttttttca ttttttttttca ttttttttttca ttttttttttca 170400
taaaatataa aatatttttca ctttttttttca ttttttttttca ttttttttttca ttttttttttca 170460
atataataat acacacgtt aacacacgtt ttttttttttca ttttttttttca ttttttttttca 170520
aaccgacaat aacaaacacgtt ttttttttttca ttttttttttca ttttttttttca ttttttttttca 170580

taccattaat tgtttactgt atatacttag atatattgt a gataagaatg tgataagatc 170640
 gttggtgat caacttccat ctctacctat cttcgatata aaatcatttg agaaattcat 170700
 atcctactgt atacttttag atgacacatt ttacgatagg cacgttaaga atcgcgattc 170760
 taaaacgtat cgatacgcatt tttcaaaata catgtcggtt gataaatacg atgttataat 170820
 aactaaatgt cacgacgaaa caatgttact ccaaactgtcc actgttctag acactacact 170880
 atatgcagtt ttaagatgtc ataattcgag aaagttaaaa agataaccta acgagttaaa 170940
 aaaatataat aacgataagt cctttaaaat atattctaattt attatgaatg agagataacct 171000
 taatgttataat tataaagata tgcgtgtc aaaggatataat gataaactat ttccctgtttt 171060
 cacagataaaa aattgtctac taacattact accttcagaa attatatacg aaatattata 171120
 catgctgaca attaacgcattttataat atcgatccaa cctaccaaaag tatagttgta 171180
 ttttctcat gcgtgtgt taaaaaaaaact gatattataat aaatattttt gtgccgtata 171240
 ataaagatga cgatgaaaat gatggtacat atatatttcg tattcattttt gttattgtca 171300
 ttccacagtt acgccccataga catcgaaaat gaaatcacag aattcttcaa taaaatgaga 171360
 gatactctac cagctaaaga ctctaaatgg ttgaatccag catgtatgtt cggaggcaca 171420
 atgaatgata tagccgctct aggagagcca tttagccaa agtcttttat cgcacagata taaagactat gggagaggct agaaaagaat 171540
 agacggcgcac aggttctaa taaacgtgtt aaacatggtg atttatggat agccaactat 171600
 acatctaaat tcagtaaccg taggtatttg tgacccgtaa ctacaaagaa tggtgactgt 171660
 gttcagggtt tagttagatc tcatattaaa aaacccctt gataatcgaa tttttttt 171720
 gaacttaggtt ctcatgataa gtatggcata gacttataact gttgaattct ttacgcaaaa 171780
 cattataata atataacttg gtataaagat aataaggaaa ttaatatcgaa cgacattaaag 171840
 tattcacaat cgggaaagga attaattttt cataatccag agtttagaaaga tagcggaaaga 171900
 tacgactgtt acgttcattt cgcacgtt agaatcaaga tttttttt 171960
 tgtaaaatac ttacggttt accgtcacaat gaccacaggta taaaactaat actagatccg 172020
 aaaatcaacg taacgatagg agaacctgccc aatataacat gcactgtgt gtcaacgtca 172080
 ttattgtatcg acgatgtact gattgaatgg gaaaatccat ccggatggct tataggattc 172140
 gattttgtatg tatactctgt tttaacttagt agaggcggtt tcaccggaggc gacccctgtac 172200
 tttgaaaatgt ttactgaaga atatataaggta aatacatata aatgtcggtt acacaactat 172260
 tattttgaaa aaacccttac aactacagta gtattggagt aaatatacaa tgcattttta 172320
 tatacattttt tgaatttattttt ttactgaattt attattactg aattattattt aattatatcg 172380
 tattttgtctt atagaatggaa tgaagatacg cgactatcta ggtatttgta tctcaccgat 172440
 agagaacata taaatgtaga ctctattttt cagttgtgtt aatatacaga tcctaattgca 172500
 tggatgtatgtt gtggatgtac ggcttttacat ggtactttt ataattatag atcagtcaac 172560
 gaaaaataca agtatacgata caacggttac tatcaatattt attcatctag cgattatgaa 172620
 aattataatg aatattttt tggatgtactt ggtatgaaca aaagtacaca actagtaggt 172680
 atcaaaaacag aatatgtatgtt ctatgtgtt acacaagatc tggatgtactt gttttttt 172740
 tacgacattt aactccaaac caatgaggat gattttatgg tggatgtactt gttttttt 172800
 tccatgatta tatagatgaa tcaatttata aagtagtata tggatgtactt gttttttt 172860
 gatggcgggaa tatatggcaaa gaacataatg atggcgatccat cgtatagaa aaggagtgca 172920
 tagataatat atacgaagac aaccataccg tagacgttccat tggatgtactt gttttttt 172980
 cagatgttgcgaa cacatataatccg cgataactaa aaaaacccatag aatcagtgtt 173040
 tgataatacc tacatttctt atcttccgtt taccatcaaa tggatgtactt gttttttt 173100
 ataagtattt ttatccatctt taaaactgtt aaataaaattt tttctatgtt gttttttt 173160
 agatgagaat ccttatttctt atcgctttca tggatgtactt gttttttt 173220
 cgggttggaaac caaatgttcaaa aatcttagaca tggatgtactt gttttttt 173280
 caggatgtgtt ggaacatatacgata ccttggatgtt gttttttt 173340
 aatccggacga ggatccaatggatgtt gttttttt 173400
 ccgttgcgtac cacagatgtt ggaatcgatccat tggatgtactt gttttttt 173460
 ctaataaaattt tgataattat aggttctactt gttttttt 173520
 aaaagaatattt ttggctgtt gttttttt 173580
 gaatttaattt gaattgtatgtt ttatccatcaaa tggatgtactt gttttttt 173640
 ttatccatgtt aaaaaataac gacatacgatccat tggatgtactt gttttttt 173700
 taacttagctt atagaacttg ctcattgtt tggatgtactt gttttttt 173760
 aattatccgaa cgcaccgggtt tcttccgtt ttctatgttcaaa acgggtacgg catataggac 173820
 aaaatataatgtt agtacacgaa tccaaataaactt caaagtatctt atcgtttttga gttttttt 173880

tcatagcaaa ttccacattc tttttcttta cttactctat acacgtcctc gtatttat 173940
agtatggta tgatatccaa ctcagaaatg gttgttgtat tattgggtgt ataggatata 174000
ttagctatgt accaatttac caacccttta aatattgatt gataatcaca tcggttatcc 174060
aatcaataac cacattaata actaaattgt agtgatata tagaccat atgtttctat 174120
tttttgaca gttacgtata gttcagtaa gtttgattg ttgtattccct gtatctctag 174180
ataagtttagt catatagtcc ctccggcga tacgtttttt ccaagcccgaa aattgattag 174240
ccaaatgtgtt atttattttt gtgatattga tataatattt cggtataatgc atactgttag 174300
tcttataatca tttgggtcat ctatgtattt taatattgtt acatgtatca tagatgtat 174360
attgattttg gcaggatcga attccatatc cgccgactaaa cagtaaaaaa aatgtaaata 174420
ctttttaaat tttaaattag taaaactttt ttttattttt tatgattcca aaaataactga 174480
atacaagtc ctaaattata aatatggaga tcatactacc acaacttattt attatgtata 174540
caaggccggt gtaatagata gatataatata attctattac accggcagac aattaccgao 174600
cggtatgtt cgttaccaac ataccgtata atatgtata tacaattcca taacccattg 174660
acagttgtta tacateaaaa ttgcaatttct tttgattacg atgttataag aatgttagtta 174720
attgatgtat gatgttaatg tgccttctt cctcttataa catcgtaatc aaaaactttt 174780
ttataatata tacctaataa tggctttaa tagttctcgat gattcgtaa acaatcatc 174840
ttataaaaata taataaagca acgtaaaaac acataaaaaat aagcgtaact aataagacaa 174900
tggatattta cgacgataaa ggtctacaga ctattaaact gtttataat gaatttgatt 174960
gtataaggaa tgacatcaga gaatttttta aacatgtaac tgattccgat agtatacaac 175020
ttccgatgga agacaattct gatattatag aaaatatcag aaaaataacta tatagacgat 175080
taaaaaatgt agaatgtgtt gacatcgata acacaataac ttttatgaaa tacgatccaa 175140
atgatgataa taagcgtaatc tggcttaattt gggttaccctt aactaataac tatatggat 175200
attgtctatg aatattttt gaaacaccga tatgtggagg caaaataaaaa ttataccacc 175260
ctacaggaaa tataaagtctg gataaggata ttatgtttgc aaagactcta gactaagata 175320
gacagcgtat cagatgtaga tgacgcggaa cacatatctc ctataactaa tgatgtatct 175380
acacaaacat gggaaaagaa atcagagttt gatagatata tggatcgta tcctcgatcat 175440
agatataatg aacattctgtt atttaaggaa tttctgtata aagtttagaaa aaatgattta 175500
gacatgaatg tggtaaaaaga attactttt aacgggtcat ctctaaacat caaggatagc 175560
agtaataagg atccaaattgc tggtttattttt agaagaacga taatgaattt agaaatgatt 175620
gatatttata acaaacatata aactattgtat gaacgaaagt atatgtata ctcttatcta 175680
aaaaatttata gaaatttcga ttatccattt ttcaggaagt tagtttgac taataaacat 175740
tgtctcaaca attattataa tataagcgac agcaaatatg gaacaccgct acatattatg 175800
gcgtctaata aaaaattataa aactcttaat tacatgaagt tattatgtta taacggaaat 175860
gatataaaacg cacgagggtga agatacacaa atgcgaacca actcagaaat ggtgttgta 175920
ttattgggtg tatagttattt attagctatg tccaattta ccaacccttta taatattgtat 175980
tgataatcac atcggttattc caattaataa ctaaattgtat gtttatatat agaccatata 176040
tgtttctatt ttttgacag ttacgtatag ttctcgttataa gtttattttt ttttattttt 176100
tatctctaga taagtttagtcc atatgtccc ttccggcgat acgttttttcaagcccgaa 176160
attgatttagc caaatgtgtat tttttttt tgatattgtataaatttttca ggtataatgc 176220
tactgttagt cttatcat tgggttcatc tatgtattgtt aatattgtta catgtatctat 176280
agatgtatgat ttgattttgg caggatcgaa ttccatatacc gcgactaaac agtggaaaaaa 176340
atgtaaataat ttttttaattt tttttttttt tttttttttt atgattccaa 176400
aaatactgaa tacaaagtcc taaattataa atatggagat catactacca caacttatta 176460
ttatgtatcac aaggccgggtg taatagatag atatataataa ttcttattaca ccggcagaca 176520
attaccgacc ggtattttgtc gttaccaaca taccgtataa tatgtatata acaattccat 176580
aaccattgtac cagttttat acatcaaaaat tgcaatttctt tgattacgat gtttataaga 176640
atgtatgtatg ttgtatgtatg atgttaatgtt gtccttcttcc ttcttataac atcgtaatca 176700
aaaacttttataatataat acctaataat gtgtttaat agttctcgat attcgtcaaaa 176760
caatcattct tataaaatataat aataaagcaa cgtaaaaacataaaaaata agcgtaacta 176820
ataagacaat ggatattttac gacgataaaag gtctacagac tattaaactgtttaataat 176880
aattttgattt gataaggaaat gacatcgatg aattttttt aatgttaact gattccgata 176940
gtatataact tccgatggaa gacaattctg atattataga aatatacaga aaaaataactat 177000
atagacgatt aaaaatgtat gatgtgtt acatcgataa cacaataact tttatgaaaat 177060
acgatccaaa tgatgataat aagcgatcgtt gttcttattt ggttacccttactaataact 177120
atatggataa ttgtctatgtat aatattttgg aaacaccgat atgtggaggc aaaaataaaat 177180

-70-

tataccaccc tacagggaaat ataaaagtccg ataaggatat	tatgtttgc aagactctag 177240
actttaaatc aacgaaagtg ttaactggac gtaaaaacaat	tgccgttcta gacatatccg 177300
ttccatataa tagatcaatg actactattc actacaacga	cgacgttgat atagatatac 177360
atactgataa aaatggaaaa gagttatgtt attgttatat	aacaatagat gatcattact 177420
tgggtgatgt ggaaactata ggagttatag tcaatagatc	tggaaaatgt ctgttagtaa 177480
ataaccatct aggtataggt atcgtaaag ataaaacgtat	aagcgatagt ttggagatg 177540
tatgtatgga tacaatattt gactttctg aagcacgaga	gttattttca ttaactaatg 177600
atgataacag gaatatacgca tgggacactg ataaaactaga	cgatgataca gatatatgg 177660
ctcccgtcac agaagatgt tacaatttc tttctagact	agtattgtat gcaaaatctc 177720
aatcggatac tgttatttgc tattatgtc ttactggta	tacggaacca cccactgtat 177780
tcattttcaa ggttaactaga ttttacttta atatgccaa	ataaaaaaattt ttgttataat 177840
atctagaggt agaggatttg tttagataaa tacaataaac	atagatacat cgcatactta 177900
gcatttttat aaatatacat aagacataca ctttatacat	tttggtaaaa atactcataa 177960
aaaaattttat aaaaattatg gcacaacccat atcttgtata	ggtagtttag ttctgtcgagt 178020
gaacctataa acagataata gacaacacat aataatgcct	actaatacaa gcataatacc 178080
gggagatggg atatatgacg ttgttagtgg tgggtttct	gaacgttgat agtctactaa 178140
tactacatgc tgacatctaa tgccgttata accatgagag	catctacaat acataccgtc 178200
aatatctcta gctgtggatac agtcaccgtg taaaacatat	ccatctccct ctggaccgca 178260
taatctgata gctggataat ctgttgttagc gtttgaattt	tctggcaatg tcgtttcgat 178320
agcgttacca ctatccggcga atgatctgtatcatagca	gctgaaacaaca acatcgatca 178380
atttatcaac atttttgcattt gattctgtgt ttatgtgtt	tctcagtgatg tttttatgac 178440
aagattggga atttttattt attaatttcg taatataaac	taataatata ttgttaattt 178500
tgtaaataat ataaaaataa caatacaata ttgaatgtgt	tgctgttaaa aatgtatgt 178560
ttaatataat agaataaaaat aaatgaggat gatcattttt	gataacgatt gattttatca 178620
ttaccgcittc attcttataat tctttgcattt cggAACCTAT	atttagaaac atctactaac 178680
aatttttat gcttgcattt ttaatggat gtaatatgtat	tgattgtgtt cgcaataacca 178740
atttggtaag tatgaataacg gggtaacaaac ataaattgaa	atthaacattt atttatttt 178800
gatatatatac gttatgttta ggtctataacc atggatatct	ttaaagaact aatcttaaaa 178860
caccctgtatg aaaatgtttt gatttctcca gtttccattt	tatctacttt atctattctta 178920
aatccatggag cagctgtttc tacagctgaa caactatcaa	aatataataga gaatatgaat 178980
gagaatacac ccgatgacaa taatgtatgac atggaggtag	atattccgta ttgtgcgaca 179040
ctagctaccg caaataaaaat atacggtagc gatagtatcg	agttccacgc ctcccttccta 179100
caaaaaataa aagacgattt tcaaactgtt aacttataata	atgctaacca aacaaaggaa 179160
ctaatcaacg aatgggtttaa gacaatgaca aatgttaaaa	ttaattccctt attgactagt 179220
ccgctatcca ttaatactcg tatgacagttt gtttagccg	tccattttaa agcaatgtgg 179280
aaatatccat tttcttaaaa tcttacatcat acagacaagt	tttatatttc taagaatata 179340
gttaccagcg ttgatatgtatg ggtgggtacc gagaataact	tgcaataatgt acatattaat 179400
gaatttattcg gaggatctc tattatcgat attccatatacg	agggaaactc tagtatggta 179460
attataactac cggacgacat agaaggatata tataacatag	aaaaaaat aacagatgaa 179520
aaattttaaa aatgggtgtgg tatgttatct actaaaagta	tagactgtt tatgccaaag 179580
tttaaagtgg aatagacaga accgtataat ctggtaccga	tttttagaaaa tttaggactt 179640
actaatatcg tggatattt tgcagatttt agcaagatgt	gtaatgaaac tattactgt 179700
gaaaaatttc tacatcgac gttttagat gttaatgagg	agtatacaga agcatcgcc 179760
gttacaggag tatttacatg taactttcg atggatatac	gtacgaaggt ctacataaac 179820
catccattca tgtacatgt taaagacacc acaggacgtt	tactttttt agggaaatac 179880
tgtatccgc aataaaatata aacaaataga cttttataaa	gagtcttcaa cgataagtat 179940
atcgacatac tacttatgtt gggaaagattt ctgaacgaga	acgactatct caccctctt 180000
gatcatatcc gcaactgtttaa atactaaatc tccactacac	tttttatcat ctatgagga 180060
atgattgcct tcgtgaaata ggaataatgg caccggaaat	agctatggat tattgtggta 180120
gagagtgcac tattctatgtt cgtctactgg atgaagatgt	gacgtacaaa aaaaataaaac 180180
tagaaaatttga aacgtgtcac aacttatcaa aacatataga	tagacgagga aacaatgcgc 180240
tacattgttca cgtctccaaat aatgcgata cagacattaa	gattgttctc tcgcggagtc 180300
gagagactttt gtagaaacaa cgaaggat tttccgtctag	gagtatacag taagcataga 180360
taactaaatctcagattgtt gcatctactg atatccagctt	attcaaattt ctctaacgaa 180420
ctcaagtcga atataaaatga tttcgatctg tattcggata	atatcgactt acgtctgcta 180480

aaatacctaa ttgtggataa acggatacgt ccgtccaaga atacgaatta tgcaatcaat 180540
ggctcggat tggggatata atacgtaacg acgcctaata cgagaccaga agtattgcta 180600
tggcttccta aatcagaatg ttacagcacc ggtaacgtat ttcgtactg tatgtacgac 180660
agtatgtatgt gtaagaactc ttccattac tataatcgat ctcatagaga atctcaatct 180720
ctatccaagg atgttaattaa atgtttgatc gataacaatg tttccatcca tggcagagac 180780
gaaggaggat cttaaccat ccaataactac tggctttct caaccataga tatagagatt 180840
gttaaattat tattaataaa ggatgtggac acgtgttagag tatacgaatc cagccctata 180900
ttagaggcgt attatctaaa caagcgattt agagaaccc catataatgt agacatggaa 180960
atcgtaatc ttcttattga gagacgtcat actcttgcg acgtaatgcg tagtattact 181020
tcgtacgatt ccagagaata taaccactac atcatcgata acattctaaa gagatttga 181080
caacaggatg tacaaggccat gttgataaaac tactacatt acggcgatat ggtcgttgc 181140
tgcgtttag ataacggaca acaaatacc tctgcacgac tactttgtta ataataatct 181200
cgtcgtatgtaa aacgtcgtaa ggtttatcgat gaaaaatatg gacacgcggc tgtaaatcac 181260
gtatcgaaaca atggccgtct atgttatgtac ggtctgatata ttcgtatataaattgc 181320
gggtatcact gttatgaaac catactgata gatgtatgg atataactaaag caagtacatg 181380
gatgatatacg atatgtatcgta taactctact atattacgcg gtcgtatgtca ataataataca 181440
atttgcaaag cggttattgg aatatggagc gagtgcacg ctcgataatc aatacggcca 181500
tccagaaaag cagttacca agagaaaaca aaacgaagct agttgatata ttactgagtt 181560
accatcccac tctagagact atgattgacg cattaatag agatataacgc tattctatatac 181620
ctgaaccatt attcgccctgt atcagataacg ccttaatccat agatgtatgtat tttccttcta 181680
aagtaaagta tgatatcgcc ggtcgtatc aggaactaaa ggcgtataga gtagacattta 181740
atagaatgaa gaatgtctac atatcaggcg ttcgtatgtt tgatataat tttaaacgaa 181800
gcaaacgcca caaattgaga tacgcaaaaga atccgcatac aaatggtaca aaaaagaact 181860
aacgtccatc attacagaaa ctgtaaagaaa caatgagagg atcgactcca tagtggacaa 181920
cattaataca gacgataact tgatttcgaa attacccatg gagatactt attactccat 181980
taaataattt atcatggagc gataatgtcc tggttcatat tttccatga cattatacaa 182040
aatcgattcc gtcggatata ataaaaacat ttacggcat cattaaacacg gagtttattt 182100
tatatgtctc gcataaaacat tactaaaaaa atatattgtc gataacttgc tttcgaaatt 182160
accatggag atacttttacttccattaa ataatttatac atggagcgat aatgtccctgt 182220
ttcattttgtt tccatgacat attacaaaat cgattccgtc caagatgata aaaaacattta 182280
ccggcatcat aaacacggag ttatattttat atgtctcgca taaacattac taaaaaaaaata 182340
tattgttctg tttttcttc acatctttaa ttatgaaaaa gtaaatcatt atgagatggaa 182400
cgagattgttgc cgcgtatgtc ggcacagtat gtggatatac cctaacgtat ttatggacga 182460
cggttaagaat gaaggtcagc ttctgtcaa caatgtctgt catabgtatt ttacgttctt 182520
tgatgtggat acatgtctc atctgtttaa gctagttattt aaacactcgat atctgaataa 182580
acgaggtaac tctccattac attgtctatatac gatgaataaca cgatttaaatc catctgtatt 182640
aaagatattt ttacaccacg gcatggtaa ctttgatagc aaggatgacc actatcaatc 182700
gataacaaga tctttgatata actaacggac accattgtatc acttttagtaa atcatccgat 182760
ctattgttgtt gttatcttag atataaaattt aatgggagct taaactattt cgttctgtac 182820
aaaggatccg accctaattt cggccacgac gatgaactca cttctcttca ttactactgt 182880
aaacacatata ccacgttctc cgaaagcaat tattacaagt taagtacac taagatgcga 182940
gccgagaagc gattcatcta cgcgataata gattatggag caaacattaa cgccgttaca 183000
cacttacctt caacagtata ccaaacatag tcctcgtgtc gtgtatgtc ttttatctcg 183060
aggagccgat acgaggatatac gtaataatct tgattgtaca cccatcatgg aacgattgtg 183120
caacaggtca tattctcata atgttactca attggcacga aaaaaaggaa gaaggacaac 183180
atctacttttata tctattcata aaacataatc aaggatatac tctcaatata ctacggatc 183240
tattagatag gttcgacatt cagaaagacg aatactataa taccgcctt caaaattgtt 183300
acaacaatgt tgcctcatac atcgatatac acatcaaccc tccgactaaa gacggatttc 183360
gacttgggtgt ttgaaaacag aaacatatac tacaaggcgg atgttgcgaa tgacatcatc 183420
caccacagac tgaaagtatac ttacccatg attaaatcgat tttctacaa gatgtctctc 183480
cctacgacga ttactacgtt aaaaagatac tagctactg cctattaagg gacggatgt 183540
tcgcggact acatgttaaa ttctgtttaa acgaggacta taaaagtgtt tttatgaaaa 183600
atatattcatt cgataagata gattccatca tcgtacata agtcgcctca aagagattcg 183660
aatctccgac accgaccctgt atacggatatac acagctatct taaagccata cattcagaca 183720
gtcacatttc atttccatgt tacgacgatc tcatagaaca gtgcctatca tcgtatggagc 183780

-72-

gtaaaaagtaa actcgctcgac aaagcactca ataaattaga gtctaccatc ggtcaatcta 183840
 gactatcgta tttgcctccg gaaattatgc gcaatatcat ctaaacagta tgggtacgg 183900
 aaagaaccat tacaatatt atccatgata gaaagaaaat atctatatga ttggagaagt 183960
 agggaaacagg aacaagacaa cgattactac attattaaat catgaagtcc gtattatact 184020
 cgtatattat gtttctctca tgtataataa taaacggaag agatatagca ccgcacatgcac 184080
 catccgatgg aaagtgtaaa gacaacgaat acaaacgcca taatttggtg cgggaacat 184140
 acgcttcag attatgcgt agcaagacta acacacgatg tacgcccgtgt gggtcgggta 184200
 ccttcacatc tcgcaataat catttacccg cttgtctaag ttgttaacgga agacgcgatc 184260
 gtgtAACACG actcacaata gaatctgtga atgctctccc ggatattatt gtcttctcaa 184320
 aggatcatcc ggtatcgaagg catgtgtttc ccaaacaaaa tggtaatag gatacgagg 184380
 atccggagac gtcatctgtt ctccgtgtgg tctcggaaaca tatttcacaca ccgtctcttc 184440
 cgcagataaa tgcaaccccg taccaggaaa tacgtttaac tatatcgatg tggaaattaa 184500
 cctgttatcca gtaacgaca cgtcgtgtac tcggacgacc actaccggtc tcagcgaatc 184560
 catctcaacg tcggaactaa ctattactat gaatcataaa gactgtatc ccgtatttcg 184620
 ttagggatcac ttctccgttc ttaataagg agcgacttca gggttcttta caggagaaag 184680
 gtgtgcactc tgaatttcga gattaaatgc aataacaag attcttcctc caaacagtt 184740
 acgaaagcaa agaatgatac tatcatgcgc cattcggaga cagtaactct agtggcgcac 184800
 atctatatac tatatagtaa taccaatact caagactacg aaactgatc aattctcttat 184860
 catgtgggta atgttctcga tgcgtatgc catacgcccg gtagtgtcga tatacataaa 184920
 ctgatcaacta attccaaacc caccacttt ttatagtaag ttttcaccc ataaataata 184980
 aatacaataa ttaatttctc gtaaaaagtag aaaatatatt ctaatttatt gcacggtaag 185040
 gaagtagaaat ctaaaagaac agtactcaat caatagcaat tatgaaacaa tatactgtcc 185100
 tggcatgcat gtgcctggcg gcagctgcta tgcctgccag tcttcagca tcattctcat 185160
 cctcttcctc gtgtacggaa gaagaaaaca aacatcatat gggaatcgat gttattatca 185220
 aagtcaacaa gcaagaccaa acaccgacca atgataagat ttgccaatcc gtaacggaaa 185280
 ttacagagtc cgagtcaagat ccagatcccc aggtggaatc agaagatgat tccacatcag 185340
 tcgaggatgt agatccctt accacttatt actccatcat cggtggaggt ctgagaatga 185400
 actttggatt caccaaatgt cctcagatta aatccatctc agaatccgct gatggaaaca 185460
 cagtgaatgc tagattgtcc agcgtgtccc caggacaagg taaggactct cccgcgtca 185520
 ctcatgaaga agctcttgct atgatcaaag actgtgaatg gtctatcgac atcagatgt 185580
 gcgaaagaaga gaaagacacgc gacatcaaga cccatccagt actcgggtct aacatctctc 185640
 ataagaaagt gagttacgaa gatatcatcg gttcaacgat cggtcgatataa aatgcgtca 185700
 agaatctaga gtttagcggt cgtatcgag acatgtgcaaa ggaatcatct gaacttgagg 185760
 tcaaggatgg attcaagttat gtcgacggat cggcatctga aggtgcaacc gatgatactt 185820
 cactcatcga ttcaacaaaa ctcaaaagcgt gtgtctgaat cgataactct attcatctga 185880
 aattggatga gttagggttaa tcgaaacgatt caggcacacc acgaattaaaa aagtgtacc 185940
 ggacactata ttccggttt caaaacaaaaa atgttcttaa ctacattcac aaaaagttac 186000
 ctctcgccgac ttcttcttt tctgtctcaa tagtgtgata cgattatgac actattccta 186060
 ttcttattcc tatttctttt cagagtatca caaaatattt aaacctctt ctgtatggtct 186120
 cataaaaaaaa gtttacaaa aatattttt ttcttctttt ctcttgcgt gtcctataaa 186180
 aaaagttta caaaatattt ttatttctt ttcttctttt gatggctcata aaaaaaaaaagt 186240
 ttacaaaaaa tatttttattt ctctttctt ctttgatggt ctcataaaaa aagtttaca 186300
 aaaatatttt tattctcttt ctctcttttga tggctctata aaaaagttt tacaaaaaata 186360
 ttttatttct ttctctctt ttgtatggtct cataaaaaaaa gtttacaaa aatattttt 186420
 ttctctttct ctctttgatg gtctcataaa aaaagttta caaaatattt ttatttctt 186480
 ttctctcttt gatggctcata aaaaaaaagt ttacaaaaaa tatttttattt ctctttctt 186540
 ctttgcgtt ctcataaaaa aagtttaca aaaatatttt tattctcttt ctctctttga 186600
 tggctctata aaaaaagttt tacaaaaata ttttatttctt ctctctctt ttgtatggtct 186660
 cataaaaaaaa gtttacaaa aatattttt ttctctttt ctctttgatg gtctcataaa 186720
 aaaagttta caaaatattt ttatttctt ttctctctt gatggctcata aaaaaaaagt 186780
 ttacaaaaaa tatttttattt ctctttctt ctttgatggt ctcataaaaa aagtttaca 186840
 aaaatatttt tattt

-73-

<211> 1131
<212> DNA
<213> Human Herpesvirus-1

<300>
<308> GenBank No. NC_00180
<309> 2004-01-13

<400> 35
atggcttcgt acccctgcca tcaaacacgcg tctgcgttgc accaggctgc gcgttctcg 60
ggcataaca accgacgtac ggcgttgcgc cctgcggc aacaaaaagc cacggaagt 120
cgctggagc agaaaatgcc cacgctactg cgggttata tagacggtcc ccacgggatg 180
gggaaaacca ccaccacgc actgctgggt gcccgggtt cgccgcacga tatcgctac 240
gtacccgagc cgatgactta ctggcggtt ttggggctt ccgagacaat cgcaacatc 300
tacaccacac aacaccgcct cgaccagggt gagatatcgg ccgggacgc ggcgtggta 360
atgacaagcg cccagataac aatgggcatt ccttatgcg tgaccgacgc cgttctggct 420
cctcatatcg ggggggaggc tggagctca catgccccgc ccccgccct caccctcatc 480
ttcaccgcgc atccatcgc cgcctcctg tgctaccgg ccgcgcgata ccttatggc 540
agcatgaccc cccaggccgt gtggcggtt gtggccctca tcccgccgac cttgcccggc 600
acaaacatcg tggggggc cttccggag gacagacaca tcgaccgcct ggccaaacgc 660
cagcccccg gcgagccgct tggactggct atgctggccg cgattcgcg cgtttatggg 720
ctgcttgcca atacggcg 580
cagcttcgg gggcgccgt gcccggccag ggtggcg 640
cgacccata tcgggacac gttattacc ctgtttcg 700
aacggcgacc tgtataacgt gtttgcctgg gcttggacg tcttggccaa acgcctccgt 960
cccatgcatttgcctt ggattacgac caatgcggc 760
ctgcaactta cttccggat ggtccagacc cacgtcacca ccccgaggctc cataccgacg 1080
atctgcgacc tggcgccgac gtttgcctgg gagatggggg aggctaactg a 1131

<210> 36
<211> 376
<212> PRT
<213> Human Herpesvirus-1

<300>
<308> GenBank No. NP_04462
<309> 2004-01-13

<400> 36
Met Ala Ser Tyr Pro Cys His Gln His Ala Ser Ala Phe Asp Gln Ala
1 5 10 15
Ala Arg Ser Arg Gly His Asn Asn Arg Arg Thr Ala Leu Arg Pro Arg
20 25 30
Arg Gln Gln Lys Ala Thr Glu Val Arg Leu Glu Gln Lys Met Pro Thr
35 40 45
Leu Leu Arg Val Tyr Ile Asp Gly Pro His Gly Met Gly Lys Thr Thr
50 55 60
Thr Thr Gln Leu Leu Val Ala Leu Gly Ser Arg Asp Asp Ile Val Tyr
65 70 75 80
Val Pro Glu Pro Met Thr Tyr Trp Arg Val Leu Gly Ala Ser Glu Thr
85 90 95
Ile Ala Asn Ile Tyr Thr Thr Gln His Arg Leu Asp Gln Gly Glu Ile
100 105 110
Ser Ala Gly Asp Ala Ala Val Val Met Thr Ser Ala Gln Ile Thr Met
115 120 125

-74-

Gly Met Pro Tyr Ala Val Thr Asp Ala Val Leu Ala Pro His Ile Gly
130 135 140
Gly Glu Ala Gly Ser Ser His Ala Pro Pro Pro Ala Leu Thr Leu Ile
145 150 155 160
Phe Asp Arg His Pro Ile Ala Ala Leu Leu Cys Tyr Pro Ala Ala Arg
165 170 175
Tyr Leu Met Gly Ser Met Thr Pro Gln Ala Val Leu Ala Phe Val Ala
180 185 190
Leu Ile Pro Pro Thr Leu Pro Gly Thr Asn Ile Val Leu Gly Ala Leu
195 200 205
Pro Glu Asp Arg His Ile Asp Arg Leu Ala Lys Arg Gln Arg Pro Gly
210 215 220
Glu Arg Leu Asp Leu Ala Met Leu Ala Ala Ile Arg Arg Val Tyr Gly
225 230 235 240
Leu Leu Ala Asn Thr Val Arg Tyr Leu Gln Gly Gly Ser Trp Arg
245 250 255
Glu Asp Trp Gly Gln Leu Ser Gly Ala Ala Val Pro Pro Gln Gly Ala
260 265 270
Glu Pro Gln Ser Asn Ala Gly Pro Arg Pro His Ile Gly Asp Thr Leu
275 280 285
Phe Thr Leu Phe Arg Ala Pro Glu Leu Leu Ala Pro Asn Gly Asp Leu
290 295 300
Tyr Asn Val Phe Ala Trp Ala Leu Asp Val Leu Ala Lys Arg Leu Arg
305 310 315 320
Pro Met His Val Phe Ile Leu Asp Tyr Asp Gln Ser Pro Ala Gly Cys
325 330 335
Arg Asp Ala Leu Leu Gln Leu Thr Ser Gly Met Val Gln Thr His Val
340 345 350
Thr Thr Pro Gly Ser Ile Pro Thr Ile Cys Asp Leu Ala Arg Thr Phe
355 360 365
Ala Arg Glu Met Gly Glu Ala Asn
370 375

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047458 A3

(51) International Patent Classification⁷: C12N 7/04,
A61K 35/76, C12N 15/863, A61K 35/74, C12Q 1/02

(US). ZHANG, Qian [CN/US]; 88348D Via Sanoma, San
Diego, CA 92037 (US).

(21) International Application Number:
PCT/US2004/019866

(74) Agents: SEIDMAN, Stephanie, L. et al.; Fish and
Richardson P.C., 12390 El Camino Real, San Diego, CA
92130 (US).

(22) International Filing Date: 18 June 2004 (18.06.2004)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:

03013826.7 18 June 2003 (18.06.2003) EP
03018478.2 14 August 2003 (14.08.2003) EP
03024283.8 22 October 2003 (22.10.2003) EP

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 03013826.7 (CON)
Filed on 18 June 2003 (18.06.2003)
US 03018478.2 (CON)
Filed on 14 August 2003 (14.08.2003)
US 03024283.8 (CON)
Filed on 22 October 2003 (22.10.2003)

(71) Applicant (*for all designated States except US*): GENELUX CORPORATION [US/US]; 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SZALAY, Aladar, A. [US/US]; 7704 North Fork Road, Highland, CA 92346 (US). TIMIRYASOVA, Tatyana [RU/US]; 7524 Charmant Drive #525, San Diego, CA 92122 (US). YU, Yong, A. [CN/US]; 11111 Via Abajo #A, San Diego, CA 92129

(88) Date of publication of the international search report:
15 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MODIFIED RECOMBINANT VACCINA VIRUSES AND OTHER MICROORGANISMS, USES THEREOF

(57) Abstract: Recombinant *vaccinia* viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organism. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products.. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism as well as antibodies reactive therewith are provided.

WO 2005/047458 A3

INTERNATIONAL SEARCH REPORT

'US2004/019866

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N7/04 A61K35/76 C12N15/863 A61K35/74 C12Q1/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92/22327 A (UNIV CALIFORNIA) 23 December 1992 (1992-12-23)	1, 6, 7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
Y	page 3, line 31 - page 5, line 9 ----- -/-	2-5, 8, 9, 32, 37, 38, 82, 95

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 June 2005

Date of mailing of the international search report

07.07.2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2000 (2000-05), MUKHERJEE SUTAPA ET AL: "Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation" XP002257646 Database accession no. PREV200000285526 abstract & CANCER GENE THERAPY, vol. 7, no. 5, May 2000 (2000-05), pages 663-670, ISSN: 0929-1903</p> <p>-----</p>	
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 1998 (1998-07), SIVANANDHAM MUTHUKUMARAN ET AL: "Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice" XP002324951 Database accession no. PREV199800394715</p>	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
Y	<p>abstract</p> <p>& CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 46, no. 5, July 1998 (1998-07), pages 261-267, ISSN: 0340-7004</p> <p>-----</p> <p>-/-</p>	2-5,8,9, 32,37, 38,82,95

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TARTAGLIA J ET AL: "NYVAC: A HIGHLY ATTENUATED STRAIN OF VACCINIA VIRUS" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 188, no. 1, 1 May 1992 (1992-05-01), pages 217-232, XP002027067 ISSN: 0042-6822	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
Y	page 217 abstract page 219, left-hand column, paragraph 4 page 220, right-hand column, last paragraph - page 221, left-hand column, line 1 page 221, right-hand column, paragraph 2 page 227, right-hand column, paragraph 6 - page 228, left-hand column, paragraph 1 page 228; table 6 page 230, right-hand column, paragraph 1 _____	2-5,8,9, 32,37, 38,82,95
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2000 (2000-01), PUHLMANN MARKUS ET AL: "Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant" XP002257647 Database accession no. PREV200000179026	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
X	abstract & CANCER GENE THERAPY, vol. 7, no. 1, January 2000 (2000-01), pages 66-73, ISSN: 0929-1903 _____	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2002 (2002-12), ZEH HERBERT J ET AL: "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers." XP002262641 Database accession no. PREV200300070352	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
	abstract	-/-

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& CANCER GENE THERAPY, vol. 9, no. 12, December 2002 (2002-12), pages 1001-1012, ISSN: 0929-1903 -----	
Y	TIMIRYASOVA TATYANA M ET AL: "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper" BIOTECHNIQUES, vol. 31, no. 3, September 2001 (2001-09), pages 534-540, XP008022947 ISSN: 0736-6205 cited in the application the whole document	2-5, 8, 9, 32, 37, 38, 82, 95
X		23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102
Y	TIMIRYASOVA ET AL: "VISUALIZATION OF VACCINIA VIRUS INFECTION USING THE RENILLA-LUCIFERASE-GFP FUSION PROTEIN" PROCEEDINGS OF THE 11TH INTERNATIONAL SYMPOSIUM ON BIOLUMINESCENCE AND CHEMILUMINESCENCE, 2000, pages 457-460, XP008023166 cited in the application page 457, paragraph 2	2-5, 8, 9, 32, 37, 38, 82, 95
X	page 457, paragraph 4 - page 458, paragraph 1 ----- -/-	23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MCCART J ANDREA ET AL: "Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes" CANCER RESEARCH, vol. 61, no. 24, 15 December 2001 (2001-12-15), pages 8751-8757, XP002331814 ISSN: 0008-5472 page 8751 abstract -----	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
X	WO 00/73479 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE) 7 December 2000 (2000-12-07) page 35 - page 44; examples 1-14 -----	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
X	PUHLMANN MARKUS ET AL: "Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy" HUMAN GENE THERAPY, vol. 10, no. 4, 1 March 1999 (1999-03-01), pages 649-657, XP002331815 ISSN: 1043-0342 page 649 abstract page 650, left-hand column, paragraph 3 page 651, left-hand column, last paragraph - right-hand column, paragraph 1 page 653, left-hand column, last paragraph - page 654, right-hand column, last paragraph ----- -/-	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 491 905 B1 (SORSCHER ERIC J ET AL) 10 December 2002 (2002-12-10) column 2, line 50 - line 63 column 4, line 65 - column 5, line 16 column 32 - column 34; examples 25,26 -----	23-30, 39-60, 63-77, 83-90, 96-102
X	DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1974, COLLINS J L ET AL: "Suppression of SV40 tumors after immunization with Group A Streptococcus pyogenes and Bordetella pertussis" XP002331817 Database accession no. EMB-1975014814 abstract & CANCER RESEARCH 1974, vol. 34, no. 5, 1974, pages 932-937, -----	23-30, 39-60, 63-77, 83-90, 96-102
X	DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1995, FENG X ET AL: "The antitumor activity of a mixed bacterial vaccine against mouse hepatoma" XP002331818 Database accession no. EMB-1995319198 abstract & CHINESE PHARMACEUTICAL JOURNAL 1995 CHINA, vol. 30, no. 7, 1995, pages 405-407, ISSN: 1001-2494 -----	23-30, 39-60, 63-77, 83-90, 96-102
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1980, YAMAMOTO A ET AL: "PRODUCTION OF L FORMS OF STREPTOCOCCUS-PYGENES AND THEIR ANTI TUMOR EFFECTS" XP002331819 Database accession no. PREV198171075184 abstract & JAPANESE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 50, no. 5, 1980, pages 383-388, ISSN: 0021-5031 -----	23-30, 39-60, 63-77, 83-90, 96-102
		-/-

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 October 1980 (1980-10-01), TANAKA R ET AL: "Preliminary evaluation of intratumoral injection of a Streptococcus pyogenes preparation in patients with malignant brain tumors." XP002331820 Database accession no. NLM6998559 abstract & CANCER. 1 OCT 1980, vol. 46, no. 7, 1 October 1980 (1980-10-01), pages 1688-1694, ISSN: 0008-543X</p> <p>-----</p>	23-30, 39-60, 63-77, 83-90, 96-102
X	<p>WO 03/014380 A (SZALAY, ALADAR, A; YU, YONG, A; SHABAHANG, SHAHROKH; TIMIRYASOVA, TATY) 20 February 2003 (2003-02-20) cited in the application</p> <p>page 52, last paragraph - page 53, paragraph 2 figures 9,10 page 55, paragraph 2 - page 71, paragraph 2 page 85, paragraph 1 - page 88, paragraph 1</p> <p>-----</p>	23-30, 39-60, 63-77, 83-90, 96-102
P,X	<p>EP 1 369 491 A (GENELUX GMBH) 10 December 2003 (2003-12-10)</p> <p>the whole document</p> <p>-----</p>	23-30, 39-60, 63-77, 83-90, 96-102
P,X	<p>YU YONG A ET AL: "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins." NATURE BIOTECHNOLOGY, vol. 22, no. 3, March 2004 (2004-03), pages 313-320, XP002331816 ISSN: 1087-0156 cited in the application the whole document</p> <p>-----</p> <p>-/-</p>	23-30, 39-60, 63-77, 83-90, 96-102

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>YU Y A ET AL: "OPTICAL IMAGING: BACTERIA, VIRUSES, AND MAMMALIAN CELLS ENCODING LIGHT-EMITTING PROTEINS REVEAL THE LOCATIONS OF PRIMARY TUMORS AND METASTASES IN ANIMALS" ANALYTICAL AND BIOANALYTICAL CHEMISTRY, DE, vol. 377, no. 6, November 2003 (2003-11), pages 964-972, XP008045750 ISSN: 1618-2642 the whole document</p> <p>-----</p> <p>A</p> <p>DATABASE BIOSIS 'Online!' BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, SHIMIZU Y ET AL: "SIGNIFICANCE OF PRIMING OF HOSTS WITH VIRUS IN THE TUMOR-SPECIFIC IMMUNOTHERAPY MODEL UTILIZING VIRUS-REACTIVE HELPER T CELL ACTIVITY" XP002331821 Database accession no. PREV198988132538 abstract & JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY, vol. 24, no. 5, 1989, pages 1007-1014, ISSN: 0021-4671</p> <p>-----</p>	23-30, 39-60, 63-77, 83-90, 96-102

INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-29, 65, 66, 73-82, 96-102 (all completely) and claim 31 (partially) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22, 31, 32, 37, 38 (all completely); 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102 (all partially)

A recombinant vaccinia or other poxvirus wherein at least the TK and HA genes thereof are modified, methods of producing the same, and the use thereof

2. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102 (all partially)

A recombinant vaccinia virus wherein the F3 gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in invention 1

3. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102 (all partially)

A recombinant vaccinia virus wherein the TK gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in either of inventions 1 and 2

4. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102 (all partially)

A recombinant vaccinia virus wherein the HA gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in any of inventions 1-3

5. claims: 42, 51-53, 58, 59, 63, 77, 89 (all completely); 23-30, 39-41, 43-50, 54-57, 60, 64-76, 83-88, 90, 96-102 (all partially)

Use of a microorganism in eliminating or inhibiting growth of immunoprivileged cells or tissues, a means for production of a polypeptide or RNA or compound via the use of a microorganism, use of a microorganism in inducing autoimmunization, a method for producing antibodies using a microorganism, kits related thereto, and wherein said microorganism is other than any included in any of inventions 1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/US2004/019866

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9222327	A	23-12-1992	US WO	5718902 A 9222327 A1		17-02-1998 23-12-1992
WO 0073479	A	07-12-2000	AU CA EP WO US	5446700 A 2375189 A1 1180157 A1 0073479 A1 2003031681 A1		18-12-2000 07-12-2000 20-02-2002 07-12-2000 13-02-2003
US 6491905	B1	10-12-2002	US US US US CA DE DE EP JP WO	6017896 A 5552311 A 2003077268 A1 2003134819 A1 2171618 A1 69431911 D1 69431911 T2 0715523 A1 9502612 T 9507718 A2		25-01-2000 03-09-1996 24-04-2003 17-07-2003 23-03-1995 30-01-2003 28-05-2003 12-06-1996 18-03-1997 23-03-1995
WO 03014380	A	20-02-2003	EP EP BR CA EP WO US US US	1281772 A1 1281767 A2 0211546 A 2456055 A1 1414994 A2 03014380 A2 2003059400 A1 2005069491 A1 2004234455 A1		05-02-2003 05-02-2003 13-07-2004 20-02-2003 06-05-2004 20-02-2003 27-03-2003 31-03-2005 25-11-2004
EP 1369491	A	10-12-2003	EP AU CA WO EP	1369491 A1 2003236696 A1 2488227 A1 03104485 A2 1509617 A2		10-12-2003 22-12-2003 18-12-2003 18-12-2003 02-03-2005

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.